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Background: The ethical basis of randomised controlled trials is equipoise, whether 
at the collective or individual level. Neonatal intensive care trials are therefore 
conducted in a context of clinical uncertainty as well as stress and trauma. The 
theoretical literature suggests that tensions exist in the trials situation between the 
aims of care and research. 
Objectives: To improve understanding of decisions that clinicians and parents make 
about neonatal trial collaboration, participation and non-participation. 
Methods: Semi-structured interviews were conducted with 30 neonatologists and 63 
parents from 5 UK hospitals who were offered enrolment in the INNOVO and/or 
CANDA trials. Qualitative analysis was aided by ATLAS-ti. 
Results: The neonatologists' interviews suggested an intermediate level of equipoise. 
A therapeutic orientation operated for the INNOVO Trial but not for the CANDA 
Trial. Neonatologists often did not connect trial participation and trial-related 
postmortem pathology studies. Most parents made very rapid decisions about trial 
participation. Perception of risk was independent of the trial under consideration but 
associated with a slower decision-making process. The 'therapeutic misconception' 
was present for parents in both trials. Many supported contributing to research. For 
some of the bereaved parents, this extended to contribution to trial-related pathology 
studies. Parents who declined the CANDA Trial saw risks in the trial situation. 
Conclusions: Decisions were complex and multi-tiered. The boundaries between care 
and research were often unclear for neonatologists and parents. Clarification of the 
nature of decisions at the heart of clinical trials is needed, so that those associated with 
research might be willing collaborators and participants, fully cognisant of the activity 
in which they are engaged. 
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Chapter I- Randomised Controlled Trials And 
The Gap Between Theory and Practice 
The methodological dominance of the randomised controlled 
trial 
There is no doubt that there is a huge degree of support for the use of the randomised 
controlled trial (RCT) around the world. Enormous numbers of trials are conducted, 
requiring the commitment of vast human and financial resources. Whole institutions, 
as well as many academic and medical departments, are given over to running trials 
and to trial-related methodological research. There are academic journals and 
societies dedicated to the RCT. Conferences on the subject abound. In the UK, 
government-sponsored funders, such as the Department of Health and the National 
Health Service Health Technology Assessment Programme make substantial 
investments in trials; the Medical Research Council (MRC) currently spends 
approximately E20 million per annurn in their support. This figure is, however, 
dwarfed by the input from the pharmaceutical industry. As demands for evidence- 
based medicine grow, it is likely that the number of trials will continue to increase. 
The RCT has achieved what Berry has described as "a hallowed status" (Berry 1989). 
The RCT is so widely used because it is capable, if well-conducted, of generating high 
quality scientific results. Randomisation, the defining feature of the RCT, is crucial in 
this respect. Random allocation of intervention groups was developed to address the 
issue of selection bias at trial entry. Proponents argue that it is the only means by 
which an observed effect may be attributed to an intervention (Chalmers et al 1989). 
Uncontrolled studies are less reliable as there is no comparison group, and even in 
controlled studies, if the groups are not assigned randomly, it cannot be stated with 
confidence that observed changes are due solely to an intervention rather than pre- 
existing inter-group differences. Results from clinical trials which have been 
randomised are said to be simply "more believable" (Pocock 1995). The 
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methodological advantages of the RCT have lead to its almost universal adoption as 
the scientific "gold standard" for assessment of effectiveness in clinical research'. 
The RCT is, however, more than an experimental tool. It is a scientific method which 
is applied in a human context. It is the concerns raised by this context which drive an 
extensive and wide-ranging debate within which a number of standpoints exist. The 
main justification for the use of the RCT is made via the dominant paradigm which 
shall from here on be termed the Theory of Broad Benefit. The main critique rests on 
what shall be termed the Theory of Limited Benefit. These two perspectives are both 
products of scientific, social, political and ethical reflection. 
The dominant approach to RCTs - the Theorv of Broad 
Benefit 
If conditions of uncertainty over the most appropriate form of care prevail, the use of 
the RCT is widely thought to offer a number of benefits to both society and 
individuals (Chalmers 1986; Silverman 1987; Freedman 1987; Tobias and Souhami 
1993; Grimmett & Sulmasy 1998; Emanuel et al 2000). 
Benefits to society 
Societal benefits are thought to accrue in the following ways: 
initial introduction of novel therapies within controlled studies (and non- 
adoption of therapies not found to be effective) 
assessment of established interventions 
appropriate use of resources 
'Although this is the majority view, there are those who reject the idea of the RCT as the gold standard 
for research about effectiveness, or who argue that valid alternatives are not always given due 
consideration (McLeod 1999). Berry (19 89) suggests that the methodological supremacy accorded to 
randomisation reflects received wisdom rather than a clearly thought out argument. He likens the 
situation to the story of the naked emperor's new clothes: "Only fools failed to see the emperor's new 
clothes. Nobody wants to be thought a fool, so everybody'sawl them. Nearly everyone praises 
randomisation. " Starzl (1985) argues that excluding other methods can lead to unnecessary research 
beyond a point where there might already be a convincing body of evidence. He describes this as 
"trialomania". Coulter (199 1) argues that the RCT is fundamentally flawed as it involves aims which 
are essentially incompatible, that is to reduce the natural variability of individuals and to produce 
generalisable findings. Coming from the homeopathic tradition he views responses to a treatment as 
highly individual in nature; like Berry (1989) and Zajicek (1995), he argues that results for the average 
patient as assessed by the RCT are unlikely to hold true for individuals. 
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Introduction of novel therapies 
The most obvious societal benefit of the RCTs links to the forces which drive the 
research in the first place, that is trial-based research may be used to bring about 
medical progress and innovation. An important example of the progress made as a 
result of clinical trials is the highly successful incremental advancements that have 
been made in the treatment of paediatric leukaemia, for which survival rates have 
greatly increased (Simone, 2003). In neonatal intensive care, there are a number of 
examples of successful therapies, such as surfactant and extra-corporeal membrane 
oxygenation (ECMO), whose introduction has directly affected the standards of care 
that can be offered. 
Assessment of established interventions 
Many interventions creep into long-term common usage without having been the 
subject of a clinical trial. This may be because the benefits seem so clear that a trial 
would not be necessary to demonstrate efficacy. Alscher (a contributor to a debate 
presented in Cook et al 2003) gives the impact of appendectomy for acute 
appendicitis, the polio vaccine, and insulin for diabetes as examples. McLeod, 
however, draws attention to the fact that "even therapies that were once accepted 
without question are being evaluated in RCTs" (McLeod 1999); he uses as an example 
a trial comparing appendectomy to antibiotic therapy alone (Eriksson & Granstrom 
1995 2 ). In other instances, there can be a pressing need for, or a great interest in, an 
intervention, which is then rapidly adopted as routine practice, as was the case with 
laparoscopic cholecystectomy (Plaiser et al 1994; McLeod, 1999) and extra-corporeal 
shock-wave lithotripsy for kidney stones (Dudley, 1986). When a shift in practice has 
already occurred it can be difficult, if not impossible to conduct a trial. Lumley and 
colleagues described how a trial to determine the best method of delivery for very low 
birthweight infants became impossible as obstetric staff were "irrevocably convinced" 
2 The results of this trial indicated that "antibiotic treatment in patients with acute appendicitis was as 
effective as surgery. The patients had less pain and required less analgesia, but the recurrence rate was high" (Eriksson & Granstrom, 1995). 
is 
of the benefit of caesarean sections for these infants and had widely adopted this as 
the norm (Lumley et al 1985)3. 
Although RCTs which assess existing approaches to care can raise some difficulties 
(unless they are included as best standard care as a comparison to a novel approach), 
they can provide important evidence to support or to suggest the discontinuation of 
interventions already in use. For instance, the use of hyperbaric oxygen for alleviation 
of symptoms of multiple sclerosis was largel discontinued after it was eventually 
shown to be ineffective after years of debate over its use (Barnes et al 1987). Some 
interventions which have entered common usage without evaluation as they at first 
appeared innocuous, have subsequently been shown to have disastrous consequences. 
This was the case with the instigation of a small rise in body temperature for preterm 
babies which was eventually recognised to have increased mortality rates (Silverman 
1980). There are also many instances of untrialed interventions which initially seemed 
to be efficacious but for which the negative consequences were later revealed through 
clinical trials: increased levels of supplemental oxygen caused blindness in premature 
babies, there was a risk of cancer for the children of women who took 
diethylstilbestrol during pregnancy, and the impact of anti-arrhythmic drugs given to 
cardiac patients resulted in the deaths of approximately 50,000 individuals (Silverman, 
2004). Roberts and colleagues recently demonstrated an unexpected increased level 
of mortality associated with the common practice of administering corticosteroids for 
head-injury as a prophylaxis against infection (Roberts et al 2004). 
Appropriate use of resources 
Where RCTs and their ancilliary studies5 provide clear evidence of the level of 
effectiveness of an intervention, and an understanding of associated comparative 
3A review of records showed that those who delivered vaginally were of significantly lower gestation 
than those delivered by caesarean section. Vaginal delivery was more likely to be used in cases where 
the particularly early gestation meant that the babies were not expected to survive. 4 Wynne (1989) carried out a study to explore why a proportion patients continued to fund their own 
use of hyperbaric oxygen after the trial in which they had participated had demonstrated no effect on 
their multiple sclerosis symptoms. This research raises a rarely considered issue about who defines 
effectiveness and how benefit is measured. Wynne concludes "at least in the case of this therapy and 
this condition, the assumptions inherent in the trial method, and its concept of genuine therapeutic 
benefit, structures the conclusions of the trial in a way that is profoundly at variance with the 
participants' own methodological assumptions and concept of benefit. " 
RCTs often include economic assessments, allowing the costs of interventions and their sequelae to be 
considered alongside clinical outcomes. 
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costs, this can allow often scarce human and financial resources to be used in the most 
appropriate ways. 
Benefits to individual trial participants 
For those who participate in RCTs, a number of advantages have been suggested. 
They are: 
beneficial effects of the trial situation 
possible access to potential benefits of novel therapies 
protection from potential risks of novel therapies. 
Beneficial effects of the trial situation 
Several studies have indicated that there may be some measurable benefits of trial 
participation itself, in that trial participants can have better outcomes than non- 
participants regardless of allocation (Reiser & Warner 1985; Schmidt & Gillie 1999). 
This phenomenon has been termed the "inclusion benefit" in clinical trials (Lantos 
1999). Some attribute this to a higher standard of care in a trial context (Skrutkowska 
& Weijer 1997). This may be because the management of care in all trial arms can be 
highly controlled, offering what is essentially a management plan for each participant, 
specifying for instance drug regimes or decision trees according to allocation. 
Furthermore, trials can be based on "optimal management advice [which is] 
incorporated in the protocols from leading ... experts" (Yates 2003). Reiser and 
Warner suggested that benefits may accrue as trial participants can be particularly 
motivated and compliant with their regime, in response to being 'selected' for a 
Gspecial trial group' (Reiser & Warner 1985). 
Possible access to potential benefits of novel therapies 
It is an ethical prerequisite that trials should offer interventions which, based on the 
evidence at the outset, are thought to be similar in their effects (the null hypothesis). 
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Clear evidence of superiority of an intervention would render allocation to the inferior 
approach unethical. It is, however, the case that the fact that a trial is taking place 
implies that a novel therapy is, at the very least, promising (Joffe & Weeks 2002). 
The possibility of allocation to an experimental arm may then be seen as offering an 
opportunity to access apotentially beneficial intervention (Snowdon et al 1997). As 
the benefits and risks for all arms of the trials are thought to be equivalent at the point 
of recruitment, the different approaches available in a trial have been described as 
offering "an equally good bet prospectively" (Edwards et al 1998). 
Protection from potential risks of novel therapies 
Trial participation is also thought to offer participants a degree of protection. Rather 
than being exposed to "uncontrolled experimentatioif', (Chalmers 1986), the informal 
and largely unaccountable process of everyday clinical encounters, whereby 
caregivers seek to find an effective treatment for a patient without the benefit of an 
evidence base to guide them (Silverman 1997), the administration of interventions for 
trial participants is subject to guidelines laid down in the trial protocol. Trial 
participants often receive a higher level of monitoring than they would otherwise 
expect. This approach is said to reduce the risks for patients in potentially vulnerable 
situations (Chalmers 1983). 
Chalmers argues that for all of these various reasons, RCTS "maximize benefit and 
minimize harre' (Chalmers 1986), that the degree of protection offered through 
administration of an intervention in a trial, with close monitoring of progress and side 
effects, is necessary because "all of our interventions in people's lives are two-edged 
swords" (Chalmers 1983). Given the potential for societal and personal benefit 
through RCT participation, and the risks, again to society and individuals, which are 
inherent in a context of uncertainty, it has been suggested that it is unethical for 
clinicians not to offer to enrol a patient to an appropriate trial protocol (Segelov et al 
1992). Baum argues that if the public were educated about clinical uncertainty and 
RCTs, they would expect or even demand trial entry (Baum 1993). 
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A 2ap between the Theorv of Broad Benefit and practice 
Although there is clear national and international support for RCTs, and the theory 
that they are broadly beneficial is widely-articulated, there is a wealth of evidence to 
indicate that many professionals and patients at the "coalface" (Sackett 2000) do not 
necessarily see trials in the same way. RCTs, regardless of specialty and location, are 
in fact beset with recruitment problems. Siminoff and colleagues comment: 
Despite the clamor by the public to more quickly develop new and better drugs, the 
first stumbling block to the timely accrual and completion of clinical trials is the 
reluctance of physicians to offer patients a chance to participate in a trial. The 
second major barrier is the low acceptance rate of patients when a trial is offered 
(Siminoff et al 2000). 
Despite the argument for the benefits of trials put forward by commentators such as 
Chalmers, Segelov and Baum, many professionals do not enrol the majority of their 
trial-eligible adult patients into trials, and the majority of patients do not demand trial 
entry. It is very common for trials to experience serious difficulties achieving target 
sample sizes (Gotay 199 1; Gates et al 2004). It is estimated that for oncology trials 
only 10% of physicians enter 80% of trial participants (Cohen 2003), and that only 
two to three per cent of trial-eligible patient are actually enrolled into a trial (Lara et al 
2001). The large disparity between the number of health professionals who indicate 
an intention to enrol patients into a' trial, and the proportion that actually does so has 
been frequently reported (Baines 1984; Lumley et al 1995; Tognoni et al 199 1). Prout 
comments: 
The common thread that runs through recruitment experiences is first and foremost 
the truth of Muench's Third Law, namely, that the number of patients promised for 
a clinical trial must be divided by a factor of at least 10 (Prout 1979). 
There can be major consequences of poor levels of recruitment. A prolonged 
recruitment period may render the results obsolete by another trial. There can be a 
reduction in both generalizability of data and statistical power (Ashery & McAuliffe 
1992). Trials affected in this way cannot answer the questions they were meant to 
address and potentially useful trials can be derailed (Lumley et al 1985; Tognoni et al 
199 1; Plaiser et al 1994; Hunt et al 200 1; Ehrlich et al 2002). 
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The factors contributing to lower than anticipated recruitment are not simple to 
disentangle. There has been a proliferation of research assessing the views of 
professionals, patients and the public, which predominantly focuses on their attitudes 
as obstacles to recruitment. A number of reviews of this literature exist (Hunninghake 
et al 1987; Ross et al 1999; Cox & McGarry 2003). The review by Ross and 
colleagues assesses 78 studies, a figure which has increased substantially in the five 
years since publication. Over and above practical constraints and protocol demands, 
important attitudinal barriers for professionals were identified as concerns for the 
impact of offering a trial on their relationship with patients, on patient wellbeing and 
on professional autonomy. For patients it was shown that trials can be difficult if they 
run counter to treatment preferences, if they raise anxiety over the background of 
uncertainty and if the consent process causes concern. 
The common difficulties with accrual are, however, only one consequence of a 
complex mix of interrelated factors which shape the management and course of a trial. 
Where professionals find the particular terms of a particular trial to be difficult, this 
can result not only in poor overall rates of recruitment, but also selective recruitment 
(Lumley et al 1985; Taylor et al 1984; Komblith et al 2002), disregard for allocation 
and the requirements of a protocol (Klein et al 1995) and subversion of randomisation 
(Oakley 1992; Schultz 1995a, 1995b). Where patients find the terms of a trial 
difficult, their responses can also have a dramatic impact upon the success or failure 
of a trial. They may quite simply decline to participate if a trial appears to be risky 
(Hutton et al 1990), to involve undesirable interventions (Plaiser et al 1994; van der 
Windt et al 2000) or to place restrictions on access to a desirable intervention (Mcleod 
et al 2004). They may enrol onto a trial but be non-compliant with the protocol 
(Williams et al 1980), or may accept randomisation but decline subsequent allocation 
to an arm other than their preferred intervention (Abramsky & Rodeck 1991). 
These problems were brought into sharp focus by the particularly pro-active stance 
taken by some patients who were recruited to placebo-controlled HIV-AIDS trials in 
the 1980s. In a bleak situation, AZT appeared to offer the only hope for those affected 
by HIV-AIDS and the then experimental drug was not available outside trials. Some 
gave false information in order to enrol on a trial in the hope of accessing AZT, some 
had their study medication analysed, dropping out if they discovered that they had 
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been allocated a placebo, and some shared trial medication with other participants to 
ensure the intake of at least some of the active drug (Merrigan 1990). These actions 
seriously undermined the validity of the trials and so had consequences for fellow trial 
participants and future patients. They did, however, make it very clear that for an 
influential number of individuals, the strictures of these protocols were counter to 
what they felt was their own interests. These actions brought about ethical and 
methodological reflection by the trials community. The trials were redesigned to take 
account of patient preferences (Institute of Medical Ethics Working Party on the 
Ethical Implications of AIDS, 1992) and AZT was made available outside trials on 
compassionate grounds (Arras 1990; Mirken 1995). 
Yates (2003) argues that poor rates of collaboration and participation are evidence of 
"a disconnect [which] exists between the collective desire for [medical] progress and 
professional and public acceptance of participation in clinical trials". Schultz argues 
that one of the reasons for non-co-operation is a disparity between the conditions 
which are set in order to run trials effectively, and the needs of the professionals and 
patients at the heart of the trials situation, an argument clearly reflected in the 
difficulties arising in connection with the HIV-AIDS trials described above. He states 
that "RCTs provide the gold standard, but they are also anathema to the human spirif' 
(Schultz 1995b). 
An alternative view - the Theory of Limited Benefit 
Given the dominance of the Theory of Broad Benefit, alongside the almost universal 
phenomenon of recruitment difficulties, one might expect logically that there would 
be less concern when individuals do choose to collaborate or participate in RCTs. In 
fact the argument that trials are appropriate for medical science but problematic for 
individuals is commonly raised in the theoretical and empirical literature; Hilden and 
Gammelgaard (2002) refer to "the eternal theme" of RCTs giving rise to ethical 
dilemmas. This does not sit comfortably with the Theory of Broad Benefit in which 
the central tenet is that trials offer protection for patients and an ethical framework to 
guide professionals. Whilst the broad benefit theorists see RCTs as the means to 
harmonise the needs of different parties, the limited benefit theorists largely focus on 
competition between social and scientific needs and the needs of individual patients. 
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According to the Theory of Limited Benefit, the RCT involves compromises for three 
main reasons, namely: 
" trials primarily offer benefits to society 
" trial collaborators may abrogate their duty of care 
" patients are often unclear about the implications of participation 
RCTs primarily offer benefits to society 
According to the Theory of Limited Benefit, the advantages of research are tipped in 
favour of society rather than the individual patients who act as participants. Several 
authors have suggested that instead of protecting patients, trial enrolment trades their 
well-being for that of patients of the future (Barber 1976; Fost 1979; Schafer 1982) 
and that for trials where mortality is an outcome measure, it can constitute a sacrifice 
of some of the patients who are allocated to what turns out to be the less effective 
intervention (Thornton 1993, Yao & Wei 1996). In this approach the needs of society 
and the needs of individuals are considered to be in direct competition. This conflicts 
with the World Medical Association Declaration of Helsinki which states that 
"concern for the interests of the subject must always prevail over the interests of 
science and society" (World Medical Association, 2001). 
Trial collaborators may abrogatc thcir duty of carc 
Fried argued that clinicians have a duty to provide their patients with "personal care" 
(Fried 1974). Several commentators have expressed concern that clinicians who 
collaborate in RCTs may find themselves compromising this important principle. 
Schafer states that "the possibility of conflict is an ever present danger" (Schafer 
1982) and Kodish refers to such a split in loyalties between research and care as "the 
most vexing ethical issue raised by RCTs" (Kodish 199 1). Those who recruit to trials 
can be seen as failing to act in the best interest of their individual patients and 
reneging on their professional duties (Hellmanl979). Kodish states that a doctor is 
obliged to "give his or her best advice, indicating not only that which he or she is sure 
of, but also those things that he or she thinks probable, likely or reasonable" and to 
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(tact in regard to the patient only as he or she perceives the patient's best interests with 
no conflicting responsibilities (Kodish 1982). 
If trial entry is offered, this requires a clinician to describe the prevailing and their 
personal state of uncertainty over the most appropriate treatment, which some authors 
do not perceive as constituting "best advice" (Appelbaum et al 1987). Appelbaum and 
colleagues argue that the use of randomisation to different inflexible treatment arms of 
a trial can constitute a compromise in care. Trials can make demands on participants 
which would not be required of patients. Adjunctive medication such as sleeping pills 
or anti-depressants which may be important to patient well-being, may not be 
permitted according to some protocols "not because they are harmful in conjunction 
with ... the experimental treatment but precisely because they may be helpful and thus 
create confusion about the source of any positive responses observed" (Lidz et al 
2004). Truog argues that there is a fundamental difference between offering trial 
entry to patients in the context of routine health care versus in potentially life-saving 
situations where it involves 'unacceptable compromises': "In such a setting patients 
want to believe that their physician is entirely devoted to pursuing their best interest, 
without any conflict of loyalty" (Truog 1993). 
This is bome out in the account of Hazel Thornton who was offered participation in 
the UK Ductal Carcinoma In Situ (DCIS) Trial after diagnosis of early breast cancer. 
She found the discussion about research particularly difficult in the context of her 
illness and her faith in her doctor was shaken: "It suddenly seemed that my belief that 
the physician's primary concern should be for me was ill-founded" (Thornton 1994). 
Patients are often unclear about the implications of 
participation 
It has been shown that there are inherent difficulties with informed consent processes 
and that trial participants are often unclear about important aspects of the research for 
which they have given their consent. The principle of informed consent, "the bedrock 
... of protection of human research subjects" (Kraybill, 2004), holds that the decisions 
of those who agree to participate in biomedical research, should be free, informed, 
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autonomous and voluntary (Beauchamp & Childress 1994). Such clarity can, 
however, be difficult to achieve. 
The information given to potential participants is intended to promote a clearer 
understanding but it may engender confusion and distress (Brewin 1982). Ingelfinger 
argues that information given to potential trial participants can be too complicated, 
and that without a training in medicine is unlikely to be understood (Ingelfinger 1979). 
If the information is not understood by those agreeing to participate in a trial, the 
standard of consent is inadequate and affords little of the intended protection to any of 
the parties involved. Even where information is less complicated, the context of 
illness which prevails in many trial situations, may not be conducive to clear 
assimilation and processing of information. Consent which is given in circumstances 
where individuals are likely to find it difficult, if not impossible to process and retain 
the necessary information to be said to be 'informed' has been described as 
"technical" (Kestin 1998) and "symbolic" (Horng et al 2002). 
Difficulties at the intersection of care and research 
It is recognised within the Theory of Broad Benefit and the Theory of Limited 
Benefit, that trials bring together care and research, two fields of activity each with 
their own tensions, stressors, dilemmas and regulations. The area of intersection is 
difficult ethical territory. 
Care is primarily based on the needs of individual patients. It involves expectations 
based on familiar rules and patterns of engagement between patients and therapists. 
Although the world is changing and patients increasingly expect and are expected to 
take an active role in decisions about their care (Coulter 1997; McNutt 2004), 
Corrigan argues that for both parties, when faced with the question of trial enrolment, 
"pre-existing norms and values ... shape their expectations and drive their behaviour" 
(Corrigan 2003). Patient expectations that the medical professional can offer effective 
treatment to individuals can be high (Williams et al, 1995; Bryan-Brown & Dracup, 
1996; Anon, 2000; Bell et al, 2002; McKinley et al 2002). 
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Research is intended to improve standards of care and to add to knowledge for the 
patients and society of the future. It does not have treatment of the individuals who act 
as research participants as a primary aim. Research using RCTs involves a shift away 
from personal care towards a system in which interventions are allotted randomly and 
individual variability is largely removed from the equation. To preserve the validity 
of research, trials can involve certain sacrifices - forgoing existing medication and 
undergoing tests and procedures such as the "invasive and uncomfortable" angiograrn 
required of Lapsley, a doctor who described his involvement with a clinical trial 
(Lapsley 2004). Other procedures, such as the close monitoring which is valued 
according to the Theory of Broad Benefit, may be demanding for patients in certain 
circumstances, and may have iatrogenic effects. Some of the nursing staff involved 
with a cancer trial who were interviewed by this author for another study, expressed 
concern that patients who felt well, but whose tumours were advancing inexorably, 
were required to have additional tests for the trial which could reveal their progression 
to them at an earlier stage than would otherwise occur (Snowdon et al for the STEPS 
Group, unpublished). 
Although the distinctions between care and research appear clear, when the two 
activities intersect, the borderland between them can, in practice, be hazy. In the most 
extreme case, they can be overlayered to a point where they are indistinguishable, 
with individuals being unaware that they have taken part in a trial (Snowdon et al 
1997). Such difficulties may be due to prior expectations, as suggested by Corrigan, 
which interfere with the ability to modify perceptions of the altered stakes and 
ground-rules. It may be due to the need to care and be cared for. The offer of 
enrolment in a trial by a health professional with whom a patient is already familiar, 
such as a general practitioner, a professional who treats a chronic condition or even 
one who has recently initiated a caregiving relationship in an acute situation, may 
serve to further obscure essential differences. Collaboration and participation may go 
ahead precisely because any potential clash in research and personal aims, such as 
risks, or the implications of a shift in professional roles, are masked. 
A lack of clarity on the distinction between the aims of research and care has been 
termed "the therapeutic misconceptioif '(Appelbaum et al. 1982) and is thought to 
constitute a major threat to the validity of informed consent for RCTs (Appelbaum et 
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al. 1987)6. It has recently been shown to be a widespread phenomenon amongst 
patients (Litz et al. 2004), and has also been identified amongst professionals by Joffe 
& Weeks (2002) who quote the National Bioethics Advisory Commission to clarify an 
important area in which misconceptions can arise: 
It is not a misconception to believe that participants will receive good clinical 
care during research. But it is a misconception to believe that the purpose of 
clinical trials is to administer treatment rather than to conduct research National 
Bioethics Advisory Commission 2001). 
This clarification however, contains within it some of the subtlety of the distinction 
which can be so difficult to grasp. Here a difference lies within the terms "care" 
which is offered in the context of a therapeutic trial, and "treatment", which is not. It 
has been argued that in order to make such a distinction clearer the terms "treatmenf' 
and "patient' 'should not be used with reference to trials (Miller et al 1998). 
The whole nature of therapeutic trials is that they set out to assess an intervention in a 
care context and, unlike phase I trials, where only a very small proportion of 
participants are likely to experience a clinical improvement, the possibility of benefit 
to individuals is higher. It would seem likely that this possibility of benefit, whether 
an aim or a side-effect, is at the heart of the intersection and so at the heart of some of 
the confusion over aims and roles. Given the almost ingrained identities of caregivers 
and patients, it may well be that it is almost impossible to keep the differences 
between care and research at the forefront of the minds of all parties. Can doctors 
faced with sick patients strip themselves of their essential 'doctomess'? Can patients 
who are ill and who seek a cure stop being patients? 
The difficulties which arise at the intersection of care and research, and a number of 
other issues which have been touched upon in this chapter, are reflected in extracts 
from two accounts of trial processes, one written by a clinical collaborator (Box 1) 
and the other by a trial participant (Box 2). These two accounts give an indication of 
the value and importance of considering trials from more than one angle. 
6 The Therapeutic Misconception is considered further in Chapter 2 
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Dobkin describes how, in the course of a double blind trial of ticlopidine to prevent stroke (Canadian 
American Ticlopidine Study or CATS), he found it difficult to confront his patients with the 
uncertainty which surrounded treatment for their condition. 
My admissions of uncertainty about the available remedies, and my willingness to leave the decision 
about their treatment to a computer's random choosing, simply compounded their anxiety about 
being sick They would look at me bleakly, unable to reach a decision. 
He felt personally responsible for those that he had enrolled in the trial. One of the trial participants in 
his care developed leukopeania, a potentially dangerous drop in white blood cell count and her trial 
drugs (ticlopidine or placebo) were quickly discontinued. Her white cell count rose after a week: 
I couldstop my restlessfretting. But I was left with some gnawing doubts about myparticipation in 
the trials. Should I risk keeping my patients in the experiments and continue asking others to enrol? 
Later came the news that a patient whose family had been against enrolment in the trial, had died. 
Dobkin wondered 'HadI nowpoisoned two people? ' Discussing the trial with potential participants 
became very difficult; split in his loyalties to patients and to the trial he felt like a 'double agent. He 
decided to unblind himself to the allocation and end his collaboration if the deceased participant had 
received ticlopidine. He felt anticipatory concern at faceing the patient's family doctor, his 'angry' wife 
and daughters. The patient had in fact received placebo: 'I smiled with reliefand my guilt dissipated. 
He continued to feel anxious over the potential for 'unrecognised harin'throughout the remaining five 
years of the trial. From his description of the collaborators' meeting to announce the trial results, this 
was a common reaction: 'You could hear the sighs ofrelief in the audience... We had done no harm ý 
Dobkin, (1990) 
Box 1. A collaborator's account 
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Rabinovitch consented to a trial which aimed to refine the use of a chemotherapeutic agent to prevent 
recurrence of breast cancer. She commented that she had "blithely agreed tojoin " this trial. 
When Dr 0, the oncologist, asked ifIdjoin an experiment, I saidyes immediately. ... I 
heard 
"trial", and thought, good, anything that turns this into something more than being ill. Anthony is 
very anxious - what if the trial compromises my treatment? ... Dr 0 is 
keen to recruit me to the 
trial - in another conversation he says, with some irritation, that all patients should 
be in trials, so 
answers would befoundfaster - but he adds that if, at any stage, the team ... 
decide I need a 
different kind oftreatment, they'll remove mefrom the regime. 
It was only when Rabinovitch embarked upon the trial regime that she appreciated that there were 
gaps in her understanding of the agreement that she had entered into. 
I am lying rigid because I didn't think to ask the one question that might have made me think 
twice. Tojoin the trial, the biopsy I've already had is not enough. Trial HQ, over in the States, 
needs more hits ofivy tumour. Dr 0 tells me this, but definitely uses the word "biopsy", singular. 
So here I am, flat on Dr K's couch. Softly, she chats away, filling cold silences. A nd, "I'll he doing 
the biopsies under locaL " "How many biopsies? " I'm on my hack, in a gown that gapes open, and 
I'm trying to sound assertive. "Three, " she says. 
Her description of the preparation for the biopsies suggests a time of anxiety and discomfort for trial 
staff as well as for Rabinovitch. An attempt to check her understanding of the trial was made, but in 
an anxious and stressed state she did not wish to engage in any further discussion. 
Dr O's research nurse is in the room too. "Do you understand about the trial? " she asks me, in a 
voice that reaches my now hyper-anxious ears as extraordinarily patronising. "Yes, "I say. "Has it 
been explained to you? " "Yes. " I'm abrupt, and struggling to sit up.... Dr K takes over, her gentle 
stream of information morefrenetic as she sees the pain on myjace. 7 can't put local anaesthetic 
right into the tumour, " she tells me. V don't want to know that, I don't want to know that, "I say. 
Under her breath she mutters: "Why ever couldn't they use the original sample? " 
The trial-related biopsies were extremely difficult. Rabinovitch ends her account with an image of a 
trial participant whose involvement in research is far from participatory. 
When the three test tubes have been placed in a refrigerated box, I sign the trialpapers, have a 
further mammogram and crumple to thefloor. The nurse brings lea, and the information that Dr K 
will be along. But I stand up and leave the hospital. Itfeels like thefirst bit ofcontrol I take over 
this illness, an iota ofdefiance against these passages of initiation into the Amazons. I don't, you 
see, want to be this brave. 
Rabinovitch, 2004 
Box 2. A participant's account 
Aims of this research 
The conduct of RCTs is very clearly a challenging area of medicine. Some inherent 
challenges, such as disentangling paternalism from consent processes, have emerged 
as clinical research, like many other aspects of 20'h and 21" century medicine, has 
undergone dramatic changes. Other challenges, such as the impulse of clinicians to 
influence or to circumvent allocation, and selective forms of recruitment (Britton et al 
1999) were clear from the first use of randornisation and have persisted over time 
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(Oakley 1982, Klein 1995, Shultz 1995a). It is evident that there is a tension between 
the drive to provide sound evidence within an ethical framework, and the impulse to 
realign the research situation with the more familiar terms of provision of care. It is 
likely that this tension permeates thinking about research and care in more varied and 
more subtle ways, for both professional collaborators and patient participants. 
It is this tension, a pull between the drive to find a solution to a clinical problem, and 
to find a solution for individual patients, which provides both the backdrop for this 
research and the impetus for the main line of inquiry and for the selection of material 
for this thesis. It is my contention that all parties involved in discussion of the 
possibility of joining a trial are subject to this tension, and that it will impact upon 
their attitudes and experiences in a number of more, and less, obvious ways. One aim 
of the study is to gain an understanding of the relevance of this tension to the nature of 
the decisions that professionals and parents make about trial collaboration, 
participation and non-participation, to understand their priorities and the forces that 
shape and drive their choices. This is done not through a direct series of pre-defined 
questions but by examining the ways that people talk about, in this instance, neonatal 
trials and the decisions they make, in relation to the context of care and research. 
Analysis of their perceptions of trials and the terms and conditions that trials create 
can help to tease out the ways in which some of the complexities and subtleties of the 
transformed care/research setting are perceived, and will shed light upon the inherent 
tensions at the heart of many of their experiences. A second aim extends the focus 
from the decision-making process for enrolment in a neonatal trial to consideration of 
decisions around trial-related post mortem studies, with discussion of how this relates 
to earlier choices about involvement in a trial 
Although attitudinal. literature is available, it is my view that at present there is no 
research which adequately explores the experiential element of both collaborators and 
participants/non-participants, treating them as dyadic contributors to a complicated 
process, and giving equal weight to understanding the ways in which they affect and 
are affected by the trials process. 
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Outline of this thesis 
This thesis reports an in-depth exploration of the views of neonatologists and parents 
associated with one or both of two neonatal trials. It is organised to illuminate some 
of the ways in which tensions are raised, resolved or remain irresolute. Chapter 2 
presents the background to the study, briefly describing the history of the RCT as a 
scientific method and the early emergence of some of the areas of difficulty which 
persist today. More recent theories on the ethical value of trials, and some 
implications and consequences of their use are also described, along with some of the 
relevant empirical literature regarding aspects of trial collaboration and participation. 
The rationale for a focus on neonatal trials is put forward in this chapter. Chapter 3 
draws upon some of the empirical work which is already available in this setting and 
charts the rise of qualitative research in relation to trials. Chapter 4 introduces the 
study itself in terms of the research history, the design of the study (including a 
critique of the methods often used in the existing literature), and implementation 
(recruitment, data collection and analysis). The results of the study are presented in 
Chapters 5 to 9. The data reported in these chapters are organised to highlight 
comparisons between the accounts of neonatologists (Chapters 5 and 6) and parents 
(Chapters 7 and 8), and across two time points in the course of involvement in a trial; 
the point of initial decision-making about involvement in a trial and a later point of 
decision-making about involvement in trial-related post mortern studies (Chapters 
5/6/7/8 and 9). The results and the broader implications of the study are discussed in 
Chapter 10 along with recommendations for future research. 
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Chapter 2 -Tension in RCTs Past and Present 
Although the Theory of Broad Benefit is the dominant trials-related paradigm, the 
Theory of Limited Benefit is a strong counter-current in the debate. An examination 
of the history of the use of the RCT indicates that this has been so from almost the 
inception of clinical trials. The tension between the two was made evident in the early 
trials which were met with suspicion and resistance. This tension has been sustained 
over time and continues to shape theoretical dialogue as well as discussions on the 
legitimacy and ethical basis of individual trials, and the appropriateness of trials for 
individual patients. This chapter focuses on this theme of tension, describing its early 
emergence and its development into more recent debates on equipoise and the use of 
randomisation. 
Part I- Early signs of tension: Austin Bradford Hill and the 
RCT 
Bradford Hill was a key figure in stimulating intellectual and methodological change 
and was instrumental in shaping the progress of medical research. Silverman and 
Chalmers quote newspaper descriptions of Bradford Hill as a "relentless statistician" 
and as having "perhaps the most remarkable career in medicine this century" 
(Silverman & Chalmers 1992). Doll saw him as having "more influence on the past 
50 years of medical science than many winners of the Nobel prize for medicine" and 
describes how he urged researchers always to consider carefully the "the fundamental 
question" of cause and effect: "is there any other way of explaining the set of facts 
before us; is there any other answer equally, or more, likely than cause and 
effect? "(Hill 1966 cited in Doll 1992) 
In the early 20'h century great strides were made in the development of experimental 
methods (see Silverman 1980, Pocock 1985 for reviews). Pocock highlights key 
stages in this process. An early trial was published in 1898 by Fibiger involving 
alternate assignment of patients to experimental and control groups. In 1927 Ferguson 
and colleagues reported a vaccine study involving single blind methods whereby 
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patients were unaware of the administration of active drugs or placebo. He describes 
a trial in 1941, published by Abraham and colleagues, which demonstrated the 
effectiveness of penicillin on war wound infections. This trial raised important issues 
for the surgeons involved. Concern about those with severe wounds inhibited surgeons 
from withholding potentially beneficial penicillin. This biased the trial as the 
experimental group included a disproportionate number of seriously ill patients. 
Penicillin had such a dramatic effect, however, that bias was of less importance in this 
particular setting. A drug with more subtle effects may have appeared ineffective 
because of higher mortality rates in the experimental arm of the trial. 
The possibility of biased selection (whether purposeful or unconscious), can clearly 
confound trial results. This led Bradford Hill to recommend the use of chance in the 
selection of experimental and control groups (Hill 1990). Like Fibiger he suggested 
allocation of groups on an alternate basis - one patient allocated to the experimental 
group, the next to the control group. By removing physician and patient preferences, 
potentially confounding factors would be equally distributed by chance across the 
treatment groups. The system was however flawed as it depended wholly upon the 
co-operation of those involved with delivery of care. Far from removing clinician 
preferences, those who were aware of the sequence of allocation were able to gain 
direct control of assignment for individual patients (Hill 1990, Doll 1992). 
Bradford Hill went on to suggest that the solution to bias was to use randomisation, a 
strict system of allocation based only upon chance. Again this was not a completely 
new concept (Hill 1990, Clarke 1996). Silverman describes how randomisation had 
been used by Fisher in the mid-1920s for agricultural experiments (Silverman 1980). 
Aware that doctors may find this prospect difficult, he was careful to phrase his 
references to randomisation in his 1937 series of articles in The Lancet in neutral 
terms. 
I deliberately left out the words "randomisatiorP and "random 
sampling numbers"... because I was trying to persuade doctors to come into controlled trials in the very simplest form and I might have scared 
them off. I think the concept of randomisation ... [is] slightly odd to the layman, or for that matter, to the lay doctor (Hill 1990). 
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He later described how unique circumstances in post-war Britain were fundamental to 
surmounting this obstacle (Hill 1963,1990), allowing him to establish a trial of 
treatment for pulmonary tuberculosis. Streptomycin had produced promising results 
in animal experimentation but the supply was limited. Once the majority of the 
supply had been distributed for priority treatment of the forms of tuberculosis which 
were usually fatal, the remainder was sufficient to treat a limited number of patients. 
Bradford Hill's argument that this supply would be best used in a rigorous clinical trial 
in which treatment was allocated randomly was accepted by the MRC. He suspected 
that with a larger supply the MRC would, like the surgeons in the penicillin trial, have 
struggled with the concept of withholding a potentially beneficial treatment from half 
of the patients. 
The streptomycin trial used sealed envelopes containing randomly ordered selections 
from tables of random numbers. The standard treatment for tuberculosis was bed-rest 
to which 52 patients were assigned, whilst 55 received injections of streptomycin. The 
results were clear, with 38 surviving to 6 months in the control group compared to 51 
in the experimental group (Streptomycin in Tuberculosis Trials Committee 1948). The 
success of this experiment was a major step in the development of clinical research 
methods. Although it was "neither the first to be randomised, nor the first to be 
controlled" (Clarke 1996), the streptomycin trial has gained a reputation as an 
important milestone in the history of the RCT. Chalmers argues that its landmark 
status does not only relate to the use of randomisation, but because "clearly defined 
precautions ... were taken to conceal the allocation schedule from those involved in 
entering patients" (Chalmers 2001). 
Part 11 - Tension in modern debates on the use of RCTs 
Clinician discomfort and Bradford Hill's caution over the inflammatory potential of 
randomisation, are rooted in different perceptions of the compatibility of scientific 
inquiry and therapeutic obligations. These differences have been held in tension 
through a debate which has continued for more than fifty years. It is a central theme 
33 
in this thesis. It drives discussion of the appropriateness of the use of the RCT method 
in two broad areas: 
The existence of uncertainty as the scientific and ethical basis for a trial 
The ethical rationale for the use of randomisation 
Uncertainty as the basis of the RCT - the concept of 
equipoise 
The point at which it is considered that there is insufficient evidence to clearly state 
the superiority or inferiority of an intervention, is termed equipoise (Fried 1974). 
Essentially given the prevailing state of knowledge, the likely risks and benefits of an 
intervention are equally balanced, and there are "no convincing grounds for supposing 
that any patient would be advantaged or disadvantaged if allocated to one treatment 
arm rather than another" (Robinson et al 2005). The Theory of Broad Benefit is 
fundamentally and explicitly dependent upon the existence of equipoise. 
A central difficulty however lies in the fact that equipoise is a subjective and variable 
concept, rather than a constant and easily definable condition (Little 2003). If the 
underlying principle of a trial is shifting, so too is the ethical foundation for that 
research. Those contributing to the theoretical literature attempt to pin down the 
conditions of equipoise; discussions focus on exactly who is in equipoise and under 
what conditions it exists. 
On whose opinion does equipoise rest? 
Whilst a trial may be initiated after trialists agree that equipoise exists, individual 
clinicians may carry personal convictions based upon experience, a hunch or existing 
data (Schafer 1982). This is not surprising as trials are carried out as there is some 
evidence that that an intervention is promising 7 and it has been asked, "are decisions 
ever so finely balanced that a situation of personal equipoise may exist? " (Edwards et 
al, 1998). If an individual feels that a patients would benefit from a particular 
7 Trials can also be carried out to assess the effects of unevaluated standard treatments driven by 
concern over the use of intervention. 
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treatment, whatever the basis of that view, they are not personally in a state of 
equipoise. Zajicek states that offering the possibility of a treatment the physician 
feels 
is inferior breaches the guiding clinical principle of non-maleficence (do no harm) 
(Zajicek, 1995). Chard and Lilford suggest that clinicians with treatment preferences 
are obliged to make these clear to patients (Chard & Lilford 1998) and Bradford Hill 
argues that whatever the implications for a trial, the clinician with a treatment 
preference is obliged to give that treatment should it be available (Hill, 1963). 
Freedman (1987) addresses this difficulty and suggests that a focus on personal beliefs 
is inappropriate and individual equipoise is a flawed concept, a "fragile" state, liable 
to change over time. He argues that "clinical equipoise" (now more commonly 
referred to as "collective equipoise" (after Johnson et al 199 1), the uncertainty of the 
broader medical profession), is a more appropriate prerequisite to recruitment of trial 
participants. Here a clinician with a preference may recruit patients to a trial of an 
intervention for which there is no consensus in the medical community, without 
violating an ethical principle. 
The concept of collective equipoise has had a mixed reception. This may in part be 
due to differences in emphasis with some theorists focusing on uncertainty over 
efficacy (a treatment-centred approach), and some on uncertainty over the 
physiological and preferential needs of individual patients (a patient-centred 
approach). In an argument which includes preferences alongside safety and efficacy 
Kodish and colleagues argue that physicians are trained to rely on rather than suspend 
their professional judgement, and that RCT recruitment is only ethical if a physician 
"cannot judge which arm of a protocol is preferable for a particular patient". They 
view randomisation as inappropriate "when patient preferences for one treatment or 
another can be elicited" (Kodish et al 1991). Hellman and Hellman see the collective 
view of the medical profession as irrelevant, arguing that patients have a right to the 
opinion of their clinician (Hellman & Hellman, 1991). 
Where the shift of focus from the personal to the collective is accepted, there can still 
be differences within the medical collective as to whether or not the profession is 
collectively in equipoise. Concern has been expressed that trials have been carried out 
despite sufficient evidence from earlier research to indicate the superiority of a 
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treatment, rendering the withholding of treatment from the control groups of patients 
indefensible (Starzl 1985; Berry 1989). Empirical research focusing on a sample of 
industry-sponsored trials suggested that the principle of equipoise was being 
("systematically violated" (Fries & Krishnan 2004). 
A definition of the level of uncertainty required to establish conditions of equipoise 
has been proposed by Johnson and colleagues (1991). Their study of potential trial 
participants indicated that a trial was viewed as unethical by 50% of their sample once 
70% of experts had a treatment preference. When 80% of experts had a preference, 
only 3% per cent saw a trial as ethical. The authors suggest "zones of indifference" 
around a 50: 50 split in opinion. Attempts have also been made to establish 
prospectively whether collective equipoise exists before a trial goes ahead (Lilford 
1994; Solomon & McLeod 1995; Young at al 2004). 
Miller et al (2000) suggested an additional "dimension7to equipoise; "community 
equipoise" would include the views of patients along with those of the medical 
collective. The possibility of patient equipoise is rarely addressed, and the term 
"community equipoise" is often taken to by synonymous with "collective 
equipoise", thus obscuring the potential role of the patient as party to the debate. 
This is in spite of the fact that public perceptions of the efficacy of an intervention 
can exert a powerful influence on trial recruitment. When media reports convinced 
patients of the superiority of laparoscopic removal of the gallbladder, two trials 
(Barkun et al 1992, Kunz et al 1992) were hampered by poor recruitment (Lefering 
and Neugebauer 1997). Lilford (2003) gives an example of how patient 
preferences could relate to decisions about participation in a prostate cancer trial. 
If the prior probability that radical treatment would improve mortality from 
prostate cancer was 5 percentage points, then a man who was particularly 
apprehensive about side effects (for example, a newly married man who wanted 
to have a child) might be better off with conservative treatment, whereas another 
(one, perhaps, who no longer placed a high premium on his sex life) might gain 
most from radical surgery. However, the losses and gains might balance for yet 
another man, both treatments having equal expected utilities, and such a person 
can accept randomisation without loss - he is equipoised. 
Although the concept of patient equipoise is useful, especially as patients are 
increasingly seen as consumers with a role in shaping the research agenda (Hanley et 
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al, 2001; Marsden et al 2004; Oliver et al 2004), when patient equipoise is addressed, 
it is largely in terms of preference (e. g. emotional responses or lifestyle factors) rather 
than through a patient-led assessment of evidence of risks, benefits and efficacy. 
Caution is added to this debate by Little who argues that an emphasis on patient 
equipoise could be problematic: 
Patient involvement in decision-making is desirable, but to shift the 
responsibility for equipoise to the most vulnerable person in the medical 
transaction is to make unfair demands on those who wish for advice and guided 
decision-making (Little 2003). 
When does equipoise exist? 
Even where there is consensus that equipoise is sufficiently clear to legitimate a trial, 
difficulties can arise over time (Schafer 1982). Results from other trials can bring 
about reappraisal of the scientific and ethical basis of a trial. The Canadian Atrial 
Fibrillation Anticoagulation (CAFA) study closed after its data monitoring committee 
considered the results of two other trials which reported during the recruitment period 
(Laupacis et al 1991). The evidence can also, and possibly more influentially, grow 
within a trial. As more patients are randomised, data accumulate. Where clinicians are 
responsible for the delivery of trial interventions, they grow in practical experience 
and can develop opinions about efficacy, especially where they witness how an 
intervention succeeds or fails (Hellman 1979). 
Data monitoring committees make periodic assessments of trial data to detect any 
early shift in the balance of evidence. While it is generally agreed that trials should 
continue until there are sufficient data to answer the research question posed (Grant el 
al 2005). It can however be the case that before a statistically significant difference 
between groups is achieved, a trend may emerge in one direction. Lantos argues that 
this raises difficulties and that clinicians should have access to interim data in order to 
make better choices for their patients. 
The self-imposed ignorance that trials require, between the time when 
we deten-nine equipoise and the time when our statisticians confirm or 
negate the null hypothesis, creates unsolvable ethical problems. No 
patient-centred moral principles justify denying clinicians or patients 
knowledge of interim results to complete a trial. ... Who wants to be the 
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last patient randomized, the one who, by failing treatment, allows the P 
value to move from 0.06 to 0.05? The answer, obviously, is nobody 
(Lantos, 1994). 
Interim data can, however, be misleading. Treatment for a sequence of patients late in 
a trial may succeed, redirecting an apparent negative trend (or vice versa). For this 
reason interim results are usually released only to an independent data monitoring 
committee. Whilst this provides clear boundaries around the data, it does not address 
the individual difficulties which may be experienced by clinicians whose equipoise is 
disturbed during a trial (Hellman & Hellman 199 1). 
Debates about equipoise have recently resurfaced (Weijer et al, 2000; Shapiro 2000; 
Lilford 2001; Little 2003; Miller & Brody 2003) with attempts to clarify meaning and 
some calls for the word to be avoided because of its lack of clarity. Sackett (2000), 
who describes it as "a term whose time (if it ever came) has surely gone", states that 
for the term to be meaningful it should be used consistently, it should "describe 
something that's real" and it should be useful: "it must be frequently employed to aid 
andjustify decisions. " He argues that equipoise fails to meet all three requirements. 
Empirical evidence 
Empirical research on clinicians' views of equipoise is rather limited; work on 
patients' views is even more restricted. The available studies suggest that discomfort 
with discussion of uncertainty can complicate the experience of trial recruitment. 
Benson and colleagues found that 55% of oncologists felt that "discussions 
concerning which treatment is the right one" are uncomfortable (Benson et al, 199 1). 
Dislike of open discussion of uncertainty was an obstacle to trial entry for 23% of a 
sample of principal investigators in breast cancer trials (Taylor et al 1984). 
Discomfort was anticipated by 58% of clinicians involved in recruitment to a substudy 
of the Collaborative Ocular Melanoma Study (COMS), which compared radiation 
therapy to removal of the eye (Taylor 1992). One opthalmologist described the 
discussions as "hard for both my patient and me". Concerns about expressing 
uncertainty were shown to have contributed to discontinuation of a trial examining 
treatment of isolated systolic hypertension in elderly people where there was a large 
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discrepancy between those who had agreed to make referrals (N=806) and those who 
actually did so (N=63) (Tognoni et al 1991). 
In contrast some authors have identified willingness to collaborate in RCTs regardless 
of uncertainty. One study showed that 53% of doctors who preferred tarnoxifen for 
their breast cancer patients would still recruit to a trial comparing tamoxifen with 
placebo (Alderson et al 1994). Another measured levels of equipoise amongst 
vascular surgeons for several clinical scenarios. For two scenarios almost all surgeons 
had a treatment preference (9 1% and 94%). Although this appears to indicate that 
collective equipoise did not exist for these scenarios and so trials would not be 
justified, 36% and 5 1% of the surgeons still indicated that they would be prepared to 
recruit their patients to trials in these same situations (Young et al 2004). 
These studies suggest that some clinicians' view of equipoise may differ in practice 
from the way it is presented in the theoretical literature, in sharp contrast to the only 
study identified which explicitly seeks to address patient equipoise. Mills and 
colleagues interviewed men with localised prostate cancer who had consented or 
declined to participate in the ProtecT trial. It was shown that the concept of equipoise 
was recalled and understood by the majority. Decisions about whether or not to 
participate directly related to whether or not they found the position of equipoise to be 
acceptable. The authors comment that "belief in clinical equipoise was key to 
participants' consent to randomization" (Mills et al 2003). 
Equipoise as the ethical rationale for randomisation 
Equipoise and randomisation are inextricably linked. As randomisation is legitimated 
by the existence of equipoise, a fluid and for some an inflammatory concept, it is not 
surprising that it provokes mixed responses. According to the Theory of Broad 
Benefit, randomisation ensures equitable distribution of possible risks and benefits of 
an intervention, and offers a means of decision-making in the absence of clear clinical 
evidence. Given the possibility of exposure to unknown hazards, it has been suggested 
that for new interventions the ethical approach is to randomise from the very first 
patient (Chalmers 1977; Spodick 1983). There is, however, evidence of much 
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discomfort over randomisation particularly for trials of potentially life-saving or life- 
changing interventions. To seek consent a clinician must give information which may 
be both technically and emotionally difficult for their patients, a process which has 
been seen as involving "overwhelming difficulty" for caregivers and is "needlessly 
cruel" for patients (Tobias and Souhami 1993). In such trials the impact of an 
intervention is demonstrated when more patients in one arm die or have poorer health 
outcomes than those in another arm. The idea that health and survival may depend 
upon chance raises almost instinctive objections. Echoing concerns expressed over 
the streptomycin trial, it has been suggested that individual patients are sacrificed for 
the greater good (Thomton 1993; Yao & Wei 1996). 
Randomisation as an indication of equipoise: a marker for the 
distinction between care and research 
The links between equipoise and randomisation are two-way. As randomisation is 
initiated by a position of equipoise, it stands as an indicator that uncertainty exists. It 
is such a clear and in some ways a startling deviation from the usual approaches to 
clinical decision-making, that it should act as a beacon at the intersection of care and 
research. Empirical studies have however repeatedly shown that there are major 
difficulties for potential and actual trial participants in appreciating the random nature 
of a 'treatment' decision, and the departures from standard approaches to care. The 
extent to which randomisation and the rationale behind its use are clear to potential 
and actual participants has been addressed by a number of researchers. 
Important data on perceptions of randomisation were first reported in a series of 
highly influential research studies which examined the decision to join a psychiatric 
trial and understanding of the implications of that decision (Appelbaum et al. 1982; 
Benson et al 1985; Appelbaum et al 1987). They suggest that in their study "vacuums 
of knowledge" about trial aims and methods could lead directly to assumptions that 
care had been tailored to suit individual needs (Appelbaum et al, 1987). This is one 
aspect of what is referred to as "the therapeutic misconception"8. In some cases 
' Taking part in research with the erroneous perception that there are no risks, or in anticipation of 
particular benefits which might be unrealistic, is another manifestation of therapeutic misconception 
(Appelbaum et al 1982). 
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participants in these studies created elaborate arguments to support the therapeutic 
misconception, distorting small aspects of the study design. 
To illustrate the phenomenon a number of case studies are described (Appelbaum et al 
1982). One participant in a trial comparing treatments for borderline personality 
disorders was able to give a clear description of the purpose and method of the trial, 
the use of placebo and was able to define randomisation, but when asked how the 
choice in her own case would have been made, she commented: I hope it isiYt by 
chance". 
There is other evidence that patients in a wide variety of settings have similar 
difficulties (Lidz et al 2004). Whilst myocardial infarction survivors participating in a 
double-blind placebo-controlled trial were well informed about various aspects of the 
trial, randomisation was less well understood with only 42% indicating awareness of 
the role of chance in allocation of treatment (Howard et al 198 1). Very similar finding 
have been recently reported amongst parents who were "highly knowledgeable of the 
main research components" of a paediatric trial of treatment for autism. Although 
99% were aware of possible risks and benefits of the trial, and 99% knew that their 
child may be assigned placebo, 27% felt that the 'treatment' that they were given was 
"based on individual needs to ensure best care" (Vitiello et al 2005). 
Interview-based studies have identified the same phenomenon. Wynne found that 
some participants who were receiving hyperbaric oxygen in a trial of therapy for 
multiple sclerosis felt that they were enrolled because hyperbaric oxygen was selected 
by their clinician as the best treatment for them (Wynne 1989). Featherstone and 
Donovan found that most of their saniple of men who participated in a trial of 
treatments for benign prostatic disease were able to recall and describe the role of 
chance in randomisation, but "developed alternative lay explanations to make sense of 
their experiences" (Featherstone & Donovan 1998). Very similar reactions to 
randomisation were reported by Gammelgard and colleagues (2004) from a qualitative 
study of Danish patients' decisions about trial participation in the context of acute 
myocardial infarction. 
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Research has also assessed the ability to understand the concept of randomisation 
outside the context of a medical encounter (Kerr et al 2004). Study participants who 
were given a variety of descriptions of random processes largely recognised a random 
element. The authors found that their participants often found randomisation to be 
acceptable only if their descriptions included a reasonable justification for its use. 
These studies consistently indicate that even with facts to hand about the trial 
situation, randomisation can be difficult to understand. This does not appear to relate 
to an inability to understand the nature of randomisation, but to difficulties in applying 
decisions based on chance to clinical care. This however is precisely the problem; 
decisions based on chance are inappropriately realigned with expectations of care. 
Without an appreciation of the rationale for its use and the difference between care 
and research, randomisation can be a puzzling and problematic concept. 
Part III - The special case of neonatal RCTs and associated 
pathology studies 
The ethical issues and underlying tensions which are raised above are relevant to all 
trials. In considering trials which are conducted in neonatal intensive care, many of 
these issues are magnified9. Trials conducted in this sub-specialty of neonatology are 
often potentially life-saving therapies; they can involve discussions of the implications 
of trial participation with stressed individuals, and the difficult circumstances involved 
can potentially impede appreciation and understanding of complicated information 
about research. These issues are all further complicated by the fact that those 
considering trial participation do so on behalf of another, vulnerable and legally 
incompetent individual. The fact that the proxies charged with this responsibility are 
themselves in a vulnerable position only serves to further problematise a complicated 
situation. 
' Although neonatal trials are often discussed in broad terms, not all neonatal trials involve intensive 
care and not all intensive care issues are issues about survival. Neonatal trials are in fact extremely 
diverse, ranging from assessment of routine everyday issues (feeding, drug dosage studies) to cutting- 
edge potentially life-saving therapies. Those enrolled in neonatal trials may be similarly diverse in 
terms of their health status, ranging from extremely premature, very low birthweight babies to fully 
mature term babies. Trial interventions may be initiated at different points post-delivery, some 
involving no time pressures whilst others involve emergency situations. 
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Trials in this setting are worthy candidates for study simply because it is important to 
understand the workings and implications of this situation. They are also instructive 
as they involve particularly difficult challenges. If the thorny issues at the centre of 
difficult trials can be addressed, it might be possible to then deal with trials in more 
simple situations. For this reason this thesis explores decision-making for clinicians 
and parents in neonatal trials in critical settings. 
Neonatal trials in critical settings 
The decision-making process for neonatal trials in critical settings involves stressed 
parents who fear for the safety of their newborn, who are asked to make an important 
decision at a difficult time. For trials where an intervention must be carried out or 
initiated shortly after birth, a decision about participation may be sought during or 
immediately after delivery. Manning defines consent for trials requiring decisions in 
less than 24 hours as "emergency consent" (Manning 2000). Neonatal trials can 
involve shorter time periods. If it is necessary to transfer a baby to another hospital for 
specialist care, the mother and baby may be separated when trial enrolment is offered. 
Fathers who accompany their baby can be asked to make a decision without their 
partner being present, as can women who are inpatients and alone when approached 
for an urgent decision. Where interventions takes place at a later stage, parents can be 
in the highly stressful position of watching their critically ill baby being cared for in a 
neonatal intensive care unit (NICU) (Miles et al 199 1; Shields-Poe & Pinelli 1997; 
Dudek-Shriber 2004) at the point of decision-making. For some decisions about a trial 
can be requested shortly after having their baby christened, named or blessed on a 
NICU, a clear indication of the seriousness of their situation (Snowdon et al 1997). 
Manning points to "severe impediments to autonomy experienced by parents of sick 
neonates", expressing concern that it is unlikely that achievement of the standards 
required for informed consent or refusal will be met (Manning, 2000). It has been 
argued that "informed consent from poorly educated parents entering a complex trial 
in stressful conditions is a sharn"(Anon 1995) and "an elaborate ritual" (Mason 1997). 
Levene and colleagues suggest that the more extreme the circumstances, the more 
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likely parents are to consent (Levene et al 1996); there is some empirical support for 
this. A review of 249 RCTs published in a paediatricjournal over a 15 year period, 
showed that I 11 trials reported a consent rate of 100% with trials in neonatal care the 
most likely (96% of the neonatal trials) to report total acceptance (Campbell et al 
1998). In a study involving parents of newborns, almost one third agreed to their 
baby's inclusion in a hypothetical trial scenario involving a moderate risk to their baby 
but no direct benefit, with the parents of NICU babies being significantly more likely 
to agree than other patents (Singhal et al 2002). This is in sharp contrast to the 
situation discussed in Chapter 1, wherein concerns are raised at how few trial-eligible 
adult patients agree to participate in a trial. 
Professional responses to collaboration with neonatal RCTs 
Neonatologists have written about their concerns over the position of vulnerable 
parents who are asked to consider enrolment of their baby into a trial. WaltersPiel 
expressed concern over the lack of autonomy and engagement that he felt was shown 
by some of the parents of babies in his care. He described parents' reactions when he 
sought consent for a simple trial of heat shields. He felt that information about the 
shields "was acknowledged like a message from a distant planet". He was never 
refused but felt concern about the encounters and the quality of consent (Walterspiel 
1990). McIntosh argued that in his experience stressed parents are quite suggestible. 
He stated that parents of babies in neonatal care will give consent for doctors "to do 
almost anything to their baby" and sees giving difficult information at such an 
emotional time to anguished parents as inappropriate (McIntosh 1993). 
Although the views of professionals associated with trials in other specialties have 
been the focus of many empirical studies, the views of neonatologists have rarely been 
assessed. One exception is a study by Mason and colleagues in which the views of 107 
European neonatologists were compared to those of 200 parents who had accepted or 
declined enrolment in one of several neonatal trials. The majority of neonatologists 
(74%) expressed concern about parental competency and almost half felt that it was 
inappropriate for parents to "know certain information". The authors report that: 
44 
Some doctors reported limiting disclosure about risks so as not to worry parents or 
to obtain consent, and ... they often simplified information (with the stated aim of 
providing the most appropriate information to parents) (Mason et al 2000). 
This difficulty with discussions around trial enrolment suggests that such research in 
this setting may involve a major clash of duties for the clinicians who act as trial 
collaborators and adds to the case for the need for further research in this area. 
Parental views on participation in neonatal RCTs 
Several research studies (mainly questionnaire-based) have focused on a number of 
areas associated with parental decision-making for neonatal trials. They are: 
" The impact of stress 
" Standards of consent 
" Factors affecting decision-making 
" Parental preferences for making a decision 
Stress 
Two studies indicated that the majority of parents did not feel that they were made 
anxious by the consent process. Although 38% of the parents surveyed by Burgess and 
colleagues and 24% of those surveyed by Stenson and colleagues felt that recruitment 
had added to their stress, most (59%) in the former study stated that they were calm 
when they made their decision. The majority of the parents in the latter study were 
happy with their decision to consent (79%) (Burgess et al 2003; Stenson et al 2004). 
Factors affecting decision-making 
The specific reasons for deciding to enrol or not to enrol a baby in a trial have rarely 
been addressed. When parents in the study by Mason and colleagues were asked why 
they had chosen to enrol their baby into a trial, 64% thought that their baby would 
benefit, 49% that babies would benefit in the future, and 39% saw no risk or distress 
to their child. The authors give no figures for the decisions that parents made not to 
enrol their baby, but they list as factors: risk, distress to the baby, distrust as well as 
"dislike of the tone of approach of the doctor", their own state of shock, and 
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inconvenience of follow-up (Mason et al. 2000). Burgess and colleagues also identified 
benefit to the baby as the primary reason for agreeing to trial enrolment (Burgess et al 
2003). Using scaled ratings Zupancic and colleagues found that parental consent for 
their baby to participate in one of three neonatal trials was associated with higher 
perception of benefit and lower perception of risk (Zupancie et. al 1997). In a study 
which included the views of parents who made decisions about enrolment in a range 
of neonatal cardiac surgery trials, five broad reasons emerged, relating to the 
possibility of societal benefit, personal benefit, risk or no risk, and to the parents' anti- 
experimentation beliefs (Hoehn et al 2005). 
Parental preferences for making a decision 
Several authors have discussed whether the standard approach to consent for certain 
neonatal trials is appropriate (Allmark 1999; Manning 2000). Three studies have 
clearly shown that parents do not wish to relinquish their role in the consent process. 
Stenson and colleagues (2004) found that 83% would not wish to pass over control of 
decisions about participation to an ethics committee and 93% and 98% in two other 
studies rejected the suggestion that doctors rather than parents should decide whether 
or not a baby is enrolled into a neonatal RCT (Burgess et al 2003; Morley et al 
2005). 10 
These studies questioned parents on the relatively straightforward issue of whether or 
not it would be appropriate for the decision about participation to be passed over to 
another responsible party. Research carried out with parents who had experienced 
standard consent procedures for an emergency neonatal trial were asked about a 
methodologically more complicated approach to decision-making (Snowdon et al 
1998). One of Zelen's suggestions for trials for which the decision-making process 
might be problematic is to randomise trial-eligible individuals prior without making 
an initial approach to discuss the trial. Those who are allocated to an experimental 
arm of a trial are approached and asked whether they wish to accept the trial and the 
allocation. Those randomised to the control arm, (which in this model must involve 
10 A fourth study also demonstrated a smaller majority of parents wishing to be involved in the decision 
about recruitment, with 32% wanting a neonatologist to "advise" them about enrolment of their baby into a trial, but ambiguous phrasing makes interpretation of this finding difficult (Zupancic et al 1997). 
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no changes to their situation, for instance allocation to an arm dictating initiation 
of/continuation with standard care) are not approached. Parents were given a set 
explanation and asked to consider their views had this approach been used in their 
case. They were evenly divided in accepting or rejecting this method of recruitment. 
Crucially however those rejecting this method were more likely to be parents of 
control group babies (in the original trial) suggesting that it is unacceptable to many of 
those that it is actually designed to protect. 
The differences in the proportions of parents who were drawn to the idea of passing 
over responsibility for consent was much higher in this latter study than in the three 
quoted earlier. This may relate to the particular approach suggested by Zelen but it 
may also be a function of method. As the parents spent time discussing the issue of 
consent in the context of their experience a greater level of engagement with the 
subtleties of the ethical issues involved may have been promoted than would be the 
case for a questionnaire-based study with a box to tick or a scale to rate. 
Standards of consent 
In the study by Mason and colleagues, a particular aim was to compare the accounts of 
the parents to agreed standards for consent. They found that in 70% of cases there 
were some difficulties with the standard of consent and 40% of the parents were 
judged not to have been competent to consent. Parents were more likely to be judged 
to have had difficulties with the standard of consent if their baby was offered 
enrolment in research which was urgent rather than non-urgent. Almost half of the 
sample (47%) did not rely upon written material about a trial but only on the oral 
information given by a doctor. In the majority of cases parents felt that they had made 
their decision voluntarily (74%) (Mason et al 2000). 
Ballard and colleagues judged that 68% of their sample of parents of babies enrolled 
in a neonatal analgesia trial understood the purpose of the trial. Although 95% could 
describe benefits, only 5% of the parents could describe risks (Ballard et al 2004). 
Singhal and colleagues judged that there were difficulties with the quality of consent 
given by 70% of the parents in their sample. The difficulties associated with 
processing and retaining complicated and potentially disturbing information about 
47 
trial participation in this highly emotional setting have also been assessed by the 
authors of all of the papers described above and it is clear that parents do often 
experience difficulties in understanding and recalling details of the neonatal trials for 
which they have given consent. Whether sufficient information was given but not 
taken on board, or never given in the first place, cannot be said. 
A further study which explored parental understanding of randomisation in a neonatal 
trial indicated, like the studies involving adult trial participants (Featherstone & 
Donovan 1998; 2002; Gammelgard 2004), that randomisation and the basis of the trial 
could be unclear for many (Snowdon et al 1997). This paper is considered in further 
detail in the Chapter 4. 
Views of neonatal trial pathology studies 
For some of those who choose to enrol their baby in a neonatal trial, there can be 
another potentially difficult trial-related decision-making process ahead which has 
received very little attention. For trials which involve conditions for which a 
substantial mortality rate is likely, a post mortern pathology study can be included as 
part of the trial design. Such studies assess the possible impact an intervention has 
had on those who have died, and if they are not carried out, potentially serious 
consequences of an experimental treatment could go undetected. Where babies who 
have been enrolled in a trial do go on to die, parents can therefore be asked to make a 
decision about the possibility of a trial-related post mortern (PM). This can be a 
complicating element in an already difficult situation. A degree of altruism is required 
of parents who are in the most stressful of circumstances, and benefits to research may 
not seem important at that time. As consent rates for perinatal PMs are declining 
worldwide (RCP 1991; Sanner 1994; Wlodaver 1994; McPhee 1996; Chariot et al 
2000; Loughrey et al 2000) it does seem that the majority of parents are either not 
being approached for permission or are declining to consent. Pathology studies with 
inadequate numbers are unreliable and so this decline clearly has important 
consequences for the quality and integrity of data. 
In attempts to improve PM rates generally there has been much interest in charting 
knowledge of, and reactions to, PMs outside of the perinatal context. Little attitudinal 
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research has been carried out in the neonatal context and none with particular 
reference to neonatal trials. Since trial participation can alter the reasons for which 
consent is sought, and could significantly alter the experiences of those involved, this 
is an important omission. There are however elements of the existing empirical 
literature in the perinatal and paediatric field which can shed some light on the 
complexity of professional and parental determinants of PM rates. 
Professional views regarding perinatal post mortems 
The literature on professional views is useful in highlighting attitudes to the use of 
PMs in different clinical circumstances, and for different groups of professionals. 
Van Marter and colleagues (19 8 7) report a records-based review supplemented by a 
questionnaire-based study. In the review they found an important association between 
rates of PM and presumed cause of death, with extremely premature babies being least 
likely, and those affected by a congenital anomaly being most likely to undergo PM. 
They also found that giving permission for a PM was associated with repeated 
perinatal loss. Both findings seem to suggest that a parental wish for an explanation 
of events is important. It is, however, unclear from a review of records whether actual 
parental views, or professional perceptions of those views, are the most influential in 
this matter. In the questionnaire-based element of the study, only professional views 
were sought. PMs were seen as more important by senior staff than by junior staff. In 
general the sample saw the importance of the PM as being strongly related to the 
likely cause of death; whilst only 31% felt that they were very important in cases of 
extreme prematurity, when the cause of death was thought to be a congenital anomaly 
or was indeterminate 94% and 91% respectively felt that they were very important. 
The views of paediatricians and paediatric residents were surveyed by Stolman and 
colleagues (1994). Although the majority felt PMs provide valuable information, 20% 
felt that they are unnecessary if the disease was known before death. Where consent is 
not sought for a PM, this related to concerns not to distress the family and 
respondents' belief that little information would be obtained. Seventeen percent of the 
sample indicated that they do not approach families who are upset. 
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In assessing the views of neonatologists, obstetricians, midwives and neonatal nurses, 
Khong and colleagues (2001) found that the most influential factor in the offer of a 
PM was perceptions of parental desire for a PM; where the diagnosis was clear, the 
parents did not desire a PM and planned no further pregnancies, there was least 
inclination to offer a PM. They argue that the determinant of PM rates in their sample 
was parental refusal, as the neonatalogists and obstetricians did not generally 
demonstrate reluctance to make an approach for consent. 
Cottreau and colleagues (1989) considered the views of pathologists and other 
clinicians. Although the majority of clinicians saw PMs as useful, 50% felt that they 
should not be offered when the likely cause of death is known. Younger clinicians and 
younger pathologists saw PMs as less useful than their senior colleagues. There was 
greater discomfort in discussing PMs amongst paediatric staff compared to those 
dealing with adults. 
Parental views regarding perinatal post mortems 
Data are available on parental attitudes in a small number of studies. Although none of 
these relate to trial-related PMs, they illustrate some of the issues which might also 
operate for parents of babies who were enrolled in a neonatal trial. 
McPhee and colleagues (1986) included parents in a sample of bereaved relatives who 
had or had not permitted a PM. Although most likely to show concern over 
disfigurement, parents were singled out as the group especially likely to see benefits 
of a PM. As 45% of those who did not permit a PM stated that they had not been 
approached, the authors argue, in contrast to the study by Khong and colleagues that 
clinician reluctance to offer PMs may be more important than reluctance of relatives 
to sanction procedures. 
Rankin and colleagues (2002) found from a postal questionnaire of parents using a 
bereavement service that 81% of responding parents had taken up the offer of a PM. 
This is a high acceptance rate and may be due to the source of the sample, and the fact 
that the study included women who had miscarried or had terminated a pregnancy due 
to an abnormality. Whilst the majority of those accepting a PM did so for their own 
50 
benefit (e. g. wanted more information, wanted closure), 24% wanted to contribute to 
research. The majority of the refusers felt that their baby had "suffered enough", and 
that a PM would not help them. 
McHaffie and colleagues found that 3 8% of their sample of bereaved parents refused 
permission for a PM, with concerns over disfigurement of the baby as "a major 
preoccupation" (McHaffie et al 2001). Crucial to decision making was whether or not 
there was any further information which the parents, rather than the medical team, felt 
they needed. 
Neonatal trials -a challenging but appropriate area for 
research 
The opinions expressed in the non-empirical literature suggest that parental consent in 
this setting is viewed as compromised and illusory. The empirical studies indicate that 
there are deficits in knowledge but that most parents still wish to be involved in the 
decisions about entry into a neonatal trial for their baby. Where parents do enrol their 
babies in a trial it is largely in the hope of benefiting their baby, society, or both. 
Assessment of risk does not feature as a prominent issue. 
Although this appears to give a useful picture of the parental experience, it is however 
based on data which are largely stripped of context. The studies mainly involve mixed 
samples with parents having considered a variety of trials. None" involve an 
assessment of the conditions of a trial, and none deal with the issue of emergency 
consent in any detail. What is missing from these studies is a sense of how the 
circumstances in which they find themselves impinges upon their experiences and the 
decisions that they made. The lack of information about the views of neonatologists is 
also striking. These are important omissions given that the ethical concerns which are 
raised in relation to neonatal trials are all in relation to the potential effects of the 
context in which they are carried out, and that professionals involved in this field have 
raised many concerns about their own and the parental position. Tensions relating to 
" With the exception of the research study which will be discussed in Chapter 4. 
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care and research, to the relative positions of collaborator and [proxy] participant, are 
highly relevant in this field but are quite simply not available. It is important that 
research should afford a greater understanding of this situation and of the dynamic 
between parental and professional experiences and views. 
52 
Chapter 3- Methodological issues for research 
on trial collaboration and participation 
The issues which are at the heart of this thesis are complex, having their origins in 
perceptions of duty, and expectations of care, and arise in a highly emotional context. 
Guidance on how these issues might best be addressed in methodological terms can be 
gained from considering the previous research literature on collaboration and 
participation in trials. The available empirical studies relating to neonatal trials 
provide pointers but it is also necessary to consider the substantial 12 evidence which 
pertains to the broader trials situation. This more general literature has provided a 
growing level of understanding of many facets of involvement with trials and has 
gradually increased in both sophistication and methodological rigour. It consists of an 
eclectic range of data from a wide variety of sources, collected by trialists and other 
researchers, from simple elements of trial data, including correlations between 
demographics and acceptance or refusal rates (van Bergen et al 1995), first-hand 
accounts (Moran 1993; Dobkin 1990; Walterspiel 1990; Klein et al 1995; Rabinovitch 
2004), questionnaire-based and, more recently, interview-based studies. Increasingly 
research is being carried out by social scientists from an independent external 
perspective. 
This chapter briefly highlights some areas of methodological concern regarding 
aspects of the body of literature, and secondly focuses on the rise of qualitative studies 
in the context of trials-related research. A consideration of the strengths and 
weaknesses of different approaches has helped shape the research methods for this 
thesis. 
Part I- Areas of methodolo0cal concern 
An examination of the existing literature suggests three broad areas of concern which 
are considered below. They are: 
12 Notwithstanding the common statement, even in recent research papers, that little attention has been 
paid to the views of those involved in trials. 
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the impact of a focus on attitudinal barriers to accrual 
the use of hypothetical data 
the treatment of trials as a collective 
0 The impact of a focus on attitudinal barriers to accrual 
As indicated in Chapter 1, difficulties with inadequate recruitment rates are a major 
problem in the management of clinical trials. Concerns to address problems with 
accrual have resulted in a proliferation of research assessing the attitudes of 
professionals, patients and the public towards RCT collaboration and participation. 
They have led to a quite striking bias which has shaped the empirical literature in 
important ways. 
Where research is driven by one dominant line of inquiry, there is the risk that other 
issues are left under-researched. Although they do exist, there are far fewer papers 
which report reasonsfor participation, or which explore more positive attitudes to 
trials. Once recruitment and randomisation have taken place, it seems that there has 
been less interest in gaining further understanding of experiences of trial collaboration 
or participation 13 . There appear to be no publications which report in detail the 
subsequent experiences and rationalisations of patients who reject trial participation. 
The aim to understand how recruitment to trials can be promoted or inhibited has also 
led to certain methodological constraints within the field. Some of the available 
publications do offer some indication of the complexity of factors affecting decisions 
that are made in relation to RCTs, such as the widely quoted group of Canadian 
studies carried out in the late 1980s and early 1990s by Taylor and colleagues (Taylor 
& Kelnor 1987; Taylor et al 1994; Taylor 1992i, 1992ii), and the more recent careful 
study of the motivators to recruitment for American oncologists by Joffe and Weeks 
(2002). Many papers however produce a simple list of barriers or incentives and it is 
common for subsequent studies to simply conform to the templates of earlier research. 
13 This is changing, as indicated by a careful study of the experience of longterm involvement in a diabetes trial and the impact of transition to care after trial closure (Lawton et al 2003). 
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The generation of hypothetical data 
A number of the early studies produced data on attitudes to trials which were 
essentially hypothetical. Research respondents were often drawn from the public (e. g. 
Cassileth et al 1982; Kemp ct al 1984), and from patient populations, the rationale 
being that such individuals constitute the pool from which future trial participants will 
be drawn. Where research involved patients, they were often selected as they had 
experience of a particular disease; cancer patients were asked for their views on 
whether they would chose to participate in oncology trials (Cassileth et al 1982), and 
more recently this approach has been used to assess the views of hypertensive patients 
(Halpern et al 2003), patients undergoing kidney dialysis (Israni et al 2001) and again 
oncology patients (Solomon et al 2003). There were also studies where respondents 
had no experience of the disease in question or trial participation (e. g. Saurbrey et al 
1984; Mettlin et al 1985; Llewellyn-Thomas et al 1991; Comis et al 2003). In this 
latter case the responses are inevitably conjecture. This type of study does not take 
into account the possibility of a disparity between how trials are seen in the abstract 
and how individual trials are perceived and experienced in actuality, an issue which is 
explored in greater detail below. 
The treatment of trials as a collective 
Although trials are very varied in terms of their settings, design, and the implications 
for those involved, they do have several common features, such as the use of 
randomisation, the need for informed consent, and their comparative and experimental 
nature. Research which explores trial collaboration and participation often does so at 
this collective macro level, as was the case with the research samples of parents 
involved in neonatal trials, assessing the common ground via individuals recruited 
from a variety of trials (e. g. Langley et al 1986; Trimble et al 1992). A sample of 
oncologists, clinical trials or senior nurses and family physicians for instance were 
asked to consider "not just one particular trial, but their entire experience with trials" 
(Langley et al 1986). Whilst research which deals with the broader, overarching 
concepts of trials is useU for mapping out common areas of concern, it does not aim 
to take account of the conditions created by particular trials. By treating disparate 
trials with some common factors, such as the medical specialty from which they 
55 
originate or their use of a placebo control, as if they were a single coherent entity, 
important aspects of trial experience may be lost. 
A paper by Taylor (1992a) is pivotal in demonstrating the difference between the data 
which are collected at the abstract collective level (the macroclimate) and those which 
focus on actual reasons for taking part in real trial (the microclimate). Taylor assessed 
the incentives of 96 clinicians to participation in RCTs generally and in a substudy of 
the Collaborative Ocular Melanoma Study (COMS) as described in Chapter 2. The 
respondents had already made a decision to collaborate and to recruit patients to this 
trial. The doctors were interviewed before commencement of the trial and five 
primary incentives to participation in the two contexts were classified. With reference 
to RCTs generally, the most frequent incentives were grouped as 'benefit to society'. 
i. e. 'answers clinical questions, provides essential quality control for entire medical 
system'. 
The response 'benefit to society', was given by 'almost all participants'. When 
considering the COMS trial there was, however, a dramatic reversal of incentives; 
'benefit to society', the primary incentive to participation in RCTs generally, was the 
leastfrequent incentive (43 % gave this response). The primary reason for 
participation in the COMS trial, given by over two thirds of the sample, 'benefit to the 
institution! ('grant support, professional renown for institution), was the most 
infrequent reason for joining trials in general (12%). 
This paper draws attention to the differences between accounting for actual (or 
'informed') and hypothetical decisions. It clearly shows that specific trials create 
specific conditions which inevitably affect attitudes, an issue which is considered 
further below. 
Part 11 - The rise and development of qualitative studies in 
relation to RCTS 
Quantitative and qualitative research methods have been regarded historically as 
"antithetical" (Pope and Mays 1995i). While quantitative researchers are often said to 
charge qualitative research with being unscientific and subjective (Pope and Mays 
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1995ii), Oakley (1998) has argued that "notions of experimentation, random allocation 
and quantitative methods are like a red rag to a bull for many social scientists. " 
Scientists and clinicians who carry out RCTs, "the epitome of the quantitative 
method" (Pope and Mays 1995i) are however increasingly working with qualitatively 
orientated colleagues and in recent years a progressive and developing field of co- 
operative research has arisen in order to better understand the impact of trials on 
participants, and to improve the quality of RCTs. 
The publications which have contributed to the rise of the use of qualitative 
approaches in this field which are described below are not all qualitative, nor are they 
all empirical, but they are selected as they represent important steps in a growing drive 
to understand more about the complex workings and dynamics of the RCT situation. 
The key developmental steps which are considered are: 
Recognition of the importance of the microclimate of individual trials 
Early use of qualitative methods 
Qualitative research as an intervention 
Qualitative research as an outcome 
Recognition of the importance of the microclimate of individual trials 
When research focuses on the conditions of an individual trial, exploring how it 
functions or how it is perceived and experienced by those involved, it is the research 
microclimate that is being assessed. To understand a trial it is necessary to come to an 
understanding of its microclimate. Such understanding, if placed into the public 
domain for a variety of trials, may then provide a base from which more sophisticated 
insight into the research macroclimate might be achieved. 
Reflection on the part of trialists 
To some extent trialists have led the way in attempting to understand the microclimate 
of trials as they have described the progress, conduct and sometimes the failure of 
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their own research (e. g. Baines 1984; Plaiser et al 1994; Hunt et al 2001, Vickers et al 
2002). 
Some trialists reported elements of their trial data which shed some light on patients' 
reactions to the constraints of the research setting. Abramsky and Rodeck (1990) 
reported dropout rates due to patient dissatisfaction on allocation in a trial comparing 
chorion villus sampling (CVS) to amniocentesis. Williams and colleagues (1980) 
reported poor patient compliance in a trial on ambulation in labour. Some trialists, 
reported on the impact of the views or behaviour of clinicians on the progress of their 
trials which illuminate the central tensions which are of interest in this thesis. 
Oakley (1992) describes how a trial of the effects of antenatal social support on 
birthweight which involved standard antenatal care or standard care plus support from 
research midwives was complicated by midwives' perceptions of need amongst the 
women involved. The trial recruitment process made it clear that additional support 
would be offered only to those women allocated to the support arm of the trial. 
During the trial some of the research midwives attempted to circumvent allocated to 
14 
the control group for the women who they felt were in particular need of support 
A similar phenomenon was observed in a trial of restricted versus liberal use of 
episiotomy in labour, which was severely undermined when obstetricians who had 
agreed to collaborate over-rode random allocation where it conflicted with their 
personal judgement of the management of labour (Klein et al 1995). It was shown that 
one third of the obstetricians did not accommodate the protocol in their practice, 
continuing to use episiotomy in 90% of cases in both the experimental and the control 
arms of the trial. The authors acknowledge the difficulty involved in trials where 
collaborators are asked to alter an established practice. They suggest that there can be 
an erroneous assumption of equipoise on the part of individual clinicians which is 
implicit in the design of RCTs. 
14 A subsequent questionnaire indicated a "deprivation effect" amongst those in the control group who 
were alerted to the possibility of support, but were allocated not to receive any additional intervention. 
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It became clear just from this reflective process on the part of trialists that if a trial is 
not acceptable to clinicians, or does not meet patients' needs, it may be doomed to fail 
with low levels of recruitment or high dropout rates. 
An empirical focus on individual trials 
Over the years the number of studies which have addressed issues pertaining to an 
individual trial has grown. Among the early leaders were Mattson and colleagues 
(1985) who focused on the motivational factors for patients who have survived 
myocardial infarction to join the Aspirin Myocardial Infarction Study (AMI S) 
15 or the 
Beta-blocker Heart Attack Trial; Elbourne's 1987 exploration of the views of pregnant 
women about their participation in a trial of patient-held medical records (Elbourne 
1987) and Henzlova, and colleagues (1994) who considered the views of patients with 
congestive heart failure with reference to the placebo-controlled Studies of Left 
Ventricular Dysfunction. These studies were not without their methodological 
limitations 16 but they are interesting as they are part of a move to consider factors 
which pertain for individual trials. 
Early use of qualitative methods 
Although most of the earlier research on trials was not qualitative, or used qualitative 
data in a rather restricted way, it did provide the basis and impetus for a wave of 
qualitative studies, and over the years much ground has been covered. Qualitative 
researchers developed an interest in understanding more about exactly how trials 
influence the experiences of those involved, as well as understanding the decisions 
that people make. Their independent position and their backgrounds in a range of 
academic disciplines often brought new insights as the factors which render a trial 
attractive or unattractive to patients or to those responsible for recruitment, may not be 
15 The AMIS participants were asked why they had decided to join the trial. The majority of responses 
are categorised into 'self-directed motivations' such as, receiving medical monitoring, reassurance, 
physical improvement and prevention, (74%) and altruistic motivations such as a desire to help others, 
to help heart patients in particular, to participate in research and to contribute useful data (65%). 
16 BHAT Trial participants completed a self-administered questionnaire. They could choose only one 
reasons for participation from a closed list from which they could choose only one factor. This method 
indicates the primary reason for participation but does not allow for inter-related reasons or multiple 
reasons which were evident in the AMIS sample. The most common response, 'my doctor 
recommended if was given by 3 1% of the sample. 
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immediately obvious to those involved in running a trial. Uncovering these factors and 
exploring professional and patient experiences became an important area for 
qualitative research. Two examples highlight the value of this approach. 
Gray was a leader in the field (Gray 1975). Although this work is infrequently cited, 
it is an example of how important it is to consider in a sensitive way, the varied 
influences on trial participation. He interviewed women who participated in a double- 
blind study comparing a conventional and an experimental drug for labour-induction. 
Gray argued that enrolment in the trial had been used as a service for private patients, 
a means of accommodating a physical or social need for induction and a way of 
bypassing a longer wait for an elective induction; for the clinic patients, however, he 
felt that enrolment was due to the need for research subjects and that their eligibility 
for induction was less clearly indicated. 
Ryan used in-depth interviews to understand the difficulties for men participating in a 
HIV trial and found that a particular problem was the clinic visits that were required. 
These made participants' HIV status explicit to other attendees and it was felt that 
presence at the clinic implied or revealed sexual orientation. Some asymptomatic 
participants were disconcerted by encounters with other attendees in a more advanced 
stage of the disease than themselves. Ryan argued that these factors had not been 
made clear to the trialists, and it was the outsider perspective and the research 
methods which allowed these issues to be uncovered (Ryan 1995). 
From the late 1980s onwards a series of reflective papers started to appear, some of 
which have already been discussed (Appelbaum et al 1987; Featherstone & Donovan 
1998; 2002; Cox 1999,2000; Glogowska et al 200 1; Lawton et al 2003; Mills et al 
2003; Rogers et al 2003; Gammelgaard 2004; Hamilton-Brown 2004). Whilst 
qualitative data are often used to add breadth to quantitative data, qualitative 
approaches have also proved to be invaluable in allowing a deeper understanding of 
the meanings attached to trial participation, which could not have been tapped by 
quantitative methods alone. Rogers and colleagues assessed understanding of 
participants in a trial of methods to manage anti-psychotic medication, and provided 
insights into the value of trial participation in terms of bringing the participants into 
contact with the trialists. They comment: "Our findings highlighted aspects of the 
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experience, process and outcome of the trial, which remain latent in the quantitative 
assessmenf' (Rogers et al 2003). Featherstone and Donovan who carried out in-depth, 
semi-structured interviews with men who had been offered participation in a urology 
trial similarly argued that a structured questionnaire would have produced potentially 
misleading results given the subtlety of the data their approach generated. They had 
found important misconceptions about the trial through their analysis and argued "[I]t 
is likely that the majority of these participants would have been shown to be aware 
that they were taking part in a trial and to have understood some or most of the basic 
aspects of the design. " 
Qualitative research as an intervention 
Whilst researchers have frequently commented retrospectively on one trial to improve 
practice in subsequent trials, more recently qualitative research has been carried out to 
guide and effect practical changes in an existing trial. Donovan and colleagues (2002) 
carried out a radical qualitative study using action-research methods in which men 
were randomised to different recruitment procedures for a prostate treatment trial. The 
results of the findings from in-depth interviews, analysis of audio-taped recruitment 
appointments and follow up interviews, brought about crucial practical changes in the 
management of the trial. They found that there were difficulties for the professionals 
involved in recruitment in discussing the basis for the trial (equipoise) and in 
presenting treatments without introducing bias or using terminology which was 
subsequently misinterpreted by participants. This insight into the difficulties that 
existed was used to train the professionals and to modify the trial procedures. Not only 
did the understanding gained through the qualitative study bring about important 
changes to the information processes to promote participant understanding, the trial 
itself benefited from an increase in the randomisation rate from 40% to 70%. The 
authors argue persuasively for the broad value of their approach, stating: 
Qualitative research methods applied in combination with open minded clinicians 
and flexible or innovative trial designs may enable even the most difficult 
evaluative questions to be tackled and have substantial impacts even on apparently 
routine and uncontroversial trials (Donovan et al 2002). 
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Qualitative research as a means to measure outcome 
The use of qualitative research to aid interpretation of trial results also marks a 
significant milestone in the collaboration between trialists and qualitative researchers. 
Describing their research as "a multimethod approach", Glogowska and colleagues 
(2002) used questionnaires and interviews with parents of preschool children involved 
in a speech and language therapy trial, and combined these with data from the RCT. 
The quantitative trial results suggested that the trial had shown the intervention to be 
ineffective. The qualitative study demonstrated parents' perceptions of important 
advantages as well as limitations, and these, the authors felt, "could only have [been] 
surmised from the pragmatic trial alone". 
The methodolo2ical lessons learned 
It is inevitable that a body of evidence as large and as wide-ranging as the trials- 
related literature will contain research studies of variable quality. A focus on the 
different strengths and limitations is valuable as it can direct the course of future 
research. It is clear from even a brief perusal of the data that are available that trial 
participants often join a trial for personal and altruistic reasons. There are however far 
more useful insights such as the differences between trials viewed from a general 
perspective or one grounded in real experience. Realisation of some of the difficulties 
that trial participants can experience, the therapeutic misconception which can be at 
the heart of their decisions, and the lack of individual equipoise are all products of a 
much broader approach to thinking about involvement with trials. 
It is important that research combines the strengths of a number of different elements 
of the literature, and opens new areas of exploration. Key lessons are: 
The use of appropriate research methods is crucial 
A focus on the microclimate of individual trials is both meaningful and 
useful 
The decision to collaborate, participate and not to participate should take 
into account the wider experience 
Unanticipated elements in the attitudes or experience of the individuals 
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involved may arise. Research should be responsive to this. 
How these key lessons have in part guided the design and conduct of the research in 
this thesis is the subject of the following chapter. 
63 
Chapter 4- The Current Study 
The research findings reported here are part of a larger qualitative study of the views 
of parents and clinicians associated with four RCTs - The Study of Views of 
Participants in Perinatal Trials (SVPPT) carried out with colleagues, Diana Elbourne 
and Jo Garcia. As the material presented for this thesis is a subset of the data 
collected for the larger study, it is important to describe the background and overall 
progress of that research and to explain the reasons for the choice of data for analysis 
for this thesis. This chapter is organised chronologically, explaining four aspects of 
the research processes. They are: 
" Origins and evolution of the research 
" Study design and methodological rationale 
" Design of the area of study selected for the thesis 
" Progress and implementation of the study 
Part I- OriOns of the research 
The focus, design and conduct of SVPPT were shaped by prior and contemporaneous 
research studies carried out by the same team. The first two studies conducted from 
1995-7 offered critical insights into how emergency neonatal trials were viewed and 
understood and brought about reflection on the qualitative research process. They laid 
the foundations for SVPPT. The entire group of studies therefore represents an 
intellectual, ethical and methodological progression. 
The ECMO qualitative studies -a developmental approach 
to researching participation in trials 
Study 1 
The first study assessed trial participation from the perspectives of parents of 
surviving babies involved in the UK Collaborative Trial of Extra Corporeal 
Membrane Oxygenation (ECMO) (Snowdon et al, 1997). The ECMO Trial involved 
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critically ill neonates and compared two methods of life-support: 'conventional' 
management (CM) with ventilatory support versus oxygenation of the blood via an 
external circuit (UK Collaborative ECMO Trial Group. 1996). The research into the 
views of parents was carried out whilst the ECMO Trial was in progress. 
Study I identified the difficulties that parents had in describing aspects of the trial. It 
was clear that even where aspects of the trial were familiar, with parents referring to 
"randomisation" or describing the use of a computer to determine treatment, they were 
often uncertain about the nature of randomisation and the rationale behind the trial. 
Some accounts involved common sense responses to gaps in knowledge. Where 
parents were (understandably) unaware of uncertainty as the basis for the trial, they 
could find other ways to explain why doctors used randomisation, such as to 
circumvent difficult treatment decisions or as a way to chose which baby should 
receive ECMO in the light of competition for scarce resources. Where the evaluative 
nature of the trial was unclear, some parents believed their baby was deprived of a 
known life-saving therapy. Allocation to CM could be taken to mean that their baby 
had been "rejected" and was not part of the trial. 
Whilst it is now widely understood that such problems exist for trials in many settings, 
when these findings were first published there was very little available empirical data. 
Previously the main evidence came from a psychiatric setting and the extent to which 
the setting and associated illnesses had contributed to perceptions of trials was unclear 
(Appelbaum et al 1982). The first ECMO study indicated that trials in other situations 
could also be difficult to understand. The insights that were gained into the subtleties 
of some of the difficulties allowed the team to develop further research questions from 
a more informed position. 
Study 2 
Once the trial was complete, results were sent to those parents who had previously 
expressed an interest in receiving the findings. It is now more common to feedback 
results to participants (Di Blasi et al 2002; Fernandez et al 2003; Di Blasi et al 2005; 
Kenyon et al 2004) but at the time this was rarely the case. As there was no empirical 
literature to guide trialists the second ECMO study was conducted to assess parental 
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reactions to feedback. This was important as the situation was highly sensitive as 
ECMO was shown to be effective, saving significantly more babies than CM without 
increasing rates of disability. Mindful of the various models of trial participation 
which emerged through the first study, and the potential for the results to upset and 
disturb parents, it was clear that the second study could tap extremely difficult 
emotions and had to be conducted with care. The study was only possible because an 
important preparatory step had been taken through the first study. The team did 
however face a major intellectual and ethical dilemma which was difficult to resolve. 
It was thought that parents of babies allocated to CM (the approach which emerged as 
the less effective arm of the trial) whose babies subsequently died, might be 
particularly affected by the results. With nothing to guide research in this area" it was 
difficult to predict the impact of some of the discussions required for the interviews. 
The team consulted widely with the trial staff and other researchers for opinions on 
whether the benefits to the research community, and in fulfilling any obligation we 
felt to offer bereaved parents the opportunity to give their views, could offset any 
potential for any distress which might arise. Whilst it was considered to be important 
to try to understand the parental perspective, it was eventually decided that it was 
inappropriate to include bereaved parents in such a difficult study when as researchers 
we had no access to support systems to offer any distressed parents, and when the 
research team was exploring essentially new and unpredictable research territory 18. 
This second study therefore involved very careful exploration of the meaning that the 
results had for a sample of parents of surviving babies. It showed that parents largely 
valued their involvement in the trial, and particularly appreciated being informed 
about the results (Snowdon et al 1998). It also showed that it was possible to explore 
with parents their attitudes to complicated methodological issues (Snowdon et al 
1999). 
17 Whilst research on bereavement more generally was available, it was the particular added element of 
the possible impact of trial participation on their experience which was the potentially complicating 
unexplored dimension of this situation. 
" The ideal situation would be to include a follow-up study with the original trial funding application. 
Such a study would give feedback and would monitor trial procedures and would be conducted with the 
co-operation and support of individual trial centres. It could tap into either local bereavement support 
services at the referring hospital if appropriate and desirable, or could involve the funded provision of a 
counselor whose details could be given to parents as a form of support and further information, to be 
drawn upon subsequent to the interview if they wished. 
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The results of the two ECMO studies have been widely disseminated. A frequent (and 
anticipated) response from audiences, and in print (Braunholz 1999, Manning 2000), 
has been that the findings may have been different had bereaved parents been 
included. As researchers we were frequently called upon to defend the decision to 
include only parents of surviving babies. Although it was described as being based on 
"perfectly understandable ethical reasons" (Braunholtz 1999), it was clear that there 
was a need to understand the impact of trial participation on those who are bereaved, 
and to assess their experiences at the time and with hindsight. During the course of 
Study 2, it was decided that sufficient experience and understanding of the field had 
been gained to incorporate an assessment of the views of bereaved parents into further 
research. In 1997 funds were awarded by the Nuffield Foundation for SVPPT, a much 
larger project which extended the focus of the earlier work, and permitted inclusion of 
the views of two potentially quite difficult groups, bereaved parents and parents who 
had declined trial participation. Whilst the decision to include these groups 
complicated the research to an extraordinary extent, it also eventually resulted in a 
more coherent, and more ethically-resolved study. 
Contemporaneous research - Study 3 
A further ECMO study was conducted in 2001 with an additional group of health 
professionals and parents of surviving and deceased babies who had undergone 
hypothermia and ECMO in a pre-trial study (Snowdon et al unpublished). This 
research was carried out in response to an invitation by clinicians to examine their 
research processes. It took place during the course of SVPPT. Although it did not 
shape the design of the larger study, the process of conducting this research, and 
interviewing more parents with experiences of ECMO, including more bereaved 
parents, served to confirm and deepen our understanding of the parental perspectives 
at an influential time, that is during a period of analysis of the SVPPT qualitative data. 
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Part 11 - The Study of Views of Participants in Perinatal 
Trials: an evolutionarv approach to research 
The plan for the study 
The original plan for this study was to examine involvement with perinatal trials for 
parents and health service staff. The aim, driven by the insights derived from the 
ECMO studies, was to gain an understanding of how the conditions established by 
individual trials shaped, and to some extent were shaped by, the attitudes and 
experiences of those involved (the microclimate). It was considered to be important to 
look at more than one trial as a central principle guiding the research was that all trials 
are not the same (although they have often been treated in the literature as if they are). 
SVPPT was to draw upon multiple perspectives to create a more sensitive and more 
rounded account of the trials. The sample of parents would include some whose babies 
survived, and some whose babies died, and could also be divided into those who had 
accepted and those who had declined trial participation. The professional sample 
originally involved neonatologists, neonatal nurses and midwives, but later developed 
to include obstetricians. 
An unusually large number of interviews was planned to allow analysis of perceptions 
of individual trials from different broad perspectives, in the detail which is possible 
with a qualitative approach. This would also create subgroups which would be large 
enough to explore key areas of interest, namely bereavement and the decision to 
decline trial participation. The study was also to be of a size that would encourage 
exploration of unanticipated issues which might emerge in the course of the 
research. 19 
Although it was originally planned to take 27 months, SVPPT started in October 1997 
and continued until July 2003. This major deviation from the initial timescale was a 
" Precisely this opportunity arose with an assessment of reactions to the issue of perinatal post- 
mortems in a trial context, an unplanned and timely strand in the data. The issue was raised in one 
interview early in the study and was incorporated into the interview schedule. This focus was 
developed as some of the issues emerged in analysis and a small group of pathologists with links to the 
neonatal trials were contacted and asked to contribute to the study either through a telephone discussion 
or by submitting their views in an email format. As the UK climate became increasingly suspicious of 
both hospital pathology and research involving children, the value of such data became clear and this 
unexpected aspect of the data was written up for publication (Snowdon et at 2003a; 2003b; 2003c). 
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result of adaptations to both internal and external factors. The study was modified and 
enlarged in important ways in response to the unpredictable nature of the trials under 
study and to a number of difficulties which arose. The study period was lengthened as 
a result of changes to the design, but also to accommodate two periods of maternity 
leave (in 1999 and in 2002). In 1999 researcher hours were reduced from full- to a 
part-time basis, and in 2001 there was a further temporary reduction in hours to 
respond to the opportunity to conduct Study 3. As the research progressed, both 
funded and time-only extensions were awarded by the Nuffield Foundation to ensure 
realisation of the study aims. 
Obstacles to progress and their impact upon the study 
The obstacles which arose and the process of modification of the study design related 
to six main areas: 
" The unpredictable nature of clinical trials 
" Delays in securing research ethics committee approval 
" Failure of some of the proposed research methods 
" Access to bereaved parents 
" Access to parents who declined to participate in a trial 
"A sensitive political environment 
The unpredictable nature of clinical trials 
The initial plan was to examine two multicentre trials, one neonatal (The INNOVO 
Trial (Field et at 2005, Appendix B) and one antenatal (The Antenatal TRH Trial 
(Alfirevie et at 1999)). The TRH Trial was unexpectedly terminated after funding for 
SVPPT was agreed but before the study began (Brocklehurst et at 2000). The first 
modification to the study design was therefore to find another trial. Several trial 
teams were approached to identify an appropriate trial, with many meetings, lengthy 
correspondence and presentation of the intended research to a number of departments. 
Over a year later the CANDA Trial was brought into the study (Ainsworth et at 2000, 
Appendix C). As this was a neonatal trial the views of midwives were lost to the 
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study. There were however important advantages of incorporating this trial as 
recruitment, as for the INNOVO Trial, was carried out by neonatologists. It would 
therefore be possible to recruit a larger, more consolidated sample from one 
professional group than had been planned. A perinatal focus was preserved as assent 
took place antenatally for a neonatal intervention. 
Delays in securing research ethics committee approval 
Obtaining research ethics committee (REC) approval was far from straightforward 
(Appendix D). It involved an initial submission to a Multicentre REC as well as six 
local RECs. The process continued throughout SVPPT as agreement to collaborate 
was negotiated with different NICUs at different times. There were considerable 
delays as there were often several iterations as local modifications to study procedures 
were requested by clinicians and as changes to the recruitment process were made (see 
below). The chair of one REC refused to allow a submission to his committee for 
over a year. He argued that as SVPPT involved study of four trials (see below) it was 
in fact four separate studies, each of which should have separate MREC approval. 
The MREC disagreed. This impasse could not be broken and a valuable NICU 
appeared lost to the study. When a new chair was appointed, he stated support for a 
submission and SVPPT was approved. Lengthy negotiations with other hospital 
bodies such the Caldicott Guardians also took place. 
Failure of a proposed research method 
The initial design of SVPPT planned to tape-record the discussions between clinicians 
and parents in which trial participation was offered (Appendix E). The recordings 
would not only act as an important data set in their own right, addressing 
methodological concerns from the ECMO studies of how to know what parents were 
told about a trial, they were also the means to identify the study sample. Once a tape 
was forwarded to the SVPPT team, procedures would then be initiated to follow up 
the parents and staff who were present at the recordings to request interviews. This 
would create a three-way dataset comprising the recorded discussion (objective data), 
and parental and clinician interviews (subjective data). 
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Pre-funding discussions with the Steering Committee and staff associated with the 
INNOVO Trial suggested that there was enthusiastic support for this approach, but in 
practice there were severe difficulties. There were practical issues to contend with, 
such as the tape-recorders being unavailable when needed, and staff forgetting to 
make a recording, but the dominant problem was professional discomfort. Senior staff 
in some centres felt uncomfortable with requesting permission to make a recording at 
a stressful time, and were concerned over how to request permission to make a 
recording without revealing to the parents in advance the nature of the discussion that 
they were about to have. 20 Very few tapes were produced in the NICUs which did 
agree to this part of the study (4 tapes from the INNOVO trial and 3 from the CANDA 
Trial), and it became clear that attempts to generate further tapes were absorbing a 
disproportionate amount of researcher time and deterring other NICUs from joining 
SVPPT. The data derived from the seven tapes indicate that this approach is a very 
valuable source of data. Within this study it can however only be used as illustrative 
material. With the permission of the funders, this important element of the study was 
discontinued and so the second major modification to the study took place. 
Access to bereaved parents 
The third modification to SVPPT was made in response to extremely slow recruitment 
of an important sub-sample of the study, the bereaved parents. Although concern was 
expressed in the field that research that did not represent bereaved parents was 
fundamentally flawed, and there appeared to be support for attempts to assess their 
views, it proved to be extremely difficult in practice to secure support to recruit this 
element of the sample. From the start of SVPPT it was clear that there was concern 
that interviews could undermine the wellbeing of bereaved parents. The means by 
which potential participants were approached and invited to join the study was 
modified during the study in response to the concerns of RECs and to bring the 
practicalities of gaining access to the parents in line with local preferences. Some 
20 Essentially it was felt that in order to consent to the recording the parents had to be told that the focus 
of the research was discussion of clinical trial participation. As the subject of trial participation was 
often raised in the context of a larger discussion about the condition of a baby, the need to introduce the 
subject before it arose more naturally in the course of the conversation was thought to be too difficult 
by many of the neonatologists and to some extent artificial. The research itself would cause the 
conversations to take a course which they would not ordinarily have taken, thus acting as an 
intervention as well as a form of observation. 
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clinicians were very supportive and clearly wished to see the data in the public 
domain. They offered much support and advice. Others, however, had misgivings. 
One clinician advised colleagues in a meeting not to join as they might find 
themselves under media scrutiny once the results of the study were available. In some 
cases a collective decision was made to permit the study in a NICU, but individuals 
were uncomfortable and withheld access to bereaved parents once the study was 
underway and REC approval had been given. In one case the objecting clinician 
reversed his decision on further discussion but in another it was decided that no 
bereaved parents would be included from his centre. It seemed that this study aimed 
to provide the research data that everyone agreed was necessary but few felt able to 
support in practice. Whilst it was clear to all involved that SVPPT must not be to the 
detriment of the parents involved, ultimately these concerns limited the potential for 
the study to answer the research questions posed. 
Access to parents who declined to participate in a trial 
Although recruitment to the INNOVO Trial was far slower than the trialists had 
anticipated, there were very few instances of parental refusal to enrol their baby in the 
trial. Only four cases were identified at three hospitals during the interview period for 
SVPPT, none of which were at NICUs which were collaborating with the qualitative 
study. It was decided that every effort should be made to access these parents, even 
though a full REC application would be needed to carry out only one interview per 
centre. Each case was discussed with the staff involved with the hope of gaining 
permission to make contact with the family should REC approval be given. In three 
cases permission was withheld as the babies had died and the consultants in question 
all felt that contact would be inappropriate. In one case permission was given to 
approach parents who had declined for their surviving baby and a REC application 
was made. Approval was granted in due course but once the contact process was 
initiated the consultant realised that baby in question had a twin who had not been 
eligible for the trial and had died. As the parents were bereaved, albeit not in terms of 
the baby for whom they had made a trial-related decision, permission to make contact 
was withdrawn. As a result no cases of refusal for the INNOVO Trial were 
represented in SVPPT. 
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Senior clinicians at one of the CANDA Trial NICUs reversed their permission to 
recruit parents who had declined to participate in the trial after REC approval had 
been granted. Permission to approach refusers was given at two other CANDA 
centres and four interviews took place. As the possible sources of access were 
becoming more limited, another CANDA NICU was approached. Agreement to 
recruit from this centre was reached but shortly after REC approval was granted, with 
only one recruit to the trial from this centre and no cases of refusal, the CANDA Trial 
was unexpectedly closed to recruitment. This had the effect of curtailing access to 
new trial participants, as well as to the elusive refusers. 
A sensitive political environment 
An important issue which undoubtedly added to the sensitivity of the research, related 
to a difficult research climate in the UK. During the course of SVPPT two relevant 
areas of concern were raised, figuring prominently in the UK media. Firstly, there 
were governniental inquiries after revelations of the lack of consent for retention of 
children's organs after post mortems at Bristol Royal Infirmary (Bristol Royal 
Infirmary Inquiry, 2001) and Alder Hey Children's Hospital in Liverpool (Department 
of Health, 2001). Secondly, there were accusations (Hall & Pook, 1999; Wilson, 
1999) and refutations (Hey & Chalmers, 2000) of misconduct with reference to 
consent for procedures in perinatal research in the CNEP Trial at North Stafford 
Hospital (NHS Executive West Midlands Regional Office, 2000). Whilst important 
questions were raised about research practices and ethical standards in relation to 
consent, it was also very clear that at the centre of these storms there were many 
families where individuals were deeply affected and traurnatised by the events 
concerned. The research for the thesis was carried out as these difficulties were 
coming to light. It is of course impossible to quantify the impact that this had on the 
progress of SVPPT, especially as SVPPT researchers were not privy to the discussions 
in which clinicians decided about collaboration. It would seem likely that keen 
awareness of public scrutiny of the conduct of research with children, and of the 
sensitivity that would be necessary for any discussions on this topic with parents, is 
likely to have had a bearing on the caution of some clinicians over their collaboration 
with SVPPT. Although it was never stated to be the case, this may also have induced 
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the particular discomfort with the aim to include bereaved parents in the sample of 
interviewees. 
Extension of the study 
These difficulties meant that the team was obliged to make an important decision 
about the design of the study at a fairly late stage. The study could either continue as 
planned, with fewer total participants, or it could be extended to include further trials 
in order to consolidate the number of interviews and to attempt to achieve the goal of 
recruiting a sample of parents who had declined further participation. In discussion 
with the funders it was agreed to extend the study to include two additional trials, the 
Antenatal TEAMS Trial (Brocklehurst et al 1999) and the ORACLE Trial (Kenyon et 
al 2001i, Kenyon et al 2001ii). With the inclusion of these two trials, the study was 
returned to the original goal of comparing antenatal and neonatal trials. It was soon 
clear that the difficulties in trying to gain access to bereaved parents would again 
hamper, if not derail, this new element of the study. It was therefore decided that no 
further attempts would be made to access bereaved parents in the antenatal trials. 
This decision to extend the study had both successes and failures. The extension in 
time which was permitted in order to recruit from the two new trials had the side- 
effect of actually increasing recruitment to the neonatal trial elements of the study. 
More recruits from the slowly recruiting INNOVO Trial gradually became available 
and it was possible to add to the CANDA Trial interviews over time. This allowed 
realisation of the target of recruiting a sample of bereaved parents via the neonatal 
trials. The small number of interviews with those who declined to participate in the 
CANDA Trial was augmented via the two antenatal trials. Both groups were however 
smaller than had been hoped as recruitment to the antenatal trials was yet again 
severely compromised. Recruitment via the TEAMS Trial was effective but 
extremely slow as the trial itself had few recruits. Recruitment via the ORACLE Trial 
was very disappointing, given the extensive and time-consuming negotiations which 
were involved. There were so few responses from those who participated in the 
ORACLE Trial that it became clear that this element should be discontinue&'. As the 
21 In one centre approximately 25 letters to women enroled in the ORACLE Trial yielded one response. 
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TEAMS Trial closed to recruitment when further funds were not awarded, this 
element of the study also came to an abrupt end. This left the neonatal element of the 
study complete but less than half of the intended antenatal sample was achieved. 
The final design of the study 
In the initial years of the research there were many serious setbacks and without the 
flexibility to reshape and rethink the research design, it is likely that an important 
opportunity to examine RCT participation from multiple perspectives in a great deal 
of detail would have been lost. The fact that the study was adapted so radically has 
actually had an extremely positive effect on the overall design and coherence of the 
neonatal element of the dataset. The shift to carrying out the research part-time proved 
to be advantageous as valuable funds were not depleted at a time when the research 
process was impeded in so many ways and the trials upon which the study depended 
were recruiting slowl Y22 . The increase in the 
duration of the study (through 
management of the funds, periods of maternity leave and agreed extensions) afforded 
the unexpected opportunity to follow the trials over time. It meant that generation of a 
larger, more sophisticated picture of the trials was possible, rather than a snapshot 
taken in the middle of recruitment. A very large number of in-depth interviews were 
carried out, mainly by one researcher and this would have been impossible within the 
original timeframe. What has resulted from a somewhat complicated evolutionary 
process is a unique and wide-ranging piece of research. To replicate a qiialitative 
study such as this would be extraordinarily difficult. Figure 1 shows the final 
structure of the study, with a central focus for all groups on the decisions that were 
made about involvement in antenatal or neonatal trials. 
22 This includes a five month period in the course of SVPPT in which recruitment to the INNOVO Trial 
was suspended after an explosion in the factory supplying the nitric oxide. 
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Part III - Selection of material for the thesis - the structure 
of the substud 
Neonatologists and parents 
Given the size and the scope of SVPPT there were several areas which could have 
been explored for this thesis. The selection reported here focuses on the attitudes and 
experiences of neonatologists and parents associated with the CANDA and INNOVO 
Trials. It would have been possible to have selected a smaller area for study, such as 
the views of only one group, or a comparison within one trial. This much larger area 
was chosen as it offered the opportunity to examine in detail some of the issues which 
gave impetus to the larger study and is true to methodological insights gained from 
previous research (microclimates, multiple perspectives, comparisons between trials to 
understand similarities and differences). 
The decisions that clinicians and parents make about collaboration and participation in 
neonatal trials are intrinsically linked and the selection of the accounts of both the 
neonatologists and the parents for detailed study offers the opportunity to explore their 
convergent and divergent experiences at what Chalmers refers to as "the front lines 
where uncertainties are encountered in practice" (Chalmers 2004). The connections 
between these two parties are important. For many patients in the broader trials 
setting, the choice to participate can be heavily influenced by their clinician's opinion 
(Mattson et al 1985; Henzlova et al 1994; Siminoff et al 2000). Stirrat (1992) argues 
that where a doctor does not support a particular trial, their patients will not be given 
the chance to participate. There are however very few examples of research which 
explores the relationship between collaborators and potential participants, either 
through direct observation, or through the interview accounts of the key individuals. 
It is now a well accepted principle that there are multiple perspectives on social 
situations, with protagonists each attaching their own meanings to information and 
events. It is therefore surprising that this influential dynamic, where it is likely that 
multiple meanings are attached to trial participation, is so under explored. 
The data for the thesis were selected to allow exploration of the perspectives of the 
four groups individually and in comparison to each other as shown in Figure 2. Each 
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trial can be treated as a case study and examined alone, or in comparison with the 
other trial (A+D). The accounts of the neonatologists can be analysed according to 
their links with a trial (CANDA Trial neonatologists =B and INNOVO Trial 
neonatologists = E) or as one professional group (B+E). The parents can similarly be 
viewed in relation to a trial, in relation to their counterparts (C+F) or to the 
neonatologists linked to the same trial (B+C and E+F). 
A 
CANDA Trial 
B 
Neonatologists 
c 
Parents 
D 
INNOVO Trial 
E 
Neonatologists 
F 
Parents 
Figure 2: Basic structure of the research 
Within this structure it is possible to look at an issue or event, such as the offer of 
recruitment, from different perspectives, assessing how each party's interpretation 
converges or diverges. It is also possible to look at how the perceptions or concerns 
expressed by one group may or may not be reflected in the other. If there is confusion 
in one group, the views of another might be explanatory. 
The two neonatal trials which were selected for study had some common ground but 
also some important individual features which are described below. 
The CANDA Trial 
The CANDA Trial compared two surfactants given shortly after birth to preterm 
babies born between 25 weeks and 29 weeks and 6 days. One surfactant, Curosurf is 
derived from the lungs of pigs; the other, ALEC (Artificial Lung Expanding 
Compound), is a synthetic form of surfactant. At the time of the trial, both were 
commonly used to treat respiratory distress syndrome in neonates. As they had been 
shown to be effective against placebo in earlier trials, the aim was to detect small 
differences between the surfactants which may affect, for instance, length of hospital 
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stay and so costs associated with care. The trial could therefore provide information 
on which of two effective and safe drugs would offer the best value. 
The intended sample size was 400 babies. Recruitment was carried out in hospitals in 
the north of England, between May 1998 and December 1999. 
Key features of this trial were: 
" the circumstances of assent and the likely condition of the babies 
" the interventions that the trial assessed 
" the course of the trial 
Circumstances of consent and the likely condition of the babies 
Where possible, assent for the CANDA Trial was sought by a neonatologist as soon as 
the likelihood of a preterm. delivery became apparent. Written information for use at 
this point was provided by the CANDA trial team, although there were some local 
variations. A typical informed consent leaflet is shown in Appendix F. For some 
women who were in a stable condition there could be plenty of time to consider their 
options; for others a decision would be made in active labour. The condition of 
preterm. babies on delivery is variable, with some needing ventilatory support and 
some less intensive care. At the point of decision-making, choices about the trial 
would be made in the light of the significant threat to the life and health of a baby, 
associated with preterm delivery. 
The intervention 
The CANDA Trial was often seen in the period of negotiation referred to above as a 
low risk trial with little to chose between the two efficacious and safe surfactants. It 
was known that Curosurf acted more rapidly than ALEC but not whether this actually 
conferred a benefit in the long term. Individual UK neonatal units tend to have a 
policy of predominantly, or exclusively using a particular form of surfactant. All of 
the neonatal units that elected to contribute to the CANDA Trial were routinely using 
ALEC. For 50% of their patients who were entered into the trial there would be a 
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shift from their normal practice to the administration of Curosurf as a result of the 
random allocation process. None of the UK departments that were routinely using 
Curosurf elected to join the trial. The different origins of the surfactants led to their 
description as "natural", and "artificial", an accurate but potentially loaded choice of 
terminology. 
The course of the trial 
During the period of the qualitative study, the course of the trial was affected in a 
dramatic form. It had been agreed from the inception of the trial that the data would 
be assessed when half of the intended sample was recruited. The data monitoring 
committee identified a surprising and highly significant difference in pre-discharge 
mortality between the two forms of surfactant. Overall, neonatal mortality was II per 
cent amongst those allocated to Curosurf and 25 per cent amongst those allocated to 
ALEC. The corresponding pre-discharge figures were 14 per cent and 31 per cent. The 
differences remained significant after adjustment for a number of variables and were 
consistent across all trial centres. The CANDA Trial was immediately stopped and 
ALEC was withdrawn from use by the manufacturer. The CANDA Trial was largely 
seen as low risk research and so this twist in the course of the trial was very 
unexpected. Questions relating to the trial results were incorporated into the 
remaining interviews as some of the interviewees reflected on the trial from a position 
of hindsight. 
The final figures recruited to the trial were therefore approximately half the intended 
sample size, with 105 babies allocated Curosurf and 107 allocated ALEC. 
The INNOVO Trial 
The INNOVO Trial compared ventilatory support with inhaled nitric oxide (INO), to 
ventilatory support without inhaled nitric oxide for neonates with severe but 
potentially reversible respiratory failure. The hypothesis was that adding INO, a 
vasodilator, to the ventilator gases would reduce the risk of adverse clinical outcomes,, 
and would be cost-effective. Previous research had suggested that INO may improve 
oxygenation in the short-term, but little reliable information was available about the 
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effects of its use in the long-term. The primary outcome measures were: (a) death or 
severe disability at the age of one year (corrected), and (b) death or the use of 
supplemental oxygen on the expected date of delivery (or 28 days post-delivery for 
the full or near term babies). The target sample size for the INNOVO Trial was 200 
preterm. babies (those under 34 weeks) and 110 term or near term babies (over 34 
weeks), to be recruited by 200 1, a recruitment period of nearly 5 years. 
Recruitment via 32 UK and Ireland centres and 4 European centres started with a pilot 
phase in February 1997 and then carried straight on into the main trial. Shortly after 
this main phase started, an explosion in the factory supplying INO for the trial meant 
recruitment had to be suspended for five months. The MRC provided funding to 
extend the recruitment period for this time, allowing the trial to close five months later 
than planned on the 31 st December 200 1. 
Key features of this trial related to: 
" the circumstances of consent and the severe condition of the eligible babies 
" the intervention that the trial assessed 
" the trial design 
The circumstances of consent and the condition of the babies 
The eligibility criteria for the INNOVO Trial babies were deliberately broad and so it 
was expected that it would involve babies with a rather wide diagnostic and 
demographic range. Those eligible for the trial were already receiving ventilator 
support in a NICU and highly stressed parents were asked to consider enrolment in the 
trial days, or even hours, after delivery. 
The intervention 
The trial intervention is known to act very quickly and to have short-term benefits 
especially for babies born at or near term. Concerns about toxicity and the lack of 
evidence about efficacy in the long-term drove the trial. There are also some safety 
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concerns for professionals over repeated exposure to INO, especially for those who 
are pregnant. 
The trial design 
INO is readily available thus raising the possibility that it could be administered to 
trial-eligible babies outside of the trial, and to babies allocated to the control arm. The 
pragmatic nature of the trial and the restricted funding meant that it was not feasible to 
set up a placebo group and so the INNOVO Trial was not blinded. 
Once the INNOVO Trial was underway, it became clear that the babies who were 
recruited to the trial were more sick than had been expected. Recruitment was very 
slow in spite of the low refusal rate. By the end of the trial in 2001, after almost five 
years of recruitment, just over half of the intended sample size was achieved with 10 8 
preterm and 60 term or near term babies recruited. 
Part IV - The implementation of the research for this thesis 
Mcthodological dccisions 
A qualitative approach 
The value of a qualitative approach as a means to gain an understanding of the 
complexities involved in the clinical trials setting was demonstrated in the previous 
chapter and borne out by the ECMO Studies. The use of qualitative research methods 
is highly appropriate for this context. Recently MRC, a major funder of clinical trials 
in the UK, highlighted the need for qualitative research to add to the evidence base in 
this area (MRC 2004). There are certain limits to the sensitivity of quantitative 
research methods (Green and Britten 1998) and the subject of interest here can require 
a careful process of unpicking perceptions and interpretations. For a study which is 
grounded in personal beliefs and extreme events, a qualitative approach is essential as 
a "means of exploring subjective experiences, meanings and voices" (Birch et al 
2002). A qualitative approach is extremely valuable because of the adaptability and 
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responsiveness which arc fundamental to this style of research, allowing the 
researcher to react to new insights as they arise, wherever they ariSe23' incorporating 
them into subsequent interviews and analytical themes. 
Focus and style of the interviews 
In this study two interview styles were drawn upon, in-depth interviewing and 
narrative interviewing (Green & Thorogood 2002). In-depth interviews are also 
referred to as semi-structured interviews as they involve the imposition on the 
'conversation' of a pre-defined framework (the interview schedule) by the 
interviewer. Unlike a structured interview, an essential feature of this approach is 
flexibility to respond to the various ways in which the interviewee reacts to the 
schedule, adding depth to a subject of interest, developing a theme and even 
refocusing and reorienting the discussion. This process of careful listening and 
following through a line of an interviewee's argument is part of the essential method 
of unravelling and connecting thoughts and beliefs. In narrative interviews, time is 
taken to allow the interviewees to piece together the 'story' of the events of interest to 
the research, adding detail, comment and reflection as they go. 
The process of conducting flexible in-depth interviews is in itself a means to educate 
the interviewer, with each encounter revealing more than simply the responses to the 
interview schedule. Interviewees can do much to explain a phenomenon through the 
tangents that they take and the previously unconsidered issues that they raise. Their 
" Reflexivity in research is a means to understand the impact of personal experiences and assumptions 
on interpretation of phenomena, and to foster awareness of one's position in relation to research 
participants (Doucet 1998). As my transition to motherhood occurred during the study, and interviews 
with some parents and neonatologists were conducted well into the third trimester, a reflexive position 
was almost inevitable, a far cry from the positivist approach of minimizing the impact of the researcher 
on the data. This was clear in interviews where parents saw me as being at the same life stage and were 
keen to talk about my pregnancy or children. It was very clear in my own responses when I visited a 
NICU, as I had done many times before, when 24 weeks pregnant with my second child. I experienced 
this visit on a number of levels. As a pregnant woman it was assumed by the staff that I was a parent 
and not a professional and my position felt very different from other visits (I was challenged about 
entry to parts of the NICU and was aware of being watched by others who were presumably wondering 
why I was in the NICU and what my 'story' was). As part of a ward round I stood by the cot of a baby 
recently born at 24 weeks gestation. The sight and emotion were familiar but additional elements 
underscored the complex relationship of researcher and researched. As a daughter of parents who 
experienced and lived with the death of premature babies I had insight into one potential future for the 
family. As the aunt of a young man who was profoundly disabled in his early months, I had could see 
another alternative future. As a researcher who had heard accounts of the birth and sometimes the 
death of many babies on a NICU, I placed the baby and family into my own intellectual frameworks. 
As a pregnant woman and mother I felt intensely sad and incredibly lucky. 
83 
behaviour, the views that they express outside of the interview, and aspects of their 
environment can all add to the interviewer's understanding of their situation. A 
particular element of studies which involve a comparison of the attitudes and 
experiences of different parties is to be mindful of the convergence and divergence 
between groups during the interviews. A high level of engagement with existing data 
allows new connections to be made in any encounter with an interviewee, and permits 
immediate response to insights as they occur. 
Interviewing clinicians 
The in-depth interview is a flexible tool which is well suited to gathering detailed data 
from clinicians. Unlike a questionnaire in which there are limits to the information 
that can be collected, the interview permits the interviewer to adapt to lines of interest 
as they arise and to develop new strands of thought. In this particular context this is 
very valuable as clinicians can vary in their approaches to the types of issues raised in 
this study. Senior academic staff can expect an interviewer to respond in an academic 
style, developing intellectual arguments as the interview unfolds. Others can be more 
experiential in style, some in the earlier stages of their careers having given less 
thought to the ethical issues raised by research. A particular challenge in this area is to 
find the means to connect for all interviewees with theoretical and scientific interests 
and to draw out views on the issues of interest to the research, but also to find 
appropriate routes into experiential elements which can shed light on practice. it is 
most important throughout the interview process to retain awareness of the potentially 
sensitive nature of research with clinicians and the ambiguities which some may feel 
about opening their own practice to scrutiny. 
Interviewing parents 
The two main issues which needed to be considered for the parental interviews were 
the sensitivity of the situation and the benefits and hazards ofjoint interviews. 
A sensitive setting 
Research in sensitive situations requires a careful, well considered approach (Lee 
1993). The parental interviews for this research were sensitive in a number of ways. 
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Firstly they would involve potentially vulnerable people and every effort had to be 
made to offer them respect and protection, even if this meant accepting a degree of 
compromise in the data. Not only is information about trial participation embedded 
within the story of the birth and sometimes the death of a baby, the interviews would 
also need careful management because they involved exploration of the potential of 
the RCT for changing the parental experience. This could be in relatively small ways, 
such as satisfaction with information giving, or if there were similarities with the 
parents involved in the ECMO Studies it could be in explosive and life-changing 
ways, such as the feeling that doctors had denied a dying baby a potentially useful 
treatment. Murray (2003) has argued that although qualitative researchers are often 
discouraged by "the task of connecting with a vulnerable population and asking them 
to disclose information about a sensitive aspect of their lives", there can be important 
"therapeutic benefits" for interviewees. Having received positive feedback from 
many parents in earlier studies who have been interviewed on sensitive subjects 
(including non-trial related research), there is truth in this argument. It is however 
dangerous to consider this as a legitimation for such research and it is important to 
remain mindful of the need to guard against an overspill from interview to a 
counselling approach (Birch & Miller 2000). 
Secondly it was important to be aware that the research interviews had the potential to 
change the parental experience. The ECMO Studies had shown that parents could use 
the terminology associated with a trial and appear to have a good appreciation of trial 
methods, but on further exploration could hold co-existing views which were at odds 
with the experimental rationale, such as feeling that their doctor influenced 
randomisation in some way. Care would be needed to explore parental views without 
interrupting their coping mechanisms, and without revealing information which might 
be difficult to integrate into their accounts of events, such as the random nature of the 
allocation. If parents felt greatly reassured that a doctor had selected the best treatment 
it would be inappropriate to deliberately introduce during an interview the role that 
chance had played in events. 
Joint interviews - issuesfor data collection 
A choice was made that invitations for interview would be addressed to the parents of 
particular babies. In this way parents would be free to choose themselves whether 
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they would be interviewed singly or jointly. The joint interview is a method which 
is 
said to lie "somewhere between individual in-depth interviews and focus groups" 
(Morris 2001). As the events that were considered at the heart of the research were 
events that in most cases had been shared, it seemed an obvious approach to take 
24 
. It 
is however a methodological decision which undoubtedly affects parental experiences 
of research and shapes the data which are generated and so needs further reflection. 
Despite the potentially influential role of this means of data collection, the choice to 
conduct joint interviews has been considered by very few researchers. The views of 
the authors who have done so are largely convergent, each making the same points 
(Seymour et al 1995; Arkesey 1996; Morris 2001). They are therefore drawn upon 
below with no further reference to the individual overlapping points that each make. 
Joint interviews have practical advantages as they may produce more accurate 
accounts than lone interviews. One partner may be able to supply details which the 
other has forgotten or was not privy to in the first place. Shared reflection may allow 
recall of important details which would otherwise be lost. Conversely it is inevitable 
that research involving joint interviews will in some cases highlight differences 
between the views of interviewees. When different views are expressed, this can be of 
particular interest to the researcher, but when differences in recollection of events 
occurs, this can complicate analysis. 
It is important to consider that a joint interview does not simply produce a more 
complete story than would be achieved by two lone interviews. It produces a unique 
shared narrative, a construction that occurs only on that one occasion where the views 
of two individuals are put forward, exchanged and intermingled in such a way, that 
they promote or inhibit in the other insight, reflection, remembrances and even 
retractions. This shared narrative is a product of a relationship, a shared event, and of 
an artificial impetus for reflection, the interview itself. 
24 A shared experience does not automatically lead to the decision to carry out joint interviews. 
Researchers with a different approach may elect to interview each partner separately in order to 
preserve the independence of the views of each partner and to offer both members of a couple a clear 
opportunity to speak openly. 
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Joint interviews - ethical issues 
When interviews involve discussion of intensely emotional experiences, participants 
may prefer to be interviewed with the partner who shared that experience. At difficult 
points in an interview they may provide support for each other, and an often quite 
natural process of tum-taking can occur, as one partner speaks while the other steps 
back from the dialogue to listen, reflect or compose themselves. 
While interviews can have a therapeutic effect, and research participants can value the 
opportunity to recall and explore emotional events in detail, the situation can be 
extremely complex when two parties are involved, particularly if each has different 
emotional needs, especially in terms of the desire to revisit experiences. The data 
generated will be richer and will offer greater insights if interviewees are honest and 
open, but it is crucial that interviewers are aware of the responsibilities that 
accompany gaining access to the private world of a couple and turning it into data for 
public consumption. It is most important to retain awareness that the purpose of the 
interview is to gather data in an ethically sensitive, methodologically appropriate way, 
and not to consciously intervene in the emotional dynamics of a couple. 
It is possible that the interview can act as a forum for revelations between partners of 
issues which have not previously been discussed, or of opinions which have not been 
articulated. Given a focus on a situation where partners are often protective of each 
other, it is not surprising to hear in interview phrases such as "What you didn't know 
at the time was and "I didn't know that you felt like that". Whilst this can be 
very positive, it is also possible that interviewees may take an opportunity to ensure 
that their partner listens to their views. They may reveal a view in a supportive 
environment that they later regret (Duncombe & Jessop 2002 
25). The interview may 
be used as a means to expose areas of difficulty, with the interviewer either acting as a 
catalyst if discussion within the couple has been difficult, being an assumed ally if one 
partner articulates what they feel are the shortcomings of another, or as a safety valve 
if the presence of a third party makes it easier to bring up a difficult issue. 
'5 Duncombe and Jessop make this point in terms of revelations between the interviewee and the 
interviewer, including recognition of previously suppressed emotions. It is however relevant to 
consider the possibility of revelations between partners which are made during interviews and cannot 
be retracted. 
87 
Data collection 
The interviews with the neonatologists 
Recruitment (Appendix FI) 
Neonatologists with experience of recruitment to the CANDA and INNOVO trials, or with a 
senior role in either trial, were recruited from five NICUs (A-E)-, one NICU recruited to tile 
INNOVO Trial only (A), three recruited to both trial-, (B-D) and olle recruited to tile CANDA 
Trial only (E). A sample of 30 Interviews was planned for this study to allow sufficient 
numbers to consider the professional experience of each trial, and to include some 
neonatologists with experience of both trials. To achieve this sample, 31 neonatologists 26 were 
approached by letter or email during 1999 to 200 1. As there was only one reftisal, it seenis 
that this is a highly representative sample of those involved in tile two trials. 
Details of the interviews 
The age range ofthe neonatologists was 27 to 54 years (mean 37). The career stage is 
broadly categorised as consultant or non consultant, the latter including specialist 
registrars (N=12), research fellows (N=5), lecturers (N=2) and an ECMO intensivist. 
Basic features are shown in Table I and 'Fable 2 gives details of career stage. 
CANDA CANDA & INNOVO INNOVO Total 
Consultant 4 4 
non-consultants 5 6 19 
Male 7 10 9 25 
Female 2 - 3 5 
hospital post 9 5 10 2) 4 
university post - 5 - 5 
Both - I I 
19 CANDA 
1 21 INNOVO' 
Table 1. Basic demographic details of the sample of neonatologists 
26 A small number had moved on from neonatology in tile time between their involvement in the trial 
and the interview. For ease of expression, and to reflect that at the tinie of their trial collaboration they 
were all working within neonatal intensive care, they are referred to throughout this thesis as 
neonatologists. 
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CANDA CANDA & INNOVO INNOVO Total Total 
Consultants 
42 (Head of Dept. ) 
Nit 
# 14 
# 15 (Head of Dept) 
416 
# 19 (Head of Dept. ) 
#22 (Head of Dept. ) 
#23 
#25 (Head of Dept) 
828 
430 
4 4 4 11 
Non-consultants 
41 specialist registrar V/ 
43 specialist registrar 
#4 specialist registrar 
#5 ECMO intensivist 
#6 research fellow 
#7 specialist registrar V/ 
#8 lecturer 
#9 research fellow 
#10 specialist registrar 
412 specialist registrar V/ 
#13 specialkt registrar V/ 
#17 specialist registrar 
# 18 research fellow 
#20 specialist registrar & 
research fellow 
V/ 
821 specialist registrar 
#24 research fellow 
426 specialist registrar V/ 
#27 lecturer 
429 specialist registrar 
Is 6 8 19 
119 CANDA 
INNOVO", '-ý,., 
Linked to the CANDA Trial but in a position to comment oil the INNOVO Trial 
** Linked to the INNOVO Trial but in a position to comment oil the CANDATrial 
'Fable 2. Neonatologists' career stage and finks to tile CANDA and INNOVO trials 
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Conduct of the interviews 
The interviews took place mainly at the place of work, either in an office or a private 
room, with the exception of one which was carried out by telephone at the request of 
the interviewee. With consent all interviews were tape-recorded and fully transcribed. 
They covered a wide range of issues relevant to participation in the trials and typically 
lasted an hour, a generous amount of time given the time pressures that many of the 
interviewees faced. Although they were often interrupted by telephone calls or 
queries from colleagues, there were no instances where the interviews had to be 
abandoned. The interviews were largely very open and frank. There was the 
occasional sense that some were guarded and careful about what they said. The 
interviews focused on their involvement with the neonatal trials, as well as their 
broader experience with trials more generally. The schedule included a number of 
areas which are addressed in the trials literature, such as informed consent 
requirements, or the use of randomisation or placebo, and it was clear that where 
doctors were familiar with the literature, they often relished the opportunity to discuss 
these issues. This resulted in interviews in which the majority of those involved had 
engaged and appeared to have given their considered opinion, as well as giving useful 
accounts of their personal experiences. 
The interviews with parents 
Recruitment (Appendix I) 
The parents were recruited via the same NICUs as the neonatologistsý 7. The aim was 
to describe approximately 20 parental decisions per trial. Based on the ECMO Studies 
it was thought that this would provide sufficient data to represent parental experiences 
in each of the two trials, and would give a large sample for detailed consideration of 
issues common to both trials. 
At the start of the study, recruitment was based on access to lists of trial participants. 
The contact process involved an initial check with the consultant neonatologist who 
had responsibility for the baby. The family GP was then contacted for permission to 
27 This could deepen understanding of the views of each of the parties, as well as the interplay between 
them. 
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approach the family. This was considered to be an important safeguard against the 
possibility of making an inappropriate contact, possibly after another bereavement or a 
miscarriage, or in cases of parental depression. A letter was sent to the parents with a 
reply slip and prepaid envelope, to return if they wished to participate. For the 
bereaved parents it was judged important that the consultants involved in their care 
should have a greater degree of control over the process, given their concerns that 
bereaved parents should be approached very carefully. They were able to choose 
whether to ask parents if they would be willing to see a letter from the research team 
about the study, either when they met at a bereavement follow-up appointment, by 
telephone, or by writing to them. 
As the study progressed changes were made to the Data Protection Act and it was 
necessary to adapt recruitment processes. As it was no longer permissible for 
researchers with no role in patient care to have access to identifying personal details, 
the recruitment process was necessarily handed over to the trial recruiting centres. It is 
therefore not possible to state the precise response rates as the actual numbers of 
conversations and letters sent to parents is not known, although the recruitment figures 
prior to this change suggested a response rate of approximately 50%. 
Details of the interviews 
There were 39 interviews involving 63 parents, most of which (33) were carried out 
by the author (see the Statement of Work). Nineteen interviews involved parents of 
babies enrolled in the INNOVO Trial, 18 in the CANDA Trial, and 2 in both trials. In 
one interview with bereaved parents of a baby enrolled in the CANDA Trial a tape 
was corrupted, leaving 38 interviews available for study. While most had agreed to 
trial enrolment, in 4 instances (all with surviving babies) the parents had declined to 
participate in the CANDA Trial. In a very small number of cases (4 INNOVO, 3 
CANDA), parents had agreed to a recording of their discussion. 
In 25 cases both parents were present and in 13 cases only the mother was present. 
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The 38 interviews involved 28 mothers and 19 fathers of 30 surviving babies 
28 (N=47) 
and 10 mothers and 6 fathers of 12 trial babies who had died (N= 16). The interviews 
took place on average 67 weeks after the baby was born (median 61), ail indication of 
the time which elapsed between the events of interest to the study and the interview. 
There was however quite a variety of time periods in order to allow more parents to 
enter the study, and the number of weeks ranges from 48 to 149 for the CANDA Trial 
and 18 to 124 for the INNOVO Trial. 
Table 2 gives details of the sample and the overlap between the trials, and shows the 
distinction between the number of interviews analysed (N=38) and the number of 
decisions that this represents (N=40). It also indicates the number of interviews with 
parents who accepted a trial (N= 34) and with those who had declined (N=4), and 
highlights the cases where parents were bereaved (N= 10). 
CANDA CANDA & INNOVO 
INNOVO 
Accepted 13 2 19 34 interviews 
(3 were bereaved) (7 were bereaved) 36 decisions 
Declined 4 - - 4 interviews 
4 decisions 
17 19 38 interviews 
40 decisions 
19 CAN DA 
JMMJW"ý " 21 INNOM-Mil I 
Table 3. Basic details of tile sample of parents 
Further parental details are given in Chapter 7 in discussion ofthe cirCUrnstances of' 
their decisions about the two trials. 
Conduct of the interviews 
The interviews with parents were carried out in the parental home. All were tape- 
recorded with consent. The parents often went to some lengths to accommodate the 
interview, arranging work or childcare to allow both parents to be present, or to allow 
time to talk without interruption. 
2" As the sample includes parents of twins and triplets the number of babies is greater than the number 
of parental interviews. 
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The interviews involved detailed discussions of personal stories, through pregnancy, 
and the birth and sometimes death of their babies. Involvement with a trial was 
embedded into this story. The parents were afforded as much or as little time as they 
wished to recount their experiences and give their views. The interviews were in 
depth and semi-structured with a high level of flexibility and also drew on a narrative 
interviewing approach. They were designed to promote a full and reflective account 
of a trial, whilst allowing parents to feel that they adequately represented their story. 
In some instances there was some disparity for couples in their inclination to discuss 
events, for instance some fathers could be present but appear to be disengaged with 
the subject. As the interviews moved on they were often drawn in by the subject 
matter and began to participate. The interviews could involve discussion of very 
emotional events and it seemed that the parents had steeled themselves to revisit these 
experiences. For some this was a very welcome opportunity but for others it could be 
met with mixed emotions. In all interviews it was made clear that if there were any 
areas that parents did not wish to discuss, then they should indicate this and the 
interview would move on or end. Similarly if emotions ran high, parents were always 
offered the chance to stop or to discontinue the interview. Whilst some did chose to 
stop, sometimes for a cigarette, a tea-break, or simply to pull themselves together 
without the tape-recorder running, none chose to end the interview. A brief 
questionnaire was left with parents which in part assessed their views of the interview 
and the impact that it had had on them. Although some, not surprisingly, indicated 
that they had felt emotional, none would have preferred not to have taken part. 
Data analysis 
As indicated earlier, the direction of the research owes much to the experiences gained 
through the ECMO Studies. Many of the lines of questioning that were set in the 
interview schedule about their decisions about involvement in a trial, and their 
perceptions of the implications of their decision, were influenced by pre-existing 
perceptions of what was likely to be important, derived from this prior experience. 
The interviews were also to some extent theory-led, taking their direction from the 
existing theoretical and empirical literature. There were many issues which arose in 
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response to the direction of the interviewees, and insights which only occurred at the 
point of detailed analysis. 
In his "adaptive theory", Leyder argues for the value of these different elements, 
including the role of pre-existing researcher knowledge and concepts (Leyder 1998). 
In contrast to a grounded theory approach, where data are given absolute primacy and 
from which themes are said to emerge, Leyder suggests an approach to analysis in 
which existing models are adapted in a process of modification and refinement as 
experience and understanding of a phenomenon grows. 
In accordance with Leyder's approach, throughout the study, initial lines of 
questioning were developed in interviews as new lines of information were introduced 
by respondents, and then explored in analysis. Analysis of the fully transcribed 
interviews involved reading and re-reading the interview texts and the application of 
detailed codes and broader over-arching code families, based on a mixture of the 
interview schedule and insights gained from the interviewer's experience of the 
interviews. The codes were expanded and collapsed as interviews were processed. 
Eventually no new codes were introduced and it was judged that the data had been 
adequately explored. This process was assisted by a textual analysis computer 
package, ATLAS-ti (Muhr 1994). 
The analytic process is not, however, simply an act of textual analysis. It is part of a 
larger process which has been carried out over the course of the study in which the 
views of the various interviewees take their place. The interview accounts are strung 
together as pieces of evidence (the most important pieces of evidence), along with 
insights gained from meeting the trialists, visiting NICUs, attending steering 
committee meetings, reading trial material, negotiating the research with clinicians 
and informal discussions outside of the interviews, all of which give a broader and a 
deeper sense of the trials. In keeping with this approach the interviews and analysis 
did not simply focus on a limited series of questions, but drew on a very wide range of 
the interview data to explore how the interviewees think about the trials, and to 
promote further understanding of their every-day clinical and personal worlds. 
94 
Chapter 5- The decisions that neonatologists 
make to collaborate with a trial 
Organisation of the data 
In Chapter I it was argued that there is a distinction between how trials are viewed as 
an abstract principle, and how actual trials are viewed in practice, suggesting two 
possible levels of thinking about trial collaboration. 
The process of conducting the interviews with the neonatologists suggested that their 
decisions about collaboration were indeed highly complicated. Data analysis made it 
clear that there were a number of important influences shaping professional responses 
to the CANDA and INNOVO trials. As these various factors were unpicked, the 
degree of complexity became more evident, and four levels of decision-making about 
trial collaboration were identified in the data. They are: 
Level I- Individual collaboration in principle 
Level 2- Local collective collaboration in principle 
Level 3- Local collective collaboration in practice 
Level 4- Individual collaboration in practice 
Once this structure was identified it was possible to organise the wider data which 
pertain to the forces which shaped professional decisions around these four. The levels 
are explored below with reference to the decisions that were made to collaborate with 
the CANDA and INNOVO trials. The decision to suspend collaboration is explored in 
the following chapter. 
Level I- Individuals in principle 
Before considering how the neonatologists viewed the two trials, their general view 
of trials-based research is presented. This broad view gives an indication of the 
principles they hold about research when separated from the specific conditions 
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created by particular trials, and gives some background to their approach to the 
INNOVO and CANDA Trials. It serves to build up a picture of the individuals 
who combine to work as a collective in relation to trial collaboration. 
The neonatologists readily expressed their views on research, with many 
spontaneous comments as to why, in principle, they felt that collaboration is 
appropriate. None stated opposition or disregard for trials at this level. The factors 
which have been shown by several studies to be associated with support for trial 
collaboration were clearly identifiable, that is: the value of research for medical 
advancement, for its potential to benefit future populations and for advantages 
which might be gained by individual participants. As these factors were heavily 
interrelated in the neonatologists' accounts, their views on the value of trials are 
described under two headings which together encapsulate these three areas: 
Advancing medical knowledge and improving patient care 
A means to balance risk and benefits for populations and for 
individuals. 
Advancing medical knowledge and improving patient care 
Almost all of the interviewees spontaneously mentioned the value of trials to advance 
knowledge and to improve care. Consultants and registrars alike were supportive of a 
research culture and made many simple statements such as: "I think we have a 
collective duty to take parV' (Int. 2 registrar29), "I think trials are critically important" 
(Int. 9 registrar), and: "I believe research has a very important part to play in the 
medical care of babies. " (Int. II consultant). 
For some contributing to research was not simply a role that they took on from time to 
time, but an intrinsic part of how they worked and how they saw their position as 
doctors. The sense of making a personal contribution to the process of generating and 
implementing findings of value in their own field could be very gratifying. 
29 Refer back to Table 2 for details of the links between individuals and the trials for which they acted 
as collaborators. 
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I would like, at the end of my career, to look back and say I've initiated this, I've 
planned that and I've participated in these other things that other people have 
planned. Because unless we do that... nothing will move forward. So very 
consciously I would wish to be involved in this sort of thing, and if I worked in a 
different type of hospital I'd still be angling to participate or looking at ways in 
which I could initiate studies that would take paediatrics forward. (Int. 28 
consultant) 
I enjoy my job but I do enjoy research and I feel that research is very important. 
Good research is the only way to improve care. There's too much bad research 
published, and unfortunately a lot of the kinds of questions that we have ... can 
only be answered really by controlled trials. There's too much anecdote and review 
and personal opinion that just muddles the whole thing. So I'm very happy to 
[collaborate]. I enjoy being involved in research (Int. 13 registrar) 
Many of the neonatologists had engaged with a range of issues relating to trials. The 
semi-structured nature of the interviews allowed discussions to take various turns 
away from the interview schedule and the neonatologists frequently talked at length 
about their own areas of interest. Some raised ethical issues; others mentioned 
procedural questions such as when to stop a trial, or who should have responsibility 
for recruitment, and some discussed sample sizes, bias and questions of trial design. 
Their own reliance on the evidence base for neonatal intensive care made them 
particularly supportive of the value of advancements through research. 
I think it's important to get involved in trials ... because that's the only way to 
advance things. [Paediatric] oncology is a perfect example as to [how) that has 
happened. On an intellectual level I find it very interesting and satisfying. I also 
find that trial results and the Cochrane Database is a very good knowledge base to 
work from, so that most of our guidelines are based on randomised trials. (Int. 23 
consultant) 
I don't have any qualms about [asking parents to take part in research]. I feel quite 
good. With all this evidence-based medicine that we're moving into, that is the 
only way that we're going to get better and it is not enough to say, "In my 
experience this is better, in my experience this is not good. " So I know that this is 
the right thing to do. (Int. 9 registrar) 
Awareness of the need for information, and acknowledgement of one's own position 
in relation to a gap in knowledge, is an important prerequisite to trial collaboration. 
This was a fundamental principle which was referred to in many interviews. In an 
interview with a consultant a question about trials-related limitations on clinical 
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freedom elicited a response about the ability of trials to prove good quality evidence 
as a foundation for care. 
I've never been very impressed with clinical freedom because it implies that ... 
what there is to know about medicine and caring for babies is already known. I 
think ninety-five percent of what we do is groping around in the dark without really 
knowing what the right answer is. I'd be much happier to be part of a clinical trial 
and try and get an answer, than not be part of a clinical trial and ... pretend that I 
know what's best for a baby without having the evidence base to back that up. 
Other people would say "I can tell in a particular baby whether this is going to 
work or my experience is this. " Now I would equate that with anecdotes which 
come right at the bottom of the pyramid of evidence. Other people would say that's 
clinical experience. ... I think there are constraints on your clinical 
freedom, 
without a doubt. Whenever you sign up to a trial it's a compromise. You may not 
treat babies exactly the same way [as you would have done outside of the trial] but 
you're prepared to compromise because you feel that the potential benefit, the 
results of the trial, outweigh these minor differences in clinical management and 
constraints of your clinical freedom. (Int. 25) 
A sense of the importance of medical advancement could lead to great enthusiasm for 
research, to a point where parental refusal to participate could be disappointing. This 
was true for those contributing to multi-centre trials as well as for those who were 
more intimately involved in running their own smaller local trials. 
In terms of helping us all know what are the best treatments for the babies, [refusal] 
bothers me because I want to get as many patients as possible, but on an individual 
level I would never think badly of one parent or another for not consenting because 
... I can understand their way of thinking. ... (Int. 
29 registrar) 
The first couple of times it happened with my trial ... I was personally offended. I 
went off the unit and I was really pissed off. ... I was actually sort of upset because 
I took it as a kind of personal slight almost, that there must be something about my 
manner. ... 
I thought "Why? Why did they not do it? " (Int. 13 registrar). 
The fact that the neonatologists were so positive about research in principle did not 
mean that they did not express concerns. Recognition of the possible tension between 
the needs of research and the needs of parents was common, a source of a degree of 
anxiety which was often detectable in the interviews. The neonatologists were keen to 
emphasise their respect for parents, and, as with the registrar (Int. 29) quoted above, 
they wished to emphasize support for their right not to participate. Their principles 
about collaboration were often presented in conjunction with their principles about 
care and relationships with patients and parents. 
98 
If I feel the study is important, either for that patient specifically, or more generally 
it's an important question which could have a significant effect on other parents, or 
other patients, then I feel that it's a very important thing to do. ... I feel 
it's very 
important to give that possibility to the parents to participate, but on the other hand 
if they say no I respect that, I respect that very very much. (Int. 6 registrar) 
I think if parents dodt want their children to be in trials we must accept that and be 
very careful that we treat them in exactly the same way prior to the discussion 
about consent and after. The parents must not be bullied into doing it. I think at the 
end of the day it will do our profession, a great disservice. (Int. 16 - consultant) 
Although there was a sense in many interviews of difficulties which can underlie trial 
collaboration, where principle-driven concerns were expressed3o, such as whether 
truly informed consent is possible, or over difficulties in defining personal equipoise, 
it was rare for these to supersede the value of trials in principle. One interviewee 
stood out as being very discomforted by the processes involved in neonatal trials. He 
described recruitment as "really difficult" several times, but still felt that trials were 
important, however hard he found them to implement. Although his view of trial 
collaboration was indicative of a problematic relationship with the role of researcher, 
he was still supportive of trials-based research, albeit with a certain degree of 
resignation. 
I think, you know, trials are a necessary evil for the benefit of the greater good. 
Once you start them you have to see it through. You can't be allowing yourself to 
be swayed by what is probably emotion (Int. 24 registrar) 
Just how trials were thought to advance medicine was also of interest. There was a 
keen awareness of the difficulties which can ensue when treatments are unevaluated. 
Whilst the knowledge gained through trials-based research was sometimes described 
as a process of incremental steps, with several neonatologists alluding to the advances 
in treatment of paediatric leukaernia, the interviewees were also very aware of trials 
such as the UK Collaborative ECMO Trial, where results can shift practice overnight. 
Occasionally another view was expressed which reflected a model of trials which was 
also present in some of the parental accounts in this and the ECMO qualitative studies. 
Here trials can be carried out to provide data to support what is already known but is 
in scientific terms unproven. In referring to an actual trial comparing two commonly 
used interventions, a registrar argued that she felt it was clear what the results would 
30 as opposed to practicalities, such as the time that it takes to go through informed consent processes. 
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show. It was essentially an exercise in validation which necessitated withholding 
treatment A from half of the patients. 
I had my own feelings about that because I've always used [treatment A] but then 
you are trying to get equal numbers [for treatments A and B]. If you are involved in 
something like that you need to get the numbers to prove what you're saying. 
(Int. 21) 
A means to balance risks and benefits for populations and 
for individuals 
According to the Theory of Broad Benefit, randomisation ensures a fair distribution of 
possible benefits as well as risks. There was a strong sense in many interviews that 
the neonatologists were aware of, and drew upon debates in which potential benefits 
and risks were weighed against each other. 
The notion of medical advancement, as described above, is clearly of benefit to 
populations generally, and valued by the neonatologists, as disease can be better 
understood and more effective treatments can be utilised. An important issue for 
trials-based research is whether or not these advancements for patients of the future 
are made at a cost to some of the individual participants involved, a central concern in 
the Theory of Limited Benefit. When the neonatologists were asked whether they felt 
that there was competition between the needs of individual participants and those of 
future patients, responses were often framed by equipoise and the null hypothesiS. 31 
If you feel you are in equipoise then you presume that there's going to be no direct 
benefit one way or another to the baby, because which ever they get, as far as 
you're aware, they'll be getting the best treatment that you know about. Any 
difference that might be shown will be of use to future babies (Int. 6 registrar) 
I suppose on occasion when I've got consent and parents have asked me "Will this 
be helping our baby or is it intended for babies in the future? " it's easier with an 
intervention trial because then you can say, potentially if you got a treatment and in 
the future it was proven to be beneficial then it will have helped your baby but you 
can't guarantee either that they will get the treatment or that the treatment will be 
effective, so there's that uncertainty. But what I try and tell them is that even if 
they were in the control group that didn't get any treatment that information would 
31 The null hypothesis assumes that there is no significant difference between treatment arms. A trial 
measures any departure from that hypothesis. 
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still be very valuable. It would not perhaps help their baby but [could] help babies 
in the future (Int. 25 consultant) 
An obvious benefit which might have been expected to feature prominently in the 
neonatologists' principles about trials is the potential for benefit through accessing an 
experimental treatment. Although this was discussed with reference to practice 
(defined here as Levels 3 and 4), when considering the benefits of trials generally 
(Level 1), there was little suggestion that babies may benefit directly by accessing an 
experimental treatment. Where this was mentioned, it was often minimised, almost a 
by-product of the research process. The comments of a consultant below are quite 
typical. 
The whole idea of doing studies is to try and benefit people for the future. I mean 
that's what we study things for, to try and advance medicine. Well it's not going to 
affect anyone in the here and now, it's going to be for the future. .... That will 
always be the driving force I suppose, but hopefully along the way you may benefit 
a few people as well. But again it depends on your way of approaching these trials. 
If you think well this is going to benefit my patients, then I think you ethically may 
have a major dilemma to face because should you really be entering people into a 
trial who may not get that treatment. If you are already convinced that it's going to 
help them, that's a problem. (Int. 11) 
There were ways in which the interviewees presented trials as beneficial for 
participants. Several mentioned the phenomenon of improved outcome for trial 
participants, regardless of allocation, when compared to non-participants. A consultant 
who stated that "being involved in a trial itself is beneficial" explained why he felt 
that this is so: 
People get spoken to more, parents are communicated with more, data is monitored 
more rigorously, patients are thought about more, perhaps more clearly in some 
ways. (Int. 23) 
Almost all of those referring to this phenomenon felt that it would be inappropriate 
information to give to parents who were considering enrolling their baby in a trial as it 
could be seen as coercive. It was therefore generally viewed as something to guide 
professional decisions about collaboration and not parental decisions about 
participation. 
What I wouldn't say to parents, but I would say if I was giving a talk about this, 
would be there are studies that show just being part of trials is beneficial. ... Even if 
parents were to consent and not get treatment [that is they are allocated to the 
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control arm] their babies are probably looked after better just by the process of 
whatever goes on around the periphery of trials. (Int. 25 consultant) 
The benefits described above have actual tangible effects, measurable as outcomes for 
individuals. The neonatologists discussed other types of benefits which were more 
complicated, such as protection from possible risks. These benefits could pertain to 
individuals or to populations. In their simplest form, trials were thought to limit the 
chance of side-effects to one portion of the participants, those exposed to the 
experimental intervention. A consultant argued that restricting the number of patients 
exposed to an unevaluated intervention offered protection to those within the trial, and 
protected those outside the trial from any risky exposure should an intervention be 
used without evaluation. 
It is my duty to expose as few people as possible to the experimental treatment, for 
fear of the unknown side effects. ... The randomised study 
is a protective strategy, 
it protects you against unknown side effects. ... [It] protects the population at 
large 
from [exposing] large numbers of children to a ... treatment that 
has unknown side 
effects. It minimises the number who will suffer the side effects. (Int. 22) 
There was a small number of interviews in which the idea of benefit through 
protection was extended to future populations who are spared risks inherent if 
treatments are adopted without evaluation. Two consultants mentioned the use of 
increased levels of oxygen for preterm babies as an example of harm which occurred 
in this way. 
Fear of the unknown is a very right situation, we should all be wary of the 
unknown. ... We have only to remember oxygen. ... 
These were the mistakes that 
were made and if there's one thing we should learn from them it is that we must do 
good studies early on, otherwise we can do terrible harm to a great number of 
patients. (Int. 28) 
If they had bothered to randomise ... high and low oxygen in premature babies in 
the fifties then there would be a hell of a lot less of them running around blind. ... I 
mean people look upon randomisation as just refusing certain people the new- 
fangled, obviously better treatment, but it's often protecting them against the 
unknown side effects of the new-fangled treatment. (Int. 22) 
A more complicated way of thinking about risk was put forward by the only 
neonatologist who felt that it was appropriate to inform parents about the possible 
benefits of trial participation. In his argument these potential benefits counterbalance 
the potential risks involved in the trial situation. The risk focused on here is the 
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possibility of not receiving what with hindsight proves to be the superior treatment. 
This provides part of his own ethical framework in which he considers trials and 
guides the ways in which he deals with parents. 
I'm very conscious of the trial entry effect, which means that any baby in any kind 
of study or trial, on the whole does better than those not entered. Now, this is well 
established in so many different fields, that it makes me feel totally comfortable 
with the idea that one isn't compromising the baby. ... What may be lost by taking 
what turns out to be the inferior treatment is gained in some measure by the fact of 
participating in the study at all, because we know that outcomes are better when 
you participate rather than if you don't participate. ... It always seems to me that 
there should be an explicit trade off. If you are asking anybody to participate in any 
kind of study I think they should always get some kind of extra kick-back ... the 
sense that they're getting more attention, there's something else going on as well, 
there's some other benefit to them from saying yes than just the knowledge that 
they're contributing to future knowledge. (Int. 28 consultant) 
The possibility of receiving "what turns out to be the inferior treatment, " is an 
enormously important issue when considered in the context of trials involving 
individuals at the edge of life. Where mortality is a very likely outcome for a 
substantial proportion of a trial population, the allocation made may mean the 
difference between life and death; where morbidity is an important issue, it could 
affect physical and mental ability and future quality of life. In a particularly frank and 
sombre comment, a registrar with a lot of research experience argued that the people 
who decide to participate in such trials are taking on a risk for their fellows. 
What you're asking them to do is to make a- (long pause) - is to enter a world of 
great uncertainty for the benefit of society. You're asking them to be guinea pigs in 
the nicest possible way, but still to be guinea pigs. ... I think you're asking them to be hostages to fortune really. It's a big thing. Huge! (Int. 24) 
Level 2- Local collective collaboration in principle 
Before an individual clinician can collaborate with a trial, a higher level of decision- 
making takes place in the department, centre or unit to which they are attached. The 
process of becoming a trial centre, where there is an undertaking to recruit patients to 
a multi-centre trial, involves consideration at a local level. The NICUs which were 
involved in this study had each been through a process of internal consultation which 
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led to a decision that they would co-operate with recruitment to the CANDA 
32 and the 
INNOVO trials. This focused on whether the proposed research was scientifically and 
ethically robust, and whether it was workable in their local setting. Whilst 
consideration of feasibility includes questions of practicality, in this section it is 
considered in terms of the broader issue of how those involved thought the trials 
should be implemented. 
The consultation process 
The nature of that consultation process seemed to be broadly similar in the different 
neonatal units, it being consultant-led. Three consultants describe this collective 
approach to decision-making. A consultant from NICU C indicated that decisions over 
whether or not to collaborate with a trial can be clear and unanimous. 
It is partly personal and partly a group decision but a good example was [a 
particular trial] ... We didn't like that protocol. 
We did not feel that we could stand 
and defend it with our patients. I don't know that we quite went as far as thinking it 
was ethically dubious, but perhaps that's saying the same thing as I couldn't defend 
it to my patients. Anyway, the bottom line was none of us felt we would be 
prepared to be involved with that so as a group we didn't become involved. (Int. 28) 
This shared element of the decision to collaborate seemed to be very important. 
Another consultant from NICU D indicated that their discussions are well debated in 
order to secure a unanimous agreement. 
We've always had a policy where we decide as a group. We don't always agree, 
but this is a situation where compromise is important and there'll be some given 
and take. When people feel strongly then we tend to give in and go along with the 
consensus view, and if you feel strongly, similarly you are obliged to back your 
own view up with some evidence and other people will hopefully give way. We 
like to do things as a consensus group. (Int. 25) 
A consultant from NICU A argued that it is important that they take a common 
responsibility for the decision to collaborate with a trial. As they represent a wider 
group of colleagues who would be required to act in relation to their agreement to 
recruit to a trial, it is important that within their consultant group a decision is sound 
and undisputed. 
32 In the case of the CANDA Trial it should be noted that it was developed and co-ordinated through a 
small number of NICUs and so some decisions were about development as well as collaboration. 
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I'm very fortunate in that as a consultant group ... we have one meeting a month 
that is dedicated to potential research topics and audits. So if as a group we want to 
conduct a research project or are approached about a multi-centre study we would 
discuss the protocol at that meeting. We have discussed over the last year some 
protocols that we have thought were unethical, and have decided as a department 
we would not enter babies into that trial. I think we [have to] have corporate 
responsibility. ... Because it needs different people to recruit at 
different times I 
think we have to have that corporate agreement that the trial is ethical and we 
should be randomising children into it. (Int. 16) 
A similar point was made by another consultant from a different neonatal unit (C). 
Unless we were all moderately happy that that was appropriate [we would not 
join]. If some people felt rather neutral ... then we might all go in for it. But if one 
person had very strong views for whatever reason, then we wouldn't join in. ... As a department we'd have to [opt out] otherwise it would be far too confusing. (Int. 19) 
This departmental rather than an individual approach avoids the situations where an 
intervention might be randomised for patients under the care of one consultant whilst 
could those under another consultant could receive the same intervention as a standard 
approach to care. This can be confusing for staff caring for the patients, giving very 
mixed messages about equipoise, care and research, as well as for any parents who 
could be aware of the disparity. 
The terms of collaboration 
The issue of local feasibility was an essential issue for most consultants who felt it to 
be important that trials are achievable given local circumstances. A NICU B 
consultant explained: 
Certainly there's a lot of in-house discussion ... to decide about which trials we'll 
take part in. We don't like taking part in a trial where we don't recruit. It's very 
easy to say, "Oh, yes, we'll do thaf', and then be hopeless at recruiting, and we're 
very aware of that. We try and pick trials where there is a genuine interest, and we 
think if s feasible for us too; some of the processes are very complex. (Int. 15) 
Once the collective local decision has been made that a NICU will collaborate with a 
trial, there can be further issues about implementation which are also worked through 
collectively. These relate to how a trial is managed locally, and can involve 
modification of the protocol, either formally or informally. A consultant at NICU E 
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explained how a local modification occurred for the ECMO Trial as it was considered 
important within his unit that any baby that they recruited should be referred on for 
more specialist forms of care, regardless of allocation. 
Dr #22: Because it depended on a failure of your current therapy, pretty much 
... - we said we will 
[recruit] them to transfer to [a specialist centre]. So we 
randomised them to the ECMO study and that decided which of two hospitals 
they would go to. The ones who were randomised for ECMO would go to [one 
hospital] and the ones who were randomised to get conventional treatment 
would go to [another]. ... It 
felt like something was happening and indeed it 
was, I mean there were other [facilities] available that we didnt have at that 
time. 
CS: Yeah. Certainly for the ECMO parents I have spoken to, it was incredibly 
difficult [when the baby was allocated to the] conventional arm and nothing 
changed. 
Dr #22: Well, thaf s why we did not accept [it], you know, we agreed to enter 
them into the study on the condition that they transferred out from here to one or 
other of those hospitals, because that seemed to be the only logical approach 
from the parents' point of view, that something changed, when things got 
difficult. 
Whilst this consultant presented a local policy which was agreed upon with the 
trialists, there were other ways, some of which are dealt with in greater detail in the 
following chapter, in which informal local modifications may have shaped 
recruitment patterns for the trial and events for individuals. One senior consultant 
indicated that problems which he felt were inherent in the INNOVO Trial design 
had led to a decision to collaborate but to informally'3 redefine local entry criteria. 
[I am] certainly in equipoise about the long-term benefit of nitric but what I'm not 
persuaded by is the methodology of the trial, simply because everybody has 
different thresholds for entering babies and it's a mess. I tried to get round it by 
actually defining a threshold within the unit (Int. 19) 
Another consultant from a different neonatal unit indicated that there was also an issue 
of thresholds for entry to the INNOVO Trial in his unit. He was asked how those 
recruited from his NICU had fared. 
Most of them died probably because we'd got a very high threshold of disease 
severity before we randomised them. We've changed that recently, we've brought 
33 i. e. without negotiation with the trial team. 
106 
that down because a lot of them died, so we were intervening too late with 
whatever intervention. (Int. 25) 
Level 3- The local collective collaboration in practice 
The collective approach was seen by the consultants as a positive and consensual 
decision-making process. It is the means by which a unit's most experienced and 
informed doctors take responsibility for accepting, rejecting or redefining the terms of 
equipoise on a local basis, and indicate to their colleagues that a trial is of an 
appropriate standard and worth. An interview with a registrar indicated that the 
assessment of trials at a senior level, especially if it was seen as a rigorous process, 
could be reassuring for the less senior staff. 
You know this is well validated or it's been exposed to a number of consultants 
who agreed that that study design is very sound. And certainly on this unit with the 
number of consultants involved and their differing views on so many things they 
wouldn't be reticent about criticising a study design. (Int. 18) 
Once a collective agreement to collaborate has been made, and local standards have 
been established, the broader group of clinicians within a NICU are required to act in 
accordance with the undertaking to recruit patients to a trial. It was sometimes, 
although not always the case, that the most senior neonatologists were infrequent 
recruiters to trials. The job of discussing enrolment could often fall to younger, less 
senior staff, sometimes during the night when fewer senior staff would be present. 
Given the less senior position of those with responsibilities for discussing trials with 
parents, and the fact that local decisions about a NICU's agreement to collaborate are 
made by consultants, it is important to explore the types of decisions that different 
members of staff feel that they make. 
How autonomous are the decisions that the neonatologists 
make about trial collaboration? 
During the interviews, a question was put to MoSt34 of the interviewees which was 
meant to assess the voluntariness and autonomy of their collaboration. Typically they 
34 The question was omitted or incompletely answered in eight interviews. Where there were time 
pressures for interviewees some interview were necessarily shortened. In some instances the semi- 
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were asked: "Has the involvement that you have had in trials been optional, or has it 
been an obligatory part of your role? " Responses indicated that almost half of the 
interviewees felt that their involvement was optional, (7 consultants, 6 registrars). 
It was the case however that seven of those who stated that their involvement was 
optional then made additional qualifying statements to indicate that although they 
could stand outside of a trial if necessary, they did actually feel pressure or under 
some obligation to collaborate. Five of these were registrars. Essentially they argued 
that they were technically free to make a choice not to recruit, but that it may be 
difficult to do so in practice. When their responses were re-categorised, as shown in 
Table 4, this suggested that only six neonatologists (5 consultants and I registrar) felt 
that they were not under an obligation to collaborate. 
Is involvement with tri Is optional or obligato 
Optional I Obligatory Q. omi ed Total 
Cons. Registrar Cons. Registrar Cons Registrar 
7 6 2 7 2 6 30 
Made statement that they felt under pressure 
or obligated (recategor sed responses) 
No Yes Q. omitted 
Cons. Registrar Cons. Registrar Cons Registrar 
5 1 4 12 2 6 30 
Table 4- Is involvement with trials optional or obligatory? 
Although these are small figures, they suggested a potentially useful line of analysis. 
The data were therefore examined to look in detail at the nature of any obligation or 
pressure, and to consider different experiences according to career stage. The aim 
here was to gain greater understanding of the nature of collaboration for different 
types of neonatologists. 
The feelings of obligation that were described varied. Some interviewees articulated 
an almost light-hearted acceptance of a general expectation that they would 
structured nature of the interview meant that the discussion moved away from a particular line of 
questioning as other lines were followed. 
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collaborate with trials. A registrar commented: "it's taken as read that you would 
attempt to recruit, given the opportunity" (Int. 18). This was especially the case for 
those appointed to a post with a specific research element. There was, however, a fine 
line between an obligatory and an optional situation, as indicated by two registrars 
whose comments are representative of many in the sample. 
Dr #24: 1 think it's as close to obligatory as it can get. I mean no-one has put the 
thumbscrews on and said "You musf ', but it has been assumed that all the 
specialist registrars would recruit for these trials. 
CS: If you came across a trial or situation where you weren't happy, would you 
feel able to opt out? 
Dr #24: Yes I would yeah, yes, no doubt if I thought it was unethical, I wouldn't 
and I would go and see whoever was responsible and explain why I fclt it wasn't. I 
think that would be fair enough, yeah. 
and: 
(laughs) You can't make a trial obligatory, so it could never be an obligatory part of 
your work. You have pressure applied to you by people running the trial and by the 
people running the unit where you are working, which means that you should 
recruit patients to the trial . ... [But] I think we should 
be recruiting children to trials 
because it gives us the information. It's never been an obligatory part of my work 
but whenever it's possible I'll do it if there's a trial going. (Int. 9) 
Some however felt a more significant sense of pressure which could be difficult, and 
this clearly related to their position within a NICU hierarchy. Several interviewees 
described being advised by a senior colleague that they would be expected to recruit to 
trials, or that a particular case fitted eligibility criteria and that they should offer trial 
enrolment. They often had to go to the trial folder to check details before going to 
speak to parents. For some there was clear discomfort. Here three registrars describe 
their early experiences of recruitment. The first two describe familiarising themselves 
with trial details, as they were given responsibility for recruitment. 
Dr #20: The first time it was horrible, because I didn't have any support and that 
was to do with the INNOVO Trial. ... My boss wasnt very approachable, fantastic bloke, but you couldn't talk to him. He just gave me a massive file, absolutely 
enormous and I had to get to know it and read it and work out the do's and don'ts 
and the inclusion/exclusion criteria. I only recruited two people in about six 
months and it was bloody hard work doing that 
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CS: Do you find the process any easier now? 
Dr #20: Yeah, well I know a little bit more about research now, ... so I think I 
understand some of the problems, and also I'm not as afraid, perhaps, now to just 
ask questions. 
and: 
I think one of the most important things is that we need to be taught about how to 
recruit and how trials should be run and have some sort of training in it, which we 
just don't get. We get thrown in at the deep end and told, "Oh, we're doing this trial 
and you've got to recruit such and such, " and you just [look] on the shelf and 
... there's all these trials going on, all these 
folders on the shelf that you need to 
make yourself familiar with. That's what we're told. ... You've got to really sort of 
try and be on the ball and know ... what sort of trials [the unit 
is] involved in, so if 
an appropriate patient comes along you need to be able to know what to do. You 
tend to learn that as you go along rather than anybody sitting you down and saying 
we've got all these trials. I think patients get missed because not everybody knows 
about all the trials. I've certainly missed a couple of patients, not with INNOVO 
but with [the CANDA Trial] when we initially started we just didnt know that 
these trials were going on. (Int. 21) 
The third registrar described how trials can be especially difficult for less experienced 
staff. 
The more you were involved in one particular trial I'm sure recruitment would 
become easier. One of the difficulties of the neonatal unit of course is we're passing 
through as part of our general training and, you know, these are studies that at the 
outset you're unfamiliar with and you have to learn very quickly and if the truth be 
known you don't get that much explanation at the outset. It's usually the typical 
scenario, in the middle of the night and it needs to be done. (Int. 10) 
The need for the less senior doctors to act in accordance with the collective decision to 
collaborate with a trial was also mentioned by consultants. The explanation of one 
consultant suggests that opting out of recruitment is technically possible, but he makes 
it clear that it could be quite difficult to do: 
I suppose it's obligatory if the consultant were to say "The child needs randomising 
into a particular trial because ... it's suitable in terms of the eligibility criteria. " It 
would often be left to one of the juniors to do that, and therefore you wouldn't 
particularly have a choice. I mean, if push came to shove and you said ... "I'm not happy getting consent from the parents, " well, you wouldn't be forced to do it but 
it's just an unwritten rule that that's what happens. (Int. 25) 
A registrar described his own experience in almost the same terms: 
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Dr #1: This was my first house officer job straight after medical school. Basically 
the impression that you got was that your consultant was doing the research, you 
had to recruit the patients. That was that! 
CS: If you'd wanted to opt out would you have been able to or would it have 
been ... ? 
Dr #1: There was a lot of pressure not to. 
The descriptions which were given by several of the consultants of their own 
experiences of recruiting to trials earlier in their careers were very similar to those 
described by the registrars, suggesting that this is a widespread, long-lived situation. 
Two consultants indicated that their freedom to make independent decisions about 
recruitment eventually came with seniority (emphasis added). 
It's never been obligatory as a consultant, except from my own conscience, as it 
were. When I was a research fellow that was what I was supposed to do, ... it was 
obligatory at the point when I said "Yes, I'll do the job". (Int. 2) 
I suppose it was obligatory as a trainee ... [If a unit] decided to try the multi-centre trial then you were de facto part of it. ... [But] if I had strong feelings about either the ethics or the science of a trial and I didn't feel it was worth doing, certainly 
since I've been a consultant then I wouldn! t have taken part in it. (Int. 19) 
These quotations are illuminating. They give a sense of the obligations to conform 
that younger staff can be under, which may be lifted at a later stage in their career. In 
part this relates to the relative lack of experience of younger clinicians with trials, 
evidence and possibly with the interventions under consideration. The issue is not 
however simply about their role in decision-making. There is also an issue of 
equipping those who are training to gain in experience and understanding of delicate 
clinical and ethical situations. Throughout the interviews there was a sense that the 
need for personal equipoise increased according to seniority. One consultant felt that 
different standards for personal equipoise were needed according to the contribution 
made to a trial. Crucially he saw a distinction between the standards required of the 
consultants and the non-consultants. 
If [I was making] an intellectual contribution to a trial, then I couldn't be 
involved in that intellectually unless I was in individual equipoise. So if I was on 
the INNOVO Steering Committee, and I actually believed that nitric-oxide is the 
best thing since sliced bread, ... I couldn't put that to one side for the greater 
good. I just couldn't be involved in that, so individual equipoise is very 
important there. However, I think when you are more junior, if you are the SHO 
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or the registrar or whoever is obtaining the consent, and you may not have all 
the papers to hand and all the evidence to hand, ... I don't think it matters what 
those individuals think, as long as they're capable of obtaining consent and 
understanding the issues on the spot. I'm not sure it matters what their 
individual view is. You know we might get a registrar that's worked in another 
place that says: "We used nitric-oxide and it's fantastic" and I wouldn't have a 
problem with their individual equipoise being perhaps not the same as the 
equipoise that's required for the INNOVO Trial. (Int. 23). 
These various accounts suggest that when the decision to collaborate with a trial is 
considered in collective terms, the roles of those involved can be very diverse, ranging 
from being a driving shaping force within a NICU to being an individual with far less 
opportunity to act independently. These accounts are however, very much shaped by 
a focus on the hierarchical and collegiate setting in which the individuals operate. 
When the focus is shifted to how the individuals view the actual trials, and how they 
deal with collaboration on a case-by-case basis, other dimensions are added to the 
mix. 
Level 4- The individual in practice 
It is in considering the views of the individual in practice, in relation to actual trials, 
that personal decisions about collaboration are finally brought to the fore. Here the 
focus is on actual decisions made in relation to real patients who are eligible for 
specific trials. The neonatologists' views of each of the two trials are considered, in 
terms of their perceptions of the interventions being assessed, the implications of the 
consent process and enrolment for the families. These are discussed in relation to 
their effects on decisions about collaboration. 
Views of the CANDA Trial 
During the interview period for this study the CANDA Trial results were announced. 
The finding that there were substantial differences in the survival rates between the 
babies in the two arms of the trial was totally unexpected and were said to be 
"shocking to everybody" (Int. 9 registrar). Some of the neonatologists felt that they 
had to square within their own moral framework the fact that some of the babies who 
had died within the trial having received ALEC, the artificial form of surfactant, 
would probably have survived had they received Curosurf. Unexpectedly the 
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CANDA Trial changed UK neonatal practice in a very important way. Around the 
country NICUs that had used ALEC shifted to using Curosurf and ALEC was 
withdrawn from use. When the neonatologists who were associated with the CANDA 
Trial were asked about their experiences and their views of the trial, for most this was 
in the light of their knowledge of the results, and to some extent their responses must 
have been affected by their own sense of comfort or discomfort with the findings. 
The trial interventions 
The CANDA Trial was viewed extremely positively by most of the neonatologists. It 
was considered to be well thought out scientifically and ethically, and there was often 
a certain satisfaction derived from having contributed to a successful trial. 
I am particularly proud to have been associated with CANDA, because I think it 
was a really well thought through, well-organised trial. ... There's a huge sense of 
professional satisfaction in having contributed to something really important like 
that. (Int. 28 consultant) 
A crucial factor in the design of the CANDA Trial was comparison of two similar, 
trusted, previously trialed interventions. Surfactant is a crucial tool in neonatal care 
and the two forms were familiar to all the clinicians involved, although not all had 
experience of working with both forms. A key issue related to the difference in the 
speed at which the two forms of surfactant worked; Curosurf, the natural porcine form 
worked faster than the artificial form, but this did not necessarily mean that this 
benefit, if indeed it was a benefit, persisted into the longer term. These issues were 
very well understood by the CANDA Trial interviewees and the neonatologists gave 
very clear descriptions of the issue of speed of action and efficacy. For instance: 
I knew that Curosurf worked faster having worked with it before and from my 
experience of working here with ALEC. I knew there was a difference from that 
point of view but what wasift clear when we started the trial was whether [there 
were] any other differences. (Int. 1 registrar) 
The neonatologists frequently described the clear state of equipoise which existed for 
the CANDA Trial. In some trials equipoise exists partly because there are different 
schools of thought on a given treatment, with professional communities disagreeing 
on potential benefits and hazards. Here there seemed to be a strong sense of 
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unanimity based on the widespread expectation that the treatments were very similar, 
despite the differences in speed of action. Some of the ease that was expressed related 
to the fact that the trial was expected to contribute to medical knowledge by 
demonstrating little or no difference between the two surfactants. Any small 
differences may have had cost implications which could then guide treatment 
decisions. A registrar described his earlier expectations for the CANDA Trial. 
You've got two treatments that were established. You are hoping that either there's 
no difference, or the difference that might be there doesn't have an effect on 
anything substantial from a health point of view. It's going to be small if there is 
[an effect]. For any study you start from a position of zero, of a null hypothesis ... 
you think there's Probably no difference, and you believe there's no difference, and 
therefore you're trying to prove that there's no difference, and therefore there's not 
a problem. (Int. 6) 
Widespread comfort with the CANDA Trial meant that offering the trial to parents 
was seen as ethically sound. 
We genuinely didn't think there was any difference, it was very easy to say [to 
parents]: "We don't think there's a difference. " (Int. 23 consultant) 
This sense of ease with the trial did not only relate to the anticipated similarity 
between the interventions. ALEC and Curosurf were seen as safe, effective, proven 
treatments. It was clear that the neonatologists did not feel that there were particular 
risks that needed to be considered. 
Unlike other drugs... there is this balance of safety, benefit and harm, whereas with 
surfactant I'm not sure that anyone's actually come up with a valid down side to it. 
(Int. 25 consultant) 
These various factors combined to make the trial seem uncomplicated. Two registrars 
said it was " very easy on the conscience" (Int. 24) and "it wasn't one that caused 
sleepless nights. " (Int. 24). Given the view that the choice of surfactant was unlikely to 
affect outcome for the babies in the trial, the parental decision about trial participation 
was often seen as relatively simple, as indicated by a registrar: "There was no 
discomfort about getting consent because you felt quite happy about giving surfactant 
of any sorC'(Int. 8). A form of surfactant would in fact be administered at delivery as 
a routine procedure, wherever there was a clinical indication, regardless of the 
parental decisions about the CANDA trial. This led to concerns for several 
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interviewees that the existence of the trial had the effect of involving parents in 
decisions which otherwise would have been made by clinicians. 
Both medicines were safe. ... There is no question of them being dangerous to the baby but it was a question of we didn't know which one was better. ... It wasn't a decision to give or not give treatment. We would have given [surfactant] ... because that's the accepted treatment .. And normally we wouldrft be consenting 
parents to give surfactant, we would just give whatever we had in the cupboard. It 
was only just because we were doing the trial that we actually ... [discussed it with] 
parents. (Int. 1 registrar) 
I always felt that it was a very minimal decision [for parents] because [previously] 
... the reason a baby got ALEC or Curosurf [related to] the way the ambulance drove. If it drove to [City X] it would have got Curosurf, if it came to [our unit] the 
baby got ALEC. You see that decision was totally out of the parents' [hands]. ... [before the trial] we never ever used to ask parents if the baby should get Curosurf 
or ALEC, theyjust got ALEC. I felt the reason they were entering the study ... 
was really saying we can collect the information on the [baby], because ... both 
were known to be effective, and no evidence suggested one was better than the 
other ... Obviously [for] a trial you need to get consent, but ... it was a minimal intervention I thought. (Int. 6 registrar) 
Although all of the interviewees felt that randomisation was acceptable for the 
CANDA Trial because of the uncertainty over any long-term effects of the surfactants, 
the known short-term differences did affect their views. Whilst there were no 
statements of a clear preference, the differential speed of action led to an inclination 
towards Curosurf for a minority. This inclination was however always coupled with a 
statement that this did not mean that they felt uncomfortable with the trial. 
There's a baby in front of me who could have Curosurf and be "better" in inverted 
commas, within a couple of hours or if it's ALEC they're better in 36 hours - but in fact you have to look further down the line and see that in two weeks or in two 
months they're both exactly the same ... one's no worse off than the other, and also look at the other side effects, the changes in blood pressure, etc with Curosurf, so I 
could rationalise it. (Int. 18 registrar) 
This registrar added another interesting comment. 
My own baby would have been eligible for the CANDA Trial -I knew that for me, for my baby standard treatment [in my local hospital] would have been ALEC. If 
I'd have entered the CANDA trial it would have been ALEC or Curosurf, and that 
was a win-win situation, because either got ALEC, which would be standard 
treatment anyway or got Curosurf which might have been slightly better. (Int. 18) 
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Whilst clinical experience with the two surfactants could consolidate personal 
equipoise (first quotation below), there was some evidence that it had had the opposite 
effect for a registrar who expressed some unease but "rationalised" his position 
(second quotation). 
We've been involved with surfactant trials before CANDA, and interestingly I've 
been very negative about artificial surfactants until we used them and [then] I came 
away thinking, well actually, maybe these aren't so bad. ... During the trial I began 
to wonder, [although the natural surfactants] worked much more quickly, whether 
they were so good or not, so my preconception had completely ... turned over. So by the time we got to this trial, I felt well this is perfectly legit. I really don't know 
whether this is the best or that. So I felt happy about that. (Int. 15 consultant) 
I came here from a unit where Curosurf had been used, and we use ALEC [here] 
and I saw quite a marked difference, ... I actually felt Curosurf was better and the CANDA trial was obviously trying to assess that. The surfactants work in different 
ways and, you know, I can rationalise that although you could see a more 
instantaneous improvement with Curosurf the final outcome may actually be just as 
good or better for one or the other. (Int. 18) 
In a rare statement a registrar expressed a clear preference which could shape a 
decision to approach parents. She was asked whether she had any treatment 
preferences. She agreed that she did but these were not expressed in terms of the 
expectation of an effect on outcome for a baby, but in terms of the effect on clinical 
management for which she would have been responsible. 
I've certainly [felt] that with the CANDA trial, hoping they were going to get 
Curosurf rather that ALEC, just knowing how babies respond to it ... From a purely selfish point of view it makes ventilation in the first few hours easier. (Int. 7) 
The impact of enrolment on parents 
An important feature of the CANDA Trial recruitment process is that it occurred at the 
very start of a relationship between a neonatologist and a family. The parents who 
were asked to consider enrolment of their baby onto the trial were approached 
antenatally as the trial protocol indicated that surfactant should be administered to the 
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baby within minutes of birtO. At a point of discussing the trial, the extent to which a 
baby would be affected by its prematurity was still unclear. The parents were often in 
very difficult and worrisome circumstances. Women were either on a ward with high 
risk factors such as pre-eclampsia, bleeding or signs of early labour, facing the 
probability that their baby would be bom early, or in the delivery suite at a stage when 
delivery was inevitable. The neonatologists discussed how they felt about approaching 
parents in these circumstances. The decisions that they made not to make an approach 
are dealt with in the following chapter. 
When the likely or imminent delivery of a trial-eligible baby was identified, the 
neonatologist with responsibility for recruitment at that time, would choose whether or 
not to offer the parents enrolment. The discussions involved could be daunting, with 
one registrar commenting that he was "hesitant about the difficulties [ofl consenting 
mums at 3 o'clock in the morning when they were about to deliver". He rationalised 
the situation with the argument that "the treatment they are going to be getting is the 
treatment they would get anyway ... therefore you are not putting upon them 
something which is very unusual". (Int. 6) 
The factors that drove the decision to approach parents were infrequently discussed in 
direct terms in the interviews. Initial decisions to approach appeared to be most 
simply made in terms of whether or not the baby would fit the eligibility criteria, with 
a subsequent judgement, made on visiting the parents and assessing their 
circumstances, as to whether a discussion about the trial would be inappropriate. 
Discussions which were considered inappropriate, because it would not be possible for 
the women to give a decent standard of consent, and the associated decision not to 
mention the trial were described in detail. A consultant described the type of 
judgement that could be made on arrival in the delivery room. 
It depends what sort of condition the woman is in. ... I wouldn't approach her 
unless there was a reasonable time period before she was likely to deliver. So [ifl 
she was having contractions every three minutes and in a lot of pain and discomfort 
and being given analgesia, then it's not appropriate to approach her then. (Int. 27) 
35 Surfactant is usually administered quickly but the point here is that the trial protocol required it to be 
consistently given within a strict timeframe in the trial centres. 
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Dealing with women who were anxious and in pain was clearly a big issue for some 
interviewees, but it also seemed that for those who did feel comfortable, they were 
very much at ease. Where they felt they could mention the trial, it appeared to be 
almost a routine issue. A registrar commented: 
Most of the time if I'm presented with a baby I dodt kind of sit down and try and 
make decisions between whether I should be trying to enrol this baby into a study 
or not. (Int. 13) 
Part of what made the decision to approach parents easier was the sense that they were 
being asked to consider something of relatively little consequence. 
People are stressed by different things, people take in different amounts of 
information at different times, but I think with CANDA, to be honest, the decision 
was a very minimal decision. (Int. 27 consultant) 
Whilst the neonatologists often argued that they felt that CANDA Trial did not 
involve a big decision, some argued that this view may not be shared by parents. A 
registrar indicated that although he felt that it was a stressful time to take on board 
information and to consider trial enrolment, his concerns about raising the subject of 
the trial lay with the impact of the discussion itself on the parents, rather than in terms 
of the effect of the trial interventions on outcome. 
To ask them to consent to treatment in their small baby who's yet to be born, I think 
that's a really big thing. And unfortunately because of all the stress and pressure 
they're under... they kind of recognise that it is a big question that they're not able 
to give the amount of time and thought to they would like to. So I think it is really 
quite a lot to ask of them at that stage. (Int. 13) 
A registrar quoted earlier who argued that the parents were being asked to consider a 
quite simple trial with only a "minimal intervention", argued that the need for consent, 
which would not be sought for the use of surfactant outside of a trial, complicated 
already difficult parental experiences. He commented: "I felt in a sense we were 
causing more anxiety than the intervention almost justified. " (Int. 6) 
There were instances where approaching parents could cause neonatologists 
discomfort and anxiety. A registrar with no previous experience of recruitment to a 
trial described how difficult she found approaching a labouring woman for the 
CANDA trial, something which she felt she had little choice about. 
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Dr #7: [It was] stressful because I'd never recruited a child to a trial before. 
Stressful because mum was in labour and was having contractions every few 
minutes and in a lot of pain and I felt I was intruding. I didn't feel it was an easy 
situation to be getting consent. 
CS: Do you think she felt that? 
Dr #7: Yes, I do and also for dad as well, because he was present. I think it was 
their first baby. And also it was stressful because I think they'd already been 
approached by obstetricians for an obstetric trial that was going on, so it was the 
second consent that they'd been asked for, for a trial in a short period of time. 
CS: So were you more or less obliged to ask those parents? Did somebody ask you 
to go and ask them or was it something you were aware of and initiated yourself? 
Dr #7: Well, no, it was because we'd been approached by [a consultant] earlier, I 
think it was only about a week before, about the CANDA Study and emphasised 
that we were to try and recruit as many babies as possible if they were eligible. And 
this just happened to be someone who was eligible whilst I was on call. 
Views of the INNOVO Trial 
The intervention 
The neonatologists were very familiar with the idea that INO, like surfactant, was 
known to have a short-term effect, but whether or not this translated into a long-term 
benefit was unclear. They did however vary in how they described the possible 
effects of INO and how they saw the INNOVO Trial. 
A limitation of this research is that in addressing the views of those working in NICUs 
which lent support to the INNOVO Trial it was not possible to access the views of 
those in NICUs where collaboration with the trial was judged to be unacceptable. 
Comments made by interviewees did, however, suggest that very disparate views 
exist. A consultant referred to colleagues in non-collaborating centres who think that 
"nitric oxide is perfectly wonderful" (Int. 11) and did not feel that another trial 
involving INO was warranted. They were not be prepared to randomise patients to the 
control arm of the trial. Mention was also made of those who were uncomfortable 
with INO and would not wish to expose their patients to the gas. Even within the trial 
centres there was some suggestion that some negative views of INO existed, with a 
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registrar commenting "Even amongst our own consultants some just don't like it, just 
anecdotally they don't like it and woWt use it. "(Int. 26), but no such views were 
directly reported in the interviews. 
The neonatologists who were interviewed varied in how they viewed INO, but the 
differences between their views were often quite subtle. The main issues addressed by 
the INNOVO Trial were efficacy and safety. Mindful of these issues, some presented 
INO as an intervention which should be treated with caution. 
This is an extremely powerful substance. It is a little bit like some of the short 
acting hormones in the body, like adrenaline. It has effects all over the body but 
we think if you give it by inhalation it's mostly acting on the lungs. We have no 
idea if there might be some terrible long-term effect of nitric oxide that we can't 
even imagine, but faced with the situation now, there's a possibility that the baby 
may benefit if we use it. (Int. 28 consultant) 
The possibility that INO might not be treated with caution, given the potential risks 
involved, was worrisome for a consultant. 
I think that one of the problems with new treatments, like nitric oxide, like high 
frequency ventilation, there's a lot of young doctors coming through the system 
who like all these brand new treatments and are very keen to use them willy-nilly 
and they're unproven. I think that we should be very careful about what we do. I 
think the risks of nitric oxide in terms of haemoglobinaemia, platelet dysfunction, 
bleeding, long-term neurological outcomes or, you know, whatever the side effects 
of the nitrous dioxide - or whatever's produced - one doesn't know. I think it's very important that we try and conduct a proper trial to look at it so that's why I would 
support it. (Int. 16) 
The views of another consultant were made clear when he explained how he would 
describe the balance of potential benefits and risks to parents: 
We know there are short-term effects of nitric-oxide, whether there's a long-term 
effect, we have absolutely no idea. However, if your child gets nitric-oxide, I can 
tell you that there will be a short-term effect. I don't know anything about long- 
term effects, that's why we're doing this trial, but equally there are potential side 
effects which - we're not convinced they're enormous but they may be enough to 
prevent it being used, particularly if [it has] no long-term effect. So it's a balance between something that's going to help, possibly in the short-term, may help in the long-term, but may have a side effect that we're not sure about. (Int. 23) 
In other accounts a greater emphasis was placed upon uncertainty over whether the 
short-term benefits persist over time. With the focus shifted from risk, the question 
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about INO related more simply to whether it is effective or ineffective. A registrar 
who defined the INNOVO Trial as "a fairly benign trial" felt that when parents are 
asked to consider enrolment for their baby, it would not be "a particularly big 
decisioW' (Int. 9) 
If we were using something that was potentially toxic, you know, some new drug 
that has potentially disastrous side effects then you might be asking them for a 
more important decision because you're asking them to increase their child's level 
of risk of an unwanted side effect. Whereas in INNOVO I think the only thing 
you're asking them is asking them to increase their risk of being exposed to nitric 
oxide that has a small chance of helping them. (Int. 9) 
A step further along the continuum of views of INO was to feel assured that there was 
no potential for risk to babies as a result of exposure to INO, an assurance which 
could be passed on to parents. Two registrars explained how they presented INO. 
You can still explain to them that ... the reason why we are doing the trial [is] because nobody knows a hundred per cent the effects of this medicine and it may 
affect the baby or it may not affect the baby, but iVs not going to harm the baby. 
You have to explain to them that yoifre doing this as a trial because ... this 
medicine hasn't been proved to be effective by scientific evidence. (Int. 3) 
I think the parents need to know that's it's not going to have an untoward effect, the 
way I always explain nitric [is] that it might help but it may not help, but ifs not 
going to make things worse, which is probably right. (Int. 21) 
The use of INO - equipoise and therapeutic intent 
When the decisions that were made for individual babies who were eligible for the 
INNOVO Trial were examined, it became clear that the line between equipoise and 
therapeutic intent could be fine and fluctuating. Although the term "equipoise" was 
not always familiar, the interviewees were clear about the principle of uncertainty as 
the ethical basis of RCTs and its relationship to decisions about collaboration and 
enrolment of individual babies. 
In considering the enrolment of individual babies, the relationship between equipoise 
and therapeutic intent was not so straightforward. Where those at the centre of the 
research situation are extremely sick and vulnerable, as was the case in this trial, and 
where those in a position to initiate trial enrolment are already concerned for their 
condition, decisions in practice could be initiated by clinical issues rather than by 
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principle-based, research-led factors. An explicitly therapeutic element in the 
decisions to offer trial enrolment was frequently articulated and explained at length 
with many striking examples, one of which is presented in detail in Box 3, conveying 
something of the more extreme circumstances in which decisions about trial 
collaboration are made. 
Analysis indicated that the neonatologists expressed therapeutic intent in one of three 
ways, with INO being seen as: 
"a potentially useful tool to be used with caution 
"a highly desirable intervention 
"a rescue therapy 
These three responses to INO broadly related to the condition of the baby in question, 
With increasing severity the possible value of INO could increase and the relevance 
and balance of equipoise for individual cases could shift. 
INO as a potentially useful tool 
Where INO was seen as a possibly useful tool, this was often, although not always, in 
the more calm, less advanced cases, If recruitment was considered for babies for 
whom a range of treatment modalities were available, this was presented as a simple 
professional decision. A consultant drew a comparison between the two trials 
considered here and his previous experience with paediatric leukaernia trials. In the 
leukaemia trials: "the whole care is based on the randomisation, whereas what we are 
doing [here] is taking one element of care, and randomising it. " He extended this 
example to include the ECMO Trial. 
For ECMO of course this was the end of the road really, and you either would offer 
ECMO, which was a new thing and might keep the baby alive, or you carry on 
where you were, so there was a really big change there. This is not so, I dolft think. 
This is Dust] a put of the treatment (Int. 1 5)36 
36 It should be noted that this observation was made by just the one neonatologist but is potentially 
significant as it places a decision about research firmly within the broader context of care. 
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Even in more difficult cases however, some maintained a position of equipoise, which 
was clearly a guiding principle in their practice. One such example was provided by a 
consultant who made it clear that he did not develop treatment preferences and was 
therefore comfortable with allocation to either arm of the trial. Whilst it was common 
for neonatologists to acknowledge some difficulties with allocation to the control arm 
for the babies who were particularly sick, here it was stated that allocation to the 
control arm "doesn't bother me in the slightest" 
I believe I stand in equipoise and it's an important question to answer. If you 
believe that then you shouldn't mind which they get. Okay I'd like to see nitric 
oxide to be proven to be safe and effective because it's a research interest of mine 
and it's something that would be another treatment to offer these babies. But you 
know, it doesn't bother me that they get the control arm because I don't think that 
we know and unlike other drugs, like surfactant, for example, there are potential 
toxicities, very real toxicities associated with it, so there is this balance of benefit 
and harm. (Int. 25) 
INO as a highly desirable intervention 
Where INO was seen as a highly desirable element of care, this was often when the 
neonatologists felt that they had nowhere else to turn. In such circumstances they 
could be very cautious in their presentation of the trial to parents. A consultant 
referred to times when there can be "a feeling this might do them some good" but in 
presenting the trial it "is something you can usually mask! ' (Int. 19). This awareness of 
a need to avoid disappointing parents was very commonly discussed, but at the same 
time the neonatologists could very much wish to access INO. Using a striking phrase 
(italicised) which occurred several times in the ECMO parents' accounts of their 
conversations with neonatologists, a registrar said that his decisions about the 
INNOVO Trial were very context specific, a clear clinical judgement rather than an 
indication of equipoise. 
If I think that my back's up against the wall and I want to go and potentially use a 
new treatment which I think could potentially be beneficial to the baby but is 
available as part of a trial, then I'd be quite happy to go and sit down with the 
parent and get it over and done with so that I can go ahead and I've got another 
treatment option there. So [my decision] depends on what I perceive as being the 
benefits of that trial to that patient at the time (Int. 8) 
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Where the issue of the INNOVO Trial arose for the smallest babies for whom there 
were few alternatives, this could increase the relative value of INO, as explained by a 
registrar. 
[For the] INNOVO trial, this thing is there at the back of my head when I'm talking 
to the parents. ... You've got a very sick baby who's needing a lot of respiratory 
support, it's a small baby who is not likely to have other modalities or treatments. 
... So the option 
for [a big] baby is to try with other vasodilators. The safest and 
easiest vasodilator for us on the unit is obviously nitric, [but] if it is a small baby 
the other option doesn't exist. So you think in your mind, okay, this baby is going 
to benefit ftom nitric, and you know it. Then you randomise and this baby is in the 
control arm, so that is a bit disheartening, yes, true. ... You have this fear at the back of your [mind]. You just want the best for the baby and this baby comes to 
control arm, the baby doesn't get nitric. (Int. 17) 
INO as a rescue therapy 
In the most severe cases it seemed that it was simply impossible for the neonatologists 
not to feel drawn into the hope that the baby would be allocated to INO. A registrar 
who was elsewhere very clear about his support for trials and his own state of 
equipoise with regard to the INNOVO Trial, described how certain circumstances can 
make the experimental intervention seem highly desirable and can lead to preferences. 
I think sometimes you get a sort of a bit of a sense of euphoria if you're going to 
try something that you think might make a difference in a dying baby. So I've 
actually generally, I'll be honest with you, been disappointed when babies haven't 
drawn nitric oxide and quite euphoric when they have. (Int. 26) 
Where local practice in a neonatal unit was to try all other options before considering 
randomisation, this could lead to INO being considered mainly as a rescue therapy. A 
registrar described circumstances which are likely to foster this situation. 
The kids that we seemed to be recruiting are the ones that we're at the end of the 
line with almost, and maybe that's the wrong thing to be doing but that's how it 
feels at that moment. You try everything else, you try all sorts, you do this, do that 
and then when you're desperate you think recruitment for the nitric trial. And 
that's how it felt that everybody on the unit was doing like that. And I think that's 
why you've ended up with all the real sickies [in the trial] that die at the end of it, 
... just because whatever they have is that bad that it doesdt matter what you do, they're not going to [survive]. (Int. 21) 
When asked if the parents might be aware that their doctor feels that randomisation is 
a last attempt at finding a solution for their baby the registrar agreed. 
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I've said to them that we're starting to run out of options and we've got to a stage 
where ventilation's difficult and there is something that we can try. It may or may 
not help. But yeah, I think parents are, because they can see you struggling away 
there and you're making all these phone calls, so yeah, they do realise. (Int. 21) 
As suggested here, the babies recruited to the INNOVO Trial were in fact at the more 
severe end of the illness spectrum than had been anticipated by the trial team. A 
consultant gave an indication of how this can happen. Interestingly, given the focus 
on the desirability of INO in extreme circumstances, he discussed how concern over 
INO could in fact cause delays in considering the trial, impacting upon the conditions 
in which the actual decisions were finally made, and caused INO to be viewed as a 
rescue therapy. He felt that the slow rate of recruitment to the INNOVO Trial related 
to "personal prejudices" and "worry about theoretical concerns about nitric oxide that 
we have yet to actually prove. In his unit he felt that there was "reluctance to use this 
experimental gas". He said "I'm frustrated by it. I don't know why it's so different. " 
and went on to describe the consequences for babies and parents. 
I think we leave it until children are very much sicker than we would do so for 
other trials before recruitment to INNOVO is considered. --- We often wait till the 
point where the child is really very much moribund but the circumstances then in 
which you approach the parent are then such that they are very anxious and 
distressed and terrified about what will happen to their baby. (Int. 2) 
In the most extreme cases, some of the neonatologists indicated that the chance of the 
baby being allocated to the control arm might not be taken, or the allocation might be 
overridden and INO administered, an issue which is described in further detail in the 
following chapter. 
In quite a complicated statement a registrar summed up how neonatologists' reaction 
to the trial situation can depend on their state of equipoise, which can change over 
time and according to their perception of a baby's needs. His description contains 
much of the variety which is present in the views identified in this study - the shifting 
nature of equipoise, the independence of each decisions for each baby, and the 
responsibilities that are owed, sometimes in competition, sometimes congruently, to 
children and their families and to a trial. 
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If at the beginning of the trial you are heavily in favour of it you are quite keen to 
recruit. Later on you get quite suspect about long-term side effects, then you may 
be less inclined to get that baby in. But you may be more concerned about the 
outcome of the trial long-term, you need to know the answer. ... There's a whole, individual baby, your patient, versus the outcome of the trial. If you think there's a 
definite advantage to the drug then you want the baby to get that drug. But then 
you're less concerned about the trial. .... If you think ... the other way round, ... 
you want to know the answer and you're doing it for the trial's purposes rather than 
for the baby's purposes, you're not too bothered if the baby gets enrolled or not 
because you're not that convinced about its effect but you think maybe it is worth 
getting the baby on board because for the trial it would be nice to know so that they 
can stop throwing [nitric oxide] at the babies. (Int. 8) 
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Dr #20 described the case of a baby admitted to his neonatal unit while he retrieved a sick baby from 
another hospital. In his absence, a senior colleague was relieved by a junior doctor at I am. 
"I found a very inexperienced SHO at the baby and the registrar was doing something else. ... 1 walked 
up and I looked at the settings on the monitors and the ventilator and we started the baby on 100 per 
cent oxygen, but he wasn't being ventilated adequately. It was on low ventilator settings, the sort ot 
stuff I start a baby off on. I thought, 'This doesn't make sense', plus they'd said he was two or three 
hours old by then., ... I quickly [increased the] ventilation and 
it made no response. I tried oscillation 
and ventilation, did all the different types of ventilation that I know, different modes to see if it actually 
responded. No response. We were really fighting against it and were under monster high pressure and 
really getting nowhere. [1] discussed it with the consultant at home. I'd spent ... probably three 
hours 
trying hard to get some life into this baby really, I mean all his vital signs were okay, but it just was 
needing absolute maximum effort to get any oxygen into the baby. So it seemed to me naturally that 
the baby was having fetal lung problems and shunting, so we had to open up a vascular bed and nitric 
oxide was thought to be the best thing for him. So I asked my boss. We talked it through and he said, 
'Let's try nitric oxide, randomise if, and thaf s when I got involved in... the INNOVO Trial. 
I had a lot of problems with the dad. .... Mum had gone 
into labour, he'd been out on the beer with his 
mates.... He was pretty inebriated. He was quite abusive. The first thing he said to me when I came in 
[was] ... "No fucking chance on this unit', and walked off. 
So ... we 
had all this and I was trying very 
hard to involve Dad, because Mum wasn't there. She'd had a section and basically I could see the 
writing on the wall for this baby, that I was really fighting and nothing was working. He was quite 
aggressive and abusive in his language, although he did listen to me. ... I wanted to make sure 
he was 
involved because it seemed to be the right thing. And then, when we did come to randomise the child, 
it was very difficult because the baby by then was starting to decompensate in his chest, in other words 
he was starting to get bad gases and really and truly we should have really said, 'Right that's enough', 
perhaps. Perhaps someone more experienced might have done that at that stage, you know, enough's 
enough. But because I'd already, fifteen minutes earlier discussed it with my boss on the phone in some 
way to make sure we were doing it all correct, and we'd made the decision to randomise, I went ahead. 
Mum was by this time wheeled upstairs. ... She was a very young mum. It was her second child 
actually. I mean she looked about fifteen. I think she was about seventeen, and he was a bit older, the 
dad. But anyway she just looked in shock, She was just frightened, pale and I had to say, 'You know, 
your baby's really -I'm worried that it won't make the night through. ' This was 5 o'clockinthe 
morning. ... We had to talk about the possibility of what other treatment, whether 
it's better to continue 
the same thing. ... She [was] 100 per cent for the trial. I explained what the trial was. It involved a gas 
and.. it can work or it can't. That's the setting I put to them. ... If you get the gas then it may work 
better than the other treatment, but it may not. But I said that I was sufficiently worried that I didn't 
think the baby wasn't going to make it through, it might be just worth trying something different, just 
for the sake of it. ... So it was quite difficult, because I 
had a dad who was getting angry and sobering 
up slowly, and a mum who was just not with us really with the shock. ... She was well enough to be 
wheeled up and come and sit by the baby and hold its hand, so she knew what was going on but she 
had a big problem when I said, 'The baby's dying!, and you know, fair enough. I don't know what I'd be 
like in that situation. So I was hoping his dad might be taking it in a bit because I wasn't sure she was 
fully taking it all in, but I was hoping he was sober enough to be able to do that really. ... So I went 
away to randomise the baby. [The baby] got nitric on the randomisation, and by the time we were 
coming back it was now starting to look a bit pale and shut down and so we put [the baby]over to the 
nitric base, so that means we had to bag and mask him ... three 
feet to the next bay and plugged him 
into nitric oxide and got that going, but by the time we'd plugged him in he'd started to have some 
brachycardias which you know, I thought, 'Here we go'. This is the beginning of the end. 
The nitric oxide got going for half an hour probably, before I said, 'Look the baby's about to pass away', 
As I had seen the brachycardias half an hour earlier, I mentioned christening. They wanted that, and 
[the father's] parents were coming in. In fact I tried very hard to keep the baby alive. I turned the 
monitors off literally as the vicar arrived. 
Box 3: Account of professional decision-making for the INNOVO Trial in difficult 
circumstances (Int. 20 registrar) 
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Discussion 37 
The division of the data into different levels of thinking about trial collaboration 
illuminates the links and the differences between the more abstract values that were 
held by the neonatologists, and they ways in which they related to trials in their 
everyday encounters with patients and their families. The organisation of the data in 
this way gives an indication of reactions to actual trials and how their defining 
features and the context in which they are conducted can shape professional views and 
actions. 
Some of the interviewees, often senior consultants, were very consistent in their 
accounts of their principles and their practice. To use the words of one consultant 
they were in equipoise and so were "ethically at peace" (Int. 23). The values that they 
espoused in principle largely held true for the actual trials. This group of consultants 
were those with the most influence in local terms and it was their response to actual 
trials that would establish the conditions of what shall be termed in this thesis "local 
equipoise". 
For many interviews there were very obvious ways in which their responses to the 
very disparate conditions of the two trials in question differed. The two trials were 
presented by the neonatologists in very different terms. 
The CANDA Trial was largely viewed in similar terms to the abstract and undefined 
trials that were considered in principle. It was almost a case-study in equipoise; the 
comparison of the two forms of surfactant raised so few difficulties that the trial was 
to some extent a non issue. There was no sense of discomfort over the interventions, 
but there was unease over asking parents to consider research at an inopportune time. 
Presentation of the INNOVO Trial was by comparison far more complicated. 
Experiences of this trial were very much grounded in intense periods of clinical 
activity. As the question of recruitment often arose in the context of a struggle to save 
37 For the empirical chapters in this thesis, there will be a short discussion which pulls together the main 
points. These will then be considered in the main discussion in Chapter 10. 
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a baby, it was very different from the CANDA Trial which arose when the 
neonatologists had not yet engaged in any struggle on behalf of a baby. The INNOVO 
Trial decisions to approach parents were often clinical judgements relating to 
individual babies, as opposed to the research-led decisions made for the CANDA 
Trial. Although there was great interest in establishing the risks and benefits of INO 
and its role within the care of compromised babies, the INNOVO Trial appeared to be 
sometimes used as a clinical tool. Where there were local constraints placed on using 
INO outside of the trial, or where the norm was that the neonatologists should recruit 
to the trial, random allocation would became a means of accessing the gas. The fact 
that it was often stated that this decision could be left until a late stage in the 
progression of a baby's illness meant that INO took on the status of rescue therapy 
rather than a trial intervention. 
For the INNOVO Trial, therapeutic intention could jostle for place with the principles 
of collaboration and risk management. Interestingly there was no sense of a conflict 
of values or of any inconsistency when the neonatologists expressed a therapeutic 
intent. In many of the difficult clinical cases, the utilisation of the INNOVO Trial was 
seen as a responsible thing to do, an action which arose directly from the care process. 
It may be the case that this arises in part from the hierarchical and collegiate approach 
to recruitment that has been identified here. In circumstances where neonatologists 
might wish to turn to every treatment modality at their disposal, they can be aware that 
in order to utilise a particular approach they are expected to act in accordance with the 
local rules about recruitment. Whilst this process would appear to leave the less 
senior individuals with little room for manoeuvre, the accounts of the less senior 
neonatologists suggest that they do not experience this as a particular limitation. They 
state quite clearly that they have little choice as to whether to recruit or not, a finding 
which was replicated in each of the study centres and confin-ned in the accounts of the 
consultants, but they also represent their decisions as grounded in valid and 
responsible consideration of the effects for their patients. This may be because they 
are generally supportive of the aims of trials and are therefore required to engage in an 
activity which, although difficult at times, is something that they may well chose to do 
anyway. This then makes the limitations within their role less obvious and their 
autonomy seem greater. It is very likely that if they had not been asked specific 
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questions about freedom, and how decisions were made in their department, this 
research would have suggested a simpler model of many individuals moving in 
towards the same goals without reference to the professional structures and 
obligations which affect and direct that movement. 
130 
Chapter 6- The decisions that doctors make 
about suspension of trial collaboration 
All of the neonatologists interviewed for this study had been active collaborators with 
the CANDA and/or INNOVO trial, lending their support through recruitment and in 
some cases through managerial roles. The role of collaborator can, for any trial, be 
suspended on either a permanent or a temporary basis. There were no instances where 
an interviewee indicated that they had decided to end their collaboration with a trial, a 
decision which would suggest dissatisfaction with the research itself, but there were 
many instance where judgements were made about suspension of collaboration in 
relation to types of parents, groups of patients or individual cases as they arose. These 
decisions, like those described in the previous chapter, could be made at the collective 
as well as the individual level. Suspension of collaboration as identified in this 
sample related to three main types of decisions: 
" Personal ethical judgements 
" Evidence-based judgements 
" Clinical judgements 
Although these headings suggest that these judgements are clearly differentiated into 
those which are ethical considerations and those that are not, clearly all decisions 
about whether or not a baby should be included in a trial involve some form of ethical 
judgement. Similarly ethical judgements are often clinical judgements. The headings 
are a means to separate out highly interrelated strands within the data in order to 
understand their role in the decisions that were made. 
Part I- Personal ethical judgements 
The neonatologists were all asked whether there were any situations where they would 
not offer enrolment in a trial to parents of a baby they know to be trial-eligible. A 
deliberately general approach was taken to access views on the principles that the 
interviewees held about recruitment to trials for the population of babies and parents 
they encounter. Occasionally their responses were directly or indirectly framed with 
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reference to specific issues raised for the CANDA and INNOVO trials, such as 
consent during labour or at a point of critical illness, but the neonatologists also drew 
on other areas of their experience, such as trials relating to pain control, feeding 
methods, drugs trials, and areas outside neonatal care. 
Five interviewees argued that there are no circumstances where they would elect not 
to approach parents. They were clear that they felt that it is important to attempt to 
overcome potential obstacles and to make an approach in all cases. The majority of 
the remaining neonatologists did indicate some circumstances where they would 
decide against discussing a trial, that is they would temporarily suspend their role as a 
trial collaborator. Some were comfortable with this. Two interviewees stated that 
there were times where they had been busy and had chosen not to try to recruit eligible 
patients and one commented that there could be a general "degree of inertia" over 
some of the particularly challenging situations (Int. 9 registrar). Most, however, felt 
that although they aim to discuss trial enrolment with parents wherever possible, there 
are circumstances where they consider it to be too difficult or inappropriate to do so. 
It was striking how specific and variable was the list of circumstances in which 
neonatologists would not approach parents to discuss a trial, as shown in Table 5. 
Circumstances in which neonatologists would not approach parents to 
discuss a trial 
N 
Parents would not understand (pain, drugs, advanced labour, info difficult) 6 
Parental stress (previous loss, particularly difficult circumstances, not coping) 4 
Parental language problems 3 
Neonatologist would not have enough time to explain 2 
Parents would not have enough time to think I 
Consent is only possible by telephone I 
Social problems (eg baby would go on to be on 'at risk' register) I 
"DifTiculf' parents (angry and aggressive) I 
Poor rapport I 
Legal issues or complaints (poor existing relationship) 2 
Educated parents wanting lots of information who would worry I 
Unmarried fathers where the mother is unavailable (can't legally consent) I 
Moribund baby39 I 
Imp oving baby" I 
Table 5- Circumstances in which neonatologists would not approach parents of trial- 
eligible babies to discuss a trial 
38 Although it would seem that the choice not to approach the parents of a moribund baby are clinical 
decisions, they are included here as they are also examples of an ethical line being drawn. These 
examples were given not in relation to the trial criteria but to parental circumstances. 39 As for footnote 39 above. 
132 
Within the accounts of some of the difficulties associated with these factors, there are 
some clues as to how approaches to care and research underpin decisions about 
suspension of collaboration. 
One of the registrars linked to the CANDA Trial gave a list of the types of situations 
in which he might choose not to approach parents. He described his decisions as 
being made on a "case by case basis". The examples that he went on to give were; 
women who had already "lost two or three babies", women who were incapable of 
understanding the information because of the impact of drugs, "very very young 
mums" and women who were far on in labour. These examples were all linked by the 
sense that it would be unfair to request consideration of a trial either because of an 
emotional situation or because the goals of informed consent are unlikely to be 
achieved. He described the need for awareness of the potential impact of such a 
request. 
if you are in equipoise then you presume that there's going to be no direct benefit 
one way or another to the baby, because whichever they get, as far as you're aware, 
they'll be getting the best treatment that you know about. Any difference that might 
be shown will be of use to future babies, so I think every time that you speak to a 
parent you have to be aware of that, and the decision as to whether or not you go 
ahead with that [relates to) whether you feel the outcome that might be found is an 
important outcome. ... Before you even start to speak to the parent you have to have got that clear in your mind. ... I had a few [cases] where it was very very 
clear that the mums were already so concerned, naturally, about what was 
happening to their baby, that to add an extra dimension seemed inappropriate, and I 
wouldn't do it, you know, I didn't do it. (Int-6) 
A similar point (italicised) about the need to carefully balance the potential benefit to 
society against the potential for harm to the individual, was made by a consultant, also 
involved with the CANDA Trial. He thought that it might be inadvisable to approach 
parents with whom "your relationship isnt greaf ', such as: 
... a parent who would rather 
just have thrown a chair through the window because 
he's upset about something already. ... It's mainly because you don't want to 
stress these people any more with something that isn't necessarily necessaryfor 
their child, so if they've got difficulties with communication or other complaints or 
other problems, then it's probable that we wouldn't involve them. (Int. 23) 
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The choice not to approach some parents for both of these neonatologists was directly 
linked to the prerequisite of collaboration, that they would be in a state of personal 
equipoise and so would not prefer one treatment or another. They conceived of a trial 
in terms of its potential value for medical science, and not with the expectation (at 
randomisation) that it would change the outcome for their patients. They drew on a 
research model, in contrast to those whose views are grounded in a primarily 
therapeutic model of a trial where participation if allocated to the experimental arm, is 
potentially of value in itself. 
In some accounts it was evident that if it was felt that there were possible therapeutic 
advantages to be gained, this could make it worth approaching parents even in dire 
circumstances. Three registrars linked to the INNOVO Trial, the first two of whom 
stated that there were no circumstances in which they would not approach parents, 
presented a position which was primarily bound up with the needs of the patient, and 
their own need for an additional clinical tool, rather than with the needs of research. 
Even where the circumstances are difficult for consent, the focus here was not the trial 
or the parents but the baby (emphasis added). 
I treat the child, I don't treat the parents, and I try and remind myself of that. ... You've got to treat the whole family in a sense, but primarily I'm a paediatrician 
and I've got to try and think about the child and what's in their best interests and 
then put that opinion to the parents. (Int. 20) 
If you felt that it was going to make a difference or you were at the end of the line 
with what you were doing, [it wouldn't] matter who [the parents] were or what they 
knew. (Int. 20) 
Language difficulties may complicate the issue, but ... if there's a sick baby and I feel strongly enough that I want that baby involved in that trial, -regardless of 
stress or language I would circumvent that and deal with it and just get their 
consent ifI think it's needed at the time. (Int. 8) 
Part 11 - Evidence-based considerations 
For the CANDA Trial there was little expectation that the research would show much 
difference between the two forms of surfactant. The evidence for the use of surfactant 
is compelling and NICUs around the country tended to adopt a policy of using one 
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form of surfactant or another. They could therefore be classed as 'an ALEC unit' or 
'a Curosurf unit'. Equipoise was strong and largely undisturbed in the NICUs 
involved in the trial to the point where a registrar commented: "I would have said that 
during the running of CANDA I was desperately unexcited whether they got the 
natural or artificial surfactanf ' (Int. 9). 
ALEC and Curosurf had not previously been compared head-to-head. There was 
therefore no objective comparative data from earlier trials to inform the clinical 
situation, but unease in relation to the trial, created by clinical experience of the fast 
acting short-term effects of Curosurf, may well have affected the decisions that non- 
trial NICUs made to stand outside of the trial. Some indication of this was given by a 
consultant: 
Dr 423 We didn't get any people that were using Curosurf that wanted to take part 
in the trial. 
CS: You didn't? Oh that's interesting. Can you speculate why? 
Dr #23: Because they weren't in equipoise. They saw their babies get Curosurf and 
saw them get better quicker because Curosurf is fast-acting, ALEC isn't. So they 
saw their babies get better quickly and they said "Well if it's isn't broken, why fix 
it. We know that it works as well as other artificial surfactants and we think it 
works better actually because we've got our clinical experience that makes us 
believe this. )940 
The situation was very different for the INNOVO Trial. Concerns about potential 
toxicity were thought by the trial team and the funders to be sufficiently important to 
outweigh the fast-acting short-term effects of INO, and a specific research aim was to 
assess long-term benefits and risks for term and preterm babies. There are however 
important ways in which INO can be seen as a desirable treatment, as indicated in the 
40 A senior consultant involved in the CANDA Trial explained how there are several issues to consider 
in the use of a faster or a slower acting surfactant. No other interviewees explored this territory, but his 
description is useful as it gives an indication of the nature of the clinical decisions which are made at a 
unit level, and of the complexity of incorporating data into judgements about research and practice. 
[There were two major] reasons that we opted for ALEC many years ago, First, there was no data to 
say that it was any better or any worse than the other and it was considerably cheaper, and that's a 
perfectly reasonable option and the second thing is, a number of babies that we were treating were 
being transferred in, having been treated [in neonatal units up to] three hours away by ambulance. 
And to have a very fast-acting surfactant where you need to make rapid adjustments on the 
ventilator in the first hour or two after [administration] was not necessarily a good idea. Giving a 
slower acting [surfactant] ... could be... an advantage. You'd be [under] less ... pressure 
[with the] 
limited time ... you're less likely to have a pneumothorax en route. (Int. 19) 
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INNOVO Trial protocol, which contains an explanation of an important aspect of INO 
and draws a comparison with alternative vasodilators. 
A big advantage of INO is that, because of its very short half-life, it only has a 
local pulmonary effect when given as an inhaled gas. Thus it can reduce pulmonary 
pressure without causing the systemic hypotension that often results from use of 
traditional pulmonary vasodilators such as tolazoline and prostacyclin. (INNOVO 
Trial Protocol 1999) 
Even at the early stages of the trial, the advantages of INO for term babies were being 
presented in UK j ournals. 
Inhaled nitric oxide is, at present, the only effective, selective, pulmonary 
vasodilator which has been established by prospective, randomised trials to reduce 
the need for ECMO in the near term infant with hypoxic respiratory failure. The 
lack of effect on systemic haemodynamics, coupled with the relative safety of 
administration, when appropriately monitored, would support the use of INO in 
preference to othei systemically administered vasodilators, including prostacyclin 
and tolazoline. (Finer, 1997) 
Growing evidence of a useful long-term role for term babies emerged in the course of 
the trial, with the publication of follow-up data for the Neonatal Inhaled Nitric Oxide 
Study Group trial (NINOS 2000) showing a reduction in the short-term composite 
outcome of death or need for ECMO and no significant difference in the outcome at 
18 to 24 months. There were, however, a number of trends in the data which showed 
a better outcome for the control group. The eligibility criteria for the INNOVO Trial 
did not change but the balance of the babies recruited to the trial shifted towards 
preterm babies and recruitment slowed, possibly as emergent evidence was 
incorporated into practice. 
Neonatologists from all four of the INNOVO NICUs represented in this study, and at 
different career stages, referred to the increasing evidence of the benefits of INO for 
term babies, and described their discomfort about the possibility of their allocation to 
the control arm of the trial. In three of the units there was reluctance to recruit term 
babies at all, although there was no specific PoliCY41 . Decisions were made as each 
case arose, with a tendency to treat outside of the trial (see below). In one NICU a 
41 In sharp contrast, all the collaborating neonatologists in one country had a policy of ONLY entering 
babies into the term stratum; they did not recruit into the preterm stratum at all. 
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policy had been agreed just prior to the start of the interviews as described by a 
consultant. 
Dr #25: We are going to exclude [term] babies from being part of the trial because 
we've reached a consensus between the consultants that those babies should be 
treated with the best vasodilator that we have, and that's nitric oxide. We'd feel 
uncomfortable about those babies getting the control arm of the trial and being 
treated with a lesser drug so we are now not going to enrol those babies. Doesn't 
amount to very much but that particular sort of baby will not now be part of the 
trial [in this unit and] will automatically get nitric oxide. ... 
CS: But you feel you're still in a position of equipoise? 
Dr #25: We are in pre-term babies ... The biggest trial of term babies with nitric 
oxide was published a few years ago and we'd been waiting for the follow-up, 
because this was the big question, it might work in the short-term but is it safe in 
the long-term? We had the results in abstract form of this follow-up study a year 
ago and people at that time pointed at this and said "Look, this is evidence that it's 
safe as well as effective in the short-term. " We've been hovering for a long time 
about these more mature babies and the definitive article was published last month. 
This obviously gives us more information ... and although it's not perfect information to say that it's definitely safe, it's more information in that direction 
and we made a decision yesterday that we wouldn't be randomising any more term 
or near-term babies, based on that paper. It might be a question we need to revisit if 
there's other studies that come out but this sort of external evidence, I think does 
influence you, and I think rightly so. It should influence both us [and] the steering 
committee. ... We need to question whether we're giving the right treatment 
package ... and whether that means randomising or treating. That's important. So it's been a difficult decision and I know a lot of other people have come to that 
conclusion some time ago and have been pointing to us and saying, "We told you 
so some time ago and you've taken a year" ... but we felt it was worth waiting for the article and doing our own critical evaluation of how good that study was. 
This process of creating a local policy, based on the collective decision of the 
consultants, served to re-establish rules on who should and should not be offered 
enrolment to the INNOVO Trial. It was evident that in all of the NICUS in this 
study, there were periods in which the rules about who could be recruited to'the trial 
had been unclear. This is reflected in the accounts that many of the neonatologists 
gave of their struggles with the clinical restrictions imposed by the INNOVO Trial 
protocol. 
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Part III - Clinical iudtiements; a focus on decisions over the 
use of INO within and without the INNOVO Trial 
The INNOVO Trial neonatologists often talked about the need to make clinical 
judgements about whether or not individual babies should be recruited into the trial, a 
concern which was rarely raised for the CANDA Trial42. Once recruited, further 
decision-points could arise. For babies allocated to the control group, some 
neonatologists felt that at times they were faced with a decision over whether or not to 
comply with the allocation, and whether to continue to abide by the allocation should 
the baby deteriorate. The INNOVO Trial protocol is clear about how the control arm 
should be managed. "If a baby is randomised to the "ventilatory support without 
INO" group, he or she should not receive INO at a later stage i. e. there should be no 
cross-over" (INNOVO Protocol 1999). A decision to administer INO outside of the 
trial, or to administer INO to a baby in the control group, would represent a decision 
to suspend collaboration with the trial with reference to that particular case. 
In the early stage of the pilot study for the INNOVO Trial, Nicholl described the use 
of INO outside a trial as a very real problem, stating that: 
INO is being routinely used in many UK neonatal units, without the safeguards 
implicit in participation in a clinical trial ... [despite the fact that] the possible long- 
term side effects of INO are not known (Nicholl 1997). 
At the start of the main study of the INNOVO Trial, there was concern that INO 
would be adopted as standard practice without appropriate evidence of efficacy and 
safety, and that a trial should be conducted "before the window of opportunity closes" 
(INNOVO Trial Protocol 1999). 
Data collected in the course of the trial indicate that INO was being used outside the 
trial, but also that attempts were being made to comply with the protocol and avoid its 
use. A log was maintained to record the numbers of non-participating trial-eligible 
babies who were treated with INO outwith the trial in neonatal units which had agreed 
to collaborate. The log indicated that during the recruitment period at least 75 preterm 
and 163 term babies were treated in this way. There was clearly less equipoise for the 
42 Where this concern was raised it was not generally expressed in interview as a clinical judgement. It 
almost always related to issues of whether consent was appropriate given parental circumstances. 
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term babies, although the numbers were inflated by the returns from one large hospital 
not involved in the qualitative study. 
Within the trial, seven of the 94 babies allocated to INO did not actually receive INO, 
three because they improved and four because they died before it could be 
administered. In addition, of the 84 babies allocated to the control arm, there were 10 
cases where INO was administered representing cross-over, prohibited in tile trial 
protocol. INO was the only vasodilator about which the trial protocol was 
prescriptive. Other vasodilators (such as magnesium sulphate, tolazoline and 
prostacyclin) could be given at clinicians' discretion. As shown in Table 6, this 
discretion was more often exercised for those allocated no INO (cross-over and use of 
other vasodilators highlighted. 
Allocation Treatment Preterm 
babies 
Term 
babies 
Total in 
trial 
Allocated INO No INO 3 4 7 
(N=84) INO 52 25 77 
Other vasodilator 5 7 12 
Allocated no No INO 49 25 74 
INO (comrol) INO 4* 6* 10 
(N=84) Otilervasodilator 16 L 31 
Total recruited _ 108 61 168 
non-participwit 
eligible 1: 
INO 1 75 163 238 L 
* In 2 cases cross-over occurred when the baby was transferred to another non-participating unit 
Table 6- Allocation, cross-over and the use of vasodilators in the INNOVO Trial. 
Analysis of the interview data could be used to explain sorne ofthe decisions that 
were made about cross-over and treatment outwith the trial, and the efforts that the 
neonatologists made not to break with the trial protocol. This could in turn illuminate 
larger questions about professional perceptions of care and research and their 
responsibilities to their patients. 
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The approaches of different neonatal units 
As accounts of decisions about cross-over and treatment outwith the trial were very 
varied across the sample, it is helpful to gain an overview of how the different NICUs 
(A-D) dealt with this issue. The explanations given by the four Local Principal 
Investigators (LPI) of how they would deal with a situation where parents request the 
use of INO, and with parental preferences for INO on allocation to control, are 
presented in Boxes 4-7 below. 
NICU B- Int. 15 
I usually put it in terms where we don't really have any choice, to be honest. That for example 
with nitric oxide, I'm saying that the babies we're giving it to, because we are ... concerned 
that we might not be right, we are randomising them. So if people don't want to go into that 
trial, that's fine. We'll say, "Right, we wont use nitric oxide, we'll use something completely 
different". So I haven't really given them the option of saying "Well we'll just have the nitric 
oxide", because we won't do that. ... So far I haven't had anybody come 
back to me [and say] 
"Well, I'll just have the nitric oxide 
(NB This neonatologist had not encountered the issue of preferences expressed on allocation 
to the control arm) 
Box 4- View of Local Principal Investigator for NICU B 
NICU A- Int. 2 
Dr #2: If parents have said "Can I have ... nitric oxide... outside of the trial" then the answer has been "Yes, technically you can in this centre because we offer it, but I ... would prefer the 
children receiving nitric oxide to receive it within the context of a trial", but no we haven't 
said that they can't have it here. .... If you make a unit policy that nitric oxide is only going to be available within the trial, end of story, then it's quite straightforward to progress when you 
are talking about randomisation. If your child doesn't get nitric oxide within the trial, he or 
she will not get nitric oxide, full stop. 
CS: That's your position here is it? 
Dr #2: No, it isift our position here. It is my position here, if you like, but if a parent were to 
ask me "Can my child be given nitric oxide outside of the trial in [this centre]? " ... can we 
physically supply it and give it, the answer is yes ... so I think it wouldn't be 100% honest to 
say that we couldWt give it outside the trial. So what we say is we really only want to give it 
within the trial because we think that's the best way to determine the usefulness of this drug, 
but it means there's a hint of an option that if the baby doesdt do well on air [if allocated to 
the control groupl that we can cross over, and I think that's where some of the confusion lies. 
Box 5- View of Local Principal Investigator for NICU A 
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NICU D- Int. 25 
Dr #25: If it was a term baby and the parents insisted on having nitric oxide, that's akin to 
saying that they're denying consent for the trial. We'd be left with a baby who couldn't go 
into the trial. We would probably use nitric oxide. I'm sure I would personally but we 
haven't got a policy for tha t43 . Now, preterm 
babies, much more difficult. It would depend 
how strongly we felt nitric oxide was likely to work ... on that particular 
baby [and] what the 
chances were for that baby without it. But we would be prepared to use it outside of the trial. 
CS: Right. How have you found it for yourself and for parents when babies have been 
allocated not to receive nitric oxide? 
Dr 425: Most of them I don't find it a particular problem, because [there are] very few 
situations [where] I feel that, because of the physiology, that you should give a particular drug 
like nitric oxide to that baby. Having said that, last week we had a baby who was exactly in 
that situation, wasn't given nitric oxide, but the physiology when we did a heart scan and 
looked at the x-ray suggested that one drug more than any other would be [useful]. Nitric 
oxide is a vasodilator and there are other less useful but similar drugs available and the 
INNOVO trial says you can use all those other drugs. We had a situation where a few of the 
consultants got together and if it had been someone else on [duty] I think we might have 
treated with nitric oxide despite [the baby] being in the control group, ... as a rescue 
treatment. The way we played it was that we used one of these lesser drugs, which had a 
similar effect but isn't as good as nitric oxide. 
CS: If the trial was not running would you have made the same decision to use the drug you 
used or would you have turned to nitric oxide? 
Dr #25 Oh, without doubt we'd have used nitric oxide. 
CS: Did you feel comfortable with using the lesser drug? 
Dr #25: It wasn't ideal but for the greater good of the trial itself we think it's important not to 
muddy the waters by using nitric oxide and there was an alternative. 
Box 6- View of Local Principal Investigator for NICU D 
43 It was in fact the case that the LPI was interviewed two weeks before the policy decision on the 
exclusion of mature babies was taken. The LPI's account is included here as it demonstrates the views 
of someone at the edge of equipoise. 
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NICU C- Int. 14 
CS: How much is the situation affected by how much you feel the parents might want the 
treatment? 
DR #14: It varies. For example if I had a baby of parents who were in their mid-forties, 
perhaps had ten goes at getting pregnant and they'd got as far as a twenty-five weeker, and 
that was going to be it, I would pull out all the stops and I think that would probably stop me 
randomising the baby, I think I might try a treatment. It's rare you're in that situation but I 
think that.. because as I say primarily with clinicians, if you think something might work you 
will try. I might use a different approach to [those) parents and say "Look, there is this 
treatment, we don't know if it works, we really don't know. There is a trial going on but I do 
not want to take the trial [in case] the baby won't get the treatment' '. ... I would ask [the 
parents for their] specific permission to use it out with in that situation. 
CS: What decision did you make departmentally about how to manage situations where a 
baby's allocated to the control group, did you have an option to then give nitric oxide if you 
wanted? 
DR # 14: Yes. 
CS: Have you ever had parents who've specifically asked you to do that? 
DR #14: No. We've randomised fairly few babies here and the babies that are randomised are 
f t44. the ones in where .. there is less evidence for a bene 1 
CS: So the ones where you haven't felt you wanted to use it? 
DR # 14 Yeah ... 
Box 7- View of Local Princil2al Investigator for NICU C 
These extracts give an indication of the different approaches that exist. In four 
different centres, the four LPIs each take a different approach. In NICU B the 
preference is to restrict the use of INO to within the experimental arm of the INNOVO 
Trial, with a clear rule that rejection of the trial means that only the alternative 
vasodilators may be used. In NICU A the LPI would like to see INO restricted in the 
same way, but given its availability prefers to encourage parents to join the trial with 
the possibility of cross-over to INO should the baby struggle if allocated to the control 
arm. In NICU D for term babies parental preference would lead to treatment outwith 
the trial with INO, a position which was soon to be changed to automatic 
consideration of INO as a treatment option. Where preterm. babies were enrolled onto 
"I That is they are the preterm babies. 
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the trial, for those allocated to the control arm it was considered necessary, where 
possible, to maintain the allocation and in this NICU alternative vasodilators would be 
used. A clinical judgement could, however, be made based on individual physiology, 
which may or may not result in the use of INO. In NICU D the LPI suggested that 
their approach is variable. He described a situation where INO would be used outwith 
the trial, based to some extent on emotional needs of parents. 
The views of the neonatologists 
It is evident that NICUs do not always have clearly defined policies on how to react to 
particular situations. VAien the responses of the larger sample of neonatologists are 
taken into account, the variability increases. It was however possible to identify 
several key themes in the analysis, all of which are touched on in the comments of the 
LPIs. They suggest that decisions about treatment outwith the trial are a product of. 
" conditions set by the trial 
" strategic thinking about the implications of enrolment 
" responses to the use of alternative vasoldilators 
"a view of professional responsibility and the need for action 
Conditions set by the trial 
There were a number of key elements in the clinical and the trial situation which 
helped to shape the decisions that were made about the use of INO. Although most 
were familiar with the possibility of toxicity and long-term risks, INO was often seen 
as a desirable and potentially useful treatment in adverse circumstances. As indicated 
in the extract from the clinical literature cited above (Finer 1997), INO was already 
being described in positive terms albeit with certain provisos. It was available in each 
NICU and although its administration could be tricky, this did not appear to be a 
deterrent for the interviewees, many of whom had experience with using the gas. As 
in the ECMO Trial, the control arm did not involve an additional treatment, and the 
trial was not blind, both of which could make it difficult to face parents if there was a 
professional or a parental preference for INO. 
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A consultant described how it could be very tempting to use INO given that both the 
gas and the means of administration were readily available. 
It was easier with [the] ECMO [Trial] because access to the treatment could only 
be within the study. ... RTNOVO of course 
has been a bit more fraught, because 
you don't have to send the child off [to a specialist centre]. ... So 
it is more 
difficult if a child is becoming progressively more hypoxic and awful. At some 
point you're quite likely, at the very least, to break protocol to try the child on 
nitric. ... 
RTNOVO is a very interesting trial. I had considerable difficulties myself 
with it. I had enough equipoise to join it but I could see enormous logistic and 
scientific difficulties with it, because of the fact that it was too easy to break ranks 
and give the nitric anyway. You don't have to have very much of that and you 
have one invalid trial. (Int. 28) 
The nature of this difficulty was explained by a registrar. 
If you know [of] anecdotal reports of babies responding to a drug in the short-term 
and if a baby in the short-term is going down the pan, then can you stick to the 
[allocation to the control group]? ... Because 
it's available in so many places now, 
you almost feel as though you are depriving that baby by putting them on the trial. 
That's where I feel a huge amount of discomfort with the INNOVO Trial. [Waiting 
to ] see what the baby gets ... you're just sitting there thinking, 'God I hope this baby is [allocated to INO] ... You! ve just looked at the parents ..., they sit there, 
they think about it and think, 'Actually this drug sounds good. ' and you're offering 
them this little ray of hope and then afterwards youre saying, 'Oh sorry, they're not 
going to get it. ' I'm quite happy I've only had to recruit the one patient. (Int. 8) 
The choice not to blind professionals and parents to the allocation was mentioned as a 
complicating factor in several interviews. It was suggested by a consultant that had 
the trial been blinded, cross-over and administration of INO outwith the trial may have 
been less of an issue. 
Dr #2: 1 had some issues with the trial. ... I think the lack of blinding which 
was done for very good reasons, has made it more difficult, ... [as well as] its 
physical availability outside or inside the trial ... 
CS: Would you have liked to have seen it blinded? 
DR #2: 1 think it would have been easier for us ... and I think the parents, because to say, you know, if you [put] your baby into this trial and he or she may or may 
not receive nitric oxide, but neither you nor I will know, then in one sense, we're 
absolved ftom this option that we have, that if things didn't work out, we've got a 
cylinder standing here and ... we could actually give it... I think that's quite difficult. 
CS: You said for parents as well. In what way do you think it would make it easier 
for parents? 
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DR #2: Because I think if all they've got is a black cylinder unlabelled and the 
child is getting worse, they won't know that they were already getting the drug or 
[not], so I think they won't know whether they had more to gain or lose by 
changing. 
Strategic thinking about the implications of enrolment 
Some interviewees touched on ways in which strategic thinking around the INNOVO 
Trial shaped which babies were considered for enrolment and at what point in their 
care, and which would be treated outwith the trial. This could relate to a judgement 
about the use of INO itself, or to the possible impact of enrolment in relation to the 
use of other treatment modalities. 
The vast majority of the evidence derived from this study suggest that this group of 
neonatologists were either in equipoise, seeing both potential advantages and 
disadvantages, or they were not in equipoise, viewing INO positively. In one 
interview there was however, some suggestion that concern about using INO may 
have affected recruitment decisions. 
If you measure [the] oxygenation index, how much breathing support a baby needs, 
there are some that as soon as the baby has reached that criteria will say, "Okay, 
well, let's consider nitric oxide now as part of the INNOVO study. " Some will let 
that figure double, triple, quadruple before they even begin to think about it. I think 
that's partly because of lack of familiarity with the equipment, the circuit, the gas 
itself. (Int. 26 registrar) 
As the trial involved wide diagnostic criteria it could be possible for a baby to fit the 
eligibility criteria for some time. There may have been delays in consideration of the 
trial within this period of eligibility while staff first tried everything else at their 
dispoSa145. Such delays could lead to a situation where a baby deteriorates to a point 
where recruitment to the trial is untenable. 
If we think that a baby looks like it needs nitric, we would give it nitric, because by 
the time you've got to a threshold where you actually need to give nitric, you can't 
afford to wait and see what the baby does if you dorft give it nitric. Because we 
know that on the whole if you've got a baby in dire straits, and [it is] the sort of 
45 Informal discussions with staff in ECMO centres suggested that this also happened in the ECMO 
Trial. 
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baby who does need nitric, then nitric at least in [the] short-term gets it better. We 
doWt know about long-term. (Int. 19 consultant) 
One registrar stated that in a smaller non-trial centre where he had previously worked, 
colleagues were reluctant to refer babies on to their local specialist NICU precisely 
because that NICU was collaborating with the INNOVO Trial. Rather than exposing 
the baby to what they saw as the risk of randomisation to the control arm, they would 
chose to maintain control of the case. Crucially this neonatologist (and presumably 
his colleagues if his account of their practice is accurate) erroneously felt that 
allocation to the control arm would preclude the use of any vasodilator. 
I'll give you an example from a hospital where I worked. Small baby, pulmonary 
hypertension, persistent hypoxia. This [would] be a candidate for randomising. 
However, you know that if you randomise the baby [there is an] equal chance that 
they may not get it, and this baby doesWt have no other option. So you stick with 
other vasodilators, give magnesium sulphate, give tolazoline, give prostacyclin, and 
try to improve their situation. There is some reluctance to recruit, yes. (Int. 17) 
After further questioning he added: 
They may not be transferred to [this hospital] because ... they would be recruited into the trial and they will get nitric only as part of the trial. (Int. 17) 
The neonatologists sometimes argued that an inherent difficulty with the INNOVO 
Trial was that the control arm offered no obvious change in the management of a 
baby. As with the ECMO Trial it could be perceived, by parents and by professionals, 
as doing nothing. Decisions to treat outside of the trial commonly related to the 
clinical decision to administer INO directly rather than taking a chance on not being 
allocated to INO. In one interview however the situation was presented differently, 
implying that a decision not to recruit to the trial could relate to a judgement about the 
additional option of ECMO. 
It would be difficult because once they've reached the end of the road on the 
ventilator ... you've then either got nitric oxide or ECMO. What tended to happen 
was that the babies who probably just needed a bit of help but were likely to pull 
through would be randomised to the [INNOVO Trial] and the babies that were 
obviously just going downhill rapidly tended to be referred for ECMO. ... So it 
was almost a subconscious decision with most people on the unit, ... If you really 
wanted to properly answer the nitric question all the babies at that stage should 
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have [gone into the trial] which would have allowed the trial to answer whether it 
was useful. (Int. 24 registrar) 
For a consultant at a different NICU the focus was not on rejecting the trial in favour 
of ECMO but on the value of avoiding ECMO through the use of INO. 
I find it quite difficult getting consent on some term babies where we know that it 
can avoid those babies being treated with ECM0- ... At the moment we're still 
recruiting babies to INNOVO, even for term babies, and that creates some 
difficulties. I find it quite difficult to put myself in those parents' position because I 
think if I was the parent making that decision and with all the knowledge that I 
have, I wouldn't like my baby to be put in the trial. I'd just like it to receive nitric 
oxide. When [term babies are] randomised to not receive nitric oxide. ... you can't help thinking ... I wish he'd got the treatment. ... I wish they weren't in the trial. We'd have something else to offer them. Of course the next thing that we can offer 
them is ECMO and we know that's an effective treatment ... but it's a less good 
option in some ways because it involves transfer to another hospital and involves 
an invasive surgical procedure. (Int. 27) 
These accounts suggest that strategic thinking about the broader context of care and 
the alternative options could lead to selective forms of recruitment or exclusion, in 
particular for those babies of at least 34 weeks gestation, the lower limit for 
consideration for ECMO, and the type of baby (near term or term) which was thought 
most likely to benefit from INO. 
Responses to the possible use of alternative vasodilators 
According to the INNOVO Trial protocol, the alternative vasodilators, magnesium 
sulphate, tolazoline and prostacyclin, could be used for babies in the control arm of 
the trial. These vasodilators could also be used where there was a policy of 
prohibiting the use of INO outwith the trial when trial participation was rejected. 
Although this was the policy in NICU B, none of the neonatologists in the study 
reported that such a case had occurred in their experience, although several described 
discussions which had taken place on this subject. Opinions on whether the other 
vasodilators; were appropriate alternatives to INO varied. The option of using other 
vasodilators was taken up for 31 babies who were enrolled in the control arm of the 
trial, in order not to break with the allocation, as shown in Table 6 above. 
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In NICU D the consultants had made a collective decision to add their own local 
limitations to the eligibility criteria for the trial, considering preterm babies as eligible 
but treating more mature babies with INO. A consultant from NICU D gave an 
example of cases where difficulties arose. 
Dr #23: We've had one or two babies where we were randomised to control but we 
wanted to give a vasodilator, so we gave another vasodilator that wasn't nitric- 
oxide . 
46 Then we thought, hang on, we're giving this other vasodilator where's there 
is no randomised trial or evidence for if s efficacy, but lots of anecdotal, historical 
personal experience. We've used that. It's had the same effect that nitric-oxide 
probably would have had. Aren't we barmy going for a second best just because the 
trial has randomised for the child not to have that! So we've altered quite a lot of 
our view of the INNOVO Trial based on that experience. 
CS: I guess it's an interesting question as to how trials fit in with clinical freedom? 
Dr #23: Yes but I think to our credit I suppose, we've been able to recognise that as 
time's gone on, rather than just blindly randomising everybody, or blindly doing 
illogical things once the child is randomised. We recognised that this is an issue 
and changed with time, which must be an evolutionary thing. 
A registrar suggested that other vasodilators could be used for those allocated to the 
control arin, but for a slightly different reason. 
Dr #26: In those patients who haven't drawn nitric oxide we do sometimes try 
some magnesium. ... I don't know whether that's to make us 
feel better or not. 
CS: So thaf s presumably to make the parents feel that you're still striving to do 
something. 
Dr #26: It might even be to make us feel like we're striving. I don't think there's 
much evidence for magnesium working in very prems, but no, I dodt think we'd do 
it just to make the parents feel better, I think that all we want to be doing is 
something more. 
Professional responsibility and the need for action 
A very common point in the interviews came when the neonatologists described a 
critical situation where they felt that it was crucial to act decisively. The registrarjust 
quoted described such a situation. 
46 The statement that "we were randomised to control" reflects intense professional involvement in 
difficult cases and the way in which randomisation shapes the options at the neonatologists' disposal, 
as well as determining the intervention that the baby will or will not be given. 
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If you've got a child who's absolutely at death's door ... you are saying to [the 
parents] there's a faint hope that this thing might work and we don't know if it's 
good, we don't know if if s bad. The only trouble is if they doift get enrolled to it 
they don't get it at all, then there's nothing. They are in status quo, and status quo is 
their child's about to die. (Int. 26) 
The use of INO as a rescue therapy outwith the trial in extreme circumstances was 
presented by some as wholly appropriate, the obvious thing to do. 
We just put [the baby] on nitric because he was so sick that we just felt there's no 
point in trying to randomise, we'd just got to try everything. (Int. 20 registrar) 
If it was my decision, if I actually thought it may be beneficial then I might try it 
outside the trial, because if you're losing the battle then you may as well use every 
tool you've got in the shed. (Int. 9 registrar) 
In some interviews there was a sense of the tension that could underlie the decision to 
suspend trial collaboration and to treat outwith the trial, here described by a convinced 
trial collaborator. 
It may be a treatment which you think will be useful in a particular baby, and yet if 
you recruit the baby into the trial then they've only got a fifty percent chance 
of receiving the treatment which you think might be beneficial. Now that situation 
... can generate some conflicts. You want to contribute to the trial and to recruit 
enough patients to get the answer to the question as to whether it really is effective 
or not ... but on the other hand you want to do the best for the baby that you're dealing with at the time. ... Your instinct as a clinician is to try to give a treatment to make things better, even if it's not completely proven, because you think it 
might make a difference, particularly in a life-saving situation. ... I think that in 
general if we don't know whether a treatment is effective or not then the best way 
to answer the question is by randomised control trials. If we've got some evidence 
that the treatment works and a baby's about to die if we don't give a particular 
treatment there's strong argument for using the treatment outside a particular trial. 
Nitric oxide hasn't been proven... to affect mortality but it improves babies' 
oxygen saturations in the short-term and essentially when that's the baby's major 
problem you can't help but feel that it's going to make a difference to that baby's 
longer-term rather than just short-term outcome. (Int. 27 consultant) 
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Discussion 
The neonatologists indicated a high level of commitment to trials and felt that they 
ought to, and wanted to collaborate, even when they found the discussions with 
parents difficult. The decisions that they made to collaborate were driven by 
commitment to the generation of evidence which would benefit future populations, 
and by the possible benefits that trial participation may have for individual 
participants. The decisions about suspension of collaboration were all made with 
reference to their views of the best interests of individuals. In no instances did the 
neonatologists suggest that suspension of collaboration represented a lessening of a 
sense of commitment to the CANDA or INNOVO trials, or to research more 
generally. 
For the CANDA Trial, when the discussions were thought to be too onerous for the 
parents, many of the neonatologists felt it would be appropriate to suspend trial 
collaboration for that case 47 . Mostly they appeared to feel that they either did so, or 
would have done so had they encountered that situation, with a sense of ease. This 
may have been precisely because the neonatologists were in equipoise and it was 
generally felt that involvement in the CANDA Trial would largely accrue benefits for 
future rather than present babies. Any personal benefits which might be gained 
through trial participation (increased attention, the possibility of closer monitoring) 
would be offset by the potential cost to parents of having to consider information 
about the trial during a late stage of labour. 
In contrast, it was shown in Chapter 5 that the INNOVO Trial was often used with 
therapeutic intent with individual patients being the intended beneficiaries of the 
decision to collaborate in their case. There was evidence that the levels of equipoise 
for the INNOVO Trial were more variable than for the CANDA Trial, with very 
different perceptions of associated risk, and this was directly related to whether INO 
was viewed as a desirable therapy or as an unevaluated intervention. In this chapter it 
was shown that collaboration with the trial could be suspended in individual cases for 
47 It should however be acknowledged that, as shown in Chapter 5, some of the less senior 
neonatologists felt obliged to abide by the unit policy of approaching parents. For them the choice to 
suspend collaboration may have been less likely. 
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the same therapeutic reasons that could underpin the choice to utilise the INNOVO 
Trial. This could be to some extent independent of the prevailing levels of equipoise. 
When babies had advanced to a stage where there were few other options available, 
the emphasis on the role of research within a caring situation could shift even for 
those with a clear view of the evidence and a commitment to the trial. In this situation 
the trial could become a barrier to treatment and would be circumvented. Essentially 
the balance of evidence and the need for something that might help, could tip. The 
need to care for a child would become paramount, and equipoise and a trial secondary. 
For the majority there was a recognition that there are situations where it is "tempting" 
(Int. 28 consultant) if not wholly ethical to act outside the strictures of a trial protocol. 
It was however interesting to note how some interviewees held firm in this difficult 
situation and did not see the use of INO outwith the trial as serving the best interests 
of individual babies. Those taking this position tended to be the more senior 
neonatologists with more decision-making responsibility within the NICUs and those 
with some particular responsibility to trials. As their exposure to trials gave them an 
appreciation of the theoretical and ethical underpinnings, their own convictions about 
the ethical framework of research could prevail. For Dr #25 for instance, the equipoise 
that led him to join a trial also meant that he would not have a preference over the 
allocation, even for the sickest of babies. He argued that it also meant that he felt no 
discomfort or responsibility for a poor outcome as he would have acted ethically in the 
light of the best available evidence at the time. When the evidence-base changed, as it 
did for term babies in the course of the INNOVO Trial, he felt that the most 
appropriate course of action was to redefine with colleagues the conditions of local 
participation. This could be seen as a partial suspension of collaboration. It did not 
represent a diminishing of commitment to the trial more generally. With the 
redefinition of local entry criteria in place, equipoise for the reduced pool of eligible 
babies was thought to be tighter and clearer. It was however out of step with the 
views of the trialists whose collective view of the evidence led them to continue to 
include term babies throughout the course of the INNOVO Trial. This would suggest 
that equipoise which is so influential in these settings, is a highly complex shifting 
entity which operates at individual, local and community levels. 
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Chapter 7- The decisions that parents make to 
accept participation in the CANDA or INNOVO 
Trials 
The direction of inquiry 
An important element of the structure of this research is the ability to examine how 
different parties experience and interpret the same events. Their accounts not only 
provide insights into their own decisions, they also shed additional light on those of 
their counterparts, illuminating elements of decision-making which might not be 
available from a single perspective. In considering these two positions the researcher 
gains a fare overview on their convergence and divergence from an external 
perspective. 
The structure also permits cross-referencing between the data from the two parties to 
guide particular lines of inquiry. The interests, concerns, insights or even lack of 
insight of one party can suggest areas of analysis in the accounts of the other which 
would not necessarily have been evident from the external perspective. Essentially the 
interviewees themselves can guide the researcher towards key issues which might 
otherwise be overlooked. 
This chapter is shaped by these internal and external vantage points, exploiting the 
broad potential of the interviewees to direct the inquiry by pursuing an issue identified 
during the analysis as being of particular concern to the neonatologists. Firstly to 
promote comparison parental decisions are considered in the same format as the 
neonatologists' decisions, that is why they made their particular choices and how they 
related to the trials involved. Secondly the data are explored in the light of anxiety 
expressed by some neonatologists that parents often make over-rapid decisions about 
trial participation. 
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The neonatologists' concerns 
It was evident that the neonatologists felt a degree of anxiety over the circumstances 
and quality of the consent or dissent that was given for the INNOVO and CANDA 
Trials. Every neonatologist in this study has had to negotiate what they themselves 
saw as problematic situations in order to discuss trials with parents and all 
spontaneously expressed this concern. They were well aware of the difficulties that 
parents experience when they are given complex and often frightening information 
about prognosis, treatment, and a trial in a context of preterm delivery or neonatal 
intensive care. They described a number of additional factors which they felt 
complicated the process and could further compromise the quality of consent, such as 
their own time constraints, inexperience with trials, and feeling under-prepared to talk 
to parents. 
The neonatologists also expressed concern that some parents make hasty judgements 
about trial participation, and that fast decisions may be made without full 
consideration of the trial information. Two comments are broadly representative: 
If they don't have any questions or they just say yes straight away, I'm fairly 
anxious that they may not have understood what we're talking about. (Int. 16 
consultant) 
They don't listen to your explanation, they almost say yes before you've even 
finished telling them about the trial. (Int. 9 registrar) 
Another neonatologist expressed unease and frustration over this situation, saying: 
I don't like it when they won't listen! ' (Int. 15 consultant). Some saw this fast pace 
of decision making as a result of parental type - "Some parents don't even 
particularly want to understand the details of what's going on" (Int. 27 registrar) and 
some saw it as parental trust leading to hasty acquiescence - "There's 25% who 
don't want to engage in the process and just say, "Yes, alright, you go ahead. "" 
(Int. 15 consultant) 
Although it was widely acknowledged that consent in difficult circumstances can be 
compromised, the neonatologists were particularly concerned about those parents 
whom they felt do not engage in a two-way process, and make hurried decisions. This 
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suggested that exploration of the parental data should take particular account of the 
speed of the decision-making process. This chapter therefore examines parental 
decisions with particular attention to the factors affecting the speed of those decisions 
and seeks to understand whether parents shared the neonatologists'concerns. 
Part I of this chapter describes the background and the immediate circumstances of 
consent, and reports parental accounts of the speed at which they felt they made their 
decisions. Part 11 describes the reasons parents gave for making faster and slower 
decisions. Part III explores possible links between speed of decision-making and 
parental perceptions of trial-related risks. This chapter largely focuses on the decisions 
to consent to participate. There are however four cases where parents declined trial 
participate which are alluded to throughout this chapter. Their choice to decline the 
trial is considered in detail in Chapter 8, irrespective of the speed at which that choice 
was made. 
Part I- Parental circumstances and the speed of decision- 
makina 
The background to parental decisions 
0 
Thirty-eight parental interviews were carried out, representing 40 decisions, (21 
INNOVO, 19 CANDA); 36 were to accept trial participation and four (all CANDA) 
were to decline. Table 7 links pseudonyms (partners who were not interviewed are 
represented in brackets), and interview numbers with the trial in question, the decision 
that they made, the allocation where known" and outcome. 
The majority of the women (N=33) gave birth to one baby. In three of the five cases 
of twins or triplets, one or more died. Most of the women gave birth prematurely 
(N=3 1). Half of the women (N= 19) underwent a caesarean section (CS), most as 
emergencies (N= 15), nine under general anaesthetic (GA). 
48Missing allocations reflect the fact that some parents did not know which surfactant was administered. 
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Trial Int. Pseudonyms Allocation Outcome 
CANDA & 
INNOVO 
41 
69 
Kerry (& Ron) CANDA - not known 
INNOVO - INO 
Survived 
CANDA & 
INNOVO 
42 
70 
Joyce (& Seb) CANDA - not known 
INNOVO - control arm 
Survived 
CANDA 43 Fiona & Geoff ALEC Survived 
44 Zod & Bernard Curosurf Survived 
45 Wendy & Derek not known Survived 
46 Maureen & Charles not known Survived 
Declined 47 Shelley & Evan not applicable Survived 
Declined 48 Gillian & Kelvin not a plicable Survived 
Declined 49 Janine (& George) not applicable Survived 
50 Freda (& Nigel) Twin I- Curosurf 
Twin 2- ALEC 
Survived 
Survived 
51 Jill (& Eamonn) Curosurf Survived 
52 Tape corrupted 
53 Mona (& Daniel) Curosurf Died 
54 Eve & Balfour not known Survived 
55 Glenda & Robert not known Survived 
56 Gina & Matt not known Survived 
57 Cathy & Kevin Curosurf Died 
58 Teresa & Simon Curosurf Survived 
59 Linda & Douglas Triplet I ALEC 
Triplet 2 ALEC 
Triplet 3 Curosurf 
Died 
Died 
Died 
Declined 60 Cilla & Terry not applicable Survived 
I 
INNOVO 61 Trisha & Michael control arm Survived 
62 Nicky &Donald INO Survived 
63 Kate control arm Survived 
64 Dorothy & Bryan INO Survived 
65 Isobel & Roger control arin Survived 
66 Julia & David INO Survived 
67 Elaine & Keith INO Survived 
68 Rebecca INO Survived 
71 Sheila & Len control ann Survived 
72 Frances & Rodney control ami Survived 
73 Esther & Mark Twin 1 INO 
Twin 2 not enroled 
Survived 
Survived 
74 Cheryl INO Died 
75 Carly & Peter Twin I control arm 
Twin 2 not enroled 
Died 
Survived 
76 Belinda Twin I INO 
Twin 2 not enroled 
Died 
Died 
77 Heather & Jeremy control ann Died 
78 Lorraine control arin Died 
79 Judith & Sean INO Died 
80 Erica & Howard INO Died 
81 Tessa (& 15ýý NO Survived 
Table 7. PseudonyMs and interview details 
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For some of the women whose babies were born prematurely, delivery came after a 
worrying period as an inpatient, aware of the need to "hold on" for even one extra day. 
Those experiencing the potentially debilitating effects of pre-eclampsia often spent 
quite some time as an inpatient, with risks for themselves and their babies increasing 
as their condition progressed. For all of these women time eventually ran out and 
labour was induced or a caesarean section ordered, sometimes to their horror, 
sometimes to their relief. The women whose pregnancies were unstable, with 
bleeding and intermittent contractions could move in and out of labour on almost a 
daily basis. Those who arrived at hospital in established preterm labour often 
underwent a period of staff trying to stop their contractions but then had to adjust to 
the idea that their baby would be delivered extremely early. For those who 
experienced placental abruptions it could be a shocking and rapidly moving event. 
The women often found themselves in dramatic situations, being taken to hospital or 
transferred between hospitals by ambulance, or facing an emergency caesarean with a 
GA and their partner excluded from the delivery. Such events made the seriousness of 
their situation very clear. Difficulties for term babies could arise at delivery, 
(meconium aspiration) or some time after the birth (streptococcus B infection, 
persistent fetal circulation). For these babies there could be immediate or delayed 
complications, a rapid decline or a slow deterioration. 
A number of the women were extremely ill themselves, with pre-eclampsia, with 
major haemorrhages, or with postnatal complications such as retained placenta or 
infections. In some instances there was a significant threat to a woman's life. 
For the fathers there were several complicating factors. For some this was their first 
experience of labour and delivery, for which they could be ill-prepared. They could 
witness distressing events and feel excluded and powerless. If the couple had older 
children they often had to arrange childcare at short notice and this could limit the 
time that they were able to spend with their partner and baby. Where babies were 
transferred to another hospital, or when the mothers were very ill, fathers had to 
choose between their sick baby or their sick partner. Some took the lead in the 
decision about trial participation when their partner was unable to engage fully in 
discussions and a small number made the decision without their partner being present. 
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Some were emotionally overloaded and became angry, distant or absented themselves 
from the processes involved in the delivery or care of their babies. 
Reproductive histories could add to stressful circumstances. For some parents there 
had been a protracted period of trying to conceive. In 5 interviews (51,57,59,72,83) 
the parents stated that they had used assisted conception. In 9 cases the parents had a 
previous loss; a miscarriage (47,49,53,76,77); terminations for abnormality (6 1), 
stillbirth (43) or the death of a preterm baby (5 6,8 1). 
These difficult circumstances provide the context in which parents decided about trial 
participation. They are summarized in Table 8 below. 
CANDA CANDA & 
INNOVO 
INNOVO Total 
Number of babies 
Singleton 15 2 16 33 
Twins I - 3 4 
Triplets I - I 
Timing of delivery 
premature 17 2 12 31 
term/near term - - 7 7 
'Cause" 
early labour 7 16 
pre-eclampsia 4 1 - 5 
strep infection I - 6 7 
placental problems 3 - 3 6 
meconium aspiration - 1 3 4 
Hydrops - - I I 
Unexplained cause - - I I 
Mode of delivery 
vaginal delivery 9 1 11 21 
emergency CS: GA 4 1 4 9 
emergency CS: SB 3 - 3 6 
planned CS: SB I - 1 2 
TOTAL CASES 17 12 19* 38* 
"'Figures do not add up as more than one cause coded **contractions, bleeding, ruptured membranes 
GA = general anaesthetic SB =spinal block 
Table 8. Parental circumstances around decision-mLking 
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Location and timing of discussion 
An important element in the decision-making process is the location and the time 
available for consideration. The three main locations were the antenatal ward 
(CANDA), the delivery room (CANDA), and the NICU (INNOVO). In two cases 
(CANDA) the location of their discussion was not clear. 
Antenatal ward 
In 4 cases women and sometimes partners were informed about the CANDA Trial as 
inpatients, in a relatively settled period if early labour had stopped, or while being 
monitored for the effects of pre-eclampsia. There was time to consider information 
and discuss the trial with a partner or family. In this setting decisions were made in the 
light of a possibility that their baby may be delivered early. 
Delivery room 
Thirteen women and sometimes partners were informed about the CANDA Trial in 
the delivery room during labour. They were anxious and the mothers were often in 
pain. Most were given information about the likely difficulties their baby would face 
and some had discussed the chances of survival. Decisions made in the delivery room 
were in the light of the fact that soon their baby will be delivered early. 
NICU 
In 21 cases parents discussed the INNOVO trial when their baby was critically ill on a 
NICU. Their circumstances varied: some babies were born ill and were ventilated 
immediately, some deteriorated gradually; some parents had witnessed their babies 
undergoing complications and unpleasant procedures, and had experienced the highly 
stressful NICU environment without signs of progress. In other cases events could 
move at a horribly fast pace. All, however, had in common stress and anxiety that 
their baby would die. If the trial was discussed on the first or second day after 
delivery, then the women were experiencing the more acute after-cffects of delivery 
and both parents were often sleep-deprived and deeply fearful. Decisions made in the 
NICU were in the context of the worst-case scenario - the habies were all critically ill. 
These locations are surnmarised in Table 9. 
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LOCATION CANDA INNOVO TOTAL 
Ward - settled 4 4 
Delivery room (active 
labour, imminent CS) 
13 - 13 
NICU - 21 21 
Info. unavailable 2 2 
TOTAL DECISIONS 19 1 21 40 
Table 9- Location of decisions 
Seven tape recordings were made of conversations between neonatologists and parents 
where trial enrolment for their baby was offered. Although this element of the study 
was discontinued, the available tapes give some indication of the circumstances and 
the types of discussion which took place in two of the three locations. Summaries and 
extracts from two recordings are given, one for each trial, but presented with the 
caveat that the extent to which they are representative of other discussions is unclear, 
given the limited range of evidence within this study. 
Extracts from a transcript of a recording of consent for the CANDA Trial during 
active labour are presented in Box 8. As the woman involved was not interviewed it 
is not possible to comment further on how she later saw this situation. From the 
transcript it seems that the information and the responsibility for making a decision 
was very much directed towards the labouring woman. It is very noticeable not only 
that she makes very few comments, but also that her partner does not audibly engage 
in the process. Extracts from the transcription are presented in italics. 
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Consent during active labour 
The neonatologist starts to describe the CANDA Trial but is interrupted after 40 seconds by a 90 
second contraction. The mother can be heard using entonox and the neonatologist comments "Take 
your time" adding after a long pause "You all right? " Once the midwife check with the woman that her 
contraction is over the neonatologist starts again. 
Sorry it's very difficultfor you this but I appreciate you're listening. As I was saying, I've 
explained to you that there's a type ofmedicine that we need to give called surfactant, to help 
Baby's lungs expandproperly and there's two different types that we can use, one's an artificial 
one and one's a naturally occurring one and we're always trying tofind the best possible 
treatmentsfor babies that come up to the neonatal unit and, at the moment, we're trying to do a 
study along with a, a number of other units in the country, to see ifthere's any benefit to giving 
.. the artificial or the naturally occurring one.. and what I'm 
here to ask is whether you would 
be willing to participate in this study. All it involves is making a decision as to whether baby's 
going to receive the artificial one or the naturally occurring one and, apartfrom that, there's no 
other difference to the care that she will get on the neonatal unit. There's no other changes, no 
other extra tasks or investigations that we need to do. But what we do before she gets there is to 
randomize and that means, at this stage, I can't tell you which type ofsurfactant that she will 
get but that both ofthem are used widely in this country and we know that both ofthem work 
Okay (Mother. Okay) So, I've got an information sheetfor you here about that, consentform. I 
don't know how youfeel about that as well? (to partner) Wouldyou be happy? (partner makes a 
positive response) Yeah okay. Well I'll give you that in a moment. 
This explanation lasts 95 seconds. The remainder of the tape involves discussion of the tape-recording, 
another contraction lasting 55 seconds, and giving out paperwork. The neonatologist acknowledges the 
position of the parents after the contraction subsides. 
Well done. It's very difficult all of this, lots of things going on at once and I'm very grateful to 
you taking the time to listen to what I've said. Shall I leave you the information sheets? 
(Mother: Yeah) and I've got a consentform to be signed as well (Mother: Yeah) which either 
one ofyou can do (Mother: Okay) ... There's a lot of bits ofpaper. I think you're going to 
struggle to read them in between your contractions but I'll leave them with you (Mother: Yeah) 
and then Illpop back down later all right [to collect theforms]. 
The entire recording lasted 7 minutes and 40 seconds. How long the neonatologist was with the 
parents, and what information might have been given prior to the start of the recording is ot known. 
Box 8. Consent during active labour 
Box 9 gives details from a tape-recording of an INNOVO Trial discussion in which a 
lone mother makes a clear decision to enrol her baby in the trial. Cheryl was in an 
extraordinarily stressful situation. Her unplanned pregnancy was conceived at the end 
of a violent relationship. When her ex-partner learned of the pregnancy and Cheryl 
would not be reconciled, he attempted suicide. Days after visiting him in hospital she 
went into labour at 23 weeks, events which she felt were causally linked. The 
possibility of enrolling her daughter into the INNOVO Trial was raised when she was 
five days old and making no progress. Cheryl was already aware of the gravity of her 
condition, but it is clear that immediately the neonatologist emphasised the severity of 
the situation, she indicated that she would accept the trial. 
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Consent on a NICU 
Cheryl was alone when she discussed the INNOVO Trial. The neonatologist described INO as "a 
newish concept", explaining how it works and the possibility of side effects. 
What it is good at doing is opening up the blood vessels that go into the lungs. There'sa 
natural tendency after birthfor the lungs to be constricted, particularly ifthey are unhealthy 
in any way, andgiving this gas we think might he helpful, you know, in opening them up. Ifit 
was all straightforward ofcourse we wouldjust go on and use it (Cheryl laughs) but it is 
not entirely straightforward because it does potentially have side effects. Certainly we think 
it can inflame the lungs. A Iright you might get a positive effect to begin with but then later 
on it might cause an inflammation. (Cheryl. inaudible). It might also cause someproblems 
with bleeding and it's also the sort ofthing that's in cigarette smoke naturally, so that we 
are worried that in the longer long term that there might be some sort offisk with regard to 
cancer. Now ofcourse i(we thought that those risks were very high (Cheryl. Yeah) we 
wouldn't think about using it. So as it is we have apotential good effect, there's some 
concern about side effects but not enough to make usfeel that we shouldn't use it (Cheryl 
Uhuh) and we want to know whether it is the right thing to dofor babies [with] this sort of 
degree ofproblem (Mother. Yeah) 
Randomisation was briefly described before the following description of the rationale for the 
INNOVO Trial and the terms under which INO could be given. 
The reason why we are doing it is to try andfind out scientifically what the balances of 
advantages and disadvantages are, you know. I don't have any concerns about giving it but 
equally i(you decideyou don't want to do the trial that is actuallyfine and we wouldn't give 
it under those circumstances. We wouldjust carry on what (Cheryl. carry on) we are doing, 
you know and I don't have any problem with that. But if we aregoingto use itl would 
rather do it now when she is stable enoughfor us to introduce it and make a decision about 
yeah it does seem helpful or no it doesn't. (Cheryl. Yeah) and I'd rather you didn't decide 
justfor a minute. Id rather you sort ofthink about it at leastfor a hatfan hour or so. Mull it 
over andperhaps talk to the dad, and then i(you are happy I can actually make this 
randomisation process go ahead very quickly. 
More details of randornisation were given and then the neonatologist turned to Rosie's condition. 
You know that she is very sick and that we are running out ofoptions generally (Cheryl. 
Yeah), irrespective ofthis trial, so you know I think wejust have to take it step by step. if 
things do get worse then she won't survive, that's - (Cheryl. Yeah) you're aware ofthat. She has had this small bleed into her head (Cheryl, - inaudible). That doesn't surprise me given 
that she's so tiny and it's sort ofmiddle sized ifyou like but it's not disastrous. IfIfelt she 
had had a huge bleed into her head and therefore a brain that had been really seriously 
dam aged, I wo u Id tell yo unow. (Cheryl. Uh u h) I wo u Id say we Aou Id s top (Ch eryl. Yeah) 
but that's not the case ... (Cheryl. Right) It is not hopeless yet, but I think if it gets hopeless then we will say we'd tell you. 
At this point Cheryl interrupted, stating "I know I am going to go ahead with it. " The neonatologist 
reiterated that she should take some time. 
Right, well look I'll give you haýfan hour anyway and then I will come back to you and say 
well look ifyou are happy that'sfine and I'll make the call, but I'lljust give you afew 
minutes to think it through 
The conversation lasted under five minutes. Cheryl explained in interview that she did not wait 
but searched for the neonatologist to reiterate her wish to enrol Rosie in the trial. She said: I just felt that I was going to do something .... you know, anything to try and help her. That's how I felt, anything, even if it didn't help, at least I know I've tried. " 
Box 9. Consent on the neonatal unit. Cheryl Ont-74 INNOVO) 
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Speed of decision-making 
In considering the speed at which decisions were made it is important to assess how 
much time parents felt was actually available, and how much time they then chose to 
take. The sample is divided into those who did and did not make rapid decisions, in 
order to explore how the two groups described their choices. 
How much time was available? 
The parents usually described at some length their conversations about the (potential) 
condition of their baby and the possibility of enrolment in a trial. Exactly how much 
time they were actually given to decide on participation was not always clear, but in 
most cases49 it was possible to categorise the time frames as long, short or minimal. 
For the long timeframes (N=3) a day or more was available to make a decision. This 
was possible as there was only a threat of delivery, because a baby had stabilised but 
could still deteriorate, or was gradually deteriorating towards becoming trial-eligible. 
In a further 33 cases, parents were informed about a trial and required to give their 
decision in less than 24 hours (the time-scale defined by Manning (2000) as 
emergency consent). Within this timeframe parents in II instances were given some 
time to think through their choice, albeit often only a matter of five or ten minutes, 
defined here as a short timeframe (N=9 INNOVO, N=2 CANDA). In the remaining 
22 instances parents were required to decide in the context of one conversation about 
the trial, defined as a minimal timeframe (N=10 INNOVO, N=12 CANDA). This 
distinction, although often short in terms of time is important, as in the minimal 
timeframe there was no opportunity for private deliberation. 
In summary, for 14 of the 40 decisions (35%) parents were offered some time to make 
their choice, (long or a short timeframe), in 22 they were asked to make a decision in a 
minimal timeframe (55%), and in 4 (10%) the timeframe is unclear. 
49 The timescale for one case is missing as the mother, Joyce, had no recollection of the CANDA Trial, 
and was unaware at interview that her baby was enrolled in the trial. In another three cases the parental 
account of the time available for their decision was insufficiently clear to categorise. 
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How much time was taken? 
Regardless of the available timeframe, in 29 of the 40 decisions (73%), parents said 
that they made their choice immediately, with 26 being to accept trial participation. 
These instantaneous decisions will be referred to as 'rapid decisions'. There were 6 
cases within the 29 rapid decisions, where parents were offered more time but still 
made their choice straight away. Where neonatologists were aware that parents had 
made a rapid decision, parents explained that they were sometimes advised to take a 
further few minutes to reflect, as was Cheryl, but it is clear in the interviews that the 
parents were already convinced. 
Clearly there is a relationship between the time the parents felt was available to them 
and the time that they took to make their decisions. In the 22 cases where they felt 
they were offered a minimal timeframe, all parents made an immediate decision. In 
the 14 cases where more time was available only 3 decisions were made immediately. 
There are no differences in between the two trials in terms of the immediacy of the 
decisions that were made, with an even split in the immediate decisions (14 CANDA, 
15 INNOVO) and in the non-immediate decisions (5 CANDA, 6 INNOVO). Table 10 
gives further details of time available and time taken. 
Time offered Time t aken Total 
Decided 
imme iately 
Did not decide 
immediately 
CANDA INNOVO C; ýN-DA INNOVO 
Long accepted 3 
refused 
Short accepted 1 4 1 5 1 
declined - - - 
Minimal - accepted 9 10 - 19 
- declined 3 - - 3 
Unclear - accepted - 1 2 3 
- declined - - I I 
14 15 15 6J - 
29 1 11 1 ýO 
Table 10. Time available for decision-making and time taken 
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Part 11 - Parents' stated reasons for the pace of their 
decision 
The data were analysed to account for the pace of parental decisions, over and above 
simply being given more or less time by the staff involved. 
Reasons for a rapid decision 
Where parents made rapid decisions (N=2950), they often made such comments as 
"there was no hesitation at all, " it was "a snap decision", "an instant decision7', and 
"we told them straightaway. " The factors associated with rapid decisions can be 
grouped into four broad areas: 
"A background of concern for their baby 
" Reactions to staff 
" The level of significance attached to the trial 
" Importance attached to contributing to research 
In describing these factors, frequencies are not given as parents described a 
complicated mix of inter-related forces driving their decisions. Emotions such as trust 
and hope, alienation and fear, could overlap to such an extent that it would be 
inappropriate to view them as independent aspects in the decision-making process. 
The factors presented here should be seen as elements within attitudes and experiences 
which combine to bring parents to the point of choosing to accept or decline 
participation in a trial. They cannot be divorced from both the wider and the more 
specific details of the parental circumstances. For this reason the parental accounts of 
their choices are placed firmly in the context of individual experiences leading up to 
the time of decision-making, with attention to the possible influence of finer details, 
such as a change in the condition of a baby, the timing of the offer of a trial, a 
comment from a neonatologist, or a specific interpretation of events. 
50 As a reminder, the figure refers to 29 decisions, not the number of interviews or the number of 
parents. It includes the four decisions to decline the trial. 
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A background of concern for the baby 
Concern for the baby was uppermost in the minds of all parents and very commonly 
was an important factor driving the choice about trial participation. The rapid 
decisions that were made were often grounded in their fear of what might happen, 
and/or the hope that they felt was offered by trial enrolment. These two emotions 
dominate the qualitative data which are presented in this chapter 51 . 
Fcar 
Fear was undoubtedly the dominant emotion. Every parent indicated that they had 
felt fearful and anxious at some point. They described themselves as terrified (Ints. 
41,49,51,70,81) scared (45,53,55,56,61,65,72,74) petrified (55,61,74), 
frightened (41,48,62,69,71,73,81 and panicking (42,73). The fear that they 
described was not uniform. Parents could fear the unknown, with delivery 
imminent, or in the case of those with previous similar experiences, they could be 
undergoing events which were awfully familiar. Their fear could derive ftom a 
good or a poor level of insight into the implications of their baby's (likely) 
condition. If their baby was receiving intensive care they could be shocked and 
frightened by the reality. They could feel anxious about the choice that they had to 
make, about the trial interventions, or could fear the possibility that they would not 
access the "right" intervention. Most commonly and powerfully parents were 
afraid that their baby would die. They described a sense of desperation, an 
overwhelming dread that this might happen. One mother's comments are typical. 
She said: "I'd have tried anything to keep her alive, I wanted her to live so muclf' 
(Lorraine Int. 78 INNOVO). 
Fear did not drive all parents in the same direction. Whilst it pushed many to make 
very quick decisions to join a trial, it also led a minority to decline. Some felt 
anxious and burdened by the decisions, taking as much time as they dared in the 
circumstances. Some decided to decline the trial from fear; in the case of Shelley 
and Evan (Int. 47 CANDA) it was an almost instinctive reaction to their sense of 
overwhelming fear and shock at the realisation of their situation. Evan explained 
51 The pervasiveness of fear and hope mean that it would be highly repetitious to fully represent these 
as independent factors. Instead they are surnmarised in terms of their role as both the backgrou. nd or 
context, and as the immediate impetus for the choices that the parents made. 
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with an evocative phrase that when they heard about the trial "the first thing we 
thought was "No, no way! " (Evan Int. 47 CANDA) 
The different types and degrees of fear that they experienced underscore almost all of 
the elements of decision-making. The majority of the statements made by the parents 
cannot actually be divorced from parental fear. 
Hope 
Fear and hope were generally the two emotional sides of the parental situation; there 
is an obvious link between despair and the desire for a solution. They were often 
closely intertwined in the explanations that parents gave for their rapid decisions. 
For instance: 
I'd had him baptised. I didn't want to lose him ... and he was really poorly. There's nothing else they can do for him so yes we participated. ... [The 
neonatologist] said ... there's nothing else they could 
do, there's no worse 
anything'll get, give it ago because it might just make him better. SoIjustclung 
on to that. I signed straight away, definitely, you know. Like I wanted what was 
best and took his advice. (Joyce Int. 41/69 INNOVO) 
Both trials could seem to offer the potential to improve the situation, to offer "a 
chance" and "a glimmer of hope". This made the trials desirable options, almost 
regardless of what they involved. The vast majority of the parents felt that they 
offered an important treatment option, ranging from something that might improve 
the situation to possibly saving their baby's life. 
For both trials parents commonly felt that the neonatologists were clear about the 
benefits of the interventions, describing them as saying, for instance, "it would help" 
and "how safe it was to use, and how they were hoping that it would really do the 
trick. " Some parents argued in a common sense way that a trial was likely to offer 
some benefit: 
They wouldn't be doing it if it didn't help him at all. I mean I know it was a trial 
to see how effective it would be, but there's got to be some kind of benefit or, or 
they wouldn't be doing it in the first place. (Simon Int. 58 CANDA) 
In the INNOVO Trial, in almost every interview, parents agreed to the trial 
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specifically to try to access nitric oxide in the hope that it would help their baby. As 
for the parents in the ECMO Studies, the experimental arm of the trial was perceived 
as far more desirable than the control arm, which was seen as effectively doing 
nothing. 
Reactions to staff 
How the parents reacted to the staff who offered the trials appeared to be an important 
factor in their decisions. Most accounts indicated that parents could make their choice 
very quickly as they trusted the individual involved, or that they were irritated or 
alienated by staff who disturbed or upset them. At a time of extreme emotions there 
seemed to be little middle ground. 
Trust 
A strong theme in the interviews was the level of trust that the parents placed in the 
staff who presented a trial to them. In some cases the neonatologists inspired parents 
with confidence. Parents described having "a lot of confidence" in the neonatologist 
(Int. 66), how "you put yourselves in [their] hands" (Int. 64) and how "youjust trust 
them" (Int. 42). Where parents exhibited trust in making their rapid decisions, it could 
be due to the inferred or the explicitly stated approval of the staff By simply offering 
a trial it seemed that the staff, who were better informed than themselves, essentially 
supported their consent to participation. 
For the parents involved in the CANDA Trial there was no pre-existing relationship 
with the neonatal staff and so a degree of confidence had to be gained quickly in 
difficult circumstances. The neonatologists often explained in their interviews that a 
common way to approach parents for this trial was to embed details of the research 
into a conversation about the implications of preterm birth and how their baby would 
be managed after delivery. The neonatologists felt that this was kinder, promoted a 
better relationship with parents, and might make consent more likely than simply 
introducing themselves and then immediately making the offer of trial participation. It 
certainly worked in some cases where parents described the neonatologists who had 
approached them as "very comforting", and "really lovely, really put me at ease". It 
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could, however, be a very difficult point as the realities and consequences of their 
situation are made clear. For Mona whose baby was delivered after she developed 
pre-eclampsia, the trust that she felt was important to her, but it was generic and not 
particularly located within the encounter with the doctor who approached her about 
taking part in the CANDA Trial. She said that she had no concerns about agreeing to 
the trial straight away. 
I trusted the people that were there ... and I didn't think for one second that they 
would ... try and do anything that would harm her or hinder her, so it wasn't a big issue. (Mona Int. 53) 
A similar comment was made by a father. Matt and his partner Gina had previously 
experienced the loss of their first baby after a placental abruption less than a year 
earlier and found themselves facing the delivery of a second preterm baby for the 
same reason. The second baby would be admitted to the NICU where their first baby 
died. Gina and Matt described the staff involved in their care, with whom they were 
already familiar, as "absolutely tremendous people" and this very positive view 
shaped how they reacted to the offer of the CANDA Trial. They were approached by 
a "dead sheepisY' doctor during labour. Gina said that she was not able to listen to 
him as she was focusing exclusively on the fetal monitor. They actively chose not to 
read the information leaflet or to take any time to discuss their options and simply 
agreed to take part in the trial. Matt commented: 
They give you a thing which tells you everything you need to know ... but there's 
no way on God's earth you're going ... to sit and read it. ... I didn't really 
understand .. about the research to tell you the honest truth. And that wasn't because of the way it was said. It was explained to us. I was given things to read, 
but 
... I don! t personally see a way that you can sit me down and make me 
understand what you want to tell us in that situation? 
For Matt there were two issues; firstly he trusted the doctors to do what was right and 
to protect their baby in a research context, and secondly he felt that they had a 
personal stake in research. Matt placed a high degree of trust in staff and the system. 
I don't think hospitals are out to hurt you, and ... I know you hear of all these 
mistakes, but I don't think they're going purposely do something that they think 
can harm babies. (Matt Int. 56) 
Some of the women described being approached in quite difficult stages of labour to 
discuss the CANDA Trial. It was in fact remarkable how trusting and tolerant they 
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were in this situation. It may be the case that in a situation where they feel unable to 
give full consideration to the information that is available, trust is their main option. 
Freda, for instance, went into early labour with twins (29 weeks). The labour could 
not be stopped and the twins were delivered by caesarean section with an epidural. 
She was initially approached to discuss the CANDA Trial after the decision to carry 
out a caesarean section had been made and before her husband arrived at the hospital. 
She was asked how she was during this conversation. She was in the operating theatre 
"bent over a cushion with a needle in my back. " She felt positive about the 
neonatologist who discussed the trial but felt that she was given insufficient 
infon-nation. 
She was quite comforting, but I felt as though they hadn't told us a lot about it, I 
think I couldn't really sort of, make a decision on the facts what [1] had, so I just 
said "Whatever is best for them", you know. 
Freda characterised the approach as almost a comment in passing - "Oh, by the way 
would you take part in our trial? " 
So I said "What is it? " and they said "It's mainlyjust one gets one surfactant and 
one gets the other, would you do it? " and I says "Well, just whatever's best for 
them really, that's all I'm bothered about". So off she went, come back with the 
papers, by then I was like on the table practically getting cut open, she went "Will 
you sign this? " but I couldn't actually sign because by this time I was actually lying 
down with drips in my hands and things. (Freda Int. 50) 
For the INNOVO Trial some parents were approached by a neonatologist who was 
unfamiliar to them, but often there was a relationship with staff prior to the offer of a 
trial. Where a neonatologist had been caring for their baby, and then offered the trial, 
the parents generally trusted that he or she felt that it would be the right thing to do. 
This was the case for Rebecca and Roger. Rebecca went into a rapidly moving 
premature labour (28 weeks) which could not be stopped. She explained how their 
relationship with staff developed over the time that their son was in the NICU. 
As time went on and they knew us a bit better, they understood that Roger and I 
could basically take anything, and we wanted to be told everything, so we were 
treated that way. So it was very good. 
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The INNOVO Trial was discussed when their son was a few weeks old 52 and not 
making progress. A consultant had been called back to the NICU in the evening to 
see their baby. The description that Rebecca gave of the discussion about the trial that 
night was wholly positive. 
I think [she] dealt with it very sensitively. She was trying not to alarm us, I think, 
because of the complications that had occurred that day ... Her main concern was 
that he wasn't improving. ... I felt very comfortable about the whole situation. 
I felt 
it was explained very well, and any questions we had, she answered. 
There is a sense in this interview of all parties being in concordance, with the 
approach of the consultant suiting the personal needs and wants of the parents. 
It was managed very well. We were not taken away ... it was easier to 
do it by his 
bedside... The consultant was great. She was very, very good ... She got us 
both 
together and she first of all explained what Raymond's condition was like, the 
complications and why she was called back in. ... They weren't 
life threatening, 
but ... 
he should have been improving probably a bit more than he was at the time. 
... So she then said that there was a trial going on, stressed that 
it was a trial and ... 
what the treatment did and then we could make a conscious decision whether we 
felt that we were happy about the trial going ahead. So she went through what the 
treatment was ... and stressed also that the treatment may not work; there was no 
guarantees that the treatment would work ... But that it would not make things 
worse, there was no way it could make things worse because it was being used 
alongside the treatment that he was already having. ... I have to say ... I wanted a 
guarantee that it wouldn! t make things worse, because at the end of the day if 
there's a possibility that it could be worse, then your decision is different. But the 
main reason we didn't particularly hesitate with going forward was because it 
coulddt make it worse ... and there was a chance that 
it could help and make 
things better. ... And also the fact that the other treatment he was on at the time, the 
ventilation, wouldn't stop, it wasrVt replacing treatment, it was aiding [it]. ... So we 
were actually very pleased about that because any sort of glimmer of something 
possibly working was great. 
Rebecca felt that although they had to think through the issues involved in the trial, 
trust in their consultant helped them to make their rapid decision. 
You do get into a situation where you completely trust the doctor. ... You have to trust them, you know. You don't know anything about what his treatment should 
be or what's the best course of treatment. And [she] actually said that she believed 
that Raymond's current situation made him an ideal candidate for the trial.... She 
believed that the treatment would be the right thing if it worked for him. But she 
did stress that there was a big chance that it might do nothing. (Rebecca Int. 68) 
52 The timing is unclear in the interview but to be trial-eligible he must have been under four weeks old. 
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Similarly Joyce, who said she "signed straight away", said that her trust in her doctor 
was highly influential in her rapid decision. For her however the situation was very 
different. She was highly stressed and fearful and was desperate for a solution. When 
her doctor suggested the INNOVO Trial she agreed immediately. 
I had a lot of confidence in him you know what I mean. Them doctors know what 
they are doing, they definitely definitely do! And you put your trust in [them], you 
just trust them. You've got to haven't you, and I did. 
Her reaction on learning that her baby would be in the control arm of the trial and 
would not receive INO is indicative of the stress that she was experiencing at the time, 
and reveals the degree of faith she had placed in the neonatologist (emphasis added). 
[He] come back and he just shook his head and he went "I'm sorry" ... and oh I just 
screamed, I just broke down again, I really thought he was going to get us in on 
that and really thought it would help but I just broke down. (Joyce Int. 41/69 
INNOVO) 
Irritation 
Some of the rapid decisions were made as parents felt a degree of irritation with the 
staff involved. Where women were themselves ill or in labour it was clear that, for 
understandable reasons, the approach was not always given close attention. Whilst 
some women were understanding, and some were quite neutral, the information, the 
interaction or the concentration that was required could, for some, exacerbate stress to 
an unacceptable level. In such cases there was a sense that having someone come to 
discuss a trial could be annoying, too much to cope with or it could even seem to be 
irrelevant. 
Lorraine found it hard to appreciate that her baby would arrive within a matter of 
hours, and when she was approached during labour felt that she did not yet need or 
want to consider what would happen when her baby was born, commenting: "I didn't 
want to know! I didn't want to know! " Some parents who were approached when the 
women were at various stages of labour had wanted the staff to leave, and signing the 
form could be a means to achieve that. Fiona, whose early labour could not be halted, 
was transferred to another hospital. 
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I just wanted to get [the caesarean section] over to tell you the truth. Just for it to 
be over with [and I said] "Just say to them "Look, I'll sign it, and you just get on 
with it! ". 
Fiona was in an extraordinarily difficult situation. In a 13 month period she and her 
partner Geoff had experienced a stillbirth at 26 weeks of pregnancy after a placental 
abruption, a miscarriage, and then this second abruption at 27 weeks for the baby who 
was enrolled in the CANDA Trial. 
Through the night I woke up and ... I thought "God", and 
I pulled the blankets 
back. I was just covered in blood. 
Fiona was sleeping in the same room as her small daughter who was "petrified". She 
was taken to hospital by ambulance where her bleeding stopped temporarily. A scan 
showed that counter to her expectations the baby was alive. She went into labour and 
underwent an emergency caesarean section later the same day. She was approached 
about the CANDA Trial at what felt to her to be a particularly frantic time. 
Fiona: It was a quick conversation. I know because they were all coming in the 
room -I was still bleeding at this point - and they were saying "she needs a 
caesarean, we've got to get her ready" and they made the tests, and everybody 
was coming in, and there was just loads of people around. 
CS: So how were you feeling then? 
Fiona: I was just dying to get it done -I was in agony, 
Geoff. There was about ten doctors in the room at the time, wasrft there? [They 
were] putting in catheters, they were putting in more for the caesarean and 
things like that? [We] didn't have time to think. 
Fiona was asked what she remembered of what she was told. She knew that a 
comparison was being made and felt that it was between "an animal steroid and a 
human steroid. " She found it difficult to explain the nature of the research. 
One didrft work better than the other, but they were trying this one out because 
maybes it could work, better than the other one. But it wouldrft work as much as -I 
cannot remember, really ... I just wanted to get it over to tell you the truth. Just for it to be over with and I thought, well, I didn't really think anything about that. 
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She could not concentrate fully on the discussion about the trial and signing the 
form was a means to end to the conversation so that the much-wanted operation 
could proceed 53 . 
I knew what he was saying but I just wasn't really taking it in, just thinking 
"Give us the form, I'll sign it, just get on with it and get [the caesarean] over 
with. " (Fiona Int. 43) 54 
A similar view was expressed by Eve who had developed pre-eclampsia but had not 
sought medical care. When she consulted her doctor, was sent to hospital and was 
then transferred as an emergency to another hospital for delivery as her condition 
rapidly deteriorated (28 weeks). She was approached about the CANDA Trial as she 
was waiting for an emergency caesarean section to be carried out. She consented 
quickly and commented: 
I was just sick of seeing people that I didn't know, I just didn't want anything more 
to do with them. ... I was 
just tired and sick. (Eve Int. 54) 
Some parents expressed concern in their interview that they were unable to give their 
decision suitable consideration given their circumstances. In the case of Maureen, as 
for Fiona described above, her partner was not present when she was asked to 
consider a trial during labour (26 weeks). A different neonatologist arrived at a very 
late stage for her decision. Although at the time of the delivery she had been less 
concerned about this, accepting the irritation of the trial because she was "so happy", 
in looking back over how the situation was handled her views became stronger. 
Maureen: I thought it was appalling. 
Charles: There [she] was in a state of shock and a state of discomfort, trying to 
deliver the placenta, uncertain about the fate of the baby, ... sat there [making] a 
snap decision on whether to do this or not, having not had a consultation period. 
Maureen: Afterwards I felt as if I wasn't given enough information and I was 
more or less given the form. "Can you sign that so she can have her 
surfactants? " and I said "Yes" you know "Go". And I didn't make a decision 
really. ... [At] the end of the day you just want to get rid of this bloke and carry 
53 It is not clear that the conversation about the CANDA Trial would in fact have delayed the operation. 
It may be that Fiona simply felt that she needed the conversation to end so that she could focus on the 
event to come. 
54 During the interview Fiona was understanding about the need to approach women in such 
circumstances, commenting "I think the way they managed it was righf' but she did add that it would 
have been easier had she been approached earlier when her bleeding bad settled. 
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on with what you're doing. I think I was in a situation where I couldn't not have 
signed it, I couldn't have sat there and said "Well, let me just query this bit 
again". (Maureen & Charles Int. 46) 
Alienation 
There were two cases where parents decisions to turn down the CANDA Trial were 
bound up with their sense of alienation from the neonatologist who approached them. 
As they chose not to participate their stories are described in more detail in the 
following chapter. One mother, Janine still felt angry by the time of the interview but 
Shelley and Evan who felt very negative at the time of the discussion, came to feel 
that the doctor in question was "very good in the field" and "we had no problems with 
him", but the key factor was "just his way of explaining it. " 
The significance of the trial 
The settings for the two trials were quite different. For the CANDA Trial the babies 
were not delivered at the time of consent. Precisely how the baby would be affected 
was unclear although the lower the gestation the more compromised the baby was 
likely to be. Antenatal steroids were administered to help to mature the lungs 
whenever possible. This and the use of surfactant on delivery were standard clinical 
responses to this situation. The range of other existing treatments and support systems 
which might be drawn upon once the baby was delivered were all still available as 
potentially helpful options. 
In comparison, the babies that were eligible for the INNOVO Trial were already 
compromised. In many cases the various treatment options had been tried and were 
ineffective or no longer sufficient to support the baby. Often the parents were aware 
that there were few available avenues left to explore. 
The speed of the parental decisions was sometimes directly related to how they saw 
their situation in terms of the available options and the significance that they attached 
to the trials. 
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The CANDA Trial 
The CANDA Trial did not add to their options 
The parents commonly felt that the neonatologists presented the CANDA Trial as a 
benign and safe research study which may help their babies but was unlikely to cause 
any harm. Some felt that that if it affected outcome it would probably be in a small 
way. Parents often were aware that the trial aimed to assess the relative values of the 
two forms of surfactant. Others knew very little about the research but had picked up 
the sense from the neonatologist that the trial was not "that big an issue". 
Maureen described confidence in the use of surfactant and did not have a preference 
for ALEC or Curosurf. A feeling that it was not a crucial decision for their baby meant 
that it could be an easy and therefore a quick decision to make. 
I know that ALEC is the one that they've used a long time --- so it's proven to be alright. So I knew that if she had that ALEC one [it] would be alright and 
that the Curosurf one would be, I thought, equally as good. They wouldn't be 
trialing it unless they were quite confident that it would work. (Maureen Int. 46) 
Cathy was not able to describe the surfactants but she did give the essential features 
of the trial in her account. 
The gentleman from special care came in to ask if we would take part in the ... 
study. [He] said it was between natural and I presume man-made ... products. [He] 
did emphasise that they would be using one anyway and that there appeared to be 
[no] difference between the two but they were doing this trial. ... I was happy with 
that. (Cathy Int. 57) 
In another two cases parents indicated that they did not have particularly high 
expectations that the trial would affect their situation. Mona explained: 
He said that they were trying to establish which one was the more effective on the lungs. ... He didn't tell me what the drugs were, he didn't tell me exactly what they did, he just said they either built up or strengthened the lungs or something like 
that, and they were trying to find out which was the most effective, because there 
was a new one that had come out and they were trying to see whether it was better 
than the one they were already using. I said yeah no problem, because I was under 
the impression that they both did the same thing anyway. It wasn't really an issue. I mean if he'd have turned round and said one's brand new and it's never been used 
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before ... I'd 
have probably been a little bit more apprehensive, but then saying that 
no I don't think I would, because I knew that literally Mandy was 1 lb 6 but it 
doesn't very often happen that babies that small survive. (Mona Int. 53) 
Balfour (Int. 54) gave two slightly different accounts in his interview, at one point 
saying that the neonatologist who discussed the trial with them indicated that it was 
unlikely to benefit their baby - "He was saying ... no 
better chances, [that it was] 
just to experiment more or less". He did not feel that it was a big decision or a 
responsibility to enrol their baby in the trial, and he commented "I wasn't really 
bothered at the time ... I just said 
"Aye, owt55. " Balfour later added. "I don't think 
I thought it was that big a deal to tell you the truth", a statement which Eve agreed 
with. He did however indicate several times in the interview that they were under 
the impression that participation in the CANDA Trial would "improve his 
chances". Eve commented that she was happy for him to be enrolled as they were 
told that "it wouldn't make anything worse. " 
The CANDA Trial might improve the baby's condition 
As suggested earlier, hope, along with fear, was a dominant emotion which ran 
throughout parental accounts of their discussions and decisions about trial 
participation. This emotion is clearly prevalent in many responses to the CANDA 
Trial. Most of those who agreed to enrol their baby did so in the hope that it would be 
beneficial. The possible benefits were often rather vague and undefined with parents 
frequently commenting that they simply wanted to help their baby; they wanted 
"whatever's best". 
Teresa and Simon's son was born when Teresa went into early labour (28 weeks). 
This extended extract of their accounts of their conversation with the neonatologist is 
very similar to those given in several interviews, showing a process of weighing up 
what they felt the trial had to offer them. They concluded that it could only be to the 
benefit of their baby to take part. 
Teresa: He came and spoke to me about it and asked if we'd both be, be willing to 
go ahead with it and he explained about the - surfacant isift it? [sic] Surfactant! - 
53 Dialect -"yes, anything" 
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what it actually does, how it opens the lungs up and you know if they needed it and 
they were doing a trial to test. There was like, one made, was it from pigs or 
something? ... And then there was an artificial one that they normally use, 
but I 
remember him saying the pigs one was more expensive than all the rest of it and 
that's why they were trialling it to make sure that it was more effective or 
something and we were quite happy. 
Simon: They said that the success rate was good at the time or something ... and 
we just said well we've really got nothing to lose, and that was just fine. We told 
them straightaway. ... 
We were just sort of anything! Anything to help at the time, 
because we were quite concerned about his sort of state and like his actual health 
and we just thought, anything that's going to sort of help him on his way is a bonus 
really. 
CS: Did you feel both of them would helP him, is that what you mean? 
Teresa: Well yeah. 
Simon: Well yeah I mean they wouldn't be doing it if it didift help him at all. I 
mean I know it was a trial to see how effective it would be, but there's got to be 
some kind of benefit or they wouldn't be doing it in the first place really. 
Teresa: Yeah. I'd say when it's got to the point of it being at a trial stage, you know 
I didn't think it would do him any harm. 
Simon: We said is there going to be side-effects and he sort of said no. 
Teresa: He said well he needs it regardless so it was either this one or that one and 
he's got to have it, you know he couldn't survive without it, so we said well yeah, 
that's fine. (Teresa & Simon Int. 58) 
Another mother, Zod, whose baby was also born after an early labour (27 weeks) 
made an interesting comment which indicated that she saw the trial as potentially 
offering an additional treatment option, Curosurf. She did not however feel that it 
was such an important option that she worried that they may ultimately be denied 
access to it: 
Some consultants thought one was best, some thought the other was best, there was 
no consensus and they wanted to decide which was the best one to use. And she 
told us if we decided not to go for the trial that we would get the synthetic one, the 
ALEC. We ... had a sort of gut feeling that we preferred the Curosurf one anyway, because it was thought that it acted quicker because it was a natural based protein 
... and so we just sort of inclined towards the natural rather than the synthetic 
anyway and thought if it works quicker, great. Therefore if we go for the [trial] she 
might be given that. If she isn't she's only given what the hospital would have given 
her anyway. So we felt it was a kind of win-win solution for us. (Zod Int. 44) 
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The CANDA Trial might save their baby's life 
Although parents often hoped for some benefit through participation in the CANDA 
Trial, it was rare that it was seen as a life or death issue. One exception was Jill who 
was approached to discuss the trial when she was an inpatient in the days preceding a 
caesarean section. Her baby was conceived by lVF. She started to bleed and leak 
amniotic fluid at 26 weeks of pregnancy and was hospitalised. She could have had 
time to make a slower decision but she did not appear to have been given this 
opportunity. She chose not to discuss the trial with her husband as she "did not want 
to bog him down with anything else". She describes her decision as if it was in one 
conversation with the neonatologist, whom she described in very positive terms. 
She was very gentle in her manner. She introduced herself, asked could she sit 
down and have a chat to me and she explained about about the baby's lungs, the 
conditions sometimes that the baby's lungs are in when they're born prematurely. 
She told me about this surfactant and where it came from, and was it pigs or 
something? Pigs' blood or something which I was sort of quite disturbed about that 
at first, you know, a bit concerned but she sort of explained to me what they'd done, 
how safe it was to use, and how they were hoping that it would really do the trick 
with the lungs, with them being sort of, is it full of holes and things? ... So I felt 
quite comfortable with signing up for it because she explained in depth and in easy 
terms as opposed to baffling you with science, you know what I mean, like they 
can sometimes, so I felt quite comfortable with doing that. 
The crux of the decision that Jill made was that she though that participation in the 
CANDA Trial could make a crucial difference for their baby. 
I thought if it's going to help her survive, I'll do anything, you know what I mean, I 
would have done anything. (Jill Int. 5 1) 
The INNOVO Trial 
The setting of the INNOVO Trial meant that the parents of eligible babies were 
inevitably stressed and anxious, hoping for something that would turn their situation 
around. It might be expected that where babies are in such a vulnerable condition, 
there might be variety amongst parents as to whether or not they felt able to join a trial 
and expose their baby to an unevaluated intervention. This was in fact rarely the case. 
The parents did vary in the significance they attached to the trial, ranging from those 
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who hoped for a benefit but were prepared for the fact that it may not prove to be a 
solution, to those who felt it offered a significant, if not the only, chance of survival 
for their baby. The latter view was by far the most common, and in all but two cases 
(65,81) the parents enrolled with a most definite hope that their baby would be 
allocated to receive INO. 
The INNOVO Trial might improve the baby's condition 
There were some parents who did not see INO as a definite solution to their problems. 
David and Julia for instance felt able to make a rapid decision because they felt that 
the trial was at least worth a try. Their baby was delivered by emergency caesarean 
section after a placental abruption (27 weeks). She was very ill and David was called 
to the hospital late at night. He had to find a baby-sitter at II pm and drive an hour to 
the hospital. He was aware of the seriousness of the situation. 
There was a real decision to be made because basically although they didnt think 
there were any bad effects of this treatment, there were a few that they had to bring 
to our attention, so there was a small chance we could actually decide something 
that would actually make the situation worse. 
They decided to join the trial. Julia commented: "It seemed the only sensible decision 
in the circumstances. ... They didWt think she was going to live so I mean we were 
willing to try anything. " David made much the same comment: "So anything that 
gave her a chance, we were going to worry about the side effects later on. " He 
expanded on this, saying that they very much wanted their daughter to be allocated to 
INO. They did not feel that they were exposing her to too great a risk: "it wasn't a 
finely balanced thing. " 
If it had gone horribly, if she'd died, basically, it would have still been worthwhile 
doing because I don't think it would have been this trial that had killed her it just 
wouldn't have succeeded in saving her life. (David Int. 66) 
Heather and Jeremy were also aware of the limitations in the offer of the INNOVO 
Trial. Their baby was delivered by emergency caesarean section when Heather's 
early and fast labour could not be stopped (26 weeks). He was very sick. They 
brought their older small son to the hospital to meet his new brother on the 
encouragement of the staff. He was baptised, and then moved to a NICU at another 
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hospital. Heather could not be transferred at the same time. She described herself as 
"emotionally shut down". Jeremy was approached by a neonatologist on his arrival at 
the second hospital and asked if they could "go off and have a chat. " He found this 
unnerving. It made him panic as it was "the stereotypical way of breaking bad news". 
It was in fact to discuss the INNOVO Trial. Jeremy explained how he saw the trial. 
The gist of it as I remember was that the trial is an alternative to the normal way of 
giving oxygen in an incubator and that this was a new bit of research that they 
didn't know a great deal about it. They were still trying to find out if it was better 
than what they were doing at present, and that it was just an alternative. It was no 
guarantee better. ... I remember asking if there were any side effects and she said at 
that stage, as far as they could tell, no. But things were at a very early, early stage 
and ... I suppose 
fairly limited. [It] sounds as though we werent given enough 
information but no, because things were so new and obviously you just want 
anything that, that could possibly help. 
Jeremy did not decide instantly because he wanted to call Heather to discuss what they 
should do. Once they spoke, they decided straight away. Jeremy described the trial as 
offering a "possibility to get Aidan through. " He explained further 
It was a fairly quick decision to go ahead with it. There didn't seem any hann in it. 
If there was, if there was an obvious side effect, a bad side effect then, you know, 
we just wouldn't have done it. ... But no, it was always made clear it was a trial, it 
was not a magic cure ... and I was well aware that he may well fall into either 
group, but I think like I say the problem is you're trying to grasp at things that are a 
magic cure. (Jeremy Int. 77) 
Their baby was allocated to the control arm of the trial and probably because they 
were not pinning all of their hopes on INO, they said that this was swiftly forgotten. 
Shortly afterwards their baby died. 
The INNOVO Trial was important as theV were runnine out of other options 
For some parents the INNOVO Trial was offered in the context of a dwindling 
number of options. In some cases they were told that ECMO was still an option but 
this could be frightening in itself. Parents were often aware that ECMO was reserved 
for the most serious cases and the possibility of allocation to INO could help to avoid 
having to resort to such an extreme option. In this setting parents could feel helpless 
and compelled to consent. Sheila and Len, whose daughter aspirated meconium 
during a term delivery, described precisely this feeling. 
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I don't feel like we made a decision. There wasn't any decision to be made. 
You just asked the consultant ... and he explained what it could do, and what 
it 
would save her from going through you just say, "Yeah", straightaway, you 
know. You don't think about it, you'll chop your arms off if it'll give her a 
chance (Sheila Int. 71) 
A father, Michael, described a rapid and focused weighing-up of options for his son. 
Michael and Trisha had terminated two pregnancies for spina. bifida, at 19 and at 24 
weeks of pregnancy and their son was bom six weeks early with a streptococcal 
infection. It was extraordinarily difficult for Michael to feel that his son may die. He 
described several times how he was barely able to contain his emotions in the NICU. 
Like Jeremy he followed his baby to a second hospital and was asked to consider the 
INNOVO Trial on his own. He was very protective of his partner, shielding her from 
information throughout their experience, and chose not to involve her in the decision 
about the trial. He described the consultant caring for the baby as saying "We have got 
to discuss what we are going to do because he is getting weaker and nothing is 
working". He did not feel that he understood the trial but still felt that giving his 
consent was the obvious thing to do. In part his decision hinged around his concerns 
about the potential difficulties involved in transfer for ECMO. 
I didn't have any choice. ... The three options I had was: carry on as we are, go for the trial and hope that it improves him, or risk transferring him [to another 
hospital], which he might not make, for ECMO. (Michael Int. 61) 
He described himself "sat cross-fingered and cross-legged" hoping for allocation to 
INO "because at that time it was the only hope that we had. " 
There were no new options other than the INNOVO Trial 
For many of parents there was a strong sense that the INNOVO Trial had been 
discussed when they were vulnerable and sometimes when they had nowhere else to 
turn. In half of the interviews related to the INNOVO Trial, parents stated that they 
were told that there were no remaining treatment options left. This appeared to result 
in two responses. Some clearly felt overwhelmed and described how they had simply 
gone along with the suggestion of the trial and others reacted in a more active and 
decisive manner. Whatever the style of the decisions, it was precisely because they 
felt that their options were so limited that they instantly agreed to take part. 
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One mother, Nicky, whose term baby was bom with a streptococcal infection, said 
that the trial represented hope in a difficult situation and they "grabbed it". They had 
already been told that their daughter may not survive. She explained how they were 
feeling when the trial was offered. 
Initially when [the consultant] told us how sick she was and what was happening it 
was 50: 50, you know there wasn't much hope. And then they pull the trial out and 
say you know this could make her better. It's possible that this could make her 
better and we were like - Yeah! Do it! He didn't push us, but in the situation we 
were in it was hope and we grabbed it. I mean if he had said there was 10% chance 
that this would work we would have took the 10%. (Nicky Int. 62) 
At another point in the interview Nicky's comments suggest that she felt that the staff 
involved were also searching for a solution. 
I think they sort of said well -not like it was your only hope but you know that 
there wasift much else that they could do for her basically and this was about the 
only other thing that they could think of that might help her. (Nicky Int. 62) 
In the case of Esther and Mark's son, one of twins, there was a clear sense of the 
process of using up the available treatment options. Esther had had a difficult twin 
pregnancy with much concern that one baby was not thriving. Her hind waters broke 
and she went into labour after nine days as an inpatient (26 weeks). The first twin, 
Toby was relatively well, breathing on his own for the first few hours. Jon however 
struggled and was "very very poorly when he was bom. " A little over 24 hours later 
Esther was woken during the night for permission to put Jon onto an oscillating 
ventilator "because the normal ventilator wasn't working". She was approached again 
at 7am when she was told that "he was still poorly and it obviously wasn't working. " 
It was at this point that the INNOVO Trial was mentioned. Esther was required to 
make a fast decision on her own. She could not understand the information that she 
was given and at first she felt that she could not make the decision. 
I did say at the time, "I cant make a decision because my husband's not here. " And 
they [said] that if he was going to be part of the trial they needed to act quite 
quickly because he was poorly. So that's why I made a decision while [he] wasn't 
there, because I felt like we didnt have enough time to wait. ... Even if I [had] rung [him] and said "Come down now. " IVs still an hour and,.. I'd never have forgiven 
myself if something would have happened in that hour while I was waiting for 
[him). 
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Even in these difficult circumstances, parents can make it very clear, as did Esther, 
that they can focus and make what they feel is a responsible decision. Although she 
struggled with the information, and felt under pressure of time, Esther appreciated the 
way in which the request that she make this decision was made. She trusted that the 
staff were "trying to do the best they can" and could see why she needed to act. 
I got the impression that we didn't have ten minutes for me to sit and think about it. 
I mean he didn't rush me into a decision at all, but I just got the impression that I 
didn't have maybe an hour or so to sit and think about it because Jon [could 
deteriorate] ... for an hour longer, which 
it difficult isn't it? It's hard for them then. 
(i. e. the neonatologists) (Int. 73 Esther) 
One interview in particular conveyed very strongly the poignancy of the parental 
situation and how their experience with a trial can have lasting effects. Carly gave 
birth to twins six weeks early. Both babies were in a poor condition and had 
contracted an infection (no further details given in the interview). One baby, Amy, 
was eligible for the INNOVO Trial. Their description of the events surrounding their 
consent to enrol her in the trial was somewhat disjointed. They described how a 
consultant had characterized the situation. Carly repeatedly focused on what was for 
her the most important element of what she said they were told: "It's her last chance. 
If she doesn't get it she'll probably die ... but if she gets this she's getting a last 
chance. " Peter said that they decided to consent to the INNOVO Trial 66as soon as he 
said it's the last [chance]". He gave a description of the consultant's explanation of 
why the use of nitric oxide was randomised as "some doctors think it does work, some 
think it's nothing to do with that, the babies just pick up". It seemed in this account as 
if the parents felt that INO was being randomised because doctors could not agree 
whether it was useful or not. Whilst this is not at all far from the truth, there was a 
subtle implication that this was largely a way to manage uncertainty. They did not 
present the trial as in any way evaluative or as a form of limiting exposure to an 
untested drug and this was a crucial element in their understanding of their 
experiences. Carly felt that "everyone should get the chance at it. " 
The news that Amy had been allocated to standard care was devastating. With INO 
no longer a possibility they felt that they were left "just sitting there watching her 
die". They felt that they process was particularly cruel, "a totally horrible thing to 
do. " The key element in their experience was a sense of having a potential solution 
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dangled in front of them, a solution which their doctor was then powerless to 
access. They felt that he too was upset at the allocation. Peter made it clear that he 
did not hold their consultant responsible, saying "we never blamed [him]. It's 
somewhere else along the line isn't it where all that comes from. It's not the 
doctors at the hospitals. " Both babies were baptised in hospital and Amy died after 
six days. Carly made a poignant comment, a point that she returned to several 
times. 
That's what goes on in my head, you know, if she would have got it maybe she 
might be still here. (Carly Int. 75) 
Where a trial is discussed in the light of little or no alternative treatment, it is perhaps 
not surprising that it is seen as a last ditch attempt when all else has failed. In the 
most extreme cases this could lead to a situation where parents are asked to consider 
research at a very late stage in the course of their baby's illness, essentially as a rescue 
therapy. The account of one couple, Erica and Howard, is described in detail in Box 
10 below. It is singled out as being particularly important because it gives an 
indication of how parents can make rapid decisions based on a mix of many of the 
emotions described above. It also describes from the parental perspective, the 
situation described by several neonatologists in previous chapters where INO is used 
as a rescue therapy. The trial is a gamble at this stage, for professionals and for 
parents alike. 
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Erica and Howard 
Erica and Howard were told that after a scan that their baby was affected by hydrops. At 34 weeks 
Erica was hospitalised and they were told of the likelihood of a poor prognosis. She soon went into 
spontaneous labour, and underwent an emergency caesarean section with a general anaesthetic. 
Howard was given a brief glimpse of the baby, Jenny, as she was taken straight to the NICU. Although 
very swollen, he felt that she was "beautiful". On spending time with her on the NICU he came to see 
that she was "very damaged" and described her chances as "20 to 30 per cent". Although he felt that 
there was little that could be done for her there they still felt at this stage that she may survive, as they 
were told that the first 24 hours would be crucial. 
It was just a case of monitoring her. It was all in Jenny's court really, there was not much that they 
could have done really apart from drain and monitor, and then if Jenny wanted to make a go of it 
they could have done more. 
In the meantime Erica developed a bowel infection. She had not seen Jenny and although she had had 
some feedback she found it difficult to appreciate what was happening to the baby. At 5arn on the 
morning after delivery Erica was woken by a neonatologist to discuss the possibility of enrolling Jenny 
in the INNOVO Trial. She was critically ill and declining rapidly. Howard was called back to the 
hospital, but there was no time to wait for him. Erica had to listen to the information in her bed and 
decide about the trial on her own. She was asked to give her decision in five minutes. She said "I was 
drugged up because I was on morphine, I was sort of out of it, I didn't know what was going on. " She 
describes the conversation and her view of the trial as follows. 
He came to me and said "Baby isn't well so we can do this trial" he said "but there is only sixty in 
the country" or something "and it's like picking you out of a haf', and I turned round and said 
"What about her chances? " and he said to me "There isn't really much hope. She's deteriorating 
fast but it's up to you what you want to do" and I said "Go for it! " 
Erica's account of the trial includes the availability of a treatment which may or may not benefit their 
daughter, and that it might not be accessible. Her focus in the interview was however solely on the 
potential of [NO to help their situation. 
As soon as he said that, the main thing that was stuck in my mind was anything that would help her 
then yeah go for it, it gave her a better chance. ... [E]ven though it was her last chance there was 
still hope. 
The allocation was made very quickly and Jenny was to receive INO. Howard arrived and they went to 
see her together. Jenny deteriorated further and INO was not used. Howard described the timing: 
I got there for about twenty past five. ... Erica 
[had] already given the nod about the trial about ten 
past and at half past five you were being wheeled in to say our goodbyes. By half past seven Jenny 
was dead. 
There are important technical preparations which have to be made in order to administer nitric oxide for the trial. From the details given in the interview it is not possible to say whether there was Simply 
not enough time to make these preparations or whether Jenny was ultimately too sick to undergo any 
changes to her circumstances. Erica and Howard were however left with the impression that the trial involved allocation to a ventilator which had to be brought to the hospital. They felt that there had not been time to get the ventilator to them. They were frustrated at the timing, feeling that they had been 
asked about the trial at such a late stage, despite the fact that Jenny's condition was clear from a week before she was born. Erica felt that she would have preferred to read material in advance so that a decision could have been made at an earlier stage. When she finally saw her daughter she realizedjust how ill she was. Erica accepted that she would not now receive INO and they chose to have Jenny 
removed from her ventilator. She found herself reflecting on their earlier fight to save her. 
When I saw her I thought is it worth it, I mean as to what problems will she have if she does 
survive, there is a chance that she will be blind, they thought she had brain damage and I thought no 
you know what are her chances in life realistically. There's no point in prolonging her life for 
another couple of years, if it was going to happen I'd rather it happene thereandthen. 
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For Howard, who described himself as "bitter" and "really disappointed', there was the sense that they 
had been lucky to gain access to the trial but that an opportunity had been missed, given what they had 
been told about the importance of the first 24 hours. 
[I]f we'd maybe been offered any time before when Jenny had could go either way, a chance, great, 
fair do's, [but] by then she was virtually gone, ... she was damaged beyond belief, so even if they 
would have had the chance to put her on the machine it wouldn't have done her the slightest bit of 
good anyway, she was gone. She was well and truly gone. 
Erica later found a website which gave information about INO which made her feel that Jenny may 
have survived had they been offered the trial earlier. She said that she was feeling "What if .. ? ". In 
retrospect Howard described the trial as potentially offering them something important but that 
ultimately it may have had "a detrimental effect" in raising unrealistic expectations. 
Box 10. Account of consent when no other options exist - Erica and Howard (Int. 90 
INNOVO) 
Importance attached to contributing to research 
The data which have been presented have already given an indication of some of the 
parental reactions to the suggestion that their baby could take part in research. Here 
the degree of importance that the parents specifically attached to making a 
contribution to research at the time that they made their decisions is considered. 
At one extreme there were those who instinctively recoiled from the idea of research, 
16 such as Shelley and Evan (Int. 47 CANDA) and Gillian and Kelvin (Int. 48 CANDA) 
and at the other were parents such as Gina and Matt (Int. 56 CANDA) who were so 
keen to contribute to research that they agreed as soon as the trial was mentioned, 
without further consideration of any of the available details. Within these extremes 
there were some parents for whom the idea of contributing to medical science was not 
part of their decisions, and some who were pleased that others might benefit but for 
whom this was not a priority. 
Where parents felt that contributing to research was not part of their consideration, 
this could lead to statements such as that from Bryan who made it clear that his sick 
son was his first and only priority. 
At the time I didn't give a monkeys about anybody else. All you're thinking about is what's lying there, so if it helps him then fair enough. Later on, when you 
56 The views of Shelley, Evan, Gillian and Kelvin are considered in detail in the following chapter. 
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probably sit and talk together about this, if it does help other people, great, but at 
the time, no, sorry, I'd just got a one-track mind. I wasn't bothered about anything 
else. (Bryan Int. 64 INNOVO) 
For those who were discomforted by the idea of research, their impulse to protect their 
baby could clash with the wish to make a contribution to medical science. This 
feeling was present in several interviews, often as an initial reaction which was 
overcome on further discussion or reflections, as was the case with Judith and Sean. 
Their account conveys something of how reactions to research can become 
intermingled with the need for care, allowing anxiety to be overridden. 
Judith: We agreed to do it because we wanted to just try anything and 
everything. ... But even so, it was a 
bit -I mean I felt a bit like.. ooh, it's research 
... But then 
it's only a gas they were giving him to breathe. It wasn't like they 
were ... you 
know. But it still made me think, oh it's research, you know, they don't 
want to be doing any experiments and stuff, do you know what I mean? 
CS: Yeah. Did you say that to [the doctor]? 
Sean: Yeah. You did. ... He said it was entirely up to us ... and said that even 
though it is research, it's giving him every chance you can, really. (Int. 79 
INNOVO) 
In some cases this initial reaction was overcome, with a different emphasis on the role 
of the individual participant. For Joyce further consideration led her to feel that the 
research would be valuable to others. 
Research when you've just had a baby, you think, eeh God! What's it all about? 
... But its got to be started somewhere along the line, hasn't it, and if there was no 
research done in the past it wouldn't be the way it was today would it? So I mean 
now, when I think, it's been good to take part ... [and] I'll explain to [the baby] one day "You might [have made] things a bit better son". (Joyce Int. 41/69 INNOVO) 
There was a group of parents who appeared to be rather non-plussed by the fact that 
they were being asked to consider making a contribution to research. That is not at all 
to say that they were indifferent to the decision that they had to make, but that the fact 
that the interventions on offer were being assessed did not figure greatly as an issue. 
Typical comments for this group of parents, when asked what they felt about being 
asked to take part in research, were: 
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It doesn't bother me at all, because I knew whatever way, like he would be helping 
somebody in the future, kind of thing, yeah. (Wendy Int. 45 CANDA) 
Fine, no problem, yeah, if it's going to help other people in the long run, fine by 
me, yeah. (Freda Int. 50 CANDA) 
I felt happy to be taking part in it, you know, because I thought if it doesn't do me 
any good it might help other people later on. (Jill Int. 51 CANDA) 
The attraction of contributing to research was made easier where parents felt that there 
were no risks associated with a trial. Teresa and Simon were "quite keen' 'to take part 
in the CANDA Trial, hoping that it would "benefit other children in the future". 
Crucially they saw the trial in very benign terms. 
Nobody's going to lose from it, nobody's going to sort of be harmed by that, that's 
what we thought. It's going to benefit other people and it's going to benefit us. 
(Simon Int. 58) 
There were some parents who were specifically attracted to the ability to contribute to 
research. The possibility that something could be gained from such a difficult 
situation could be a direct influence on their decision. Linda and Douglas had used 
assisted conception and were "over the moon7' to find that Linda was pregnant with 
triplets. Two of the three babies were bom in a poor condition after a very 
complicated vaginal delivery initiated after Linda went into early labour (24 weeks). 
Douglas had some difficulty remembering the conversation about the CANDA Trial, 
but Linda described how it took place with her "bent double" having "strong 
contractions". The registrar who approached them left the trial literature for them to 
consider. They read the paperwork and Douglas said "we agreed straight away". 
Linda said "we didn't hesitate". When they were asked to sum up their reasons it 
seems that their clear priority was to contribute to research. 
Linda: The situation Douglas and I found ourselves in is daunting enough, but to 
know that maybe years down the line ... our boys being in that trial might help 
somebody or make somebody else's life that little bit easier, or a baby's life that 
little bit easier - there's no comparison is there? 
Douglas: No 
CS: So it was essentially to benefit other people? 
ion 
Linda: Yeah 
CS: Did you feel at all that it might benefit your children? 
Douglas: Well, we hoped so. 
Linda: We hoped it would. (Linda & Douglas Int. 59) 
Both parents said that there was not much time to make their decision and Linda said 
that "our minds were just all a jumble". Neither could remember many details about 
the CANDA Trial; Linda described it at first as involving oxygen. Some elements 
gradually came back to them during the course of the interview but both felt that it 
would have been very difficult for them to gain much of an understanding of the 
research in their situation. Their decision was based not on an evaluation of the merits 
of the CANDA Trial itself but on the value of medical research and a sense of 
empathy with others in a similar predicament to themselves. This was also very much 
the case for Cathy and Kevin, and Gina and Matt. 
Cathy explained that there was a direct connection between previous research, from 
which they were themselves beneficiaries, and research that might change the future. 
Our feeling is that other people must have gone through trials to get medicine 
advanced to the point where our [baby] would survive and therefore we were 
involved in a trial to get the next lot of babies, with any luck, on. And if everybody 
did that, it might move on a bit faster. (Cathy Int. 57 CANDA). 
Gina and Matt felt that they had already reaped the benefits of research in their 
experiences with their first premature baby who died. Second time around they had 
their opportunity to make what they felt was an important contribution to medical 
research. Matt explained: 
One thing we believe in is research. The only reason he's alive now, and the only 
reason that [our first baby] managed to stay alive for a fortnight was because of 
progress. You cannot progress without research, and tests. It's just impossible, isn't 
it? 
They felt so strongly that they did not feel the need to try to understand the research 
that they were being offered. The fact that the CANDA Trial offered an opportunity 
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to become actively involved in research was sufficient for them to consent 
immediately. 
I didn't really understand ... about the research. To tell you the honest truth, I didn! t 
understand. ... I feel that [it is] the only way that these children are going to 
survive, and they are going [to] get [as far as] they've come in the last fifty years, 
you know. Where are we going to be in the next fifty years if you dowt take part in 
the newest research? They're going to be the same as they are now. And there's 
going to be babies dying. Whereas if you take part, maybes in another fifty years, 
there's going to be such a slim percent of these babies dying, you know. A lot more 
of the ones that are surviving are not going to have the same breathing problems. 
(Matt Int. 56) 
In a small number of cases the parents discussed how they felt that the ability to 
contribute to research could serve as a form of emotional insurance, allowing them to 
make some sense of the situation should their baby die. Kate's explanation of this 
element of her decision-making process still caused her to feel very emotional, as 
conveyed in this extract from her interview. Her baby survived but at the time of 
considering the INNOVO Trial, anxiety that she might die was at the forefront of 
Kate's mind. 
Kate: I think to be honest with you, amongst my blur of tears, that was one of the 
biggest things I could think of, the fact that if she did die - oh dear all emotional 
now - but if she did die then probably at some point - on some level - oh dear! Oh! 
(Pause) Oh! 
CS: Would you like to stop, or are you 
Kate: I'll be alright. I mean at some level that she probably would have helped by 
being there. So I think it's actually quite comforting to have that there. 
CS: Yeah. 
Kate: So it was good. It was a good thing to think that probably her being here 
hadn't been a waste of time. 
CS: Yeah. I've certainly had ... some parents who have felt that quite clearly at the time. Other parents have felt that feeling came later. 
Kate: I think mine actually came there but it comes very much now as well. Yeah, 
it would have made some sense of her being here because otherwise it was just 
like, what was the point in her being bom ... to kind of die? (Kate Int. 63) 
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Reasons for a slower decision 
Whilst it has been shown that the majority of parents made their decisions about 
enrolment in a trial vary quickly, there were 11 cases where parents did not make such 
rapid decisions (5 CANDA, 6 INNOVO). This is in spite of the fact that they often 
shared the same dominant emotions as the parents who did make rapid decisions, and 
were faced with similar situations. Three reasons for the slower decisions were 
identified as: 
Time was available 
Parents wanted further discussion 
The decision was difficult 
Time was available 
The parents could take their lead from those who discussed trial participation with 
them. Where their style was more leisurely they could feel that they too could take 
time to reflect, albeit with some constraints. Some of those who took more time were 
in less acute circumstances than many of the parents who made rapid decisions. A 
sense of not being rushed allowed some parents to take time to consider their choice; 
two of the three cases where parents were offered more than 24 hours to decide did 
take the time that was available. Tessa and Bill's baby was born at term and gradually 
declined. 
They said I could take as much time as I wanted .-.. [within] a certain time you know as [the baby] did need something to be done. They didn't rush me into 
making a decision. [The doctor] said "I'll leave [the form] with you, ... and I'll leave you to talk and you come down to me when you're ready. " So there was 
no pressure on the doctor's part. He was really good, ... sitting talking to us for 
a good half hour, forty five minutes explaining everything to us. He went 
through everything. (Tessa Int. 81 INNOVO) 
Glenda (Int. 55) who spent seven weeks in hospital with pre-eclampsia before her baby 
was delivered was very bored as an inpatient and was Pleased to be approached about 
the CANDA Trial; "the thought of having somebody to talk to was great. " She did 
not discuss why she took additional time to make her decision but it seems likely that 
there was simply no need for a fast decision. 
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Parents wanted further discussion 
In 4 of the II cases where parents made slower decisions, the women were 
approached to discuss a trial without their partners being present, and in I case a man 
was in this position. The lone women made up their minds fairly quickly but they 
wanted to confirm their decision with their partners. For Heather and Jeremy (Int. 77 
INNOVO) whose story was described earlier, their actual decision, made by telephone 
as Heather had not been transferred to the same hospital as her baby, was made very 
quickly. It was however deliberately delayed by Jeremy until they could make a 
shared decision. Cilla (Int. 60 CANDA) delayed her decision until she could get the 
advice of a friend who was a paediatric nurse and Janine (Int. 49) discussed the 
CANDA Trial further with midwifery staff, albeit at their instigation. 
The decision was difficult 
In a small number of instances the parents found the decision to be very difficult and 
needed to take time to be sure that they were doing the right thing. This was the case 
for Tessa and Bill (Bill was not interviewed) who were offered enrolment in the 
INNOVO Trial. They had had a very preterm baby previously who had survived for 
four months. This time the baby appeared healthy and was delivered by planned 
caesarean near term (37 weeks). The baby gradually declined and was taken to the 
NICU, a very difficult environment for Tessa as her previous baby had died in the 
same unit. She could see the cot where she was cared for and in which she was 
baptised. One day she saw screens placed round another baby who was baptised in 
the same cot. The baby was affected by Respiratory Distress Syndrome and a 
consultant explained that the seriousness of the situation. 
He said that if it didn't work they'd have a helicopter on standby to take him to 
Leicester to put him on ECMO, you know, ECMO, it's the bypass machine isWt it? 
Tessa explained that the mention of a helicopter on stand by made it "hit home how ill 
he was. " This added to her confusion. 
To be honest it was just like going in one ear and coming out the other ... I remember saying to him, "Is there a chance we can lose him? " and he said "Yeah" 
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then after that I just wasn't thinking straight at all. ... He went back down and I 
didn't want to sign the form because he said to me "It's only been on trial, it hasn't 
been proved". ... It's not been proven. There's no known side effects of 
it but I 
was like that, kind of thing, I didn't really want him to have it. I said to Bill "What 
if it makes him worse rather than better? " 
They were given plenty of time but found the decision difficult. Tessa described how 
she worried about time ticking on while they were turning over what to do. 
I was thinking, the longer I take to make this decision, the longer [the baby] has to 
wait for something to help him. You know if I took like twenty-four hours to 
decide, and in them twenty-four hours something bad might have happened to 
[him], he might have deteriorated so much that the nitric oxide might not have 
[worked] on him. ... We made a decision in about two 
hours.... Bill was all for it, 
totally. I was in two minds ... My mum and Bill's mum [thought] we've got 
nothing to loose ... My mum said, "Well it's between life and death7 so reluctantly I did sign the paper. (Tessa Int. 81INNOVO) 
Another example of parents who made a slower decision because they found the 
choice to be difficult is presented later in detail in Box 11 (Isobel and Roger Int. 65 
INNOVO). 
Part III - The role of risk in decision making. 
Quantitative and qualitative approaches to understanding the role of 
risk 
The data described above suggest that there are important ways in which parental 
choices are shaped by the difficult circumstances in which they find themselves and 
the style and content of their discussion of a trial. Appropriate questions given these 
difficulties and the speed at which most of the decision were made, are: 
Were the differences in likely risks 57 of the two trials reflected in the 
parental perceptions of risk? 
Did the parental perceptions of risk relate to the speed at which they made 
their decisions? 
The number of decisions represented in this study allows these questions to be 
explored firstly in a basic quantitative format, and then with a qualitative approach. 
57 Using the risks presented in the trial protocols and by the senior trialists who were interviewed, the 
CANDA Trial would be seen as not risky, and the INNOVO Trial as involving some risks. 
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Quantitative data 
Comparison of perceptions of risk in relation to the two trials 
The parents were asked whether they had felt that there might be any benefits or risks 
for their baby as a result of taking part in the trial that they were offered. They were 
almost equally divided in their views; in 21 interviews the parents felt there were risks 
associated with participation for their baby and in 19 they felt there were no risks. 
Although the trials were seen as very different by the neonatologists, the distribution 
of the parental perceptions of the possible risks involved showed that the trials were 
viewed in very similar terms; the INNOVO Trial was seen as involving a risk in II 
interviews and no risk in 10 and the CANDA Trial as involving a risk in 8 interviews 
and no risk in II as shown in Table 11. 
CANDA INNOVO Total y risk 
Accepted Refused Accepted Accepted Refused 
No risk 9 2 10 19 2 
Risk 6 2 11 17 2 
Total 
decisions 19 21 40 
Table 11. View of potential risks of the two trials 
Relationship between perception of risk and speed of decision making 
For just over half of the decisions that were made about enrolment in the INNOVO 
and CANDA Trials, the parents were judged to have felt that there were no risks and 
many made their decisions very quickly. An examination of the relationship between 
these two factors is given in Table 12. 
These factors were cross-tabulated and suggest that there is a relationship between 
parental perception of risk (which is independent of the trial under consideration) 
and the time taken to make the decisions. This can be considered in two ways: 
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Most of the parents who made rapid decisions felt that there were no risks 
(20/29) whilst almost all of those who did not make rapid decisions felt that 
there were risks (10/11). 
The vast majority of those who felt that there were no risks decided 
immediately (20/21) whilst for those who felt that there were risks, there was 
an equal split as to whether or not they made a rapid decision (9 immediate 
and 10 not immediate). 
Perception of risk Time t aken Total 
Decided 
Imme iately 
Did not decide 
immediately 
CANDA INNOVO CANDA INNOVO 
Perceived no risk 10 10 1 - 21 
Perceived risk 4 5 4 6 19 
14 15 5 6 
29 11 40 
Table 12. Speed of decision-making in relation to views of potential risk 
A )? -test shows the relationship between speed of decision making and perception of 
risk is highly unlikely to be due to chance & with I degree of freedom = 9.19; 
p<0.002). The coding system that was used is given for reference in Table 13 below. 
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Time available Time taken Perceived risk 
>24 hrs short Minimal instant or not Risk No risk 
CANDA 
41 * Unclear x 
42** 
43 
44 
45 V, 
46 
47+ 
48+ 
49+ 
50 
51 
Unclear 
1J 
x 
N/ 
V -- 
1 
V, 
52 
53 
54 
No da ta for this interview 
55 V x 
56 V/ 
57 x 
58 
59 
60+ Unclear x 
2 2 12 14 8 11 
INNOVO 
61 V/ V 
62 V, 
63 V/ V, 
64 
65 x 
66 V, V, V" 
67 V/ -W/ 
68 VI 
69* x 
70** V, 
71 
72 Unclear 
73 
74 V1, x 
75 
7- 
V 
' 
V/ V, 
76 V, 
77 V/ x 
78 V., V, 
79 x V 
80 VII V1, 
81 x V/ 
1 9 10 15 11 10 
TOTAL 3 11 22 39 19 
Ints 41 and 69 are the same mother 
Ints 42 and 70 are the same mother 
+ parents who declined to enrol their baby in the CANDA Trial 
Table 13. Coding for each interview in terms of time available for decisions, time 
taken and perception of risk 
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Qualitative data 
The CANDA Trial 
The two sources of information about possible risks associated with trials are the 
neonatologists and the parental information leaflets. From the interviews with the 
neonatologists it was clear that they did not view the CANDA Trial as risky. The trial 
information leaflet explains in some detail the key elements of the research, including 
a reference to the possibility that there may be differences between the two forms of 
surfactant in terms of their safety, as the extract below shows: 
We are currently looking at two different surfactants. The first, ALEC (Artificial 
Lung Expanding Compound), is a man-made artificial surfactant and has been used 
in [this hospital] and other centres for several years. The second, Curosurf, is a 
naturally occurring surfactant and is derived from pig lungs. This also has been 
used in many Special Care Units for some time. 
Both artificial and natural surfactants have been shown to work in preterm babies. 
Natural surfactants actually work faster but whether this means they are better is 
still unclear. Artificial surfactants; on the other hand are cheaper and may be safer, 
not being derived from animals. The only way to be sure about this is to perform 
trials making a randomised decision about which surfactant a baby will receive, 
and then comparing the two groups of babies (CANDA Trial parental information 
leaflet - Appendix F). 
The extent to which parents drew upon the information leaflet for the CANDA Trial is 
unclear. Certainly there were parents who said that they did not receive a leaflet, and 
there were others who were given written information but said that they were not in a 
position to read it. This was especially the case for the women who were in labour. It 
was noticeable that unlike many of the parents associated with the INNOVO and 
ECMO trials", none of those associated with the CANDA Trial brought out, or 
mentioned keeping a copy of the leaflet, at interview. Key elements mentioned in the 
information leaflet, the distinction between natural and artificial substances, the pig 
connection, and the different speed at which the surfactants work, were all frequently 
discussed in the interviews in relation to risk. 
58 Parents commonly brought out mementos of their baby's time in a NICU. They felt that the 
information leaflets (which for the ECMO Trial included photographs of the ECMO circuit), would 
help their child to understand what had happened when they were older. 
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As shown above, the parents were equally divided in terms of their perception of risk 
for the CANDA Trial. Further details on those who saw no risks, and those who saw 
risks are given below. 
The CANDA Trial involved no risk 
In II interviews the parents presented the CANDA Trial as involving no risks for their 
baby. Typically they said that they were told that the trial may or may not help their 
situation and that it would not make things any worse. In a small number of cases 
parents felt that they were explicitly told that the trial offered an important 
opportunity, with effectively no downside, "a win-win situation". Matt said: "Wasn't 
no risks. ... One wasn't 
better than the other. They both had their benefits" (Int. 56). 
It was often assumed that trials would not be carried out, and that a doctor would not 
offer them enrolment, if there were any possible risks for their baby. 
I thought that the risks ... couldn't really 
be that high, if you've got hospitals on 
one hand doing one, hospitals on the other doing [the other]... If something was 
drastically wrong with one of them, if there was a major advantage of one over 
the other then both wouldn't be in circulation. (Bernard Int. 44) 
The parents were very protective of their babies and where they felt that there were 
no risks associated with the trial, they often stated that they would not have 
consented if they felt there was any danger to their baby. Charles commented: 
Obviously if I'd thought there was a risk of one of them was a lower quality 
then I wouldn't have done it. (Charles Int. 46) 
Freda's twins were both enrolled in the CANDA Trial, a particularly delicate 
situation if there are professional or parental perceptions of potential differences 
between intervention arms. Freda, like Charles, said that she would not have 
condoned any risk for her babies. 
[The neonatologist said] they are both near enough the same, you know. If 
she'd said one was lesser than the other I would have said "No. Give them both 
the same. " (Freda Int. 50) 
Zoý was very confident about the safety of the trial: 
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It felt like a fairly safe trial to be in because you were told "some hospitals use 
this, it works, some hospitals use this, it works, but we want to know 
categorically which is best. " So either way you felt you were going to get 
something that works . ... The 
idea that there was some preferences was fine. 
(Zoe Int. 44) 
The CANDA Trial involved risk 
In eight interviews the parents presented the CANDA Trial as involving some degree 
of risk for their baby. These were predominantly expressed in terms of the different 
origins of ALEC and Curosurf. The parental information mentioned that Curosurf is 
"derived from pigs" but just how was very unclear in the parental accounts59. None of 
the parents were aware that porcine surfactant is collected from the lungs of pigs and 
there were a number of different accounts of what was used in the trial. Some parents 
felt that they had been offered "animal fat' ' (Int. 45), a transfusion of pig's blood, 
(Int. 48), "bits of pig" (Int. 49) and drugs derived from either "pig offal" (Int. 46) or 
"pig's blood" (Int. 5 1). For some parents the origin of Curosurf was simply irrelevant 
given their pressing concerns for their baby. Geoff (Int. 43) dismissed the issue 
outright saying "I just wanted the best one. " For others who felt that there were risks 
in this situation, the link with animals was unnerving: 
I didn't like the idea of that straightaway, I just thought I don't want [my] 
thirty week baby that's been nurtured inside me suddenly having pig derivative 
put inside it. (Janice Int. 49) 
At the time of the interviews the subject of BSE -'Mad Cow Disease' and its 
transmutation into a human form - CJD, had recently been in the news, and this made 
parents wary about possible long-erm effects. For Cilla and Terry this was sufficient 
to make them decline the CANDA Trial. 
The thing I remember about it was thinking that it was pig surfactant and I think 
in the light of BSE, I wasn't sure whether I wanted any sort of animal products. 
... [It was] just in case in years to come, there was some sort of link with any bizarre kind of new virus that was around, you know, that you just sort of don't 
know. (Cilla Int. 60) 
There was also some confusion over ALEC in relation to the term "artificial". It was 
interpreted by Gillian and Kelvin to mean that the trial would involve "artificial 
59 The parents were not asked how they thought it was derived but raised this issue spontaneously. 
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blood" which they said they "didn't feel comfortable with" (Kelvin Int. 48). For 
Teresa and Simon the term led them to prefer Curosurf. 
We thought that was better really because it's more natural than an artificial one, 
we just thought it was more compatible than an artificial thing. (Teresa Int. 5 8) 
The INNOVO Trial 
The parental information sheet for the INNOVO Trial discussed the possible risks of 
INO in very broad terms: 
The study will find out whether or not adding a gas (nitric oxide) to other ventilator 
gases allows babies like yours to breathe more easily. It will also find out if they 
get well sooner, and are healthier, or whether they would do better without nitric 
oxide. 
Neither you nor your doctor will be able to choose whether or not your baby 
receives nitric oxide. Instead this decision depends on chance, rather like the toss 
of a coin. This is important so that nitric oxide can be tested fairly. At this time 
there is not enough research to know if it is better or worse than the usual 
ventilatory gases alone. (INNOVO Trial parental information leaflet - Appendix G) 
From the parental accounts, and comments made by the neonatologists, the 
neonatologists varied in the extent to which they supplemented the information leaflet 
with specific details of any risks that might be involved. The parents also varied in 
their ability and willingness to engage with the issue of risk. 
Th e INNO VO Trial involved no risk 
In 10 interviews parents presented the INNOVO Trial as involving no risk for their 
baby. As with the parents associated with the CANDA Trial it was common for 
parents to report that they were told that participation in the INNOVO Trial may or 
may not help their baby, but it would not make things worse. Two mothers indicated 
that their decisions were based on the absence of risk. 
You are willing to try anything provided there isn't a risk that it can do anything 
wrong, and that was the key. That was the key! (Rebecca Int. 68) 
We decided because it had benefited people and as far as they knew, it hadn't done 
any damage. We decided "Yes" there and then. We might as well try it as soon as 
possible really, to see if it helped him. (Dorothy Int. 64) 
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Michael, who was extremely anxious during the randomisation process and upset and 
angry on learning of allocation to the control arm, was asked whether he had any 
concerns about INO. He answered "No, because I really didn't know what it was" 
(Int. 61). Similarly Frances said that she did not see INO as involving any risks but 
that that may have been a consequence of her circumstances - "You don't think that 
deeply. ... At the time 
it was on top of everything that was going on. " (Int. 72) 
In one case a father, Keith, whose daughter had aspirated meconiurn on delivery, felt 
some concerns about the issue of experimentation. Notably he was reassured on the 
subject of INO. 
I was a bit dubious about it really because I thought well if it is only research it 
could go wrong. ... I mean it's like a crash test dummy isn't it. ... But there was no 
choice. They said it could make her better. They never said to me she could go 
worse off it. They never said that. They always said she would benefit from it so 
that's why I just signed the form. (Keith Int. 67) 
Th e INNO VO Trial involved risk 
In II interviews parents presented the INNOVO Trial as involving some degree of 
risk for their baby. Where they talked about risks they often used quite hazy and 
unspecific terms. Nicky, for instance said: 
They didn't know if there would be any side effects, you know, it's just the chance 
you take because it's a trial. (Nicky Int. 62) 
Parents could be aware of the possibility of side effects but rarely spoke about what 
these might actually be. Belinda, who was under the impression that agreeing to the 
trial would mean that INO would definitely be used, gave an indication of how 
irrelevant long-term risks can seem at the time. 
I remember him saying that because it's a new trial they don't know what the long- 
term side effects will be, but I think when you are in that situation you don't really 
think about that. It was the here and now that was important, not the future. 
(Belinda Int. 76) 
Whilst taking a risk for their baby was something that some parents felt they would 
never do, for others parents it was the responsible thing to do. For Joyce, the situation 
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was so grave that the consultant's statements that he could not sanction simply giving 
her baby INO was extremely difficult. In her circumstances the possibility that INO 
might help her son was sufficiently persuasive to over-ride the possibility of long-term 
risk. 
He explained "There's nothing to lose... he's bad, he couldn't get any worse. ... I 
would love to come to you now and say "I'm going to put it in his machine. I'm 
going to give it now and see if it helps. " But he said he [couldn't] because it 
wasn't a legalised thing and that in ten years time you could come back and your 
baby could be - you know - and you could sue. I was sobbing saying "But I 
wouldn't do that! " (Joyce Int. 41/69) 
A small number of parents focused on short-term risks. Given the precariousness of 
their baby's condition they were wary of initiating anything that might actually 
lead to a worsening of the situation. Cheryl felt "nervous" because she did not 
know whether or not she was "doing the right thing" but felt happier when she 
checked with her consultant and was told I can't see it harming her. " (Int. 74). 
Some however, like Tessa quoted earlier, found that their concerns about possible 
risks complicated and delayed their decisions. 
For Isobel and Roger, whose story and extracts from the tape-recording of their 
discussion with a consultant about the INNOVO Trial is presented as a case-study in 
Box 11, the impact of their view of risk upon their decision-making process provides a 
contrast to much of the data presented in this chapter. For them the offer of the 
INNOVO Trial created a major dilemma; the risks of participation were unacceptable, 
but turning down the trial and so access to the potential benefits of nitric oxide also 
constituted a risk. They took the time that was available to think through what they 
felt was "the hardest decision" they had ever had to make. 
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Isobel and Roger 
After a placental abruption Isobel was taken by ambulance to hospital for an emergency 
caesarean section with general anaesthetic (26 weeks). She continued to bleed after surgery 
and underwent a second operation and was warned might involve a hysterectomy. The 
bleeding was controlled without a hysterectomy but Isobel was very ill and did not see her 
daughter, Janey, for four days. Roger divided his time between his critically ill daughter and 
his very sick partner. Janey made no progress. After several weeks of "rollercoaster 
emotions", Roger and Isobel were approached about the INNOVO Trial. The tape-recording 
of their conversation with a consultant indicates that they were given a very detailed account 
of the potential risks which might be associated with INO. 
What the INNOVO study is about is comparing two ways of trying to help babies with 
their respiratory difficulties. One is called nitric oxide which is added in a very small 
amount to the ventilator. ... Nitric oxide is a gas that's 
in the atmosphere, largelyfrom 
pollution actually. It's in car exhaustfumes, it's in cigarette smoke and it's also in us. 
... [Ilt helps to relax the 
blood vessels inside the body, particularly inside the lungs. ... 
Now in term infants ... there's quite a lot of evidence that it may 
have a role to play. But 
it's still not clear cut by any means, ... but the evidence 
begins to point a little way 
towards that. In the premature infants the evidence isfar less clear cut whether there is 
a benefit above and heyondjust using conventional treatments, and the reasonsfor that 
are that there are some side-effects also associated with the use of nitric oxide. Some of 
them are theoretical. In laboratory experiments certain things are seen, and... there 
are side effects or reactions that are seen in adult human volunteers, so they may not 
necessarily apply to the prem baby. (Mother - No) But none the less they exist and it Is 
important that you know that. (Pause) 
The side-effects that we are concerned about - nitric oxide can cause inflammation 
inside the lungs particularly ifcombined with a high amount of oxygen, it causes 
damage to the lining and the cells of the lungs. It can make the platelets, which are the 
cells in the bloodstream that stop us bleeding, make them less sticky (Mother- Mm) . .... 
In theory at least, it may interfere with DNA, the gene code you possess, how that 
repairs itself These are theoretical concerns ... These aren't proven (Mother: No) but 
they're there and it would be dishonestfor parents not to be told of these ... The upside 
... is that, certainly in some children it appears that it 
does help the blood vessels to 
dilate and improve the amount of oxygen reaching the bloodstream so one is able to 
reduce the amount ofsupport that babies are getting with the benefit [that we don V 
use as much oxygen. ... [Slo there are some upsides to it and there are some theoretical downsides to it but the problem is that we're not in the position yet ... to identifyfor 
which babies the risk/ benefit (Mother: Right) is infavour ofgiving it and which babies 
actually we ought not to give it. (Mother. Min) That's really the purpose of this study. 
When it came to making a decision about the trial, Isobel and Roger explained how worried 
they were about tipping a delicate balance the wrong way. 
We were being put in a situation that was virtually impossible for us to make a decision, I 
mean if the expert didn't know what this drug might do to our baby, how were we 
expected to decide? We potentially could have been killing or making our baby worse 
because really it was unknown what the gas would do. (Isobel) 
He said, "For all we know it might actually go the other way, it might make her worse, the 
other alternative is that it may improve her in the short term. " My view was that I didn't 
want to use it because it was such a gamble and we were potentially making a bad 
situation worse. I think it was the not knowing, I think it was the lack of information. 
(Roger) 
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After what felt like "a day of discussion" but which they agreed was probably half an hour, 
they decided that turning down the trial would be a risk in itself They made their decision, 
unlike most other parents in this study who consented to the INNOVO trial, without hoping to 
access [NO. Isobel described it as "one of the hardest decisions I think I've ever had to 
make. " Roger commented: 
It was absolutely hideous, it was a bad bad experience, especially at that stage to have 
to make a decision like that then. It's bad but it had to be done, and my view was that 
we should try and do everything that we possibly could and therefore we must go for 
the test, but I was hoping that when they tossed the coin we wouldn't get it. 
Isobel and Roger's thought processes hinged on how to deal with illness and the risks inherent 
in a new treatment. The random element of the trial became the means of dealing with that 
degree of risk. For most parents the decision-making process was very much in the context of 
management of care and was close in style to other decisions which would have to be made in 
the context of illness. For Isobel and Roger the trial situation was at the heart of the process. 
Their decision, which was made in full light of the known facts, was certainly complicated by 
the information they were given and by the lack of certainty that existed, but in their interview 
they argued that it was right that they went through this process. They thought very highly of 
their consultant and were clear that however difficult their experience, it had been wholly 
appropriate to have the information about risk and uncertainty upon which to base their very 
difficult decision. 
Box 11. Account of consent in relation to risk - Isobel & Roger (Int. 65 INNOVO 
Discussion 
The factors affecting parental decision-making about participation or non-participation 
in the INNOVO and CANDA Trials were undoubtedly complicated, drawing on a 
range of influences to which there were highly individual responses. Parental 
decisions were in part a product of an emotional setting, and were shaped by a 
discussion in which complex and potentially stressful information was given and 
received in very different ways. The presence or absence of a trusting relationship 
with a professional is an important factor, as is the extent of their tolerance, interest or 
enthusiasm for making a contribution to medical research. This inherent complexity 
and variety that exists is belied by the fact that so many of the parents, whatever they 
made of their situation, made the same decision, that is to accept trial participation. 
What is more, the majority did so at great speed, as was suggested by the 
neonatologists interviewed for this study. 
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Parents made their rapid decisions in very constrained circumstances: the situation 
was often urgent with little time for deliberation. The neonatologists were concerned 
that in these circumstances, the quality of parental decisions might be compromised 
by the speed at which they are made. Certainly there were some cases, notably of 
women in labour, where parents felt simply unable to participate in the processes 
required for consent, and where a rapid decision was made without engagement with 
the substantive issues. In some cases decisions were made very quickly, despite the 
fact that more time was available. 
Although the neonatologists were often worried that rapid decision-making suggested 
a lack of engagement with the information they were offering, from the parental 
accounts it would seem that they felt that they had some appreciation of the issues 
involved. In situations where it could be difficult to focus on the broader details, many 
parents appeared to sift information until they perceived a critical factor (it might 
help; it won't harm; there might be risks; it might benefit future babies; the doctor 
thinks it is a good idea; your baby might die). This crucial detail then seemed to 
propel them on to make a rapid decision about trial participation. Other information 
could be to some extent extraneous. For some this resulted in them eagerly joining a 
trial in the hope of accessing a potentially life-saving treatment; for others the 
unacceptability of possible risks was the element which led to a quick decision to 
decline participation. These might be termed 'instinctive consent' and 'instinctive 
refusal'. For many parents, 'instinctive consent' did not appear to be closely related to 
the actual conditions set by the trials, to their view of the trials, or to medical research 
more generally. For others, such as Isobel and Roger, there was a close engagement 
with the implications of participating or not participating in a trial. 
The distinction between care and research could be very unclear in the parental 
accounts. When parents spoke positively about medical research generally, or the 
trials in particular, it was not always clear whether these were driving forces in their 
decisions or a position that they have come to in retrospect. When the parents 
discussed how they felt about making a contribution to research, they often used very 
broad and abstract notions of "helping", rather than focusing on their role in enabling 
specific people to answer specific research questions. It may be that what they were 
demonstrating was a reaction to research in principle. Here they can be very positive 
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as long as the issue of contributing to medical research is separated from the notion of 
risk. Parents often said that if they felt there were risks to their baby they would not 
have agreed to participate. 
The parents did not appear to share the neonatologists' feelings that rapid decisions 
are problematic. In fact the converse was true. In their accounts of the speed at which 
they reacted to the situation it was quite obvious that they felt that they were acting 
swiftly in the best interests of their child. Responsible parenting could include 
accepting possible risks in the hope of gaining a much needed advantage for their 
baby. Even in some of the cases where the research itself did not seem to the parents 
to be a big issue, they still could feel that they were making an onerous decision. In 
fulfilling their obligation to protect their child, many felt that they also took on 
personal responsibility if anything should happen to the baby. It was very rare in this, 
and in the previous ECMO studies for parents to feel that allowing a treatment to be 
allocated within a trial would remove responsibility from them in any way. 
While a perception of risk did not appear to affect whether or not the parents agreed to 
enrol their baby into a trial, it did seem to be linked to the speed at which they made 
their decision. In all but one case, those who perceived no risks made rapid decisions. 
Slower decisions were made by made parents who felt that there were risks. This may 
be because longer timeframes afforded greater opportunity to give or to take on board 
information about a trial, or because the perception of risks (actual or anticipated) 
leads to a more problematic and therefore time consuming decision-making process. 
For Isobel and Roger, whose consultant gave a very full and detailed description of 
the potential risks of the INNOVO Trial, the threat which they felt could be posed by 
the trial, coupled with the threat of inaction, served to intensify the difficulty of their 
position and to complicate and extend their decision-making process. 
These data raise the important question, would the parents involved have made the 
same decision had the balance of likely risks and benefits been clearer? Not one 
parent said that they were unhappy with the choice that they had made, but we do not 
know if that view would still hold if they were more familiar with the possible risks 
and benefits. In the CANDA Trial for instance, there were some who consented as 
they were hoping to access a better treatment. Had it been clearer to them that both 
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surfactants at that time were thought to be equally effective, and that trial participation 
was not aimed at improving the care of their baby, their decision would have had a 
different basis. Parents who were aware of the possible risks associated with nitric 
oxide may have made a different choice. Those who rejected the CANDA Trial 
because they did not wish their baby to have a transfusion of pig's blood, may have 
consented had the reality of the treatment been explained in a way that they were able 
to understand and incorporate into their view of their baby's needs. 
Although the parents did make their decisions quickly, these data suggest that they 
still went through an analytical process, based on what they felt were the key factors 
in their case. Parents filtered the information that they were given and went to what 
they felt was the heart of the matter, making their choice to protect their children as 
best as they could. This may or may not have included an assessment of potential 
risks. At the time of the offer of trial enrolment, most of the parents did not focus on 
the larger world of trials with responsibilities for a population as well as for 
individuals, but on the micro-world of their family, focusing in on what should be 
done for this one baby in the next few crucial hours. The parents had a very personal 
basis for their decisions, grounded in intense emotions and parental responsibility, and 
which could not easily be grafted on to the public world of clinical research with its 
wider concerns. 
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Chapter 8- The decisions that parents make to 
decline trial participation 
Refusals for the INNOVO and CANDA Trials 
One particular aim of this research was to provide insights into the views of parents 
who declined to participate in the trials. Neonatal trials have been shown to have 
higher consent rates than other trials, with some reporting 100% acceptance 
(Campbell et al 1998). With so few parents rejecting trial participation, it is useful to 
consider how and why they might differ from the majority of parents who give their 
consent. 
The two trials considered here do not have the extremely high consent rates reported 
above, but they still show what appears to be low numbers of refusal in comparison to 
trials in other settings. For the INNOVO Trial there were 168 babies whose parents 
accepted the trial, and parents of 10 were known to have refused 60 (94% accepted). 
For the CANDA Trial, parents of 199 babies accepted the trial, and parents of 37 were 
known to have refused (84% accepted). 
As indicated in Chapter 4 it was not possible to interview any parents who had 
declined to participate in the INNOVO Trial, but four interviews were achieved with 
parents who decided against enrolling their baby in the CANDA Trial. With such a 
small number of interviews there are undoubtedly limitations to this data set. The 
most appropriate use of the material is therefore to treat each interview as a case 
study, examining the parental accounts in detail. In this way the nature of the 
individual experiences are brought to the fore and the value of this type of qualitative 
data is made clear. 
60 These are best approximations of consent rates (personal communication - Truesdale (INNOVO), 
Ainsworth (CANDA)). When parents declined participation this was not always reported to the trial co- 
ordinators. The figures therefore relate only to the known cases of refusal. 
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Four case studies 
The parents in the four case studies have common experiences with those who 
accepted participation, and have already been referred to in the previous chapter. 
Exploration of commonality is important as this can suggest how information and 
insights can be generalised to other trial situations. In considering the various 
elements in these four unique accounts, it became clear that they are also valuable 
precisely because of their individuality. They are not simply idiosyncratic 
interpretations and reactions; they suggest important ways in which alienation and 
confusion about trials can arise, in three of the cases leading directly to the decision to 
decline to participate. 
Cilla and Terry (Int. 60) 
Cilla started to bleed and to have intermittent pains at 28 weeks of pregnancy. She 
was sent home from hospital but returned when the pain continued and her waters 
broke. She went through a stressful six day period of uncertainty as to whether labour 
would progress but felt certain that her baby would not survive if delivered. She was 
reassured by a visit to the NICU but was still anxious and exhausted by the time her 
baby was born. 
It was tiring, because I never slept really from that Saturday night. I never had a 
full night's sleep. So it was just a very tiring week and obviously stress wise, it was 
quite tiring as well. And then the labour progressed but very slowly from that sort 
of Wednesday night into Thursday and sort of by Thursday afternoon I'd got to 
about eight centimetres dilated and then it stopped again. 
Her baby was eventually bom that evening after labour was accelerated. 
Cilla could not remember when she discussed the CANDA Trial, fluctuating 
throughout the interview between feeling that it may have been in the period before 
delivery or that it could have taken place some days later on the NICU61. Terry 
thought that he was not present but could not be sure. The discussion may not be 
61 Although it was possible that parent could discuss the trial shortly after delivery, the trial would not have been offered at the much later period in the NICU that Cilla described . 
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anchored in their memories because of the nature of the stressful time preceding 
delivery, or because of how they perceived the trial. 
It was when I was by the cot side I remember somebody mentioning something 
about it. They might have asked me whether I'd decided which surfactant. It might 
have already been mentioned and they might have said, "Have you decided whether 
you're going to go with the trial? " Because the trial was for the pig surfactant, 
wasn't it? Yeah. But I just remember it not seeming to be such an important - you 
know it didn't seem - it was just one of the things that was happening. It didift 
seem like a major event, it was just one of the things that was happening at that 
time. (Cilla) 
Cilla's concern about the CANDA Trial related to the origins of Curosurf. She was 
very comfortable with the staff who offered the trial; she felt that, although stressed, 
she had benefited from her preparatory visit to the NICU and was positive about 
research. She telephoned a friend who was a paediatric nurse and discussed the trial 
further with her. She was very clear about the reasons for her decision - "I wasn't 
going onto the trial because I didn't want the pig surfactant. " She was concerned 
about possible long-term risks which may emerge. 
The reason why [was] just in case in years to come there was some sort of link with 
any bizarre kind of new virus that was around, you just doift know, do you? ... I 
think in the light of BSE I wasn't sure whether I wanted any sort of animal 
products. If anything happened in years to come that they found that there was - 
you know with the human growth hormone - they found that there was something 
like that kind of link. I thought if there was a synthetic equivalent I would go for 
that. 
For Cilla the conditions of the CANDA Trial were important and this seemed to be a 
crucial element in her decision. In a comment which is similar to some of those made 
by the neonatologists, she explained how her choice had been made easier by the 
certainty that her baby would receive a form of surfactant whatever she decided. She 
understood that if she turned down the trial her baby would be given ALEC. 
I wasn't choosing to have or to have not, it was one or another [L e surfactant within 
or outwith the triafl so it didnt seem too huge a responsibility. .... I knew he 
needed surfactant. As long as he was getting some surfactant, you know, as long as 
it did the job. 
Before making her decision she also checked whether she would be passing over any 
advantages by closing down possible access to Curosurf. 
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Cilla: I did ask if ... they felt at this stage there were any real 
benefits with the pig 
surfactant. 
CS: If they had, would you have let that override your concerns about the nature of 
that surfactant? 
Cilla: Possibly, yeah, if it had proven to, you know, aid ventilation. 
An important element in this decision was that Cilla appreciated what alternatives 
were available. She saw the trial as involving unknown risks which were not 
counterbalanced by possible benefits. She knew that surfactant was an appropriate 
and useful treatment and that her baby would receive surfactant regardless. It is this 
knowledge which allowed her to make what she felt was a well-considered choice. 
Her lack of clarity in her recollection of other elements of the discussion were to some 
extent irrelevant. As far as she was concerned, she had focused on the crux of the 
matter, confirmed the soundness of her decision with a trusted friend, and felt that she 
had acted in the best long-term interests of her baby. Both parents were very 
comfortable with the decision not to take part in the CANDA Trial. 
Gillian and Kelvin (Int. 48) 
Gillian was 17 when she and her partner, Kelvin, made their decision about the 
CANDA Trial. She developed pre-eclampsia at 27 weeks of pregnancy and after two 
weeks as an inpatient in her local hospital, she was transferred to another hospital for 
delivery. When she was told that labour was to be induced, Gillian asked for a 
caesarean section with a general anaesthetic instead, for fear of seeing "anything 
horrible". On further questioning her fear related to the possibility of witnessing her 
baby stillborn or die on delivery. She was induced but as labour failed to progress and 
the baby became distressed, she did in fact undergo an emergency caesarean with a 
general anaesthetic. While she was in labour she was approached about a trial. She 
was not clear what the research was, but said that she consented. 
When I was in labour someone come in and asked if they could do medical 
research on him, and I said yeah because they wouldn't know what they do today if 
they hadn't done nothing like that. 
It is likely that this was the CANDA Trial although this was a surprise as Gillian was 
listed in the trial records as having declined to participate in the trial. Her partner, 
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Kelvin, joined the interview part of the way through. The introduction of a third party 
completely changed the direction and content of the discussion, mainly through his 
different recollection of events and the dynamic between the couple as they tried 
between them to piece together the events and to work out what had happened. 
It is difficult to understand exactly what model of the trial they held, but it appears 
that two trials merged into one in their recollection. It seems likely that they declined 
the CANDA Trial during labour, and accepted another trial involving a comparison of 
long and short lines for delivering nutrition at a later stage 62 - At times the two trials 
seem to be discrete in their account but on further consideration of the data this may 
well be because they were asked separate questions about the trials, almost forcing 
them to make a distinction 63 . At one point the couple discussed 
how they had taken 
several days to make their decision about participating, something which would not 
have been possible for the CANDA Trial, again suggesting that the two trials were 
discussed on separate occasions but have become linked in their memories. Mostly 
they were described as one decision about one trial which involved two elements, the 
long and short lines, which they were happy about and accepted, and the content of 
the lines, which they rejected. This is the basis of their amalgamated account of the 
decision to turn down the trial. 
Kelvin: I know there was something mentioned about a long line and a short 
line, and I think it was the long line one that they wanted to try more, because they 
were only used to using the short line, or it might have been the other way round. 
And there was two, there was ALEC and there was another one where they used 
artificial blood in the other one, is that right, artificial blood? 
Gillian: Yeah. I can't remember. 
Kelvin: And I think we didift feel comfortable with using the artificial blood. 
Gillian: That one, yeah, they were going to use pigs'blood or something? 
Kelvin: They were going to use pigs'blood, so we didift um. ... 
62 As this trial had not included in the terms of the Research Ethics Committee Approval for SVPPT it 
was not possible to ask the trial co-ordinators for any clarification of whether or not Gillian and 
Kelvin's son was enrolled in their research. 
63 The accounts given by Gillian and Kelvin were convoluted and during the interview the fusing of the 
two trials was not clear. This emerged on careful examination of the interview transcript. In an attempt 
to ensure that the data would be understandable and usable, the parents were asked questions for 
clarification during the course of the interview which presented them with the two trials as separate. 
Had this not happened there would have probably been no distinction made between the trials. 
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CS: And were you asked about that at the same time, or was it a different doctor? 
Kelvin: It was the same time, everything was asked at the same time. 
It seems as if the long and the short lines in their account were a means to deliver a 
blood transfusion, one of which could contain "artificial" blood. Kelvin explained: 
Kelvin: We weren't bothered about the lines or anything, because at the end of the 
day it was just a line and there was that many lines in him anyway, that it di&t 
make a difference, but the fact that they were using artificial blood was something 
that neither of us was happy about. 
CS: Yeah, did they tell you what they would do instead? 
Gillian: He just had blood transfusions, normal blood transfusions. 
The parents were asked whether it was a big decision to make, and what it felt like. 
Interestingly they spoke at the same time, before there was a chance of influencing 
each other's accounts. Kelvin exclaimed "Massive! Massive! " and Gillian said 
"Nothing, you could just sign there and there. " Gillian contributed to the interview far 
less once Kelvin arrived and she may have been confused at this point given her 
original feeling that she had consented to the trial during labour in order to help other 
people. For Kelvin the enormity of the decision related to the responsibility he felt for 
making a potentially influential choice for a baby which was in such a vulnerable 
condition. 
Kelvin 64 : You see the way we had to think about it was that at the time our baby 
was nearly dying, and even though you could sense in the doctors'voices that they 
could see that what we were going through, they had to ask them questions. It was 
one of the - possibly some of the hardest decisions we'll have to make in our lives. 
CS: Are you saying that you would have felt responsible for what happened to him 
in making these decisions? 
Kelvin: I think, me personally, if we'd had made that decision to let them go ahead, 
and anything did happen, I would have possibly blamed myself, yeah, because the 
method that they used was tried and tested, but this method that they wanted to use 
was relatively new, so if anything did have happened, I'd have been, like, we 
should have stuck with the tried and tested method. 
64 Note that Kelvin talks as if the baby were already delivered at the time of decision-making. 
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It is important to note here that neither surfactant nor long and short lines are new 
interventions and neither should have been presented as life-or-death decisions. 
Kelvin's emphasis on the difficulty of the decision and his description of them as 
novel interventions may be linked to his anxiety and his negative feelings that his son 
would be the subject of experimentation. He later expanded on what he felt were 
simply unacceptable risks. 
If they'd have said we're going to use normal human blood, and possibly put 
vitamins into the blood, or something like that, then that wouldift have been a 
problem, not with humans' blood, but the fact that it was going to be pigs' blood, it 
don't matter how many times you filter it, no matter how many times you do 
whatever to it, there's always going to be a chance that something could go wrong, 
with animals'blood. ... I always remember thinking "oh he's going to get mad 
cows disease or mad pigs disease or summat. " ... If [they] hadn't have mentioned 
pigs'blood it would have been a big possibility that we would have went ahead 
with it, but obviously they had an obligation to tell us everything. 
He went on to develop the idea of the trial as a risk, feeling confident that they had 
made the right decision. 
Kelvin: I think if we'd have rushed into it, if we'd just said " OK" and signed, that 
would have been the worst thing we could have done. 
CS: Why do you say that? 
Kelvin: Because it was a big decision, I mean, like we were saying, if anything was 
to happen and we went for this relatively new thing without thinking about it, we 
dove into it, we were the ones that would have had to suffer. 
Although they felt that they had been offered something which was to them 
unacceptable, they were very positive about the doctors involved in their care. Kelvin 
felt that they were tolerant of his own suspicion and irritability. 
I think the doctors put it the best way they could, because like I say I was very 
ratty at the time ... because what I'd got into my head was they were using him as 
a guinea pig. ... I made it clear that I wasn't happy with it, and the doctors just sat down and had a word with us and said "Look, there's no way in the world we 
would put him at risk, ifs just something being tested at other hospitals and we are 
just wanting to test it here. " 
A very important element of their experience was their relationship with the 
neonatologist who described a trial to them. Gillian felt that he respected the decision 
that they made. Kelvin described him very positively. 
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Very fair, very professional. He could see two people who were still young, still in 
the wilderness, not knowing what was going on or anything. Gillian was only 17 at 
the time, and it's a big thing for any couple to go through, but young couples! He 
took us through the whole procedure, didn't pressurise us at all, spoke to us as if we 
were [equals] because like sometimes you get doctors who speak down to you, and 
not realise they're doing it, but this guy was straight on the level, and he says "look, 
at the end of the day it's your decision, entirely up to you, " and then told us all the 
details. 
It may well be that their comfort with the staff involved in discussing the trials, made 
it easier to make their decision to decline, and to feel positive at a later stage about the 
choice that they had made. 
Shelley and Evan (Int. 47) 
In Chapter 7 it was shown that fear could push parents to make very rapid decisions to 
join a trial. It also has the potential to drive parents in the opposite direction, as 
illustrated by the interview with Shelley and Evan. 
Shelley went into early labour at 26 weeks of pregnancy and after observation in her 
local hospital was transferred by ambulance to another hospital with appropriate 
neonatal facilities. Her labour stopped and she felt very positive. 
I was fine. The pains had stopped and the contractions were slowing down, so we 
were like "Okay, this is obviously going to work. " Because they'd started to slow 
down ... [we were] quite cheerful. The midwives were good, ... the ones that were 
on duty were fine. They would bring us drinks and stuff, and they were jolly, so 
we were quite mellow, [feeling] I think we might stop this, and you know, we'll 
go home and [be] quite happy" 
It was at this point that they were approached about the CANDA Trial. The 
neonatologist who discussed the trial with them initially gave them some idea of the 
problems that their baby might face if delivered. They repeatedly referred to this 
conversation throughout the interview, both saying that they were told that their baby 
"only had a ten percent chance of survival" and that there was a possibility of brain 
damage. It was a terrible blow to Shelley and Evan who had had not been particularly 
worried prior to this discussion. For them the description of the various problems that 
their baby might face, and the suggestion that labour might continue, was devastating. 
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Then he come and said that! That was when it all sort of like dawned. Once you 
knew, deep down that there is the risk of having a baby that early, and all the 
possibilities of them dying - until they actually said it, we hadnt really, you know, 
considered it. As far as I was concerned, you know, it was stopping and she was 
going to be fine. 
The neonatologist then went on to describe the CANDA Trial and ask whether they 
would consider enrolling their baby if delivered. Shelley felt that this was insensitive. 
I think he chose the wrong time to ask us, because he was telling us the worse case 
scenario and what could happen to her, and then in the next sort of breath he was 
telling us 'Can we use this new drug? ' 
The couple instantly and unanimously declined to participate in the trial. Shelley 
characterised the gist of the conversation as "[the baby] didn't have much chance of 
survival, and they wanted to try this new procedure out on her. " They focused on the 
experimental nature of research and saw testing drugs on a vulnerable new baby as 
wholly unacceptable. Evan said: 
I thought, a young baby that wasn't going to have much chance of survival, and 
they want to use an experimental type procedure! Well, the first thing we thought 
was "No, no way! " 
They stated that they did not feel under any pressure to consent, and that the 
neonatologist was "'fine" about their refusal. They felt that he was "a very good 
doctor" (Evan) but that he was "very uncomfortable" (Evan), and "very nervous" 
(Shelley) in his approach to them. Shelley empathised with his position "I wouldret 
like to be put in that situation. I wouldn't like to have to go up and ask people that". 
Shelley explained that "the midwife came back in after he [the neonatologistj was 
gone, and she was quite a big help in calming us down. " Clearly shock and fear were 
an important part of their immediate reaction, but there were other important elements. 
Firstly they felt very alienated by the way that they were approached. They felt that 
the neonatologist had been insensitive in asking about the trial at that time, but also 
that they were given insufficient information. Certainly they were not aware of what 
the trial involved, talking only about "a new thing" and a "new procedure". They 
were unaware of any link with animals in terms of the origin of the intervention so this 
was most definitely not part of their concem. It may well have been that the 
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neonatologist discontinued his approach once he realised that they were unhappy 
about the research, and Shelley and Evan agreed that this might have been the case. 
This would have resulted in them receiving only limited information about the trial. 
Secondly they were not aware that the trial involved an intervention commonly given 
to assist babies with breathing problems. They felt that the trial involved new drugs 
and used the word "experimental" throughout the interview in a way which suggested 
mistrust of the trial situation. 
Thirdly they interpreted the information about the trial in a very particular way which 
may have been a result of their shock at the thought of experimentation. As they. did 
not know what the trial intervention was, they simply saw it as something new and 
threatening. Unlike other parents they did not see it as something that might help their 
baby but as something that they were being asked to agree to out of altruism. Their 
interpretation hinged on the potential seriousness of their baby's condition. Evan 
explained: 
[She] didn't have much chance of survival, and they wanted to try this new 
procedure out on her. Well just because she didWt have much chance of survival, 
why would they try this new procedure out! 
They both felt that it was precisely because of the likelihood that their baby would die 
that they were being asked to agree to allow drugs to be tested on her. Evan said: "we 
were just adamant that it wasn't going to happen! 
This last point is very important, especially as it rests on an assumption that other 
people in their situation might also make. From the interview as a whole however it 
would seem that the key element in their instant decision to decline the trial was their 
very intense emotional reaction to the realisation of their predicament. The dynamic 
of their encounter with the neonatologist was summed up simply by Evan who said: 
"when he asked us, he had us right at the low point. " 
Janine (Int. 49) 
Janine was admitted to hospital at 29 weeks of pregnancy in early labour. She 
continued to move in and out of labour over a four day period. In a similar situation 
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to Shelley and Evan, she described her husband as "terrified" by a conversation with a 
consultant in which there was a discussion of the baby's chances of survival if 
delivered at that stage. She described herself as "shocked. " At a later point during her 
labour they were approached about the CANDA Trial by a neonatologist. Her 
accounts of the discussion were very negative and she was clearly still angry about her 
experience 65 . Janine said that she was given a very 
brief explanation of the research 
which she characterised as: 
"I'm doing some research. I need twenty-five babies under thirty weeks to do it. 
It's about a drug that'll help them breathe. Will you just sign here? " And that was 
as brief as it was. ... Here it is, just sign, as if that's what 
I was expected to do. 
She was about to comply, to consent quickly without fully understanding the nature of 
the research, essentially to get the doctor to leave. 
I nearly just sort of went "well yeah, give it here" because you're not thinking. You 
are just like - "go away! " you know. There's too much going on for someone to 
bustle in and not really introduce themselves or show any understanding of what 
you're going through. 
Janine said that the midwifery staff were uncomfortable with the situation that they 
witnessed and they intervened. The neonatologist had not brought an information 
sheet and the staff asked him to go and find some written details that they could go 
over with her. Janine described them as "just horrified by the way he'd done it. " 
Although she had initially meant to give her consent, once she discussed the trial with 
the midwifery staff she subsequently declined to participate in the CANDA Trial. She 
felt that she had narrowly avoided being "railroaded" into the trial, not in a forceful 
way but because the trial seemed unimportant. 
I don't want you to think that it was someone who was trying to be false because he 
wasn't. ... It wasn't forceful it just .... seemed so insignificant. That's probably 
why I was going to do it. Because it seemed so like, well, this is what you need to 
63 It should be noted that Janine was extremely angry and this is likely to have shaped her account of 
events and of the conversation with the neonatologist. It was clear in the interview that her emotions 
were gaining momentum. She became increasingly negative about her care and about other members 
of staff whom she met in the course of her hospital stay. Her distress is of course a valid emotion but 
her increasing hostility has resulted in a degree of caution in presenting data from her interview. It may 
well be that her descriptions, especially reported speech and descriptions of the tone of the 
neonatologist, are filtered through the very dominant anger that she expressed. Probably the anger 
resulted from her experience is the most important and instructive finding to have recorded. 
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do. That was why I was going to do it, because it didn't seem important. ... [But] 
it 
was so important! 
Janine went on to describe how she came to see the decision as important in terms of 
the implications which she felt were involved. She did not describe any sense of 
possible benefits for her baby of taking part, but she did feel that there were 
significant risks. These risks were linked, as with Gillian and Kelvin, to a somewhat 
confused model of what the trial involved. She was under the impression that the trial 
compared a steroid, dexamethasone, to a "pig derivative". This involved risk on two 
levels. She felt that participation would have meant that her baby could not have had 
access to dexamethasone, and would have been given the comparative treatment. 
Essentially the trial would have resulted in "my tiny tiny delicate baby having pig 
shoved in him". It is most likely that this represents a combination of different 
conversations about preparations that might be made for a premature birth, the use of 
antenatal steroids to mature the lungs and administration of surfactant on delivery; this 
is, however, the model of the trial that Janine based her decision upon. This was a 
hugely important issue for her as she felt shocked that she had almost placed her baby 
at risk, not only in terms of exposure to something which she found deeply unsettling, 
but also in terms of denying him an effective treatment. She said: 
As soon as he was born and I saw that every other baby in the [neonatal] unit was 
on clexamethasone, it's what made me think I had no doubts whatsoever that I'd 
done the right thing. 
One of the features of this encounter which was particularly alienating for Janine was 
that she, like Shelley and Evan, had a sense that she and her baby were a means to an 
end, despite the difficulty of their circumstances. She said that there were 66no 
pleasantries, no nothing" and felt that she was almost "conned". 
I don't think he was concerned at all about my predicament. He just wanted to get 
my name down on a piece of paper. 
Janine described this encounter as "a bad experience with research. " 
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Discussion 
The neonatologists involved in the CANDA Trial generally felt that it was not a 
difficult trial. It compared apparently equivalent safe treatments and it was often 
thought that it was unlikely to change either parental experiences or the outcome for 
the babies. The INNOVO Trial, by comparison was far more problematic given the 
uncertainty which exists over the use of INO, the issue of withholding INO from the 
control group, and the serious condition of the babies who were trial-eligible. 
It is therefore interesting to note that there were many more refusals in the CANDA 
Trial than in the INNOVO Trial (16% or more versus 6% or more). 
The data presented here suggest that for the CANDA Trial, one possibly important 
factor which may have led to higher refusal rates was that parents could turn down the 
trial (for whatever reason) without feeling that they were depriving their baby of a 
potentially valuable treatment. Parents could feel that they were deciding against an 
add-on piece of research, not an integral part of their baby's care. 
This small group of parents who declined to participate in the CANDA Trial were all 
happy with the decisions that they made, and in part attributed their baby's current 
condition to the choice not to join the trial. In a setting where parents are acutely 
aware of how the life and death balance can shift, and where the threat of disability is 
ever present, they can focus on various elements of care which might subtly or 
dramatically affect the outcome for their baby and their family. In three of the 
accounts it was felt that participation in the CANDA Trial would have posed such a 
threat to a delicately balanced situation which they all felt had finally tipped in their 
favour. Their decisions to decline participation were given retrospective legitimation 
as any change to the treatment that their baby had received might not have led to the 
positive outcome that they experienced. Evan commented "I still think we still made 
the best decision, because [ofl the way she's come out now. " Kelvin made a similar 
statement: "I would refuse it again because it might not put us to where we are now. " 
The parents made their decisions based on different dominant emotions. For Cilla and 
Terry they focused on their concern over long-term risks, risks which they felt were 
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unnecessary given satisfactory alternatives to participation in the CANDA Trial. For 
Gillian and Kelvin their choice arose out of a sense of distaste for research which they 
felt could involve the use of pig's blood. Shelley and Evan were clearly shocked and 
distressed and in no position to think through the issue of trial participation when the 
option was presented to them, and Janine was disturbed and alienated by her 
encounter with the neonatologist who offered her the trial. 
Despite these differences, there is much common ground in these interviews. It is 
quite obviously the case that all of the parents felt that they were acting in the best 
interests of their child, protecting the baby from what they felt were unacceptable risks 
of one sort or another. In three interviews (Cilla and Terry, Gillian and Kelvin, and 
Janine) the parents were very suspicious of the use of a product derived from animals. 
In three cases they were anxious and repelled by the notion of experimentation and 
they could feel that they and their very vulnerable babies were being used 
inappropriately (Shelley and Evan, Gillian and Kelvin, and Janine). 
There are also very important gaps in the knowledge of most of this small group of 
interviewees. There were important areas of confusion, with Janine, Gillian and 
Kelvin mixing details from different elements of care (steroids and surfactant) and 
different trials (surfactant and feeding lines). In two of these interviews there was a 
significant sense of discomfort with the way that they were approached and in all three 
there was hostility to the offer that was made. By comparison Cilla and Terry felt 
more relaxed about the encounter and the trial, but felt that it was an unnecessary risk 
to take. 
The parents all appreciated the fact that they had not felt under pressure to consent and 
that their decisions had been accepted by the staff involved. They all stated that had 
there been a different explanation (Shelley and Evan), a different approach (Janine), or 
different research conditions (Cilla and Terry, Gillian and Kelvin), they they might 
have participated in the CANDA Trial. They were all keen to indicate that they had 
not declined simply because they were negative about research. Gillian and Kelvin, 
Shelley and Evan, and Janine all however indicated that they had also declined to take 
part in other research studies during the rest of their baby's hospital stay. This could 
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suggest that they became sensitive to research after this initial experience, or that they 
may generally have felt reluctance to join research on their baby's behalf 
For this group of parents questions about the research situation were at the forefront of 
their decisions. For many of those who accepted trial participation the research was 
either desirable, acceptable or not an issue. Even where the wider group of parents 
felt that there were risks they were seen as risks worth taking given the greater 
background risk of their baby's likely or actual condition. Those parents relied on the 
neonatal staff to protect their baby and the trial was often incorporated into the 
dominant therapeutic situation in which they and/or their baby were already receiving 
care. Those who refused the trial placed it outside of the therapeutic setting in the 
unsettling realms of experimentation, and the staff involved could be viewed 
negatively, as insensitive researchers instead of trusted carers. They did not argue that 
the staff would still have their best interests at heart, or that they were trying to 
suggest something that might help their situation, as did many of the parents who 
accepted the trials. As they did not perceive a particular benefit to their baby of trial 
participation, risks took a more prominent position and the parents took on a defensive 
role. It is perhaps a sad fact that these distressed parents, although often poorly 
informed and working with models of the research which were far removed from the 
CANDA Trial practices, were possibly the clearest in the sample on the fact that the 
doctors were not actually trying to find a solution to their individual problems, but 
were conducting research for which they wanted their assistance. 
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Chapter 9 -Attitudes of doctors and parents to 
trial-related perinatal post-mortem pathology 
studies 
Perinatal post mortems -a second trial-related decision 
point for professionals and parents 
The decisions that the neonatologists and the parents made about trial enrolment could 
relate to the opportunity to contribute to research and to the potential value or costs for 
individuals. These were not however consistent or equally weighted factors. 
There were important differences between the setting and conditions of the trials 
which affected the neonatologists' views, and the balance of these factors could shift 
on a case by case basis. Although some felt that the CANDA Trial offered few likely 
benefits to individuals, the value for medical science and low associated risk made the 
offer of enrolment generally acceptable. This could change for those parents for whom 
the neonatologists felt that that an approach would impose unacceptable stress factors, 
namely the need to listen to information and to make a decision at a difficult time. 
For the INNOVO Trial the possibility for risk was generally thought to be higher, and 
the introduction of additional stress factors into even some of the most extreme 
parental situations was justified because the potential for personal gain existed. In 
such circumstances scientific gain was never presented by the neonatologists as a 
driving force in the decision to raise the subject of the trial with parents. 
For the parents trials were acceptable because they were thought to involve little or no 
risk, or the risks were counterbalanced or outweighed by the possibility, however 
slim, that their baby may benefit. For the INNOVO Trial the parents rarely felt that an 
approach to discuss the trial had been at too great a cost, the notable exceptions being 
Erica and Howard whose baby died shortly after allocation to INO. 
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A similar process of balancing possible costs, risks and benefits can occur at a 
subsequent and even more difficult point in the trial situation. Where there are high 
mortality rates associated with the underlying condition of trial participants, 
postmortem (PM) pathology studies can be an essential element of the trial enquiry. 
The INNOVO Trial had a PM protocol and specific organ studies (heart, lungs and 
brain). The CANDA Trial had no PM pathology study, but where PMs took place 
information from lung tissue was used to supplement trial findings. The aim of such 
studies is to gain an understanding of any possible positive or negative impacts an 
intervention has had on those who have died. An assessment of differences between 
the pathology of those allocated to different trial arms is as much a part of the drive to 
understand the effects of an intervention as the processes of testing and follow-up for 
those who survive. Where babies who were enrolled in a trial go on to die, parents 
can be asked to consider permitting a PM to contribute to trial-related pathology 
studies. The trial procedures at this point are of little, if any, benefit to the parents and 
there may be associated emotional costs. The benefits which might be accrued by the 
collection of trial-related PM pathology samples are predominantly for medical 
science. 
The trials could therefore involve two decision points for neonatologists and parents. 
The extent to which their decisions about PM pathology studies involve a similar 
balancing of cost and benefit as was demonstrated at the point of enrolment, is 
considered below. Part I gives details of the PM rates for the two trials in the NICUs 
included in this study. Part II describes the views of the neonatologists and Part III 
describes the views of a small number of bereaved parents. 
Part I- PM rates in the two trials 
The heads of the NICUs in this study all stated that it was their usual practice to offer 
all bereaved parents a PM on clinical grounds. In theory, therefore, all bereaved 
parents of babies enrolled in the CANDA or INNOVO Trial could have been offered a 
PM irrespective of their inclusion in a trial. The consultation for these parents may or 
may not have included discussion of the use of PM material for trial purposes. 
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Given the fact that the INNOVO Trial involved extremely sick babies, a high 
mortality rate was expected. It was acknowledged in the trial pathology study 
protocol that "perhaps the biggest challenge for the pathology study is ensuring that 
the majority of those babies in the trial are included in the study. " Indeed almost half 
of the babies died (80/168 - 48%), but very few PMs were carried out. 
Postmortems were carried out for 27 of the 80 babies who died (34%) as shown in 
Table 14. This was more likely for ten-n babies (10 out of 15 cases - 67%), than for 
preterm babies (17 out of 65 cases - 26%). In the four INNOVO NICUs in this study 
there were 15 PMs, that is 3 1% of the 48 that died in these centres and 56% of the 
total number for the trial. Two of the NICUs had higher PM rates than the trial 
generally and two had lower. This is not accounted for by a skew towards recruiting 
more term babies for whom a PM was more likely. For instance NICUs B and D 
recruited similar numbers of babies but B recruited slightly more preterm babies. The 
mortality rate for Centre B is however far higher, suggesting that the profile of the 
babies recruited to the trial from this NICU may be sicker than those at NICU D. The 
two NICUs with the highest mortalities have the lowest PM rates (B and C). 
Pre- Died PM Term Died PM Total Total Total 
term babies died PM 
A 5 1 1 2 1 1 7 2(29%) 2 
(100%) (100%) (100%) 
66 
B 23 19 2(11%) 12 6 2(33%) 35 25 4(16%) 
71%) 
c 11 8 2(25%) -- 11 8(73%) 2(25%) 
D 19 11 5(45%) 12 2 2 31 13 7(54%) 
1 - 
(100%) (42%) 
A-D 58 39 10 26 9 5(56%) 84 48 15 
Total 26% (57%) (31%) 
Trial 108 15 10 60 65 17 168 80 27 
total (67%) (26%) /10j 
. 
(4 V_ 
. 
(34%) 
Table 14. PM rates for the INNOVO Trial 
The CANDA Trial involved only preterm. babies and PM rates were higher than for 
the INNOVO Trial. Of the 199 recruits whose data were analysed in the trial, 45 died 
and 17 underwent PMs (45%). There were some large differences between the NICUs 
66 The 100% PM rate for NICU A is uninformative given the small number of deaths. 
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that collaborated with this study, with NICU C carrying out far more PMs than the 
others, and many more than were conducted for the INNOVO Trial. The figures for 
each NICU are shown in Table 15. The PM rates inNICUs C and Dare reversed for 
the two trials. 
Total babies Total died Total PM 
B 2 0 
c 44 12 9(75%) 
D 83 17 5(29%) 
E 30 9 3(33%) 
B-E total 159 38 16(42%) 
Trial total 199 45 17(45%) 
Table 15. PM rates for the CANDA Trial 
These very variable figures reflect the difficulties highlighted in the literature and 
anticipated by the INNOVO Pathology Study team. Whilst PM rates in NICU C for 
the CANDA Trial approached the recommended level of 75%, (Joint Working Party 
of Representatives from the Royal College of Surgeons, 199 1) overall they are 
generally low. Even where PMs were carried out, it did not necessarily follow that 
tissue was contributed to trial pathology studies. It was in fact the case that the 
INNOVO Trial pathology studies were discontinued due to insufficient material for 
analysis. The interviews with the neonatologists and parents shed some light on 
possible reasons for these lower rates, and the problems associated for those involved. 
Part 11 - Views of the neonat 
Although the neonatologists were interviewed primarily because of an association 
with the R-4NOVO or CANDA trials, PMs generally raise salient issues for their 
profession. They were therefore in a position to reflect on the need for pathology 
investigations within and without the trial context. They were asked whether trial 
enrolment affected their approach to parents. Responses reflected the responsibility 
they felt to the trial, to parents, and how they viewed the impact of the approach. 
Their views on how consent in this situation should be managed are also presented. 
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Responsibility to parents and to the trial (care and research) 
The neonatologists articulated varying degrees of responsibility to contribute to trial 
PM pathology studies, which appeared to be determined by their knowledge of trials 
and their allegiance to parents. They varied in familiarity with PM processes both 
generally and for the INNOVO and CANDA trials. Most consultants were 
knowledgeable about requirements and described alternatives such as limited PMs 
where parents are uncomfortable with certain procedures. Their views of their duties 
to parents and to the trial (care and research) suggested a sense of responsibility which 
was (i) equal, (ii) divided or (iii) prioritised. 
A sense of equal responsibility 
Neonatologists with a sense of equal responsibility saw their contributions to trial- 
based pathology studies as important, and felt that they can be compatible with the 
needs of families. Some described a moral responsibility to contribute to such studies, 
with a consultant arguing that he feels "mandated" to do so (Int. 16 consultant). Those 
who talked very positively of the role of PMs in a trial context, also felt that they were 
of great value in a purely clinical sense. A consultant explained how he approached all 
parents where possible but where babies were enrolled in a trial he felt a degree of 
self-imposed pressure to secure consent. Not conducting a PM would be an 
"opportunity lost". He said: 
I feel even more of an imperative to try to get postmortem tissue within the trial 
context. I'm fairly keen to get postmortems with trials wherever we can 
anyway. ... I do feel, particularly for experimental agents such as nitric oxide, 
that we should have postmortems wherever possible, partly to reassure parents 
that it wasn't the drug, if we can reassure them it wasn't the drug that caused the 
death, 
... 
but partly also if you learn stuff from histology that we're not learning 
from the clinical data, that may make a difference to how long the trial runs. 
(Int. 2 consultant) 
These neonatologists felt they could combine what they saw as their duties to 
individuals with duties to the wider community. 
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A sense of divided responsibility 
Some neonatologists described with some anxiety, their feelings of responsibility to 
research, as well as to families in their care. They demonstrated some doubt over 
whether the two could be served by inclusion in PM studies. For some there was great 
tension between the ideal of contributing to research whilst also providing care. 
With the knowledge that neonatal trials aim to improve care, one neonatologist 
described a moral pressure to gain consent for a PM. He foresaw a potential conflict of 
interests between individuals and the wider community. 
There would be some pressure on the person requesting the autopsy, that they do 
so for the benefit of the trial and prospective future babies who might be 
enrolled in that trial. ... [Ifl 
it was causing problems and causing deaths then it 
clearly would be to everyone's advantage to find out that early. You have to 
balance that against the parents' wishes to not have an autopsy. (Int. 18 registrar) 
The sense of an external pressure was, for a small number of neonatologists, a 
significant issue. Whilst intellectually they felt that PMs were important, and that trial 
collaboration carried with it a responsibility to explore the possible impact of trial 
interventions, practically and emotionally the shift from providing care in a clinical 
context to conducting research could cause great problems. Where possible tensions 
exist between the academic benefits of a PM for a trial and the difficulties for parents, 
their position could become untenable. A registrar described how a difficult situation 
can arise. 
[Normally] if you say to parents, "Can we do a postmortem? " and they say no, 
you say, "Well, OK. " Whereas ... you're under a little bit more pressure 'cos 
you're in a study to actually then push them a little bit harder and say, "Look, 
we really do need this, this will help other babies. " They say, "Look, I've 
already helped other babies [by being] in the study to start with, now you're 
asking me to ... chop my baby up into lots of different bits, I just want his pain to end. " ... You nearly always back down and think, well they've got a point there. (Int. 26) 
A prioritised sense of responsibility 
Some expressed views in which parental needs were prioritised and responsibility to 
trials was attributed varying degrees of importance. Neonatologists could see trial- 
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related PMs as important but very much secondary to parental needs, as unimportant, 
or as a potentially inflammatory issue which they were simply not prepared to 
consider. 
A consultant indicated that he aims to offer trial-related PMs but was adamant that 
there be no further discussion once parents indicate their choice. He argued that this 
was the only way to manage consent given recent concerns about retention of organs 
at Alder Hey, and the issues raised over consent for the CNEP Trial67. 
In the current climate we have to discuss [research requirements] in full with 
parents and if they say no, they say no, end of story. [L]ooking after the family 
comes way before the trial. (Int. 14) 
Some neonatologists described PMs only in terms of the individual for whom they had 
clinical responsibilities, and were unaware of their trial-related value. They had not 
considered a role other than to ascertain cause of death and argued that trial enrolment 
made no difference to consent. Registrars were often unfamiliar with the pathology 
elements of the trial. This may not be surprising given the various career stages of the 
interviewees and different levels of exposure to consent for PMs which tend to be 
handled by senior staff. The younger and less senior neonatologists were however 
often responsible for initial trial recruitment and it might be argued that awareness of 
the trial requirements should be expected of those with this role. Few of the younger 
doctors had considered that trial participation might change the importance of a PM, 
the grounds upon which it is required, or the information that may be requested by 
parents. A striking element in the data was the lack of a connection between the trial 
and a subsequent PM. This was particularly clear where four neonatologists who had 
recruited to the INNOVO Trial, including a consultant, were unaware of the Pathology 
Study until it was mentioned in interview. One was technically aware but had not 
connected this information with the need to initiate any trial-related procedures when 
parents consent to a PM. 
I hadn't particularly thought about it to be honest. ... In the back of my mind I knew that as part of the INNOVO protocol they were looking at some postmortem 
specimens but ... I've never thought of that when I'm getting consent for a 
As discussed in Chapter 3. 
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postmortem. ... But it is covered by the consent form and the consent that we get. (Int. 27 registrar) 
I doift think ifs something that we ever really thought about until Liverpool and 
Bristol. ... I certainly think it probably will colour the way people are now going to 
ask for postmortems, and I suspect that people will ask for them less and less. 
Because you think, the parents are going to ask, "Are they going to take this out, 
are they going to do that? " and you don't know. ... I suddenly thought, well 
actually, I never really think about what the pathologists do, and you're the one 
who's talking to the parents, so when they find out subsequently that this is what's 
happened it makes your relationships ... with them 
difficult because they would 
see you as somebody who's not given them all the information. [That] isift 
necessarily something that you did purposely, you were just probably unaware that 
that's what happened. (Int. 4 registrar) 
Some neonatologists indicated that the inherent difficulties were so problematic that 
they had chosen to opt out of neonatal trial-related pathology studies altogether. One 
consultant argued outside of his interview that since the problems with consent for 
PMs at Alder Hey, and for the CNEP Trial he would be reluctant to ask parents for a 
trial-related PM. He also doubted whether any of his colleagues would do so. Another 
consultant commented that consent for a PM for neonatal RCT purposes "wouldn't be 
top of my priorities" (Int. 23). 
The impact of the approach 
The neonatologists were very concerned about the possible emotional impact of any 
approach to parents and the possibility that parents would feel subject to a degree of 
pressure. 
PMs could be requested purely for trial purposes 
Over and above the rather obvious statement that consent for a PM is sought at a 
stressful time, an important issue which was frequently raised was the difficulty in 
asking for a PM when it already seemed to be clear why a baby had died. If there is 
no query over cause of death, but a baby could be included in a neonatal PM 
pathology study, essentially newly bereaved parents could be asked to permit a PM for 
purely altruistic reasons. For some this was simply asking too much of parents; it was 
an inappropriate request which would achieve little. A registrar argued that PMs 
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generally are not so useful, stating that "nine out of ten of postmortems ... [are] quite 
unnecessary because we know exactly why they died. " (Int. 24). Some neonatologists 
saw it as appropriate to make such a request, albeit with great caution, some saw the 
value of data but viewed it as inappropriate to make this request, and some saw it as 
unnecessary, particularly for preterm babies where much is known about causes of 
death. One consultant felt that few neonatologists would be enthusiastic about 
approaching parents in such circumstances. This is bome out by low PM rates for 
preterm babies as compared to the term babies in the INNOVO Trial (26% preterm 
underwent a PM versus 67% term). The CANDA Trial PM rate was 45% (all 
preterm). A registrar commented: 
[P]ostmortems are of very limited value. You usually know why a baby has 
died. So ... why cut them up. If you don't know why a baby has died then it's 
perfectly valid ... but if you've got a prern baby ... I think that the parents 
might well think that you're pushing it because of the trial. (Int. 24) 
Such concerns provide a backdrop to the request for samples for research purposes. 
Where clinicians are uncomfortable, as for preterm babies where they feel a PM has 
little to offer parents, there are clear difficulties in making this request. This point was 
made by a registrar who was very well informed and had thought through his own 
concerns. He argued that it was far more discomforting for him to ask for a PM for a 
trial rather than purely on clinical grounds. 
[I]n a conventional postmortem you restrict the area to somewhere you're 
unsure [e. g. ] the cause of death ... [T]he problem with ... INNOVO [is] that 
even in babies who died of something completely different ... or we know the 
cause of death, their brain and a chunk of their lungs and a chunk of their heart 
are going to go to different areas of the country, and the baby's going to be 
buried without those organs ... [T]here are lots of issues around that I do feel a bit uncomfortable with. (Int. 26) 
Concerns over causing distress and the application of pressure 
Regardless of where doctors saw their responsibilities, they were concerned that 
bereaved parents should not be pressured to consent to a potentially disturbing 
procedure. There was also concern that requesting a PM for the benefit of others 
might be construed as "emotional blackmail" or "a bit callous". It might also suggest 
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to parents that their baby may have been hanned as a result of their decision to join a 
trial. 
[I]t's almost unfair to suggest to them that there's more of a reason to do a 
postmortem on their baby than another baby who wasn't part of the trial. [It] 
might suggest that there might be something that the trial did that we need to 
find out. (Int. 13 registrar) 
Neonatologists commonly said that they back down as soon as they sense parental 
discomfort. One said that when he realises that parents are going to decline, he 
does not feel that it is "appropriate in any way to push beyond that. " He felt that 
dropping the subject very quickly eased his own situation. 
I never felt under pressure to get parents to consent to a postmortem, in fact 
quite the opposite. If the family didn't want [one] we really left it very rapidly. 
(Int. 10 registrar) 
The concerns that the neonatologists expressed indicated that they often felt that the 
discussions that they had with parents could be very disconcerting and this may be 
why they often take a tentative approach. Department of Health guidelines state that 
consent fonns should involve decisions about which body parts may be studied, what 
may or may not be retained, how body parts should be disposed of and whether 
samples may be used for research purposes (Department of Health 2003). Whilst some 
saw detailed information-giving as appropriate, others felt it marked a shift to a more 
defensive professional position and placed too great a burden on parents. One 
neonatalogist described it as "absolutely ridiculous" and "not fair on the parents" 
(Int. 12 registrar); another asked "how brutal do you really want to be with bereaved 
parents? " (Int. 9 registrar). A senior consultant said: 
We have a consent form that's actually talked about removal of the brain ... it's been written down explicitly. And now this is obviously making it even more 
explicit for every single bit. [T]here's no question at all, it becomes 
uncomfortable. Because on the one hand you are trying to support the parents at 
a terrible time and on the other hand you are ... [asking] them to do something 
very horrible to their [baby]. I can see myself refusing postmortem too. (Int. 19) 
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It is important to note that this consultant had not, however, lost faith in the consent 
process, which he valued highly. 
On the one hand it's much more uncomfortable for them having to think through 
that at a time when they're very distressed but on the other hand they're more 
informed and they've made a clear and informed choice. So it has to be better, 
I'm in absolutely no doubt at all about that. (Int. 19 consultant) 
Part III - Views of the bereaved parents 
There were 10 available interviews for analysis, involving 16 parents (10 mothers, 6 
fathers), 7 for the INNOVO Trial and 3 for the CANDA Trial. In three cases a PM 
was not conducted, in five cases the parents agreed to a PM. In two cases information 
is not available. These details are linked to parental pseudonyms in Table 16. 
The parental reactions to the subject of PMs were explored after the analysis of the 
neonatologists' data and so it was possible to consider whether or not they felt 
discomforted and under pressured. Of particular interest was whether they articulated 
any sense of connection between the trial and a PM. 
Trial Int Pseudonyms Allocation Outcome PM? 
CANDA 
_ 
52 Tape corrupted Died 
53 Mona (& Daniel) Curosurf Died No 
57 Cathy & Kevin CuroSýrf Died Yes 
59 Linda & Douglas ALEC 
ALEC 
Curosurf 
Triplet ID CANDA 
Triplet 2D CANDA 
Triplet 3D CANDA 
Yes 
Yes 
Yes 
INNOVO 74 Cheryl INO Died Yes 
75 Carly& Peter Control arm 
Not applicable 
Twin ID INNOVO 
Twin 2S not INNOVO 
? 
76 Belinda INO 
Not applicable 
Twin I D, INNOVO 
Twin 2D not INNOVO 
No 
77 Heather & Jeremy Control arm Died No 
78 Lorraine Control arm Died ? 
79 Ju ith & Sean INO Died Ye 
80 Erica &Howard INO Died Yesq 
Table 16. PseudonyMs, interview and PM details for the bereaved parents 
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Reaction to the offer of a PM 
There were no particularly negative parental accounts of discussions with 
neonatologists on the subject of a PM for their baby. One mother did, however, 
feel a 
degree of pressure. One of Belinda's twins was enrolled in the INNOVO Trial. She 
felt that it was clear why her babies had died, having been delivered at 24 weeks of 
pregnancy at very low birth weights, but that there was some doubt remaining about 
one particular aspect of their case: 
Sally had a hole in her heart and they wanted to see whether there 
would be a risk to any future pregnancies, [and] there was a suspicion 
... that there was something wrong with 
Charlotte's heart in terms of 
how it was pumping blood around her body. 
They were asked if they would consider PMs and wanted to think the issue over. The 
consultant telephoned them at home for their decision. Belinda was clear that she did 
not view the neonatologist negatively and reported that he specifically said that he did 
not wish to pressure them, but she commented: 
I must admit I didn't feel comfortable saying no to him. I remember 
thinking at the time that -I don't know if it was his manner, but I just 
felt like a postmortem would be more for him than it would be for us, 
and I just wasn't prepared to do it. (Belinda Int. 76) 
Although she knew that there was the possibility that PMs would provide them with 
useful information, she found the idea very difficult as her babies were "like dolls". 
Belinda was clear that this request was not made in connection with the INNOVO 
Trial. It is of course possible that had the parents agreed to the PMs on clinical 
grounds, then the consultant may have raised the subject of contributing tissue for 
Pathology Studies. 
The desire not to pressurise may have led to very limited discussions, leaving parents 
feeling that a PM was irrelevant in their case. Heather and Jeremy stated that in 
discussing the possibility of a PM, there was no mention of enrolment in the INNOVO 
Trial, and that their consultant viewed a PM as unnecessary. 
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[A postmortem] was brought up as an option and I think [the doctor], without 
wishing to put words in our mouths said as far as they could see [he] was born 
premature and there was nothing really wrong with him ... Maybe he was hinting 
that they wouldn't actually find anything out that they didn't really already know 
and really that [was] coupled with the fact [that] he'd had more than enough done 
to, to him. (Jeremy Int. 77) 
These parents felt that they were being spared the stress of deciding about a PM. 
They said they appreciated being guided by a "particularly outstanding" neonatologist 
who had eased the situation for them. Heather commented that they "didn't feel 
pressured at all either way. " They were asked whether they had had any discussion of 
the INNOVO Trial in connection with a PM and both were clear that they had not. 
Appreciation of the connection between PM pathology 
studies and the trial 
Four couples had made a connection between the trial and a PM. In three cases the 
parents agreed. Cathy and Kevin sought out a PM, raising the subject with their 
baby's consultant. This was part of their strong desire to understand their baby's death 
and to make sense of events. They wanted to know whether inclusion in the trial could 
have contributed to his death, and in this regard they felt the PM results had been 
reassuring. The generation of valuable scientific information was also an important 
coping strategy for both parents. 
It's getting the positive from the negative because a baby's death becomes a 
very negative thing. ... When it's a prem baby, they don't make a noise, they don't open their eyes, so you never see the colour of their eyes. The only thing 
you've got is that touch ... The only events that you remember are painful 
events so that's why ... you have to start getting positives. And the positive for 
us was that, number one we may have got an answer but number two that 
somebody else may gain from that. 
They had a very generalised sense of contributing to medical research. They stated 
that their aim was not particularly to add to the CANDA Trial, but to make a 
broader contribution. 
There were two reasons behind it, - .. the need to know for [the baby's] sake [and] for our sake, and also it's for medical research and that wasn't just because 
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of this trial. ... The more information that people can gather, if they can use that 
and therefore if they gain something from the postmortem that might help 
another baby that was in that situation, or could be in that situation in time to 
come [then] ... with any luck they might 
have got the information. They may 
have got some information back for the trial. I don't know if they did but at 
least it answered the question that it was nothing to do with that that had caused 
his demise. (Cathy Int. 57) 
Another couple, Judith and Sean, whose baby was enrolled in the INNOVO Trial also 
articulated altruism but specifically in terms of the trial. They felt that the discussion 
about a PM was "handled well". Judith initially felt very uncomfortable whilst Sean 
was prepared to go ahead. Although at first she was "adamant" that she would not 
permit a PM, Judith came to feel that there would be certain benefits in clarifying the 
cause of death for themselves, and as a contribution for others. 
[W]e agreed ... because even though it [nitric oxide] didn't work for us, if they 
could get anything from it that would help other people then it was worth it. 
Sean explained how they came to view the PM as valuable, with a direct connection 
made in his account to the trial. 
[We felt that] he's had this trial and they might as well get what infon-nation 
they can about it. You know at least he hadn't gone to waste then. (Judith & 
Sean Int. 79) 
Parents of two babies appeared to have considered a PM on purely altruistic grounds. 
Mona, whose baby was enrolled in the CANDA Trial, said "if it'll help somebody else 
later on then I'm fine" (Int. 53). Her partner however subsequently refused and 
because of this the PM did not take place. Another mother, Cheryl, whose baby was 
enrolled in the INNOVO Trial, discussed the possibility of a PM with her baby's 
consultant. Her account indicates that although she reversed her initial decision and 
agreed to a PM, she did not feel under pressure to do so. 
[H]e asked if they could do an autopsy and I said no, and then he says "well 
she's been on a trial and it would help". I says "well if it's going to help another 
baby ... yeah, you can do it". He says 'we're just going to take part of her lung 
away, just to see what it was" and I said "Okay then. " 
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Thereafter her story involves the type of experiences which can, understandably, make 
neonatologists nervous of approaching parents. It also highlight some of the ways in 
which gaps in parental knowledge or understanding about the nature of PMs, however 
those gaps come about, can have deleterious effects. Cheryl wanted to bring her 
daughter home before the funeral but there was a delay because of the PM. After three 
days she called the neonatologist saying "I'm [doing] this as a favour to you, but I 
want her home". When the baby was returned to her she was distressed when she 
found an expected incision in the head. 
I'd dressed her [in a] little dress and a hat [but] they put her hat on back to 
front, so I took [it] off and they'd gone into her head and I didn't know. And it 
was just horrible. ... I'm annoyed that they didn't say that they were going to go in. I didn't know and I did say to [the doctor] when I went back in, ... "when 
you say they're going to have an autopsy, I think you should tell them that 
you're going to go into their head" because that has stayed with me and that's a 
sight that will never ever leave me. (Cheryl Int. 74) 
For Cheryl there was a sense that something quite inexplicable had happened. She 
could see no reason why it was necessary to have carried out an examination of the 
brain. Whether or not she was told of the various elements of the PM cannot be 
determined. What is clear is that she did notfeel that she had been informed of this 
detail and was subsequently confronted with the reality of a PM in a shocking and 
brutal way. She was asked if it might have helped to have written information about 
what was going to happen, and she felt that it would. Despite this experience, she 
spoke very positively of the neonatologist, saying "I got on really well with him. " 
Discussion 
It was very clear that for the neonatologists and the parents the possibility of 
conducting PMs for babies who have died in such traumatic circumstances was not an 
easy subject. 
The neonatologists sometimes felt that they themselves were vulnerable in what are 
precarious political circumstances. As professionals they can be exposed to a degree 
of risk in a threatening environment where consent is the focus of much media 
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attention and social scrutiny; choosing to stand outside research-related pathology 
studies may be part of that. The new consent forms may also affect the likelihood of 
parents being offered a PM, although a recent survey (Rose et al 2005) suggests that 
only 8% of those not approaching parents gave the forms as the reason. In fact the 
biggest single reason (35%) was that a perinatal pathologist was unavailable. 
Some neonatologists were positive about pathology studies and felt that the 
information derived from PMs offered a degree of protection to babies who could be 
exposed to a particular intervention in the future should it prove to be harmful. This 
was however to be weighed against a sense of responsibility to current bereaved 
parents. There was a very strong sense that the neonatologists felt that the offer of a 
PM could be very stressful for parents who were seen as wanting to protect their 
babies from further interventions and mutilation. They were also thought to need 
protection from unpleasant details of PM procedures, from the stress engendered by 
decision-making, and in particular from any sense of pressure. It is therefore not 
particularly surprising to find that the neonatologists were cautious in dealing with 
bereaved parents. There is however a consequence of the speed with which the 
neonatologists could discontinue their approach as parents may be less likely to be 
told how a PM might be of value to a trial. They cannot therefore be said to have 
given an informed refusal to their participation in this element of the research. 
Another and very important response to this difficult situation is to present the subject 
of trial-related PMs in only selected cases and in what some of the neonatologists felt 
were less discomforting terms. When a baby is alive, its best interests are quite clearly 
the central concern of the neonatologist. Once a baby has died, the request for samples 
for research purposes makes explicit a research role explicit. Whilst for some 
neonatologists this was simply not an issue as they felt comfortable in their combined 
roles of researcher and clinician, many seemed to be at greater ease when linking a 
request for a PM to clinical rather than research reasons. Crucially this allowed them 
to realign themselves as carer rather than a researcher, a discomforting role at this 
particular juncture. This does however mean that in cases where there is no clinical 
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indication for a PM, for instance the particularly preterm babies, contribution to a 
trial-related pathology study may be unlikely6g. 
The parental interviews provide support for this careful approach, but also suggest that 
it may be possible to approach more parents without undermining their wellbeing. The 
parents demonstrate the variety of reactions to PMs that one would expect to see, from 
those who did not want any further intervention to others who felt that they needed the 
information from the examination. Within these two extremes there were parents who 
were initially discomforted but who then decided to go ahead. Parents who elected to 
have a PM did so for their own needs, or to contribute to a trial, or for both reasons. It 
is reassuring that the fact that the subject was raised was generally not seen as 
inappropriate and none stated that they were pressured into a decision. 
The data also suggest that for some parents the caution and selectivity exercised by the 
neonatologists may not be wholly appropriate. If bereaved parents are not given 
information about the research value of PMs they may be denied the chance to make 
their own decision about contributing to research. This type of research may in fact be 
highly valued by some parents who have been affected by neonatal loss, as was the 
case for Gina and Matt whose views were described in Chapter 7. From the 
interviews with parents here and in the ECMO studies, it seems that neonatal research 
is often highly valued. Parents can be keen to make a contribution and often express 
this in interview. Whether or not this may extend to the larger group of bereaved 
parents, and would be applied to pathology studies, cannot as yet be answered. It 
would seem, however, that this small amount of data provided some evidence that 
some bereaved parents may support the idea of contributing to research through a PM. 
The specific context of a trial may make their contribution more concrete than an 
abstract notion that a PM may contribute to knowledge in some general way. 
A major difficulty in this area is the way in which parental emotions and professional 
sensitivities converge and to some extent obscure the point where care ends and 
research starts. Where the two overlap this appears to cause additional difficulty, 
69 In anticipation of poor participation rates, there may well be a shift towards excluding pathology 
studies from trials, as has happened at a leading UK perinatal trials centre (personal communication, 
Peter Brocklehurst, Director of the National Perinatal Epidemiology Unit). 
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possibly because the rules and roles involved can be imprecise. This problem arises at 
both the initial point of enrolment in a trial, and for some at this endpoint where PMs 
might be considered. The two decision-points are linked, occurring at different points 
in a linear process. The circumstances are, however, very different and in practice 
have become rather disconnected. This can mean that some of the neonatologists who 
are willing to recruit to trials can be reluctant to recruit into trial-related pathology 
studies; parents who were prepared to enrol their baby in research probably vary as to 
whether they continue to feel a connection with a trial after their baby's death. Whilst 
the parents who consent out of a wish to contribute to research may not be typical, 
their views may be shared by others who were not given the option of a PM. 
Undoubtedly there are those who would find the request very difficult. The difficulty 
for neonatologists is working out who will be receptive to research and who will be 
disturbed, a minefield they tread with understandable caution. 
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Chapter 10 - Discussion and conclusions 
The aim of this thesis was to improve understanding of the decisions that clinicians 
and parents make about collaboration, participation and non-participation in neonatal 
trials, and to add to the existing theoretical literature which deals with the conduct of 
randomised controlled trials. 
The theoretical literature is substantial and can be divided into two approaches, 
described in this thesis as the Theory of Broad Benefit and the Theory of Limited 
Benefit. In the former, the dominant image is of ethical balance; trials are considered 
to be the moral response to prevailing conditions of uncertainty, offering potential for 
benefit to individuals and society, and minimizing the chances of harm through 
controlled conditions. In the latter, the dominant image is of competition, with 
concern that the needs of research can be met at a cost to individual trial participants. 
The available empirical literature is also large and wide ranging. There are, however, 
certain limitations in much of the data produced. Many studies have focused on 
decisions which relate to trials in principle. Whilst this has a certain value, it is only 
one part of the way that people think about trials. Stripped of context, generalised 
accounts of decision-making may or may not relate to the decisions that are made in 
practice about individual trials. 
The value of this research 
The research reported here explored the context of decision-making from two 
different perspectives (clinicians and parents). Unusually, it was comparative in nature 
and involved a substantial number of interviews. It was conducted over an extended 
period which allowed close examination of two trials across time. Although there are 
studies which have involved both professionals and those offered trial participation 
(Joffe et al 2001; Mason et al 2000) this appears to be the only available qualitative 
research which explicitly grounds decisions within a dyadic structure, exploring the 
attitudes and experiences of each of the parties in detail and in relation to each other. 
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It is through the detail that an understanding of the background as well as the 
foreground of the decisions was possible. 
It was suggested early in this thesis that research which seeks to present a list of causal 
factors for decisions about trial collaboration and participation may underplay key 
ways in which people act in relation to trials. This seems to be supported by this 
research which has shown for instance that clinicians do not make decisions in 
isolation but in as part of a complicated local collective system. For the parents their 
often rapid choice to participate could be almost independent of the conditions of the 
research that they were asked to consider. Instead of weighing key elements of the 
research, such as risk, many focused directly on the potential of an intervention to 
benefit their baby. The therapeutic misconception which was present in many of the 
parental interviews, may have had its roots in the therapeutic orientation of many 
clinicians which was also identified. This research highlights the extraordinary 
complexity of interrelated factors which shape the decisions made by clinicans and 
parents. 
The key points which emerged from this study are summarised in Boxes 12 and 13. 
Key Points - neonatologists 
Trials could be viewed on a number of levels, in principle, in practice, 
collectively and individually 
An intermediate level of equipoise, "local equipoise" was identified in the 
collaborating NICUs 
Collegiate and hierarchical elements of decisions about collaboration were 
observed 
A therapeutic orientation existed for one trial but not the other suggesting a 
relationship between different research conditions and the balancing of duties 
to care and research. It also suggests that, rather than treating all trials as a 
single entity (trials in principle), the neonatologists are discriminating 
" Decisions to suspend collaboration (for groups or individuals) did not 
undermine commitment to a trial or to a broader sense of equipoise 
" Decisions to suspend collaboration could relate to strategic thinking about care 
in the context of research 
" The disconnect between the initial decision about enrolment in a trial and a 
possible subsequent decision regarding a trial-related PM is guided by the 
therapist-led principle of non-maleficence 
Box 12 - Key Points to have emerged from the interviews with the neonatologists 
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Key Points - parents 
" The context of parental vulnerability and stress have a direct impact upon 
decision-making 
" The therapeutic misconception was present in many of the parental accounts, 
including parents in the CANDA Trial 
" Parents who tolerated being approached about research even in the most 
difficult of situations, often saw the trials in therapeutic terms. Parents who 
did not see the trials in therapeutic terms could be less tolerant. 
" The vast majority of the decisions were made very rapidly even if more time 
was available 
" Perception of risk was independent of the trial under consideration and did not 
affect the direction of the decisions, but was associated with slower decisions 
" There was a significant degree of support for research amongst parents which 
may extend to consideration of contribution to trial-related PM pathology 
studies. 
Box 13 - Key Points to have emerged from the interviews with the parents 
The contribution of this research to current debates 
These key points feed directly into a number of live debates about aspects of research 
and care, three of which are considered below. They are: 
" Equipoise and responsibility for the decision to collaborate 
" Clinician orientation in relation to care and research 
" The influence of recruitment in extreme circumstances on the development of 
the therapeutic misconception 
Equipoise and responsibility for the decision to collaborate 
The ethical underpinning for research and randomisation is widely agreed to be 
provided by equipoise. It is seen to operate at two levels, at the larger clinical 
community level known as "clinical equipoise", or at the level of the individual, 
known as "personal" or "individual equipoise". In this study it was shown that prior to 
agreeing to collaborate with a trial, clinical equipoise was carefully considered by 
senior representatives within each NICU who define the position that will be taken 
within their local setting. This was not simply a pronouncement that the individual 
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equipoise of one person, for instance the Head of Department or the potential Local 
Principal Investigator, should stand for an entire NICU; nor was it a rubber-stamping 
of clinical equipoise. It was a process by which evidence put forward in a trial 
protocol was considered in relation to the views of local experts and with reference to 
local considerations. Formal or informal modifications to protocols could be made to 
ensure that trials fit with local approaches to care. This process of assessment and 
refinement effectively sets local standards for equipoise and ethical practice. It has 
two effects which are relevant to broader clinical research situations. 
Firstly, if this finding is replicated in other settings, it would suggest that another, far 
more subtle but influential, intermediate level of equipoise exists which might be 
termed 'local equipoise. ' Local equipoise bridges the existing concepts of clinical or 
community equipoise and individual equipoise by taking into account the relationship 
of individual clinicians to the systems in which they operate, which shape and direct 
the choices that they make. The establishment of local equipoise by local clinicians is 
in part based on their interpretation of the scientific evidence, but is also firmly 
grounded in the need to work with a local population of patients in a local setting. An 
example which illustrates this point is the potential advantage that the slower-acting 
surfactant, ALEC, could offer a NICU which frequently had to deal with long 
transport situations. Here rapidly induced changes in a vulnerable baby could 
introduce additional risk into an already delicate situation. Such an issue might not be 
factored into the equipoise equation for a trial generally, but could have a direct 
bearing on effectiveness and safety in the local situation. 
Secondly local equipoise may provide a more realistic picture of the ways in which 
less senior staff operate within collaborating trial centres. To some extent they are 
expected to comply with a higher-level (here consultant-led) decision to collaborate 
and it is not, therefore, always clear that non-consultants actually made personal 
decisions to become trial collaborators. In some instances it was clear that the personal 
equipoise of less senior staff had less bearing on decisions about recruitment than 
those of their senior colleagues. There was often a sense in the interviews that the 
neonatologists were explaining "what we do here" rather than "what I do". Where 
collaboration is based upon local equipoise this involves a degree of trust, (as does 
parental co-operation with a trial), that the decision made by senior colleagues 
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indicate that a trial is ethical and scientifically justified. It also brings the less senior 
staff a degree of security and protection from the weight of personal decision-making 
about collaboration in difficult circumstances. Thus for staff who are not in a position 
to assess community equipoise, as they are unfamiliar with trials, with an intervention 
or are insufficiently experienced to judge the quality of the relevant evidence, local 
equipoise stands in for community equipoise. 
When individual equipoise was considered, it was shown to be highly context- 
dependent. For the CANDA Trial individual equipoise appeared to be consistent with 
collective equipoise and was a stable and widely stated position; for the INNOVO 
Trial it was a labile, multi-tiered state. It was not particularly surprising to find that 
equipoise could shift for individuals over time with growing experience with an 
intervention or as the weight of research evidence increased; this phenomenon has 
been discussed on several occasions (Hellman 1979; Schafer 1982; Hellman & 
Hellman 199 1). It was however interesting to see how, for the INNOVO Trial, it was 
a state which could change according to perceptions of the need for INO of individual 
trial-eligible babies, babies for whom community equipoise indicated that it was 
unclear whether INO would be helpful, harmful or ineffective. Whilst the 
neonatologists could feel that they were in equipoise, as their view of the clinical 
needs of a deteriorating patient increased, so did the potential value of INO. 
Eventually perceptions of escalating need could tip the balance sufficiently that 
equipoise no longer existed for an individual clinician for an individual case. In these 
circumstances either a decision would be made to continue with the policy of 
recruitment with a sense of unease (as indicated by the neonatolgist's account in Box 
3, Chapter 1), or collaboration would be suspended and INO would be given outwith 
the trial. This may link to a phenomenon which has been referred to as 66micro- 
certainty/macro uncertainty" identified in a study of breast cancer specialists who 
were shown to pursue their own treatment decisions despite their awareness of the 
lack of consensus which pertained for that clinical situation (Deber & Thompson 
1987). The research presented here suggests that equipoise can exist for individuals 
on macro and micro levels, and that the micro level can be subject to fluctuation 
without undermining the stability of the macro level of equipoise. If however the loss 
of micro-level equipoise became the dominant position for a sizeable proportion of 
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clinicians, local or community equipoise can shift, as was seen in INNOVO for term 
babies. 
Clinician orientation in terms of care and research 
In earlier debates on the role of clinicians collaborating with clinical trials, concern 
was expressed that their commitment to generating scientific evidence would mean 
that the welfare of individual trial participants (their patients) would no longer be their 
primary concern (Schafer 1982; Hellman & Hellman 1991). The existence of clinical 
equipoise was not always seen as a solution to this issue as some suggested that it is 
unlikely that a clinician would have no suspicion about the superiority of one arm of a 
trial (Appelbaum et al 1987); enrolment of patients with the possibility that they will 
receive what their clinician views as an inferior treatment, would constitute an 
abrogation of responsibility and negation of the Hippocratic Oath (Zajicek, 1995). In 
recent years the pendulum appears to have started to swing in the opposite direction 
with the suggestion that those involved in trials often enrol their patients for 
therapeutic rather than research purposes; in this account the role of therapist is 
prioritised over the role of experimenter. Clinicians are said to have a "therapeutic 
orientation" in relation to clinical trials (Miller & Rosenstein 2003). 
The research reported here suggests that the clinicians involved in this research did 
indeed exhibit a clinical orientation but this did not reflect a blanket approach to 
research. It differed according to the conditions set by the two different trials. While a 
therapeutic orientation was commonly expressed in relation to the INNOVO Trial, a 
clear research orientation predominated for the CANDA Trial. For the INNOVO Trial 
there was evidence that as the condition of a baby worsened, a research orientation 
could shift to a therapeutic orientation in tandem with diminishing micro levels of 
equipoise as described above. 
This difference in orientation between the two trials is indicated in a very clear 
difference in approaches to recruitment. For the CANDA Trial a decision to approach 
parents could be reversed mid-conversation if a neonatologist realised that the parents 
would be stressed by information that they were about to give. For the INNOVO Trial 
there was a delicate balancing act in changeable circumstances, in which clinical 
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judgements were made alongside strategic consideration of research collaboration. 
The neonatologists rarely described situations where they decided not to make an 
approach due to difficult circumstances. It was in fact the case that they could feel 
that an approach was appropriate even to parents in the most stressful of 
circumstances because of the potential, however slim, to bring a therapeutic advantage 
to a critically ill baby. Wbilst this could lead to recruitment with a specific therapeutic 
intention (the hope that a baby will be allocated to the experimental arm of the trial), 
in the most extreme cases this drive could tip over into a decision not to risk 
recruitment but to give the experimental agent directly, or to override allocation to the 
control arm, decisions which are wholly therapeutic in intent. This suggests a 
temporary suspension of the role of investigator and a return to an exclusive role as a 
therapist. 
It seems very likely that the therapeutic climate of some trials may complicate the 
experimenter-therapist tension. The setting and style of individual trials may well set 
up particular difficulties in establishing or maintaining a clear distinction between 
research and care. The essential difference between explanatory and pragmatic trials 
is one example of how this might occur. For explanatory trials there are restrictive 
regimes governing the comparison of an intervention and a control arm of a trial, with 
the aim being to explain possible differences under controlled conditions. For 
pragmatic trials the aim is to assess an intervention in the context for which it is 
intended, taking into account the variability of clinical decision-making, local 
expertise and the condition and compliance of patients. As pragmatic trials assess an 
intervention in light of the different ways that it might be used in practice, clinicians 
are given a greater degree of freedom to interpret eligibility criteria and to shape 
implementation of an intervention. In pragmatic trials such as the INNOVO Trial it 
may well be that the role of the therapist is actually given a degree of prominence 
precisely because assessment of an intervention in context requires the investigator- 
therapist to act according to the norms of clinical care. By comparison, the CANDA 
Trial was explanatory and so the use of the trial intervention was highly regulated. 
The neonatologists were required to modify their usual clinical use of surfactant to 
ensure that in each trial centre it was administered within the tight timing schedule as 
laid out by the trial protocol. This requirement for a clear and regulated shift in 
practice emphasises the difference between usual care and research. 
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This complicated situation where allegiance to care and research are often poorly 
delineated has been widely seen as problematic. Although some of the senior 
neonatologists were very clear on the terms of their own collaboration with research, 
and were familiar with debates on equipoise and the experimenter-therapist tension, 
they also could exhibit the same oscillation between care and research as their 
younger, less experienced colleagues. This may well be because the ability to fluctuate 
and change loyalties can be seen as highly appropriate and a responsible professional 
approach. The comment from an experienced trialist and LPI that "looking after the 
family comes way before the trial, " is essentially the same argument that is made in 
the Declaration of Helsinki, that the needs of society must not be placed ahead of the 
individual. 
Miller and colleagues (1998) argue that it is possible for individual clinicians to 
achieve a consistent position in which responsibilities to care and research are 
understood and incorporated into a personal ethical position on clinical trials. This 
hinges on personal clarity over the primary aim of that individual - that is, whether 
they are caring for their patient and providing personalised care, or are contributing to 
research in accordance with a trial protocol. Whilst clarity over the aims may well be 
achievable, the findings presented here suggest that perfect consistency may not. The 
neonatologists clearly prioritised the needs of a baby and their parents over research, 
and this was an essential precondition of the collective approach to a trial. For this 
reason there was clear oscillation between the rules of care and research. 
Links with the theoretical literature 
The work of Taylor and various colleagues was instrumental in advancing the earlier 
theories relating to the experimenter-therapist tension through empirical study. 
Taylor and Kelner put forward the Physician Orientation Profile by which individual 
physicians could be placed on a continuum between pure experimenter and pure 
therapist (Taylor & Kelner 1987). The scale has also been adapted to fit the UK 
situation and termed the Trial Orientation Profile (Fallowfield et al 1997). This 
approach is grounded in the concept that clinicians are consistent in their responses to 
research and care. It taps what has been described in this thesis as views of trials in 
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principle. Given the focus on abstract responses to research it does not take into 
account the variability of responses to trials, such as those which have been shown to 
exist for the CANDA and INNOVO trials, shifts in allegiance over time for different 
subgroups of the trial target population, or different responses to individual patients 
The dual role of experimenter and therapist has since been considered by several 
authors but of central interest here is the work of Miller and colleagues (Miller et al 
1998). Whilst the two Orientation Profiles are premised on clinicians having a 
consistent and measurable identity in responses to research and care, Miller and 
colleagues suggest instead that professional responses are based upon confusion and 
competing loyalties with clinicians oscillating between allegiance to care and to 
research. They contend that this is part of a deep-seated lack of clarity in the world of 
clinical trials over the different aims of care and research which is complicated by the 
identity of clinical trial collaborators as therapists. 
In view of the deep socialization of investigators as clinicians and the blurring of 
clinical medicine and clinical research ... investigators tend to rely on their moral 
self-understanding as healers to navigate the murky moral waters of clinical 
research (Miller et al. 1998). 
A lack of clarity amongst professionals over the difference between the roles of 
experimenter and the therapist can spill over into encounters with patients who are 
invited to become trial participants. If the professional works with the notion that a 
trial can be used primarily for therapeutic purposes then so will the potential 
participant. 
Insofar as investigators conflate the context and language of medical care with that 
of research, they not only reinforce the therapeutic misconception for patient 
volunteers, they also fall prey themselves to the therapeutic misconception. ... Overcoming the therapeutic misconception is a primary ethical task for physician 
investigators, both in their self-understanding and the understanding of research 
that they strive to foster in patient volunteers (Miller et al 1998) 
This would seem to be supported by the data presented in this thesis, which showed 
how responsive parents were to the suggestion that trial enrolment "might help": a 
phenomenon which was true for the CANDA Trial, as well as for the INNOVO Trial, 
in spite of the clear differences in the neonatologists' responses to these trials. It may 
be the case that even where clinicians work with a clear research model in mind, it can 
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be difficult to find new ways of talking to patients which do not draw on the norms of 
therapy-led conversations. Communication difficulities have been highlighted in 
several studies (Donovan et al 2002; Kodish et al 2004; Simon et al 2004)). When 
Simon and colleagues compared the consent processes for adult and paediatric 
oncology trials, they found that despite similar levels of associated risk, discussion of 
risk occurred significantly more often for the adult trials, as did attempts to distinguish 
the trial risks from those associated with standard therapies. Whilst none of the 
paediatric consultations included a numerical assessment of the potentials risks of a 
trial, one third of the adult trial consultations included this information (Simon, et al 
2004). Kodish and colleagues observed the information process for parents 
considering a paediatric leukaemia trial, and in 12% of the encounters, randomisation 
was not mentioned (Kodish et al 2004). It is not exactly clear what is happening in 
these situations but it may be the case that clinicians are offering a degree of 
protection to vulnerable parents, as was the case for some of the neonatologists 
studied by Mason and colleagues (2000). It may be that their own responses are 
complicated and the distinction between care and research can be difficult to maintain. 
It has been suggested that the conflation of research and care in this situation can be 
addressed by encouraging clinicians to take on the role of investigator in isolation 
from their caring role (Katz 1993). Although Miller and colleagues argue that there is 
a need for greater understanding of the fundamental difference between the positions 
of experimenter and therapist, they do not suggest that these roles should be separated. 
Instead they call for close attention to the divergence of duties in care and research to 
promote understanding of the essential "moral conflicf 'between them. 
We need to cultivate a conception of the moral identity of the physician 
investigator that integrates the role of the clinician and the scientist without giving 
predominance to one or the other. ... The construction of such a conception of 
professional integrity is not a matter of creating a new identity but of bringing to 
light and cultivating the refined self-understanding and comportment of exemplary 
clinical researchers (Miller et al 1998). 
The ability to hold steady the roles of experimenter and therapist fully cognisant of 
their differences would also lend "integrity" to clinical research. The development of 
an integrated sense of one's relation to research and the researched is however 
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recognised by the authors as "a challenging task for physician investigators in view of 
the inherent ethical complexities of clinical research. " 
The theoretical perspective of Miller and colleagues draws on phenomena which are 
clearly present in the data presented in this thesis. For many of the neonatologists, 
decisions to offer enrolment in a trial could be made with the specific interests of 
individual patients predominating. Their reluctance to consider asking bereaved 
parents if they would consent to trial-related PM pathology studies is part of the same 
drive to protect, and stems from within a therapeutic framework. This therapeutic 
drive behind trial recruitment has also been observed amongst clinicians recruiting to 
oncology trials (Joffe et 2001) and to early phase gene transfer trials (Henderson et al 
2004). Henderson and colleagues suggested that balancing the "hopes and 
expectations for themselves and for their subjects" could be "extraordinarily 
challenging" for clinicians, a statement which could also be applied to the 
neonatologists. Certain clinicians did however appear to have achieved a sense of 
balance in their responsibilities to research and to their patients, displaying a sense of 
integration of the clinical and research work that they do. They were, to paraphrase 
the words of one consultant, at peace with themselves. This may come with growing 
experience and exposure to clinical trials, a result of a gradual process of enculturation 
into the world of research. 
The influence of recruitment in extreme circumstances on 
the development of the therapeutic misconception 
It was not surprising to find that the therapeutic misconception was present in many of 
the decisions made by the parents interviewed for this study. This phenomenon has 
been previously demonstrated in neonatal trials (Snowdon et al 1997) as well as in 
many other settings (Joffe et al 2001; Lidz et al 2004; Vitiello et al 2005). The 
analysis of the neonatologists' interviews indicated that there were situations, 
especially in relation to the INNOVO Trial, where they utilised the research for 
therapeutic purposes. It is likely that this was communicated to parents who then also 
viewed participation from a therapeutic perspective. It was however particularly 
intcresting to find that the therapeutic misconception was prevalent amongst the 
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parents for the CANDA Trial as well as for the INNOVO Trial even though the 
former was thought by the neonatologists to be unlikely to benefit the individual 
babies in the trial. This would suggest that the therapeutic misconception could have 
arisen for a number of additional reasons, some of which have been considered for 
trials in other settings. 
There are some parallels between the views of parents who are asked to consider trial 
participation in dire circumstances, and the views of participants in Phase I toxicity 
trials. Those agreeing to participate in trials at an early stage of the development of an 
intervention, especially in oncology, are often those for whom other treatment options 
have been exhausted. There is a considerable body of evidence to indicate that they 
often do so in the hope of benefit, despite the chances of benefit being low (Cox 1999; 
Daugherty et al 2000, Meropol et al 2003, Weinfurt et al 2003). Weinfurt and 
colleagues suggest that the strong wish of those involved in Phase I oncology trials to 
see a therapeutic potential in a trial situation, may lead them to misconstrue the 
likelihood of benefit (Weinfurt et al 2003). Minogue and colleagues describe patients 
whose "autonomy is diminished by fatal illness" who consent to trials in order to 
access experimental treatment, as "desperate volunteers" (Minogue et al 1995). The 
parents involved in these trials may be similarly compromised. For those offered the 
INNOVO Trial there may be few options left and consent can be given out of a wish 
to turn around their situation. Their vulnerability, coupled with the speed of their 
decisions might have made it difficult to gain an appreciation of the exact nature of 
the offer that was being made and the undertaking involved. 
There may also be some common ground with adult patients asked to make decisions 
about trial participation in stressful circumstances. The views of myocardial infarction 
patients (AgArd et al 2001; Williams et al 2003; Gammelgaard et al 2004) and those 
with subarachnoid haernmorhages (Yuval et al 2000) for whom consent for enrolment 
in a trial is sought in an emergency setting have been considered empirically. These 
studies indicated how potential trial participants could be confused, anxious, in pain, 
and be required to make decisions under certain time constraints. One of the 
participants in a myocardial infarction trial made a comment which is strikingly 
similar to those made by many of the parents involved in the CANDA Trial: 
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All I remember was that there were two equally good clot dissolving preparations A 
and B. That [information] was sufficient for me to say 'I'm in. ' (AgArd et al 2001). 
This interviewee describes exactly the same process of sifting information given at a 
time of crisis for the critical factor that results in a rapid decision about a trial. 
The parental interviews in this study highlighted one possible way in which the nature 
of the decision that was required may have been obscured. The offer of enrolment to 
the CANDA Trial was commonly embedded within a standard conversation about the 
implications of preterm and basic features of an intensive care approach. Whilst the 
clinicians viewed this as appropriate, rather than a cold approach, it may have reduced 
the chances of parents distinguishing between care and research. Similarly for the 
INNOVO Trial the parents were often given an update on the condition of the baby as 
a precurser to an explanation of the details of the trial by the neonatologist who was 
already providing care. Wherever a conversation included discussion of the threat that 
exists for a baby, whether this is a revelation or a reminder, seems to create a 
heightened moment of vulnerability. At this point they parents were particularly 
receptive to anything that "might help". This was demonstrated in Cheryl's instant 
statement that she would accept the INNOVO Trial the moment that the consultant 
touched upon the worst case scenario. The flip-side of this is Shelley and Evan's 
instant rejection of the CANDA Trial. Whilst for them alientation was a driving force, 
for many other parents, trust, usually a very positive element in medicine, may have 
acted as an impediment to critical thinking. In situations where urgency is an issue, a 
particular type of trust comes to the fore, a leap of faith which for some was not based 
on a particularly clear understanding of what they were being offered, but on 
appreciation of the need for action and that feeling that the neonatologist saw the trial 
as a possible solution. Trust and the broader context of care in which all other 
decisions about a baby are being made, might make it difficult to appreciate that this 
decision has a different basis and the needs of the baby are not central to the decision. 
In circumstances where the needs of the baby are in fact central to the professional 
decision, as suggested by this research, then such an appreciation may be impossible. 
In circumstances which are complicated and sometimes stressful for professionals as 
well as for parents, it can be difficult to tell what information an individual desires, 
fears, or is able to absorb. Even the small number of tape recordings of the discussions 
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asking for consent to participation in the INNOVO and CANDA trials indicated 
differing amounts of information proffered, as well as a variety of styles in which 
information was delivered by the clinicians to the parents. This may lead to a selective 
approach to information giving. The information that the parents were, or were not 
given might have led them to believe that the trial might benefit their baby. 
Sunestions for addressiniz some of these issues 
Some of the problems identified in this thesis are complex and deep rooted. The 
challenge is to find ways to improve the situation in which research is considered 
which incorporate and accommodate the needs of the various parties involved. Much 
work is already underway to address these issues, at theoretical and empirical levels. 
Some of the relevant broad areas of inquiry and intervention, along with suggestions 
which arise from this research, are considered below in terms of- 
" Professional training 
" Alternative approaches to recruitment 
" Approaches to information giving 
" Earlier communication about research 
" Continuous consent 
" Payment of participants 
Professional training 
Very few of the neonatologists had received any formal training in research. Some 
had covered this topic as part of higher qualifications but the main way that they 
learned about trials was through the literature, in house-discussions in preparation for 
trials (not in all NICUs), and a gradual process of exposure to recruitment processes. 
Some of the consultants argued that learning by observation was a standard approach 
in medicine, but very few of the younger doctors stated that they had spent time 
observing colleagues discussing trials with parents. There was a very strong message 
that there is a stressful period of struggle with recruitment which gradually recedes 
with growing experience. For some of the younger interviewees, all of whom had 
current responsibilities for recruitment, that struggle was ongoing. 
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Although some were reticent about the value of training, feeling that communication 
skills are innate rather than taught, almost all of the neonatologists felt that training 
which would improve appreciation of the rationale for research methods, research 
ethics, and the practicalities of recruitment, would be desirable. Novack and 
colleagues suggest that there is a need to promote professional awareness of how 
personal responses can shape decisions about offering trial participation to patients; 
they referred to the process of raising awareness as "Calibrating the physician7' 
(Novack et al 1997). For the shift in perspective suggested by Miller and colleagues 
to work in practice it would require a process akin to consciousness raising in which 
clinicians work though their motivations, allegiances and deal with the emotional 
responses that are integral to their drive to protect and care for individual babies and 
their parents 
Any trial-related training should be timed so that it has a direct bearing on practice 
when it is most needed. Perhaps it is incumbent upon trialists and trial funders to 
ensure that those who will recruit to their trial are adequately prepared; recruiters may 
need training to ensure an appropriate level of understanding of the research in 
question, of the broader ethical issues that are raised, and of their own, and their 
patients' positions in relation to care and research. This could take the form of in- 
house training, or visits by trialists for active training sessions. The ORACLE Trial 
team responded to failing recruitment rates with a highly successful multi-pronged 
training programme. Local midwives were employed to work 3 hours a week in the 
participating units. They underwent an intense two-day induction course, six-monthly 
trial updates and were in regular contacts with regional midwives who provided 
support and advice (Kenyon et al 2005). Trialists and funders may also need to 
consider the use of external courses. Successful programmes do exist (Fallowfield et 
al 2002; Fallowfield et al 2003) but currently the majority of UK health professionals 
receive no such training. 
Perhaps it is appropriate to consider the need for informed consent from those who 
will be responsible for recruitment as a prerequisite to trial collaboration. It is wholly 
feasible that tools such as BICEP (Sugarman et al 2005) which are designed to test the 
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quality of consent could be modified for use with professionals to promote familiarity 
with a trial and to ensure that broader research issues are fully appreciated. 
Alternative approaches to recruitment 
Undoubtedly the offer of inclusion in a trial can exacerbate stress for those at the 
centre of the decision-making process. Some of the suggestions which have been 
made to address this situation were touched upon in Chapter 2. These largely relate to 
not informing patients at the point of randomisation of their inclusion in a trial 
something that was first put forward by Bradford Hill in 1963 (Hill 1963). Zelen 
(1979; 1990; 1997) suggested that randomisation could take place before consent, so 
that decisions are made in the knowledge of the allocated treatment. In some Zelen 
consent designs, only those randomised to the experimental arm of a trial are asked to 
decide about trial participation; those allocated to the control arm are included as a 
matter of course. Manning (2000) suggests that for emergency neonatal trials women 
should be informed antenatally and unless they opt out, their baby should be enroled 
should the situation arise. Parents do however seem to value the consent process, 
despite any associated stress and the need to take on board complicated information. 
The majority do not wish to see it replaced with alternatives, such as Zelen's approach 
to consent (Snowdon et al 1998) or allowing doctors to decide who should or should 
not participate in research (Zupancic et al 1997; Mason et al 2000; Burgess et al 2003; 
Stenson et al 2003; Morley et al 2005). Parents generally want to be active 
participants, even if it is in what may seem to the observer to be in a limited form. 
Menikoff (2003) suggested that choice should be given greater prominence, and only 
those who do not want to select their treatment should be randomised. For those with 
a preference, trial treatments could be made available to them outside the trial. It is not 
clear however that such an approach would decrease stress in such an uncertain and 
difficult situation, as patients and proxies would have direct responsibility for 
choosing a treatment, as well as for choosing not to choose a treatment, a welcome 
option for some but a possibly unsettling responsibility for others. 
Approaches to information giving 
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There have been many attempts to improve levels of comprehension of information 
about randomised trials given in the standard approach to consent, but few have 
shown an appreciable level of success (Flory & Emanuel 2004). There has been a 
move in some research situations to warning potential trial participants of the 
possibility that they will be asked to consider taking part in research. For some 
perinatal trials, leaflets are left in antenatal clinics to wam parents that they may be 
approached about research at a later date. In some trials labouring women could only 
be offered trial participation if there was a sticker in their obstetric notes to indicate 
that they had been personally given an antenatal leaflet. Some of the women who 
were approached for the CANDA Trial in labour commented that they had been in the 
hospital for some time and would have preferred to have been approached at an earlier 
point, a finding also reported by Ferguson (2000). Improving communication 
between midwives, obstetricians and neonatologists would seem to be a useful area to 
explore, to work out the most effective mechanism for identifying those who are 
eligible for a trial. Earlier approaches do however mean that some consent to a trial 
but do not go on to fulfil eligibility criteria, (e. g. delivery is averted, a baby does not 
deteriorate to the point of eligibility) and this may raise false expectations and 
unnecessary anxiety. Some of the parents in the ECMO Trial Study were approached 
at an earlier stage as a preparation and were left with the feeling that their already 
struggling baby needed to decline further before they might be considered for a 
potentially helpful treatment (Snowdon et al 1997). 
For certain trials it will always be necessary to approach people who are in extremis. 
It is therefore highly appropriate to develop methods which are specifically focused on 
professional and patient/proxy needs in these situations. Continuous or ongoing 
consent, has been suggested (Wendler & Rackoff 2002; Cattorini & Mordacci 1993; 
Angiolillo et al 2004) and has been seen as potentially valuable for particularly 
difficult neonatal trials (Manning 2000). Continuous consent is currently being 
explored in a neonatal trial of hypothermia (TOBY) for which the trial intervention 
must be initiated within six hours of birth (Allmark et al 2003). The trial includes a 
concurrent qualitative assessment of a process whereby parents are given preliminary 
information shortly after delivery whilst their baby undergoes eligibility assessment. 
If eligible the parents are given further information and offered trial participation. 
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During the course of the intervention period the trial is discussed with parents on one 
further occasion. 
Such an approach may be a step towards addressing some of the difficulties of the 
type which affected Carly and Peter, who were left with distressing concerns about 
their experiences with research. It may help with the difficulties experienced by 
parents such as Janine whose anger was to some extent further fuelled by 
misconceptions about the research that she had been offered 69 . It does not however 
address the fact that parents give their initial consent for possible allocation to an 
intervention which cannot be reversed. The option of withdrawing from a trial once 
an intervention has been initiated may be valuable if parents feel a sense of discomfort 
over their decision, but it may have limited value for those concerned about initial 
exposure or for those allocated to the control arm. An additional value which might 
arise from the involvement of staff in continuous consent is an increased focus on the 
need to ensure understanding amongst those who have given consent, emphasising 
that consent should be substantive rather than "technical" (Kestin 1998) or "symbolic" 
(Horng et al 2002). 
If the continuous consent process were to be continued to a later point, for instance to 
discharge or a bereavement follow-up visit, this could include a form of debriefing in 
which parents would have the opportunity to gain an understanding of events and their 
role within them in the light of the outcome for their baby. Debriefing as a form of 
psychological support after traumatic obstetric events have been explored (Priest et al 
2003; Lavender & Walkinshaw 2005). This may be particularly valuable in helping to 
address the grief of any bereaved parents, especially those who were allocated to a 
trial arm which was shown to be associated with higher rates of mortalitY70 . This 
69 That is, participation in the CANDA Trial would have resulted in her baby being denied access to 
dexamethasone, a steroid which she felt was given to all of the other babies who were cared for in the 
NICU alongside her son. 
70 During this study an issue arose which indicates just how difficult this situation could be. With the 
co-operation of several consultants, interviews with bereaved parents from one NICU were arranged. 
Immediately prior to the interview a letter was sent from the NICU to this small group of parents to 
inform them of the trial results and the allocation for their baby. This placed me potentially at the front 
line of any difficulties that the parents might have had. In all cases however the parents were told that 
the outcome for their baby was unlikely to have been affected by the trial allocation. Whilst this might 
well be the case, where there are differences between trial arms, some participants must have been 
subject to that difference. Although a kindly approach, this appeared to reflect an enormous difficulty 
which pertains for trials in situations where differences in mortality are an essential aspect of the 
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approach could be applied to other emergency situations outside of neonatology where 
consent may have been complicated by stress and the urgency of the decision-making 
process. 
Payment of participants 
Payment of research participants is a practice which currently relates to healthy 
volunteers choosing to participate in commercial trials. Payment in the type of 
circumstances considered here is a very alien concept. It has however been suggested 
as a means to ensure that trial participants see that what they are consenting to departs 
from the usual terms of the doctor-patient relationship (Dickert & Grady 1993). 
Discussion of this issue, even if rejected, could raise the profile of the need to find 
ways of making explicit the terms of the decisions that individuals are required to 
make, improving appreciation of the differences between care and research. 
Limitations of this research 
It was a great pity that a central aim of the study (tape recording the conversations in 
which trial enrolment was offered) was abandoned. The value of such tapes is made 
clear through the small amount of recorded data which are available. Although some 
transcripts have been used for illustrative purposes, without a larger dataset it was 
necessary to reorient the research to consider only the information which the 
neonatologists felt that they give and that which the parents felt they were given. 
The parents interviewed here were in very particular circumstances and some of their 
views may not generalise to other settings. They were required to decide about 
research with a focus on the effects upon their highly vulnerable baby and decisions 
which are made by proxies have an extraordinary level of associated responsibility. 
The speed at which their decisions were often required may also be unusual. 
The fact that data on the subject of PMs were collected as an adjunct to the larger 
issues of professional experiences of trials, means that the study was not set up 
research inquiry. To some extent the difficulties that many professionals appear to experience on 
discussing trials with potential participants may relate to anticipation of just this situation. 
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primarily to explore these issues. As PMs were not the specific focus of the 
interviews, the data are incidental and do not provide a full description of experiences 
of and reactions to the consent process. As the number of parental interviews is 
limited a narrow range of experiences is represented. Access to the parents was 
negotiated via their consultant and it is likely that this acts as a filter. Consultants 
were very protective of bereaved parents and those who were considered to have been 
particularly distressed were less likely to be asked to participate in research which 
would explore their painful experiences. 
Recommendations for future research 
It is most important that the issues raised through this research should receive further 
attention, through discussion by the wider research community and through dedicated 
research. 
The actual consent process should be documented to elucidate sources of therapeutic 
misconception. Although this element of the research proved to be so problematic, 
other researchers have since published observational data collected in difficult 
circumstances. This indicates not only that this is feasible but also that there may be 
increasing support for such an empirical approach. It would be valuable to assess the 
continuous consent process in several trial settings from the perspectives of all 
relevant parties. A measure of the impact of this approach on parental wellbeing, 
professional research skills, and on the prevalence of the therapeutic misconception 
would be valuable. 
Quite clearly, all parties require a degree of support in this stressful situation. The 
neonatologists were very clear that training which would improve appreciation of the 
rationale for research methods, research ethics, and would assist with the practicalities 
of recruitment, would be desirable. A fruitful and positive area for research would be 
to fully assess these needs to guide training which might be provided by individual 
NICUs or as part of the preparatory period for given trials. If training were to address 
the issues suggested by Miller and colleagues (Miller et al 19998), it may be the case 
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that it should be based upon sound developmental research and its implementation 
evaluated. 
Research is necessary to understand the ways in which additional support might be 
needed and implemented for parents involved in trials in very difficult situations. 
They may benefit from access to an advisor trained in clinical trials with specific 
knowledge of the research in which they agreed or declined to participate. Such an 
advisor may clarify areas of confusion, offer a form of debriefing, as suggested above, 
and offer longer-term support should it be required. An investigation into parental 
reactions and experiences of such a service would be desirable. 
There has been a surge in the use of qualitative research to understand collaboration 
and participation in clinical trials. The next step is for qualitative methods to be 
included as an integral funded part of trials, as are dosage or toxicology studies. 
Donovan and colleagues have shown that action research can act as a monitor 
throughout the trial, allowing feedback while a trial is in operation so that research 
findings can influence and improve an existing trial rather than only trials of the future 
(Donovan et al 2002). For the INNOVO Trial a dedicated qualitative study which 
aimed to monitor recruitment may have led to an understanding of why the sicker 
babies were being recruited which might have allowed an intervention by the trial 
team to encourage earlier randomisation. 
There is a move towards informing participants of the results of trials and in this 
context in particular this should be done with careful evaluation. As yet the 
implications for bereaved parents who receive feedback of trial results are unexplored. 
Just as trialists exhort that a new intervention should be the subject of research, so 
should this type of intervention in the lives of potentially vulnerable individuals. 
Conclusions 
Although there were considerable methodological and practical difficulties in carrying 
out this study, the research nevertheless resulted in original insights which may add to 
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theory and be of practical use to trialists and clinicians. Whilst the study did raise 
some concerns for some clinicians, it seemed that it was conducted without any 
obvious adverse effects. 
In its simplest form it was shown that whilst the neonatologists viewed the two trials 
in very different terms, the parental accounts of the trials were very similar. The 
therapeutic misconception was present for both neonatologists and for parents. 
Further debate is necessary to consider where the therapeutic drive best fits in relation 
to clinical trials in such extreme circumstances. 
At a more sophisticated level, this study has shown that the neonatologists' decisions 
about collaboration were complex and multi-tiered, and made in relation to very 
variable factors. Arguably the most important finding to emerge is the delineation of 
local forms of equipoise and the exploration of their influence on the redefinition of 
terrns of collaboration within trial centres. Decisions to collaborate were made in the 
context of collegiate and hierarchical local systems, and were driven by research 
principles and the desire to benefit the individuals who act at trial participants. 
Decisions to suspend collaboration, by comparison, were made wholly within the 
context of the doctor-patient relationship with the interests of individuals firmly at the 
forefront. This suggests that the interplay of research and care can change according to 
circumstances and has implications for how this important issue might be understood. 
It feeds directly into discussions of the presence of therapeutic orientation as an 
impetus for recruitment and professional responsibility of clinicians associated with 
trials. 
The parental decisions superficially appeared to be much more simple. They were 
made quickly, often in response to the timescale that was set by their circumstances, 
and largely in order to benefit their baby. The parents involved in the CANDA Trial 
often displayed little understanding of the nature of the research, expressed few 
treatment preferences and were frequently unaware of the allocation that was made for 
their baby. By comparison the parents involved in the INNOVO Trial almost all 
consented with the explicit hope of accessing INO. Although there was some 
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confusion about the trial, none were unaware of their allocation 
7 1. The support that 
the parents expressed for neonatal research may be shown through future dedicated 
research to extend to support for trial-related PM pathology studies, an issue which the 
neonatologists were generally quite reticent about raising. 
Although the neonatologists viewed the CANDA and the INNOVO trials in very 
different ways, for the parents there were few differences in the ways that they saw the 
two trials. The neonatologists took an essentially discriminatory position, judging the 
trials according to the terms and conditions that they set in relation to local practice 
and local concerns, and according to the possible impact on individual babies. Those 
associated with the CANDA Trial appeared to view the trial quite clearly within an 
experimental framework. It may have been precisely because it was to some extent 
seen as a form of non-therapeutic research 72 , where the trial 
interventions were 
unlikely to differentially affect the outcome for an individual baby, that the role of 
therapist and experimenter could be more evenly balanced. The therapeutic 
orientation in the INNOVO Trial appears to have been stronger precisely because 
equipoise amongst the neonatologists was unstable and because the therapeutic need 
of individuals was high. It may be that the life-threatening circumstances that could 
pertain for the INNOVO Trial were sufficient to override all other considerations 
leading the neonatologists to act predominantly as therapists. The parents almost 
universally hoped for a benefit from trial participation and were just as likely to see 
risk in one trial as the other 73 even if they were not particularly clear as to what the 
trials entailed. Their responses to the trials were largely driven by a sense of fear, 
hope, trust and expectations of care. 
The relationship between the neonatologists and the parents, what was said, not said, 
and inferred, are central to the experiences of all involved in this research. Much of 
what was discussed in the interviews revolved around professional and parental aims. 
Sometimes these were divergent; often they converged. They were rarely separated 
71 One possible exception is Kerry (Int. 70) whose baby was allocated to INO. She was aware of 
randomisation but substituted INO with steroids in her account of the trial intervention. 
72 This is not the usual usage of the term, non-therapeutic research, but it is used here to convey a 
distinction between how the CANDA and the INNOVO trials might have been seen. 
73 This comment is based on a comparison of the views of the different groups of parents. The parents 
were not asked to make a comparison. 
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from the broader and the immediate context of care. This intermingling of care and 
research, and a lack of a clear distinction between therapeutic and non-therapeutic 
research, are precisely the elements that many theorists argue need to be addressed in 
the trials situation. The ethical duties and framework of care provided by the doctor- 
patient relationship was however central in the accounts of the neonatologists, and 
would probably be seen as an appropriate safeguard for those who enter research in 
their care. 
This is the fundamental issue at the heart of this thesis. For the neonatologists the 
trials were introduced into a developing or an existing caring relationship. To separate 
out only one element of the care of a baby, and one part of a relationship with parents, 
and apply different rules of engagement, was an almost impossible task without clear 
guidance and training. The process by which most doctors were prepared for this 
particular philosophical and ethical challenge appeared, however, to be somewhat 
haphazard with an indication that they could be "thrown in at the deep end. " This 
could be extraordinarily stressful, especially for those with less exposure to clinical 
trials. With little training and a high expectation that they should recruit to a trial in 
accordance with the local collective decision, it may not be surprising to find reliance 
on the more familiar approach to discussions of treatment options with parents which 
is grounded in the firmly ingrained drive to provide care. Parents, with little else to 
guide them, respond to the direction of a trusted clinician and their own instinct to 
protect their child. Both parties need assistance so that the precise nature of the 
decisions at the heart of clinical trials can be made clear, and to ensure that those who 
are associated with research are willing collaborators and participants, fully cognisant 
of the activity in which they are engaged. 
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Perinatal postmortem rates are declining world wide. In the 
United Kingdom, perinatal pathology has recently been 
seriously undermined by controversy. There are important 
consequences for perinatal trials that include pathology 
studies. This review looks at the reasons for the decline in 
perinotal postmortem examinations and the effects on 
research. 
........................................................................... 
D cspitc the widely acknowledged value of 
the postmortem examination (PM), there 
has been a sustained decline in PM rates 
around the world. " Although perinatal PM rates 
arc higher than rates of PM In other contexts, " 
they arc considered to be suboptimal' and arc 
following this downward trend. ' ` This Is In spite 
of the fact that they are of particular value in 
several ways. As well as offering parents Infor- 
mation about the cause of death of a baby and so 
a degree of closure, their value lies in giving 
Information for subsequent pregnancies, their 
role In audit, and In being an important research 
tool. " 13 
"A degree of altruism is required of parents 
who are in the most stressful of circumstances, 
and benefits to research may not seem 
important at that fime. " 
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As pcrinatal PINIs can provide crucial empirical 
data, in research terms this decline is worrisome. 
Without pathology studies, perinatal trials can- 
not assess the possible impact an intervention 
has had on those who have died. with assess- 
mcnt incomplete, potentially serious consc- 
qucnccs of an cxpcrimental treatment could go 
undetected. it Is therefore important that, when 
babies who have been enrolled in a trial do go on 
to die, parents should be asked about the 
possibility of a PM. This Is, however, a cornpli- 
cating element in an already difficult situation. A 
degree of altruism is rcqired of parents who are 
in the most stressful of circumstances, and 
benefits to research may not seem important at 
that time. Their doctors may be uncomfortable 
requesting such altruism from them. Given 
declining consent rates for perinatal Pi'vis gcn- 
crally, it does seem that most parents are either 
declining or arc not being approached for 
permission. This is already having a tangible 
effect on research. "' A UK consultant pcrinatal 
histopathologist is quoted as saying "Consent for 
the use of tissues for research Is about 10%. In 
the past it would be unusual for anybody to 
refuse. "" Pathology studies with inadequate 
numbers are unreliable, and so this decline 
clearly has important consequences for the 
quality and integrity of data. 
Low rates of perinatal PMs arc likely to be a 
product of highly interrelated factors. A number 
of studies have examined clinical and other 
characteristics of babies and mothers to assess 
any links with FM rates. It has been shown that 
prematurity, ' 11 11 11 lower birth weight, ` and a 
specific diagnosis-for example, birth asphyxia" 
and congenital anomaly"-are all associated 
with a P1141 not being performed. Separation of 
mother and baby through hospital transfer"' is 
also associated with no PM. Studies found no 
significant association between no P, %A and basic 
characteristics of the infant (birth hospital, age 
at dcath, birth and death weight, race, sex, year 
of death)'O or of the mother (age. religion, 
gravidity), ' except for lower parity` and fewer 
perinatal losses. " These studies have not 
addressed the contribution of parental and 
professional views. 
in recent times several important social and 
political factors are also likely to have exacer- 
bated the problem. Pcrinatal pathology as a 
specialty is said to be undergoing a period of 
crisis. There are now few experienced perinatal 
pathologists in post, Insufficient numbers of PAMS 
to retain specialised skills, and few new recruits 
to the specialty. " 11 Furthermore, two relevant 
areas of concern have been raised in the United 
Kingdom; firstly, there have been governmental 
inquiries after revelations about the lack of 
consent for retention of children's organs after 
PNIs at Bristol Royal Infirmary" and Alder Hey 
ChildreWs Hospital in Liverpool" and secondly, 
there have been accusations" 11 and rcfutations" 
of misconduct with reference to consent for 
procedures in pcrinatal research in the CNEP 
Trial at North Stafford Hospital. " It is against 
this highly sensitive background, In -a time of 
unprecedented mistrust between the medical 
profession, the public. and the mcdia", 14 that 
all UK discussions about PIMs are taking place. 
"An o6vious tension lies 6etween Worming 
the parents oF difficult details and managing 
the request vAth the sensitivity it deserves. " 
These concerns have contributed to the recent 
shift in clinical practice towards dctailcd consent 
forms, which now explicitly request permission 
for aspects of the PM that parents may not 
previously have considered. Requests for removal 
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and retention of whole organs, decisions over methods of 
sampling, and decisions over subsequent disposal of body 
parts, has rendered the consent process "a legalistic and 
clerical business". " An obvious tension lies between inform- 
ing the parents of difficult details and managing the request 
with the sensitivity it deserves. Recent discussions about the 
management of consent for PMs have focused on who should 
raise the issue of the PM with newly bereaved parents and 
how those discussions should be handled. " " I" 
In attempts to improve PM rates generally, there has been 
much interest in charting knowledge of, and reactions to, 
P4*As outside of the perinatal context. There have been various 
surveys of the attitudes of professionals, such as hospital 
doctors, * I` junior doctors, " " general practitioners, " med- 
ical students, " 11 and nurses. ' Perceptions of difficulties with 
the consent process have been shown to be an important 
block to offering a PM, ' "" as Is degree of certainty over the 
cause of death" " and increasing age of the patient. " " 
Although hospital clinicians, general practitioners, " junior 
doctors, " and nurses" arc shown to have positive views of 
the value of the PM, junior staff in one study were unaware 
of the benefits. " 
"ClariFying the cause of death was also importont, as was 
gaining reassurance From the results. " 
The views of bereaved relatives"" have also bccn sought. 
When relatives had consented to a PNI, the most common 
rcasons given were altruistic, that is the advancement of 
science" ' and to help others. " Clarifying the cause of death 
was also important, "" as was gaining reassurance from the 
results. " Reasons for refusal were concerns over disfigure- 
ment, " "a sense that the relative had "suffered 
cnough", " " and unease with the PM itself. " " Difficulties 
svith the process of giving permission for a PIM was cited by 
one study" as a reason for refusal. 
Less attitudinal research has been carried out in the 
pcrinatal context and none with particular reference to 
pcrinatal trials. As trial participation can alter the grounds on 
which consent is sought, and could significantly alter the 
experiences of those involved, this is an important omission. 
There are, however. elements of the existing empirical 
literature in the perinatal and pacdiatric ficld that can shed 
some light on the complexity of professional and parental 
determinants of PM rates. 
PROFESSIONAL VIEWS 
The literature on professional views is useful in highlighting 
attitudes to the use of PMs in different clinical circumstances 
and for different groups of professionals. Four papers" 
report findings on attitudes to Pbvis. 
VamNlartcr and colleagues" report a rccords based review 
supplemented by a questionnaire based study. in the review, 
they found an important association between rates of PM 
and presumed cause of death, with extremely premature 
babies being least likely, and those affected by a congenital 
anomaly being most likely, to undergo PIN4. They also found 
that giving permission for a PIM was associated with repcatcd 
pcrinatal loss. Both findings seem to suggest that a parental 
wish for an explanation of events is Important. It is, howevcr, 
unclear from a review of records whether actual parental 
vlcws, or professional perceptions of those views, arc the 
most influential in this matter. In the questionnaire bascd 
element of the study, only professional views were sought. 
pxis were seen as more important by senior staff than by 
junior staff. In general, the sample saw the importance of the 
PIM as being strongly related to the cause of death; whereas 
only 31% felt that they were very important when the cause 
F201 
of death was extreme prematurity, when the cause of death 
was congenital anomaly or an indeterminate cause, 94% and 
91% respectively felt that they were very important. 
The views of paediatricians and paediatric residents were 
surveyed by Stolman and colleagues. " Respondents indicated 
on a multiple choice questionnaire that, although most felt 
F, Ms provide valuable information, 20% felt that they are 
unnecessary if the disease was known before death. When 
consent is not sought for a PM, this related to concerns not to 
distress the family and respondents' belief that little 
information would be obtained. Seventeen percent of the 
sample indicated that they do not approach families who arc 
upset. 
In assessing the views of neonatologists, obstetricians, 
midwives, and neonatal nurses, Khong and colleagues" 
found that the most influential factor in the offer of a PM 
was perceptions of parental desire for a PM; when the 
diagnosis was clear and the parents did not desire a PIM and 
planned no further pregnancies, there was least inclination to 
offer a PIM. They argue that the deterntinant of PM rates in 
their sample was parental refusal, as the neonatalogists and 
obstetricians did not generally show reluctance to make an 
approach for consent. 
Cottrcau and colleagues" considered the views of pathol- 
ogists and other clinicians. Although most clinicians saw PMs 
as useful, 50% felt that they should not be offered when the 
cause of death is known. Younger clinicians and younger 
pathologists saw PIMs as less useful than their senior 
collcagucs. There was greater discomfort In discussing PMs 
amongst pacdiatric staff compared with those dealing with 
adults. 
PARENTAL VIEWS 
Data are available on parental attitudes in a small number of 
studies" '" that provide some information on perceived 
advantages and disadvantages of FMs. A positive view of 
contributing to research is mentioned in two studies. 
McPhee and colleagues" included parents In a general 
sample of bereaved relatives who had or had not permitted a 
PM. Although most likely to show concern over disfigure- 
ment, bereaved parents were singled out as the group 
especially likely to see benefits of a FM (listed in order of 
importance as advancement of medical knowledge, knowing 
the cause of death, and reassurance that all appropriate care 
was given). As 45% of those who did not permit a PINI stated 
that they had not been approached, the authors argue, In 
contrast with the study by Khong and colleagues, " that 
reluctance of clinicians to offer PMs Is likely to be more 
important than reluctance of relatives to sanction procedures. 
Rankin and colleagues' found from a postal questionnaire 
of parents using a bereavement service that 81% of 
responding parents had taken up the offer of a P41.1. This is 
a high acceptance rate and may be due to the source of the 
sample, and the fact that the study included women who had 
miscarried or had terminated a pregnancy because of an 
abnormality. Although most of those accepting a P, 1A did so 
for their own bcnefit-for example, wanted more informa- 
tion, wantcd closurc-24% wanted to contribute to research. 
Most of the refusers felt that their baby had "suffered 
enough", and that a PM would not help them. 
McHaffic and colleagues" found that 38% of their sample 
of bcreavcd parents refused permission for a PNI, with 
concerns over disfigurement of the baby as "a major 
preoccupation". Such concerns were also Identified in 
relatives in non-pacdiatric settings. " 14 16 Crucial to decision 
making was whether or not there was any further informa- 
tion that the parents, rather than the medical team, fclt they 
needed. 
www. archdischild. com 
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DISCUSSION 
The available literature sheds some light on attitudes to PMs 
generally and to perinatal and paediatric PMs outside of a 
trial context. This can be uscd as a first step towards 
understanding some of the issues likely to affect the 
management of PMs within a trial context. It describes some 
of the pre-existing conccrns about PMs, on which the 
complicating factor of the rcqucst for PPA information for a 
randomised controlled trial is superimposed. 
"... it is not clear whether actual parental views or 
professional perceptions of parental views are most 
influential" 
These papers give some insight into ways in which parental 
views may intcrscct with those or professionals. Although 
they appear to show that, in usual clinical practice, PM rates 
arc driven by parental inclination or disinclination towards 
further information, it is not clear whether actual parental 
views or professional perceptions of parental views are most 
influential. 
The professional literature does suggest quite clearly that 
perinatal PI'vis appear to be valued only in certain circum- 
stances. There is a strong theme that they are justified onlyif 
they have something important to offer parents-that Is, if 
there is a query over th, -ausc of death or if further 
Informat; un mij5hc t)c made available. If the likely cause of 
death appears to be clear, as in many cases of prematurity, 
then PNis are seen as inappropriate. As doctors decide 
whether or not to approach parents, there is clearly a process 
by which certain parents can be screened out. It is therefore 
likely that the subject of a PM is often not raised with parents 
of premature babics, or those who arc thought to have no 
need for further Information. It may be that those who are 
highly stressed, or who arc thought to have suffered greatly, 
are d1sc, subject to a similar screening process. This Is In spite 
of the fact that various studies have shown that PMs can 
provide unexpected findings that do not support the initially 
stated cause of death, ' "" leading the Royal College of 
Pathologists to recommend that "relatives must be informed 
of the probability that a certified cause of death is wrong". 41 
Given this apparently dominant view that PMs are only 
warranted In certain circumstances, it is likely that request. 
ing a PM in a trials context will further complicate the 
situation. If a P11A Is thought to have nothing to offer parents, 
the request to carry out a PIM for a pathology study for a 
clinical trial would be seen as being only for the benefit of the 
wider community. Rather than having family wc1farc at the 
heart of the request, essentially newly bereaved parents could 
be asked to consent for altruistic reasons. With professional 
concerns to offer Pl%ls only whcrc there appears to be strong 
grounds, this may be seen as an Inappropriate request. 
Although some parents have a strong desire not to have a 
PIM, the literature does suggests that some parents may wish 
to make a contribution to research. It is, howcvcr, inadequate 
to assess whcthcr parental reactions to these particular 
circumstances arc similar to or different from their profes. 
sional counterparts in this setting. 
In addition to assessing attitudes to trial related Pims, it is 
important to determine what actually happens when parents 
arc approached for consent, and what are the consequences, 
if any, of the approach. The offer of a PINI, and the request 
that samples should be used for specific research purposes, 
raise particular Issues for both professionals and parents. The 
combination of the dynamics bct%vccn parental and profcs. 
sional views, and a fraught political setting, produce a 
complicated and multilaycred encounter. As yet there are no descriptivc data to afford a greater understanding of this 
www. archdischild. com 
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situation. and no detailed information on reactions of 
the various parties. As the experiences of the offer and the 
decision making process could be very different from the 
usual clinical situation for all parties involved, the current 
literature is inadequate to aid understanding of experiences 
of perinatal pathology in a research context. 
it is clear that further research is needed to explore this 
specialised area of consent and its consequences for those 
involved. A first step Is taken in two linked papers, which 
report a qualitative study of the vicws of neonatologists and 
pathologists involved in two nconatal randomised controlled 
trials14 and interview data from a small number of bereaved 
parents of babies enrolled in both trialS. 4' 
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Objective: To describe the attitudes of neonatologists to trial related perincital postmortem examinations 
(PMs), in the light of declining perinotal PM rates and poor levels of parficipation in pathology studies. Methods: A qualitative study was carried out, using semistructured interviews. Twenty six neonatologists from five UK neonatal units were interviewed; Five UK perinotal pathologists also contributed to the study. The professionals involved were all linked to one or both of two neonatal trials. Results: Pathologists expressed concern over the difficulties experienced in UK perimatal pathology and the 
impact on research of inadequate levels of samples. The interviews with neonatologists reveal discomfort bereaved parents far PMs, and a wi ýread concern that parents should not e over approachin ides 6 Further distressed or fee under pressure to consent. Although ere was support for neonatal trials, the study highlights a View that PMs may be unnecessary if the cause of Oeotb seems apparent or when a 606Y was born prematurely, and a devaluation of PMs among some younger staff. Poor rates of participation in 
patholO studies may be accounted for by a notable sense of disconnection between trial interventions 
and p0t%logy studies. Conclusions: Neonatologists were concerned to protect vulnerable parents and varied in whether they saw 
this as compatible with inclusion in trial related pathology studies. Dedicated research is needed to document and gain an understanding of the consent process and should examine the usefulness and 
impact of consent Forms. it should assess whether proFessiionols might benefit From training, to help parents 
to come to their decisions. 
n the first of three linked papers' we argued that 
potcntially complcx reasons for declining perinatal post- 
mortcm (PIM) rates warrant further research. This paper 
reports a qualitative study of views of 26 neonatologists and 
five pathologists Involved In two neonatal randomised 
controlled trials (RCTs). A further paper' reports interview 
data from a small number of bereaved parents associated 
with these trials. 
METHODS 
Neonatologists 
The neonatologists were associated with one or both of two 
RCTs. The INNOVO trial (www. innovo-trial. org. uk) com- 
pared giving babies of any gestation either inhaled nitric 
oxide using a ventilator or standard ventilator care. The 
CANDA trial' compared two surfactants for preterm babies. 
The INNOVO trial had a PM protocol and specific organ 
studies (heart, lungs, and brain). Although the CANDA trial 
had no specific PM study, if PMs were carried out, 
information from lung tissue was used to supplement trial 
findings. 
Thirty onc neonatologists involved with recruitment to 
these trials from five ccntres were approached to participate 
in the qualitative study during 1999-2001. Centre A recruited 
neonates to the INNOV0 trial only, B-D to both trials, and E 
to the CANDA trial only. One neonatologist declined to be 
intcrvicwcd. The scmistructurcd Intervicivs covered a widc 
range of Issucs raised by RCTS. They were all conducted by 
CS, tapc rccordcd, fully transcribed, and analysed with the 
assistance of a computer based qualitative analysis package. 
Atlas-ti-4 CS was primarily responsible for the analysis, but 
DE and JG also rcad all transcripts and agreed the analysis. 
The subject of PiMs was first raiscd in the fourth interview, 
and then incorporated into the Interview schedule. Data are 
thcreforc presented from 26 interviews. Eleven Interviewces 
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were consultants. Twenty three were male. Ages ranged from 
30 to 54, mean 37 years. Eight were linked to the INNOVO 
trial only, eight to the CAN DA trial only, and 10 to both trials. 
Pathologists 
The pathologists' views were collected after analysis of the 
neonatologists' views. Six pathologists associated with 
the INNOVO trial pathology study and one associated with 
the CANDA trial were invited to respond to the issues raised. 
Five responded In writing or by telephone. Their anonymised 
comments contextualisc the neonatologists' views. 
Ethics 
Relevant multiccntre and local research ethics committee 
approvals were givcn for the two trials and for this qualitative 
study. 
RESULTS 
Pathologists' views 
Pathologists expressed much concern over the difficulties 
experienced in UK pcrinatal pathology. in addition to a long 
standing problem of few specialist training posts, they felt 
their profession was under a great deal of strain, "a very sad 
state Indeed". 
(Pathologists) have taken a huge bearing and are giving 
up. ... Vital research cannot be done, end it has a huge knock on effect. I used to see 150 baby (organs] per year. 
Lost year I had 13. if I have this level of material I cannot 
make diagnoses, cannot help parents to understand why 
......................................................... 
Abbreviations: PM, postmortem examination; RCT, rondomised 
controlled trial 
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their baby died and will not retain my. own diognosric skills 
For lack of experience. 
Another pathologist had received only one sample for the 
INNOVO trial in the previous year. A third described sharply 
declining rates since involvement In an earlier neonatal RCT. 
and felt this is "to the detriment of clinical care and to the 
extreme detriment of the parents who fail to get useful 
information to help them come to terms with their loss. " 
Pathologists were asked to reflect on the value of pathology 
studies for neonatal RCTs. Their views were clear, arguing 
that there is an Inherent danger in poorly evaluating 
potential ill effects of expcrimental trcatmcnEs. 
[Postmortems] should be almost mandatory in any 
situation where any kind of therapy is being tested in a 
clinical trial. ... [We should not] treat these children as 
some kind of experimentol laboratory animol. For from it. 
it is the case however that each individual child who 
receives treatment and each individual child who unfortu- 
nately succumbs to their pathology while under treatment 
represents an irreplaceable source for the assessment of 
innovative therapies. We have a responsibility to ensure 
not only efficacy of treatment in a positive sense but also 
absence of deleterious effects. It would be a great sadness 
if these treatments were to escape into the general usage 
and subsequently be identified as being deleterious in the 
years to come. 
As pathologists arc not involvcd In the consent process, 
they depend on nconatologists as mediators, with the 
potential to affect the situation positively or negatively. 
When consent rates wcrc low, thcy felt this related to 
professional discomfort and lack of knowledge about the role 
and value of RNIs. 
[They) must be seen as a continuation oF the trial not as a 
Further intrusion in [be borrowing process that parents 
suffer leading up to the death oF their children. It is critical 
, 
fle who are that the consent process is handled by peo 
committed to all aspects of the trial protoco and do not 
have an agenda which excludes the PM From that process. 
There is rather too much oF a view that the child has 
-suffered enough" which intrudes in the process oF asking 
For a PM examination. It is entirely appropriate that 
parents should be encouraged in the 6elief that they are 
making a signiRcont contri6ution to the greater good. 
Many parents find some sarisfaction in the hope that their 
loss can prevent similar things happening to other 
children. 
Neonatologists' views 
Responsibility to the trial and to the parents 
Neonatologists were asked whether a baby's enrolment in a 
trial affected their approach to parents. Responses were 
linked to the responsibility they felt to the trial, to parents, 
and how they vicsvcd the Impact of the approach. 
They articulated varying degrees of responsibility to 
contribute to RCT pathology studies, which appeared to be 
determined by their knowledge of trials and their allegiance 
to parents. They varied In familiarity with PM processes 
generally and specifically for the INNOVO and CANDA trials. 
Nlost consultants were knowledgeable about requirements 
and described alternatives such as limited Mis if parents are 
uncomfortable with certain procedurcs. ' Neonatologists' 
views are divided into three broad groups:. those suggesting a 
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sense of responsibility that was (a) equal, (b) divided, or (c) 
prioritised. 
A sense oF equal responsi6ility 
Neonatologists with a sense of equal responsibility viewed 
their RCT contributions as important, and felt it is possible to 
combine these with full consideration of the needs of 
families. Within this group, some described a moral 
responsibility to contribute to trials, with a consultant 
arguing that he feels "mandated- to do so. Another feels 
"even more of an imperative to try to get PM tissue within 
the trial context". In his view, not carrying out a PIM would 
be an "opportunity lost". These neonatologists felt they could 
combine what they saw as their duties to individuals with 
duties to the wider community. 
A sense of divided responsibility 
Some neonatologists described with some anxiety, their 
feelings of responsibility to research, as well as to families 
in their care. They exhibited some doubt over whether the 
two could be served by inclusion in PM studies. For some, 
there was great tension between the Ideal of contributing to 
research while also providing care. 
With the knowledge that trials are used to improve care, 
one nconatologist described a moral pressure to gain consent 
for a PM. He foresaw a potential conflict of interests between 
individuals and the wider community. 
There would be some pressure on the person requesting 
the autopsy, that they do so For the benefit of the trial and 
prospective Future babies who might be enrolled in that 
trial. ... (11] it was causing problems and causing 
deaths 
then it clearly would be to everyond's advantage to find 
out that early. You have to balance that against the 
parents' wishes to not have an autopsy. 
The sense of pressure was a concern for a few. 
intellectually they felt that PMs arc important, and that 
inclusion in a trial means that there Is a responsibility to 
explore the possible Impact of Interventions. Practically and 
emotionally, however, the shift from providing care In a 
clinical context to a research context could cause great 
problems. 
[Normally] I you say to the parents, "Can we do a 
postmortem? " and they say no, you say, 'Well, OK. " 
Whereas ... you're under a 
little bit more pressure 'cos 
oulre in a study to actually then push them a little bit Cder 
ond say, "Look, we really do need this, this will 
help other babies. " They say, "Look, I've already helped 
other babies (by being] in the study to start with, now 
you're asking me to ... chop my 
baby up, I just want his 
pain to end. " So I do feel ... they've got a point there. 
A prioritised sense of responsibility 
Some expressed the view that parental nccds should be 
prioritiscd, while responsibility to trials was attributed 
varying degrees of importance. Neonatologists could see 
trials as Important but secondary to parcntal nccds. A 
consultant commented that consent for a Pm for neonatal 
RCT purposes "wouldrVt be top of my prioritics. 1' Another 
consultant who aims to offer trial related FAMs was adamant 
that there be no further discussion once parents Indicate th& 
choice: "if they say no, they say no, cnd of story. Looking 
after the family comcs way before the trial. " 
www. archdischild. com 
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Some neonatologists described P2Ms only in terms of the 
patient for whom they had clinical responsibilities and 
were unaware of their value for neonatal RCTs. They 
seemed unaware of a role other than to ascertain cause of 
death and argued that trial enrolment made no difference 
to consent. Although less senior neonatologists were 
often responsible for initial trial recruitment, some were 
unfamiliar with pathology elements of the trial. This may 
not be surprising given the various career stages of 
interviewecs, and supports similar findings In the literature. ' 
Few of these had considered that trial participation may 
change the importance of a PiM, the grounds on which it is 
required, or the information that may be requested by 
parents. It was striking that. in the interviews (which 
explored various ways in which practice and parental 
experiences were shaped by inclusion In neonatal RCTs), 
the FM and the RCT were often considered to be uncon- 
nected. This was particularly clear when four neonatologists 
who had recruited to the INNOVO trial, including a 
consultant, were unaware of the pathology study. Some 
neonatologists placed little value on PINIs themselves, arguing 
that they were unnecessary as it is often clear why a baby has 
died (see below). 
PMs solely as trial requirements 
if there is no query over cause of death, but a baby could be 
included In a neonatal RCT pathology study, essentially 
newly bereaved parents could be asked to pcrmit a PM for 
purely altruistic reasons. Some neonatologists saw It as 
appropriate to request such a PM, albeit carcfully, some saw 
the value but viewed it as inappropriate, and sonic saw it as 
unnecessary, particularly for prctcrm babies %vhcre much is 
known about causes of death. One consultant fcIt that few 
doctors would be enthusiastic about approaching parents In 
such circumstances. This Is bornc out by lo%v prctcrm PM 
rates In the INNOVO trial (26% preterm v 67% tcrm) and the 
comments of a less senior neonatologist. 
(Postmortems] are of very limited valve. You usually know 
why a baby has died. So... why cut them up. IF you don't 
know why a baby has died then irs perfectly valid ... but if 
you've got a prern baby ... I think that the parents might 
well think that you're pushing it because of the trial. 
when doctors were' uncomfortable and when they felt a 
PM had little to offer parents, there were clear difficulties. A 
specialist registrar who was well informed about trial 
requirements felt it was far more discomforting to ask for a 
pm for a trial than purely on clinical grounds. 
(in] a conventional postmortem you restrict the area to 
somewhere you're unsure leg] the cause of death ... 
[The] 
problem with ... INNOý6 
[is] that even in babies who 
died of something completely different ... or we 
know the 
cause of death, their brain and a chunk of their lungs and 
a chunk of their heart are going to so to different areas of 
the country, and the baby's going to be buried without 
those organs ... There are 
lots of issues around that I do 
Feel a bit uncomFortable with. 
Concerns over application oF pressure 
Regardless of where doctors sa%v their responsibilities, they 
were concerned that bereaved parents should not be 
pressured to consent to a potentially disturbing procedure. 
There was also concern that requesting a PM for the benefit 
of others may be construed as "emotional blackmail" or "a 
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bit callous". There was also concern over the possible 
Inference that a baby may have been harmed as a result of 
the parental decision to join a trial. 
lies] almost unfair to suggest to them that thereýs more of a 
reason to do a postmortem on their baby than another 
baby who wasn't part of the trial. [It] ... might suggest that 
there might be something that the trial did that we need to 
find out. 
Neonatologists commonly said that they back down as 
soon as they sense parents' discomfort. One nconatologist 
said that when he realises that parents are going to decline, 
he does not feet that it is "appropriate in any way to push 
beyond that. " Another felt that dropping the subject vcry 
quickly eased his own situation. 
I never felt under pressure to get parents to consent to a 
postmortem, in Fact quite the opposite. If t6e Family didn't 
want [one] we really leh it very rapidly. 
Management of consent 
if parents are approached, local practice and legal require- 
ments have to be carefully balanced with parental needs. 
Current Department of Health guidelines state that consent 
forms should involve decisions about which body parts 
may be studied (a full or limited PM), how body parts 
should be disposed of, and whether samples may be used 
and retained for research purposes! At the time of the 
trials, information followed the then standard guidelines 
and was much less explicit, but by the time of the present 
study, most ccntres had drawn up their own very detailed 
forms. There was some variety In how these forms were 
viewed and used. They could be seen as a means of 
bringing parents to an understanding of their options, but 
could also give professionals a sense of being "covered by 
the consent form" precisely because they refer to research. 
They could be used after an Initial discussion, with 
parents being given the forms to read on their own when 
they felt able to do so. This could be due to the time It takes 
to go over long, legalistic documents, or to allow parents 
some privacy. They could also be used to frame discussion oi 
the details of a FK including the collection of research 
samples. 
Confronting parents with unsettling information and 
asking them to make decisions, such as whether or not to 
permit removal and retention of a brain. can be stressful for 
everyone. Whereas some saw detailed information giving as 
appropriate, others felt It marked a shift to a more defensive 
professional position and placed too great a burden on 
parents. One nconatalogist described it as "absolutely 
ridiculous" and "not fair on the parents"; another asked 
"how brutal do you really want to be with bereaved parents? " 
one senior consultant commented: 
We have a consent form that actually talks about removal 
of the brain ... (There's] no question at all, it 
becomes 
uncomfortable. You ore trying to support parents at a 
terrible time ... [but you are also asking] them to 
do 
something very horrible to their (baby]... I can see myself 
refusing post-mortem too. 
It Is important to note that this consultant had not, 
howcver, lost faith in the consent process, which he valued 
highly. 
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On the one hand irs much more uncomFortable For them 
having to think through that at a time when they're very 
distressed but on the other hand tkey're more informed 
and they've, made a clear and informed choice. So it has 
to be better, I'm in absolutely no doubt at all about that. 
DISCUSSION 
The doctors interviewed for this study are working in a 
difficult climate. There is a worldwide move towards greater 
openness In research and clinical practice, with a high value 
placed on the quality of Informed consent. Most centres now 
use detailed forms for consent for both RCTs and RCT related 
FINIs. These two consent processes were, however, often 
viewed by the doctors in this study as discrete events, not as 
part of a linear process. 
Although some doctors embraced the direction that 
consent for PINIs has taken, openness in discussion of P? vIs 
led some to feel that they arc engaging In something that Is 
potentially rather "brutal". The need to discuss research 
further complicates an already sensitive area, and they clearly 
felt that all parties require some protection in precarious 
emotional and political circumstances. Most found FM 
discussions problematic, and all tread a careful path in 
dealing with bereaved parents. As professionals, they expose 
themselves to a degree of risk by entering an arena that has 
caused such a political furore in the United Kingdom, and 
this can only add to their misgivings. 
one response to this situation is to approach parents with a 
great deal of caution. This can involve immediate disconti- 
nuation of discussions when parents are uncomfortable. 
Another response Is to make selective approaches to those 
who seem to be coping or when a PIM is already Indicated for 
other reasons. The request for samples when a PM is for 
clinical purposes allows a doctor to put the request in less 
discomforting terms. Crucially this offers realignment with 
the role of carer rather than researcher. it may also, however, 
make the role of samples for trial purposes less clear for 
Some. 
A third response which may become increasingly common 
is to make no approach and to opt out of neonatal RCT 
pathology studies altogether. A head of department in this 
study stated that, given the UK political climate, he would be 
reluctant to ask any parents for a neonatal RCT PM and 
doubted whether any colleagues would do so. 
This undoubtedly offers individual parents protection. 
However, when few samples are sent for pathology studies, 
not only arc there fewer data on which a trial data 
monitoring committee can base its recommendations about 
continuation or otherwise of the trial. but also the scientific 
rigour of the pathology study is undermined. This is 
especially the case if samples arc sent from a highly selected 
group. The effects of low numbers of samples are already 
being felt in the trials world. In anticipation of poor rates, 
there is likely to be a shift towards simply not including 
pathology studies in RCTs. 
Conclusions 
There arc two separate impulses at work here: to tell and not 
to tell, both based on the desire to protect parents and to case 
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a professional situation. This reflects an uneasy climate In 
which the tensions between the expectations of the trials 
community and the everyday practicalitics of caring for 
families have not always been fully worked through. If 
professionals arc uncomfortable, it Is likely that parents will 
also be. It is therefore important that those involved In 
neonatal RCTs find a clearer way through the situation which 
is feasible for clinicians and not to the detriment of 
vulnerable parents. 
To date this Is the only study reporting on attitudes to RCT 
related FbAs. There arc, however, limitations to this study. 
The fact that views on the subject of PMs were collected as an 
adjunct to the larger topic of the professional experiences of 
recruitment to RCTs means that the study was not set up 
primarily to explore these issues. It is most important that the 
concerns doctors and parents should receive further atten- 
tion, through discussion by the wider research community 
and through dedicated research. Research should document 
the consent process and clarify the effect of the difficulties 
described here. It should assess the steps taken to protect 
these parties from problems over consent, and most 
spcciricaUy should examine the usefulness and impact of 
particular consent forms. It should assess whether profes- 
sionals might benefit from training In the skills that go along 
with helping parents to come to their decisions. Quite clearly, 
all parties require a degree of support. Research is needed to 
decide what that support ought to be. 
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Background: Interviews with neonatologists in a related study had revealed a degree oF discomfort with 
cpproaching bereaved parents For postmortem examinations (PMs) and a Videspread concern that 
parents should not be further distressed or feel under pressure to consent. 
Objective: To report the attitudes of bereaved parents to trial related perinotal PMs, in the light of declining 
perinotal PM rates and poor levels oF participation in pathology studies. 
Methods: A alitotive study was carried out, using sernistructured interviews. The study involved II 
interviews wiltu 18 bereaved parents From five UK neonatal units. The parents had consented to the 
enrolment of their baby in one of two neonatal trials. 
Results: The data rovide support for the careful approach described by neonatologists in a related study, 
but also suggest 
Zt 
it may be possible to approach more parents without undermining their wellbeing. 
The interviews show the variety oFreactions to. PMs that one would. expýct, From pgrents. who were clear 
that they did not went a PM to others who Felt that they needed the information [rom the examination. 
Between these extremes were parents who were initially discomforted by the idea but who then made the 
decision to go ahead. Parents who elected to have a PM did so For their own needs, or to contribute to a 
t6ol, or for both reasons. The Fact that the subject was raised was generally not seen as inappropriate, and 
none stated that they Felt that they were actually pressured into making their decision. The data also 
suggest that For some parents the degree of caution end selectivity exercised by the neonatologists may not 
be entirely appropriate. in two cases, consent for the PM was cleiven by a sense of making an altruistic 
contribution to research, and, in another two, altruism was expressed in the context of their own desire for 
information from a PM. 
Conclusions: it is important to determine whether trial related pathology studies are considered by 
professionals and loy people to be worth while and Feasi6le. If there is support For such studies, the 
....................... challenge is to 
develop the means to approach more parents in the most sensitive way. 
na review of the literature' and through a qualitative 
study of the views of pathologists and neonatologists. ' 
we have examined issues raised by neonatal post- 
mortem examinations (P1Ms) conducted for research pur- 
poses. We conclude that little is known about the impact 
on parents of requesting a PANI on an Infant who has 
been enrolled in a clinical trial. Although there Is some 
evidence that contributing to research is important to some 
parents' I and to other bereaved relatives, " the effect of the 
request to make such a contribution has not previously been 
explored. 
our research with professionals showed that some 
neonatologists were uncomfortable about approaching 
bereaved parents for P, %Is because of their concern that 
parents should not be further distressed or feel under 
pressure to consent. Others have shown that families can 
experience diýtress if communication is poor' or may be 
less likely to agree to a PNI If an approach is perceived as 
insensitive. ' Two important obstacles that also emerged- 
that is, devaluation of PNis among younger staff, and 
the feeling that P, 'As may be unnecessary in certain cases 
(known cause of death, prematurity)-havc also been high- 
lighted In the wider literature. ' 6'A most important factor 
that has not previously been described was a sense of 
disconnection between trial intcrventions and pathology 
studies. 
We wished to learn whether the concerns expressed by the 
neonatologists are reflected in the parental accounts. We 
used the opportunities afforded by a related study to explore 
parents' views. 
www. archdischild. com 
METHODS 
The research was carried out with bereaved parents of babies 
who were carolled in one of two neonatal trials at one of five 
ccntres. The trials were the INNOVO trial (which compared 
giving Inhaled nitric oxide to babies with severe respiratory 
failure with the usual ventilatory care (ww%v. innovo. trial. 
org. uk)) and the CANDA trial (which compared two sur. 
factants for preterm babies). ' The professionals Interviewed 
in the linked study' were associated with the same two trials. 
Approval was obtained from all relevant ethics committees. 
Almost half of the babies recruited to the INNOVO trial 
died, and there was a low PIM rate. In the trial, 90/168 babies 
died and 27 Pryis were carried out (34%). More PlMs were 
carried out for term than for pretcrm babies (67% v 26%). In 
the INNOVO ccntrcs linked to this qualitative study. 48/84 
babies died and 16 (33%) PMs were carried out. For the 
CANDA trial nearly a quarter of the babies died (451199) and 
17 underwent a PM (45%). In the CANDA centres In the 
qualitative study, 38/159 died and 16 underwcnt a PM (42%). 
Contact with the parents was negotiated by the local 
hospital consultant, who would approach them either at a 
bereavement visit or by letter or telephone to ask If the 
researcher could write to them about the qualitative study. 
Access to bereaved parents In fact proved to be very difficult. 
Permission to approach parents was withheld at one of the 
largest study centrcs, and many cases in which consultants 
had concerns over parental wcIlbelng were excluded. 
Twenty one letters were sent to parents (16 INNOVO and 5 
CANDA). No remindcr letters were sent, at the request of the 
research ethics committees. Eleven Interviews were carried 
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out, by CS (8). MM (2). and DE (1). The interviews took 
place In the parental home and were tape recorded and fully 
transcribed, with the exception of one, which was corrupted. 
The loss of data from this one tape left 10 interviews (seven 
INNOVO and three CANDA) with 16 parents of 12 babies 
who had died. The transcripts were analysed by identifying 
and grouping emerging themes until no new issues were 
raised. This process was assisted by a textual analysis 
computer package, Atlas-ti. ' One of us, CS, was primarily 
responsible for the analysis, but DE and JG also read all the 
transcripts and agreed the analysis. 
VIEWS OF THE BEREAVED PARENTS 
in four cases, the parents had decided that they did not want 
any further examinations for their babies. In five cases, the 
parents agreed to a PM. The information is not available for 
two cases. 
Themes that emerged from the interviews Included the 
parents' reactions to the offer of a PIM (in particular whether 
or not they felt pressured In the discussion), whether they 
articulated any sense of connection between the trial and a 
PM, and the value attached to the information derived. 
Reaction to the offer of a PM 
There were no particularly negative accounts from -the 
parents of their discussions with neonatologists. There was 
only one case in wl-dch parents specifically stated that they 
refused because of the organ retention controversies. ' 2 
A mother of twins cnroUcd in the INNOVO trial described a 
feeling of pressure. She felt it was thought to be clear why her 
babies had died, but that there was some doubt about one 
particular aspect of their case. They were left to think the 
issue over, and their doctor telephoned them at home for 
their decision. The mother reported that he specifically said 
that he did not wish to pressure them, but she commented: 
I must admit I didn't feet comFortable saying no to him. I 
remember thinking at the time that-I don't know iF it was 
his monner-6ut I just Felt like a postmortem would be 
more For him than it would be For us, and I just wasn't 
prepared to do it. 
She found the Idea of a PIM very difficult, even though 
there was the possibility that It would provide them with 
useful information. She told her partner "I just caWt". on the 
grounds that their babies were "Uke dolls". 
The desire not to pressurlse can result In very limited 
discussions, leaving parents feeling that PMs are Irrelevant in 
their case. One father stated that during their discussion of 
the possibility of a PM, there was no mention of previous 
participation in the INNOVO trial, and that In fact they were 
encouraged to view a PINA as unnecessary by their consultant. 
[A postmortem) was brought up as on option and I think 
(the doctor], without wishing to put words in our mouths 
said, you know as For as they could see (he] was born 
premature and there was nothing really wrong with him ... Maybe he was hinting that they wouldn't actually And 
anything out that they didn't really already know and 
really that [was] coupled with the fact [that] he'd had more 
than enough done to him. 
These parents felt that they were being spared the stress of 
deciding about a PINA. They said that they appreciated being 
guided by a caring neonatologist who had eased the situation 
for them. The mother commented that they "didn't feel 
pressurcd at all either way. " 
F209 
Connection to the trial 
Four of the couples had made a connection between the 
trial and a PM. One couple sought out a PM, raising the 
subject with their doctor. This was part of a strong desire 
to understand their baby's death and to make sense of 
events. They wanted to know whether Inclusion in the trial 
could have contributed to the death, and felt that the 
results were reassuring. The generation of valuable Informa. 
tion, from a PM was an important coping strategy for both 
parents. 
Irs getting the positive From 16e negative because a 6abys 
death becomes a very negative thing. ... When irs a prem baby, they don't make a noise, they don't open their eyes, 
so you never see the colour oF their eyes. The only thing 
you've got is that touch ... The only events that you 
remember ore painFul events so thars why ... you have to 
start getting positives. And the positive for us was that, 
number one we may have got on answer, but number two 
somebody else may gain From that. 
Another couple whose baby was enrolled in the INNOVO 
trial also articulated altruistic feelings, spccif ically in terms of 
the trial. The mother had initially felt very uncomfortable 
with a PM, whereas her partner was prepared to go ahead. 
She changed her mind as she came to feel that there would 
be certain benefits from the Information, In clarifying the 
cause of death for themselves, and as a contribution for 
others. 
[We] agreed ... 
because even though it [nitric oxide] didn't work For us, iF they could get anything From it that 
would help other people then it was worth it ... 
The father explained how they came to view the PM. 
(We 61t that) he's had this trial and they might as well get 
what information they can o6out it. You know at least he hadn't gone to waste then. 
Parents of two babies appeared to have consented to a PM 
on purely altruistic grounds. One mother consented and said 
In the interview, "if Wit help somebody else later on then I'm 
fine. " Her partner, however, subsequently refused, and the 
FM did not take place. Another mother of a baby enrolled In 
the INNOV0 trial specifically discussed the value of a PM for 
research purposes. Although her Initial reaction was to 
refuse, after a further discussion with her baby's consultant 
In which she was told that the examination would bc useful 
for research purposes, she agreed. She stated that she did not 
feel under pressure. 
(He] asked iF they could do an autopsy and I said no, and 
then he says "well she's been on a trial and it would helpý'. I says "well if irs going to help another baby ... yeah, you can do it". He says 'we're just going to take part 
of her lung away, just to see what it was" and I said "Okay then. " 
Thereafter her story involves the type of experiences which 
can, understandably, make neonatologists nervous of 
approaching parents. She had wanted to bring her baby 
home before the funeral but had a five day delay because of 
the PM. After three days she caUcd her doctor. saying "I'm 
[doing] this as a favour to you, but I want her home". When 
the baby was returned to her she was distressed when she 
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examined her baby's body, as she had. not expected to see an 
incision In the head. 
rd dressed her [in a] little dress and a hot [but] they put 
her hot on back to Front, the wrong way so I took [it] og 
and they'd gone into her head and I didn't know. And it 
was just horrible. ... I'm cn2oy! 
l that they didn't say that 
they were going to go in. I didn t know you know and I did 
say to [the doctor] when I went back in,... whenyousoy 
they're gonna have an outopZ,, I think you should tell them 
that , to go into eir head" I says "because 
t, 
ru re going I 
a as stayed Vith me and thars a sight that will never 
ever leave me". 
Clearly she was unprepared for such a disturbing sight, and 
for her there was a sense that something quite Inexplicable 
had happened. She could see no reason why it would have 
been necessary to have carried out an examination of the 
brain. Whether or not she was told at the time that she gave 
her consent of the various elements of the PM cannot be 
determined. What is clear Is that she did not feel that she had 
been told of this detail and was subsequently confronted with 
the reality of a PM In a shocking and brutal way. She was 
asked in the interview if it might have helped to have written 
information about what was going to happen, and she felt 
that it would. Despite this experience, she spoke very 
positively of the doctor involved, saying "I got on really well 
with him" 
DISCUSSION 
it has been argued that, in a context of stress, desperation, 
and vulnerability, parents of babies in neonatal care will give 
consent "to do almost anything to their baby". '* and that 
consent in certain neonatal trial settings Is "an elaborate 
ritual"" or "a sham". " There is also empirical evidence that 
neonatal trials may have higher rates of consent than trials In 
other settings: Campbell et al" found that, in a sample of 
trials, 96% of neonatal trials reported 100% consent rates, 
compared with 68% of general paediatric trials. Whereas few 
decline to participate in neonatal trials, the numbers agreeing 
to trial related PMs for neonates are, in contrast, very low. 
The two consent encounters are in theory linked, taking 
place at different points In a linear process and Involving the 
same parties. The circumstances are, however, clearly 
different and in practice have become rather disconnected. 
At consent for recruitment to a trial, the fact that the offer of 
enrolment Is often In the context of trying to save the life or 
Improve the condition of a very sick baby is likely to motivate 
professionals to offer enrolment and parents to consent. At 
the second point, the death of the baby Is uppermost in the 
minds of all concerned, and there is nothing more that can be 
done to benefit that child. The sense of striving for a solution 
is replaced by the need to deal with the emotional sequelac of 
bereavement, and any further requests can be seen as 
inappropriate. In cases when parents are grief stricken or 
even angry, engagement with discussion of the benefits of 
PMs for others is highly unlikely. This broad division of 
circumstances can mean that, as shown by our study of the 
views of neonatologists, ' doctors who arc willing to recruit to 
trials can be reluctant to go on to recruit into trial related 
pathology studies, for fear of making seemingly inappropriate 
and Insensitive requests. 
The data from this small study of the views of bereaved 
parents provide support for this careful approach, but also 
suggest that it may be possible to approach more parents 
without undermining their wellbeing. The parents who were 
Interviewed show the variety of reactions to PINIs that one 
would expect, from those who were clear that they did not 
www. archdischild. com 
want a PM to others who felt that they needed the 
information from the examination. Between these extremes 
were parents who were initially discomforted by the Idea but 
who then made the decision to go ahead. Parents who elected 
to have a PM did so for their own needs, or to contribute to a 
trial, or for both reasons. it is reassuring that the fact that the 
subject was raised was generally not seen as inappropriate, 
and none stated that they felt that they were actually 
pressured into making their decision. 
The data also suggest that, for some parents, the degree of 
caution and selectivity exercised by the neonatologists may 
not be entirely appropriate. In two cases, consent for the PM 
was driven by a sense of making an altruistic contribution to 
research, and, in another two, altruism was expressed in the 
context of their own desire for Information from a PM. 
Although these parents are not necessarily typical, their views 
may be shared, but in a more private way, by other parents 
who arc not always given the option of a PM. if bereaved 
parents are not given information about the value of PM 
samples, even those from a limited PW they may be denied 
the chance to make their own decisions about contributing to 
research. This type of research may In fact be appreciated by 
some parcnts who have been deeply affected by neonatal 
loss. " From our interviews with many parents who have been 
involved in neonatal trials, '" It seems that neonatal research 
is often highly valued. They can be keen to make some 
contribution and often express this when interviewed. 
Whethcr or not this can be said to extend to the larger group 
of bereaved parents, and would be applied to pathology 
studies, cannot as yet be answered. It would seem, however, 
that there Is evidence in the literature" " and In our small 
study, that some may support the idea of contributing to 
research through a PM. The specific context of a trial may 
make their contribution more concrete than an abstract 
notion that a PM may contribute to knowledge in some 
general way. We would suggest, although it Is conjecture, 
that a positive sense that babies of the future may benefit 
from this decision may be important to such parents in the 
longer term. Undoubtedly. however, there are parents who 
would find the request very difficult. The difficulty for 
neonatologists is working out who will be receptive and who 
will be disturbed, a mincrield they tread with understandable 
caution. 
Conclusions 
It is Important that the trials community explores this issue 
further to determine whether or not trial related pathology 
studies arc considered by professionals and by lay people to 
be worth while and feasible. If there is support for such 
studies, the challenge is to develop the means to approach 
more parents In the most sensitive way. 
There arc Important limitations to this very small study. 
PMs for trial purposes were not the focus of the interviews. 
As the data are incidental they do not provide a full 
description of experiences of and reactions to the consent 
process. We would suggest that a larger study dedicated to 
researching the issues raised here is appropriate and timely. 
The practical and methodological problems associated with 
such a study should not be underestimated. Access to 
bereaved parents is difficult, as clinicians and ethics 
committees wish to protect the families under their jurisdic- 
tion. Access here was negotiated by consultants, and It Is 
likely that this acts as a filter. Consultants wcrc very 
protcctive and were less likely to allow those who had been 
particularly distressed to be approached about participation 
in research that would explore their distressing experiences. 
Inevitably, interviews do raise some difficulties for parcnts In 
drawing on a traumatic time, but we found the parents to be 
thoughtful and often keen to be heard. They constitute a 
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group with a considerable personal kiVestment in develop- 
mcnts in neonatal intensive care. Their opinions should be 
sought on the best ways to protect parents with similar 
experiences to their own. 
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CLINICAL ETHICS 
TRIALS 
Clinicol Triols 2004; 1: 170 -178 
Equipoise: a case study of the views of clinicians 
involved in two neonatal trials 
jo Garcia', Diana Elbourne and Claire Snowdon a, b 
Background It is considered to be a fundamental ethical premise of human 
experimentation, that it should be carried out only where the effects of an 
intervention are unclear. The point at which it is considered that there Is insufficient 
scientific and medical evidence to clearly state the superiority of an intervention has 
been termed equipoise. This concept has been the subject of much recent 
impassioned debate but little empirical research about the views of people involved 
in recruitment to randomized controlled trials (RCTs), and none in the particularly 
emotive area of neonatal intensive care. 
Methods Thirty neonatologists recruiting into one or both of two neonatal RCTs in 
five centres In England were interviewed using a semi-structured schedule to explore 
their involvement in randomised trials. The interviews were tape-recorded and 
transcribed. Equipoise was one among a range of topics covered. Concepts relating 
to equipoise were identified by close reading of the entire Interviews. Themes 
emerging from the data were noted in their contexts then discussed between the co- 
authors. Interviewees also completed a brief questionnaire about their demographic 
background, and their experience of research and RCTs. 
Results Almost all the neonatologists used the concept of equipoise [using words and 
phrases such as uncertainty, lack of knowledge (or ignorance), strengths of views, 
and balancing of pros and cons] In their interview and, for most of them, equipoise 
seemed to be a useful term. They explored ideas about equipoise at the individual 
and community levels, and some linked equipoise with notions of the responsibility 
that should be exercised by the scientific and professional communities. They 
differed In the Importance they gave to individual equipoise, and in how they 
reacted to threats to equipoise. Feelings of doubt about a trial and disturbed 
equipoise were more often expressed by more junior doctors. 
Conclusions Our findings suggest that the concept of equipoise goes beyond the 
idea of uncertainty. In part this is because it includes the balancing of benefit and 
harm; this balancing is part of a professional obligation and requires engagement 
with 'expert' knowledge. Equipoise could therefore be seen as 'active' or 
'responsible' uncertainty. Elucidation of this difficult concept may help to facilitate 
recruitment for both clinicians and parents in future trials and thereby help to 
find answers to important clinical questions. Clinical Trials 2004; 1: 170-178. 
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are unclear. The point at which It is considered that 
there is insufficient scientific evidence to clearly 
state the superiority of an Intervention, has been 
termed equipoise [1,2]. The aim of a trial is to shift 
the balance of evidence in one direction or the 
other. 
A frequently discussed Issue is that of individual 
versus collective equipoise. Whilst a trial may be 
initiated after collaborators agree that equipoise 
exists, individuals may carry personal convictions as 
to the best treatment, based upon clinical experi- 
ence, a hunch or existing data [3]. if a physician feels 
that a particular treatment would be beneficial to a 
patient, whatever the basis, they are not personally 
in a state of equipoise. According to the Hippocratic 
Oath a physician must do no harm. Zaiicek [4] states 
that offering the possibility of a treatment the 
physician feels is inferior breaches that oath. 
Bradford Hill [51 argued that whatever the impll- 
cations for a trial, the physician with a treatment 
preference Is obliged to give that treatment. In 
contrast, Freedman [6] suggests that focussing on 
personal beliefs is inappropriate and the concept of 
individual equipoise Is faulty. He states that "clinical 
equipoise", that is, the collective uncertainty of the 
medical community, is more relevant. Under this 
concept, a clinician with a preference may recruit 
patients to a trial of a treatment about which there is 
no consensus in the medical community without 
violating an ethical principle. 
The concept of collective rather than Individual 
equipoise has had a mixed reception. Hellman and 
Hellman [7] do not accept that the general view of 
the medical profession is relevant, arguing that each 
patient has a right to their physician's opinion. In 
an argument which Includes preferences alongside 
the issues of beliefs about safety and efficacy, 
Appelbaum et al. [8] suggest that it Is unlikely that 
a clinician would have no suspicion as to which of 
several treatments may suit the physical or 
emotional needs of a particular patient. Similarly 
Kodish et al. [91 argue that physicians are trained to 
rely on rather than suspend their professional 
judgement. They focus on the individual doctor- 
patient exchange, taking the preferences of each 
party into account, stating that RCT recruitment is 
only ethical If a physician "cannot judge which arm 
of a protocol is preferable for a particular patient" 
and randomization should not be used "when 
patient preferences for one treatment or another 
can be elicited". Although the Issue of patient 
equipoise Is rarely addressed [10], public perceptions 
of the efficacy of an Intervention can exert a 
powerful influence on trial recruitment. For 
example, when media reports convinced patients 
of the superiority of laparoscopic removal of the 
gallbladder, two trials [11,12] were hampered by 
poor recruitment [13]. 
Defining when equipoise exists raises further 
difficulties. StarzI [14] and Berry [15] voiced 
concerns that specific trials were carried out when 
there was already sufficient evidence from earlier 
research to indicate the superiority of a treatment. 
They disagreed that equipoise existed and felt It was 
indefensible to withhold the experimental treat- 
ment from the control groups of patients. 
Equipoise can also change in the course of a trial 
due to the growth of knowledge over time [3]. As 
more patients are randomized, data accumulate and 
physicians grow In experience. If the treatment 
allocation is not concealed, they may see treatment 
succeed or fall In one arm of a trial [161. One 
difficulty lies in the Issue of access to Interim data. It 
is generally agreed that trials should continue until 
there are sufficient data to answer the research 
question posed. Before a statistically significant 
difference between groups can be observed, a trend 
may emerge in one direction. Lantos [17] argues 
that this raises particular difficulties and that 
physicians should have access to interim data in 
order to make better choices for their patients. 
Interim data can, however, be misleading and hence 
are usually released only to an Independent data 
monitoring committee [18]. Whilst this provides 
clear boundaries around the data, It does not address 
the Individual difficulties which may be experienced 
by clinicians whose equipoise is disturbed during a 
trial [7]. 
Authors also differ In whether they see "equi- 
poise" and "uncertainty" as being Interchangeable 
terms [19]. These concepts have been central to 
discussions about the feasibility of, ethical basis of, 
and necessity for, RCTs. They have been the subject 
of much recent debate [10,20-25], as correspon- 
dents try to pin down the precise meanings of these' 
subjective and Inconstant concepts. Discussions 
revolve around exactly what uncertainty and 
equipoise are, who is uncertain or in equipoise and 
under what conditions are these states maintained. 
Clearly these issues raise an Inherent difficulty in 
RCTs; equipoise and uncertainty provide the ethical 
foundations for a trial, but are also shifting concepts 
and a source of dispute. 
If we are to be able use RCTs to answer important 
health care questions, we need to explore these 
concepts from the perceptions of the people directly 
Involved - especially patients and their families, 
and professional caregivers Involved In RCTs. 
Previous empirical work on the views of health 
professionals in oncology, ophthalmology and 
general practice about clinical uncertainty and 
equipoise has been very limited [26-30], but 
suggests that one barrier to recruitment to RCTs Is 
discomfort with having to admit to uncertainty. 
The circumstances In which equipoise or 
uncertainty are discussed are likely to affect the 
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attitudes of clinicians. Where patients are vulner- 
able, for Instance, having received the news of a 
life threatening Illness, the news that the most 
appropriate form of treatment is not known can be 
particularly difficult to give [27,31,32]. No empi- 
rical studies have been conducted in the particu- 
larly emotive area of neonatal intensive care. This 
setting may raise further difficulties as consent 
needs to be requested, often In times of great stress, 
from one vulnerable person (a parent) for another 
(a child). We have previously conducted qualitative 
studies [33-36] in the neonatal field which 
considered randomization from the perspective of 
parents of babies In the UK ECMO trial [37]. The 
present paper extends this work by focusing on 
equipoise and uncertainty in the context of 
randomization from the perspective of neonatolo- 
gists who had been recruited to this interview study 
because of their involvement in two neonatal RCTs 
(INNOVO and CANDA - see below). They had been 
Interviewed as part of a larger study of parents and 
clinicians about RCTs in the perinatal period. 
Methods 
The clinicians whose views are reported in this study 
had been Involved In one or both of two neonatal 
trials. The INNOVO Trial (www. innovo-trial. org. uk) 
compared giving inhaled nitric oxide via a venti- 
lator versus standard ventilator care to babies in two 
gestational age groups: term or near term, and 
preterm. The CANDA Trial [38] compared two 
surfactants for preterm babies. Research Ethics 
Committee (REC) approval for the study reported 
here was given by the North Thames multicentre 
REC and by appropriate local RECs to work in 
five centres In England. One centre recruited to the 
INNOVO Trial only, one to the CANDA Trial only 
and three recruited to both trials. The interviews 
with neonatologists were part of a wider study that 
also included the views of parents. Clinicians were 
identified over the course of the study and Inter. 
views arranged at times convenient to them and to 
fit In with the rest of the work. 
We aimed to interview 30 doctors who had 
recruited at least one baby to the INXNOVO or 
CANDA Trials. In order to achieve this sample, we 
approached 31 doctors, either In person, by letter or 
by e-mail. Only one declined to be interviewed. 
Interviews took place between February 1999 and 
November 2001. All Interviews were carried out by 
one of the authors (CS) usually at the doctor's 
place of work, either in their own office or in a 
private room. One took place in a communal room 
at the suggestion of the doctor, and one was a 
telephone interview to the doctor's own home. The 
interviews were tape recorded and fully transcribed 
Clinical Trials 2004; 1: 170-178 
and usually took around an hour. They were 
semi-structured with a high degree of flexibility as 
areas of Interest to participants and particularly 
interesting lines of thought were explored. A topic 
guide was used to make sure that key Issues were 
covered. 
The Interview explored the views and experiences 
of the doctors about their Involvement in random- 
ized controlled trials in general and INNOVO and 
CANDA in particular. They were asked about their 
clinical and research roles, about training for 
research and support from senior staff (if appli- 
cable), and about communication with parents and 
colleagues. A number of specific topics were also 
raised In the course of the interview including, for 
Instance, post-mortems in the context of an RCT 
[39-41]. The topic of equipoise was only one of 
many issues discussed. In the interview the term 
"equipoise" was introduced with a question In 
which it was used without an explanation, for 
instance: "Do you talk [to parents, when explaining 
a trial] about the Idea of equipoise? " Most Interviews 
proceeded like this but In a few cases the question 
was not put in this way if, for instance, the topic was 
raised spontaneously by the neonatologist earlier In 
the interview, or the person's limited level of know- 
ledge was clearly such that it was not appropriate 
to ask it like this. If the Interviewer was asked for 
clarification about the word by a respondent who 
did not recognize It, a typical explanation was 
that equipoise Is when "the Information about the 
treatments Is equally balanced, so that It's not 
possible to say one way or another which treatment 
would be the best". 
Demographic data were collected by a brief 
questionnaire left with the doctor after the Inter- 
view. The respondent's experience of RCTs was 
assessed from the information given In the Inter- 
view. The analysis for this paper was done by one 
author UG) with Input from the coauthors In 
clarifying themes and subthemes. The aim was 
not, at first, to focus on equipoise but to look at the 
interviews as a whole to see what themes emerged. 
However JG, on reading all the transcripts, found 
that equipoise emerged as an Important Issue. The 
next step was to go back and identify key Ideas that 
were judged to be about equipoise and to find all 
relevant examples from the transcripts. Although 
no qualitative analysis package was used, all the 
transcripts were examined In detail and themes and 
sub-themes emerging from the data were noted In 
their contexts. At this stage ideas were shared with 
the other authors who also read the transcripts and 
commented on these themes. In addition, data from 
the Interviews were tabulated by hand byJG in order 
to describe some of the key characteristics of the 
interviewees including their research background, 
experience of RCTs, views about training and 
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education and use of the word equipoise in the examples of the ways that equipoise was expressed. 
interview. First, uncertainty: 
Results 
The average age of the 30 participating neonatolo- 
gists was 36 years (range 27-54), 25 were hospital 
employees and five employed by a university, and 
25 were male. They varied In their level of clinical 
experience and current responsibility. Eleven were 
consultants with many years of experience. All the 
Interviewees had been approached because they 
were recorded as having recruited to either INNOVO 
or CANDA but they had not all had the same level 
of Involvement in randomized trials. Thirteen had 
extensive experience and had been recruiting to 
trials for many years or bad run their own trials. In 
contrast, two interviewees had very little experi- 
ence, perhaps having recruited one or two babies to 
one of the trials. Respondents who had experience 
with trials other than INNOVO or CANDA drew on 
that entire range of experience. 
Use of the term "equipoise" 
Of the thirty interviewees, nine used the word 
spontaneously before it was mentioned, nine under- 
stood it when it was raised, eleven did not know the 
word and in one interview it does not seem to have 
been addressed. It was striking that almost all 
the interviewees, even those who did not recognize 
the word, discussed the key ideas that make up the 
notion of equipoise, though they used different 
language to express it. Three respondents who did 
not were among those who did not recognize the 
word when It was raised in the Interview; two of 
them were classified as having had limited experi- 
ence of RCTs and one as having "some" experience. 
Ways of talking about equipoise 
We judged that there were four words or phrases 
which respondents used to reflect the linked ideas 
that made up their notions of equipoise about the 
Interventions: uncertainty, lack of knowledge (or 
ignorance); the strengths of their views; and the 
balancing of pros and cons. These ideas came from 
sections of the interviews where we had judged that 
equipoise was being discussed or explained by the 
respondents even if they did not use the word; they 
sometimes used more than one of these words or 
phrases when talking about equipoise, even within 
the same section of the interview. They discussed 
equipoise when talking about their own experiences 
of Involvement In RCTs and also when telling us 
how they explained RCTs to parents. Here are some 
... for a trial to be ethical you have got to have 
sufficient uncertainty to make the two approaches, 
or an approach and a placebo, of equal uncertainty. 
... if we believed that the evidence was strong 
enough then we wouldn't be asking for con- 
sent ... we'd be treating [with nitric oxide], but at the moment It's still uncertain. 
It was relatively unusual for the word "uncertainty? 
to be used. More often the respondents used 
ignorance or lack of knowledge: 
I mean the reason we're doing trials Is because we 
don't know the answer to the question... 
[in explaining a trial we would say] ... we genuinely do not know the best thing to do. This is a situation 
where we're at the cutting edge of progress and we 
don't know the best way forward. 
One of the most common ways of expressing 
equipoise in this group of clinicians was to refer to 
the strength of a person's view. Equipoise existed 
where strong views about the treatments were 
absent: 
... like I said I haven't had any strong views about 
whether it [nitric oxide] worked or not. 
... so I know that this (involvement In trials) Is the 
right thing to do, however, at the same time I have 
to be certain in my mind that the treatment that 
you are going to give the baby Is not detrimental. If 
I'm convinced that It is a detrimental treatment 
then I think I would rather be out of the trial, and If 
also I know .. - I'm convinced that It Is a better treatment, I think that is again a very unfair 
situation to be submitting parents to randomize. 
... for example some people thought ECM0 was the 
greatest thing since sliced bread and so they thought 
what's the point of doing a trial ... when you may be denying the baby a potentially life saving pro- 
cedure. Equally other people felt that ECMO was the 
worst thing you could ever do to a child, that It was 
totally Inappropriate and they would never recruit 
to a trial so there's two extremes. 
The Idea of balance was expressed by several 
respondents: 
... I don't think we know ... there are potential toxicities, very real toxicities associated with it, so 
there is this balance of... benefit and harm... 
... when it came to the surfactant question that 
we were talking about, it was relatively easy to 
say: "... we think we know that animal derived 
surfactants work faster than the chemically... " but 
there's still the problem that that carries, on the 
animal product side, which presumably is not on 
the other. So one can Illustrate the uncertainties; it 
doesn't necessarily have to be a global uncertainty, 
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this one's better than that one. we know that 
the risks with this one are this and with that one are 
that, and we don't know overall which makes the 
most difference. 
This next comment includes two of the ideas - lack 
of knowledge and the balance of advantage and 
disadvantage: 
The next sort of thing I would emphasize Is that we 
don't know which approach is better... And so I'd 
talk around the pros and cons of both arms and 
I think it's a bit nalive to just say: "We don't know' 
which Is better". I think it is probably better to go 
into the disadvantages of either... 
This respondent was talking about how he would 
explain the trial to parents. Other words used by 
respondents to describe how they would convey 
their equipoise to parents included neutrality, 
unbiased and balanced. 
Different levels of equipoise 
Because there has been discussion for some time 
among clinicians and trialists about the relationship 
between equipoise at an Individual and wider level 
we looked for this theme in the data, and In some 
interviews respondents were asked about It expli- 
citly. Some recognized the different levels at which 
judgements could be made about a trial but 
expressed the view that they would not be able to 
take part If not individually In equipoise. 
I think if you're having an Intellectual contribution 
to a trial, then I couldn't be involved in that 
intellectually, unless I was in Individual equipoise. 
So if I was on the XX Trial Steering Committee and 
I actually believe that XX Is the best thing since 
sliced bread, I couldn't ... I couldn't put that on one 
side for the greater good. I just couldn't be involved 
in that, so individual equipoise is very important 
there. 
... but If I'm in a trial where I've actually got to get 
consent, I've got to be in a position to actually get 
that across to the families. And if I can't do that, 
then I'm actually not much use, I don't think. 
Because if I'm there... you know, putting my doubts 
on to them, then I think that's wrong. 
In addition to this moral obligation to be in 
equipoise as an individual, some respondents also 
said that they would not -be able to recruit parents 
effectively If they had doubts: 
... certainly the babies that I recruited, when I was 
recruiting, I had no preferences whether the baby 
was in or not. I think that probably makes quite a lot 
of difference because ... if it's obvious that you think the medicine's fantastic then I think the parents will 
pick up on that. 
Clinical Trials 2004; 1: 170-178 
Some of the respondents who were more senior and 
experienced in RCTs discussed different levels at 
which equipoise might function. 
... for example, I might have quite a bit of experi- 
ence to say that (drug X) works better than (drug Y) 
or that (drug Y) works better than (drug X) ... I also have to appreciate that ... the evidence to support that doesn't exist, and therefore even though my 
personal experience might be one thing, I would 
need ... proof of that, and therefore even though my 
personal equipoise might be a bit fudged, a bit 
dodU, then you'd have to go to the community 
equipoise. But basically I think It depends on ... the 
quality of the evidence ... generally speaking if the study Is worth its, you know, tuppence worth, 
then the community equipoise and the personal 
equipoise should be more or less the same. 
In considering what might be meant by collective 
equipoise and how agreement might be obtained, 
one respondent described how recently published 
research results had caused the team at his hospital 
to reassess their collective equipoise and make a 
decision to exclude certain babies from one of the 
trials: 
Well, It's sort of a personal data monitoring 
committee for the unit. That's how we see it. We 
still need to question whether we are giving the 
right treatment package, management package, and 
whether that means randomizing or treating, that's 
important. So it's been a difficult decision and I 
know a lot of other people have come to that 
conclusion a long time ago and have been pointing 
to us and saying, "We told you so some time ago and 
you've taken a year and perhaps not randomized 
some babies In that time". But we felt it was worth 
waiting for the article and doing our own critical 
evaluation of how good that study was. 
This doctor is referring to two levels of collectivity 
beyond the individual: the medical unit and the 
wider clinical and academic community. The doctor 
then goes on to describe the approach taken at that 
unit, which is to decide as a group and avoid 
individual consultants having their own policies 
and approaches to Issues like trials. Another 
consultant described how a similar arrangement 
worked: 
... a study would be unworkable here If all-of us (consultants] did not sign up to it, and for that 
reason alone we would want complete consensus 
between ourselves about that. So It could be that In 
debate someone with an Individual preference 
actually, after the debate, comes into equipoise. 
I've certainly done that when we've had discussions. 
I thought I knew what the answer was. When we get 
Into the stuff I find, well, actually no, no, how 
Interesting. Yeah right, I'm game for this now. 
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Another respondent talks about the level at which 
responsibility exists for evaluating Interventions 
that are in use. 
... you know the question thats faced us is that 
we should have done this study ten years ago 
or ... eight years ago, but... there's a sense of com- munity, you know, medical community culpability, 
or ... reflection rather, and also (... ) some of the consultants have reflected very clearly on: "Well, 
why did we actually stick with (Drug Y) for so long 
without doing a study". Now that isn't just related 
to our unit, that's related to Great Britain. 
So, particularly for the more experienced respon- 
dents, equipoise Is linked to an Intellectual 
responsibility both at the Individual level and as part 
of a wider professional and scientific community. 
Not being In equipoise 
Several of the interviewees described problems with 
equipoise, including recruiting when feeling doubts 
about a trial: 
I think recently, because we've started to lose 
equipoise ... I suppose a couple of babies who've been in the control limb ... I've felt 10h, I wish It was the other group. * but not usually. 
Being, or going out of equipoise Is usually expressed 
In a way that mirrors the main Ideas about equipoise 
described above. So, for example, our respondents 
describe lack of balance about the effects of two 
Interventions, or a growing strength of feeling In 
favour of one treatment. This was sometimes the 
result of new research findings from elsewhere but 
more often was because of clinical Impressions 
which seemed to be accumulating on the side'Of one 
treatment. In some cases, the trial as a whole was 
not undermined but the respondent expressed a 
need to reconsider the Inclusion criteria for the trial 
so as to leave out babies that were felt to be clearly 
likely to benefit from the intervention. 
I would have thought If It was a term baby, a mature 
baby, then this is the sort of baby that at the 
moment we're not absolutely sure we're going to 
carry on randomizing ... because the evidence [about nitric oxide] Is getting stronger and stronger. 
These feelings of not being in equipoise were 
uncomfortable for our respondents; they used 
words like "difficult", "uncomfortable", "struggle". 
The opposite feeling, comfort, was mentioned by 
many when they were talking about being in 
equipoise. Feelings of doubt about a trial and 
disturbed equipoise were more often expressed by 
more junior doctors. Senior doctors are nearly 
always part of the decision to take part In the trial 
and if something happens to disturb their equipoise 
(like the publication of relevant findings) they are 
able to change the unit's approach, or decide to 
withdraw from a trial. More junior doctors are not 
usually involved in the decision to join the trial and 
are less able to shift policy If they feel uncomfor- 
table. Their participation in recruitment is seen by 
them as an expected part of their job and they may 
find it difficult to voice their doubts about a study: 
... obviously when you are In a training regime, obviously you don't want to be upsetting too many 
people ... too many senior people, so the safest thing for me to do is to ask somebody else to do It 
[randomize to a trial that they have doubts about]. 
In some cases they may not feel that they know 
enough about the trial In question: 
... you get thrown in at the deep end. You go Into a job and they say, 'OK, you know, we're involved In 
such and such trials and if you get a patient under 
this many weeks or with such and such ... you need to speak to the parents and get them into the trial 
'cos we need the numbers. " That's how it always 
comes across. 
Finding out about the details of the trials being done 
in a neonatal unit may be difficult, mainly because 
of lack of time. Quite a number of the less experi- 
enced doctors described the feelings of time pressure 
and anxiety that accompanied involvement In 
trials. They wanted support from senior staff and 
opportunities to learn about the technical, ethical 
and human aspects of trials by working with and 
observing more experienced staff. 
Expressing uncertainty when talking to parents 
In order to explain a trial to parents of eligible 
babies, clinicians need to express their uncertainty, 
or lack of knowledge about the treatments. Some of 
our respondents said that they were uncomfortable 
doing this and some thought that parents find it 
difficult to be presented with uncertainty in this 
way. Although not the subject of a specific question 
In the Interview schedule, the issue was raised by 
around a third of the sample. This relatively junior 
respondent said: 
It's difficult, you know. I think as medical prac- 
titioners it's, I think in medical practice we find it 
difficult to ... We have to accept that we don't have all the answers in terms of treatment ... and of course I'm sure that comes as a disappointment to 
the families. 
Another, more experienced respondent said: 
... but when you actually mention this, say, NIVell, In fact you know, we don't really know what's the 
best treatment, N It is a delicate moment. I'm not 
really bothered from how they perceive me, as a 
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person, because you know, there's lots of things I 
don't know In life, but their confidence of how their 
baby's going to be managed, that's the Issue that 
comes up. Again I think It depends you see, because 
it depends on the thing you're studying ... if you 
can say to them that as a clinician you feel both of 
these treatments are the best that's available, then 
in a sense you're offering them either way the 
best treatment, and therefore it's not a problem. 
Several mentioned that in neonatology they worked 
against a background of clinical uncertainty that 
they had to communicate to parents. They recog- 
nized that this is difficult for parents, but being 
honest about that uncertainty was very important if 
you were to be trusted by parents: 
It's about trust, you know. I will trust someone who 
was honest and said he didn't know (more) than 
someone who lied. 
Discussion 
Chalmers [42] states that "all of our interventions in 
people's lives are two-edged swords", with potential 
for benefit counterbalanced by potential for harm. 
Many argue that given this potential for harm, In a 
climate of uncertainty over the potential impact of 
an Intervention, RCTs offer the best option for both 
individuals and society [43-46]. The argument that 
RCTs are a means of "minimizing harm and 
maximizing benefit" (44) has been extended to 
suggest that in such conditions it is unethical not to 
enrol a patient to an appropriate protocol [47]. 
Our qualitative study of doctors who had 
recruited to two neonatal trials adds to the previous 
empirical research about the views of professionals 
in other specialties. We judged that almost all the 
neonatologists used the concept of equipoise in 
their Interview. The ways that they talked about It 
included words and phrases like, uncertain, strength 
of view, don't know the answer, balance, pros and cons. 
We found that the concept of equipoise that they 
are using goes beyond the idea of uncertainty (at 
least as the word is used in common parlance). 
Equipoise could be seen as "active" or "responsible" 
uncertainty. In part this is because it Includes the 
balancing of benefit and harm; this balancing Is part 
of a professional obligation and requires engage- 
ment with "expert" knowledge. The doctors that we 
Interviewed varied In the extent to which they had 
absorbed the language of clinical trials and some of 
the more experienced did use the word equipoise; 
others did not recognize It when It was mentioned. 
There seem to be two main Issues arising in the 
recent debate about equipoise - whether it is a 
useful term at all and whether it can or should refer 
to the individual view of the clinician or the view of 
the wider clinical or scientific community. We 
would argue that for those clinicians In our study 
most involved with the design and running of trials, 
equipoise seemed to be a useful term. They explored 
with us ideas about equipoise at the individual and 
community levels, using the word equipoise In both 
contexts. Community equipoise was linked to the 
responsibility that should be exercised by the 
scientific and professional communities. They 
differed in the importance they gave to individual 
equipoise, and in how they reacted to threats to 
equipoise. 
One reason why it Is difficult to discuss Ideas 
about equipoise is that everyday words are being 
used in the debate In ways that go well beyond their 
normal meaning. Uncertainty can be as simple as 
not being sure what jacket to put on In the morning 
or can be a much more specific term that some 
would rather use Instead of equipoise (e. g., Sackett 
(22]). One argument for using a word like equipoise 
is that it does not have an everyday meaning. In 
previous work [33] we have pointed to the problem 
that can arise when a word like trial has a specific 
meaning for researchers that maybe at odds with the 
common use of the word. So we would suggest that 
using the word equipoise would also be helpful to the 
less experienced among our interviewees to crystal- 
lize the ideas that they used and to give them 
the tools to discuss their role as clinicians involved 
in the challenging business of enrolling patients In 
trials. 
By exploring these Issues with people who have 
actually engaged in the process of recruitment, we 
were able to consider their practical as well as 
theoretical experience. From this sample, we are not 
able to say anything about the views of people who 
did not recruit to the trials. It is possible that their 
views may be different. 
Because of the experiences reported to us by 
some of the more junior doctors we would stress 
the importance of new staff not merely being 
given information about ongoing trials but also 
the opportunity to discuss them and their own 
uncertainties with senior staff. New staff may then 
feel more confident about recruitment and better 
able to raise concerns about a trial. We would also 
recommend that medical training should Involve 
consideration of trials Including ethical and prac- 
tical issues about recruitment and consent. There is 
a growing body of research on communication 
about RCTs to support such training [48,49]. 
Reporting the thoughtfulness and comfort or 
discomfort expressed by the people who are actually 
involved in the recruitment process can elucidate 
these difficult concepts and may thereby help ease 
recruitment for both clinicians and parents. Ideally 
such qualitative work could form an Integral part of 
the pilot stage of trials (48]. The present findings 
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could not provide help for INNOVO and CANDA as 
these trials had already completed recruitment. For 
future trials, the practical effectiveness of building 
these Insights into, for example, patient infor- 
mation letters and accompanying guidance to 
recruiting clinicians, may be tested empirically. 
Those results may help to better recruit both 
participating physicians and patients, and thereby 
find answers to important clinical questions for this 
vulnerable group of patients. 
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ABSTRACT. Background. Although inhaled nitric ox- 
ide 6NO) may be a promising treatment for newborn 
infants with severe respiratory failure, the results from 3 
previous small trials were inconclusive. 
Methods. Infants of <34 weeks' gestation, <23 days 
old, and with severe respiratory failure requiring venti- 
latory support were randomized to receive or not receive 
WO. The study was not blinded. 
Findings. Recruited were 108 infants (55 allocated to 
receive WO and 53 not allocated to receive WO) from 15 
neonatal units in the United Kingdom and Republic of 
Ireland. Fifty-nine percent (64 of 108) died, and 84% of 
the survivors (37 of 44) had signs of some impairment or 
disability, 9 (20%) of them classified as severely disabled. 
There was no evidence of an effect of WO on the primary 
outcomes: death or severe disability at I year corrected 
age (relative risk IRRI: 0.99; 93% confidence interval [CII: 
0.76 to 1.29); death or supplemental oxygen on expected 
date of delivery (RR: 0.84; 95% Cl. 0.68 to 1.02); or death 
or supplemental oxygen at 36 weeks' postmenstrual age 
(RR: 0.98; 95% Cl: 0.87 to 1.12). There was a trend for 
infants allocated to the WO group to spend more time on 
the ventilator (log rank: 3.6), on supplemental oxygen 
(log rank: 1.4), and in hospital Oog rank: 3.5) than those 
allocated to receive no WO. This pattern predominantly 
reflected the infants who died. Mean total costs at I year 
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corrected age were significantly higher in the WO group, 
partly because of the costs of the gas but mainly because 
of the difference in initial hospitalization costs. 
Interpretation. - Evidence of prolongation of intensive 
care and increased costs of such care, without clear ben- 
eficial effects, implies that WO cannot be recommended 
for preterm infants with severe hypoxic respiratory 
failure. Pediatrics 2005; 115.926-936; neojiatal intensive 
care, Wtric oxide, ventilatioti, pretenn infants. 
ABBREVIATIONS. NO, rtitric oxide; iNO, inhaled nitric oxide; 
INNOVO, Neonatal Ventilation With Inhaled Nitric Oxide Versus 
Ventilatory Support Without Inhaled Nitric Oxide for Preterm, 
Infants With Severe Respiratory Failure, 01, oxygenation index; 
Pao,, partial pressure of oxygen, arterial; NHS, National Health 
Service; RR, relative risk; Cl, confidence interval; DNIC, data- 
monitoring committee. 
W hen it became clear in the late 1980s that the 
previously unidentified endothelium-de- 
rived relaxing factor was in fact nitric oxide 
(NO), it offered doctors the opportunity to use, for 
the first time, a selective pulmonary vasodilator in a 
variety of patient groups. In relation to the newborn 
(those with respiratory disease frequently have rela- 
tively high pulmonary artery pressure), this agent 
seemed to offer particular therapeutic opportunities. 
In preterm infants, increased use of surfactant and 
antenatal steroids during the early 1990s altered the 
pattern of preterm lung disease, with fewer infants 
developing severe acute respiratory failure. As a re- 
sult, trials of inhaled NO (iNO) were focused on 
those preterm infants who continued to have major 
respiratory problems despite antenatal steroids and 
surfactant, ie, the sickest and smallest infants. A Co- 
chrane review of iNO studies' includes 3 trials, 2-4 the 
total recruitment of which is 207 preterm infants. 
Since then, another trial has been reported. s The 
earlier studies were each relatively small and are 
hetero-eneous in terms of their cha racte ris tics. These 
individual trials each reported that iNO produced 
statistically significant short-term improvements in 
oxygenation, but none showed a statistically signifi- 
cant impact on any medium- or longer-term outcome 
measure. However, few longer-term follow-up data 
exist for infants after treatment with iNO. 
The other important change in relation to iNO in 
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the last 10 years has been the increase in cost after its 
designation as a "drua, " by the US Food and Drug 0 Administration and the recent granting of a product 
license by the Medicines and Healthcare Products 
Regulatory Agency (United Kingdom). The high cost 
of the intervention means that it is particularly im- 
portant to assess the relative cost-effectiveness of the 
agent before recommending its widespread use. 
AIM 
The aim of the INNOVO (Neonatal Ventilation 
With Lnhaled Nitric Qxide Versus Ventilatory Sup- 
port With. Qut Inhaled Nitric Oxide for Preterm In- 
fants With Severe Respiratory Failure) trial was to 
assess the clinical effectiveness and cost-effectiveness 
of a policy of adding or not adding WO to the 
ventilator gases of neonates with severe respiratory 
failure. Two parallel trials were conducted. This ar- 
ticle focuses on the preterm infants (<34 weeks' ges- 
tation). The results of the trial of term or near-term 
infants entered at ZtM weeks' gestation will be re- 
ported elsewhere. 
METHODS 
Hospitals were eligible to participate if they were accustomed 
to providing long-term ventilatory support for newborn infants, 
had facilities for providing iNO, and had research ethics commit- 
tee approval to participate in the trial. On-site facilities for echo- 
cardiography were recommended so that infants with congenital 
heart disease could be excluded and the presence of pulmonary 
hypertension confirmed. 
Infants of <34 weeks' gestation, aged <23 days, and with 
severe respiratory failure requiring ventilatory support (and hav- 
ing had surfactant when appropriate) were eligible for trial entry 
if the responsible clinician was uncertain about whether an infant 
nalght benefit from NO. Infants were excluded if there was at trial 
entry (1) evidence of an uncorrectable bleeding disorder (defined 
as a platelet count of <50 000 cells per mm" and a Kaolin partial 
thromboplastin time of >72 seconds or international normalized 
ratio of >2), (2) cerebral ultrasound evidence of intraparenchymal 
lesions (Papile grade IV [for full definition, see Appendix 11), or (3) 
a contra ind ica tion to continuation of all intensive care (such as 
severe congenital abnormalities or lethal chromosornal anomaly). 
if an eligible infant met the entry criteria, and the parent(s) 
consented to the infant's participation in the trial, a brief trial entry 
form was completed, and the local neonatologist telephoned the 
central randomization service to check eligibility and record entry 
details. To take account of the treatment balance across prognostic 
factors on an ongoing basis, we used a minimization algorithm 
with a probabilistic element. The infant was randomized to I of 2 
policies: "add NO to ventilatory gases" or "ventilatory support 
without NO. " The minimization categories were: center, postnatal 
age (: r. 3 and 4-28 days); principal diagnosis at trial entry (acute 
preterm lung disease [presenting with lung disease immediately 
after birth and randomized it _-53 days of agel, chronic preterm lung disease [presenting with lung disease immeciiatelyafter birth 
and randomized for continuing problems after 3 days of age], and 
%ther" [in general, these were infants who developed lung dis- 
ease after recovering from an initial respiratory problem]); and 
respiratory disease severity at trial entry based on oxygenation 
indices (01) of <30 and ; -*30; the 01 was calculated from the formula 01 - (mean airway pressure in ci-n H, O X fraction of 
inspired oxygen x 100)/postductat partial pressure of oxygen, 
arterial (Pao, -) 
in mm Hg. 
During the recruitment phase, the British Oxygen Company 
(United Kingdom) paid the cost of the supply of NO. The sug. 
gested starting dose was 5 ppm, doubling to 10 ppm if no satis. 
factory response was achieved; if necessary, the dose was doubled 
again to 20 ppm and then again if required to 40 ppm. A satisfic. 
tory response was defined as an increase in postductal Pa02 of >3 
kPa (22.5 mm Hg) after the first 15 minutes of giving iNO. If, at 
any point after having achieved a satisfactory response, an in. 
crease in dose did not produce further improvement in oxygen- 
ation, then the dose was decreased to the previous level and 
maintained there. A nested, randomized study of doses of 5,10, 
20, and 40 ppm did not find evidence of a dose-response relation- 
ship U. A., unpublished data). Subsequently, to ensure the lowest 
possible effective dose, the concentration was repeatedly reduced 
by -10% every 2 to 3 minutes until a decrease (2-3%) in oxygen 
saturations was noted. WO then was Increased to its previous 
level (reverse dose-response weaning). Infants not showing a Sig- 
nificant acute response were continued on WO at 5 ppm for 12 
hours; if there was still no satisfactory response, then they were 
weaned off of iNO. Infants randomized to the ventilatory support 
without UNO group were not to receive WO at a later stage, le, 
there should be no 'crossover. " From January 1999 to December 
2001, online centers were asked to return a quarterly log recording 
some details of the administration of [NO to infants outside of the 
trial and giving reasons for treatment or nonrecruitment. All other 
care was left to the discretion of the responsible clinician. Neona- 
tologists and parents were not blinded to the group assignments, 
although assessment of outcome was without knowledge of ran- 
domized or actual treatment when possible. 
Outcome was assessed at 2 points: discharge from neonatal 
services (or prior death) and I year corrected age. The primary 
outcomes were death or severe disability (see Appendix I for 
definitions) at I year corrected age (as a composite outcome and 
also separately) and death before discharge from hospital or 
chronic lung disease (being on supplemental oxygen at 36 weeks' 
postmenstrual age and/or on the expected date of delivery). 
Secondary measures of outcome (see Appendix 1 for defini- 
tions) also included (at discharge from neonatal services): length 
of stay In hospital; length of time on supplemental oxygen; len-th 
of time on ventilatory support; pneumothorax; other pulmonary 
air leak; pulmonary hemorrhage; major cerebral abnormality; ne- 
crotizLng enterocolitis; patent ductus arterlosus needing medical 
treatment; treatment of retinopathy of prematurity; infection (sus- 
pected or confirmed on blood culture); and age at which full oral 
feeding was established. Secondary outcomes at 1 year corrected 
age included disability and/or impairment of neurotnotor devel- 
opment, vision and hearing, respiratory problems, seizures, 
growth, 6 and hospital admissions. This information was obtained 
by the local pediatrician who completed a brief questionnaire 
when seeing the child in the routine follow-up clinic. 
Data about health service usage during the first hospital stay 
were collected on the specially developed trial data shects. Infor- 
mition about health and community service usage and costs to 
parents between discharge home and I year corrected age were 
ascertained from a series of cross-sectional questionn aires sent to 
parents at home and mailed at 6 monthly intervals. Some parents 
received only I questionnaire between hospital discharge and I 
year corrected age, and none of the parents received >2 question- 
naires. Unit costs for hospital services were taken from-the Na-- 
tional Health Service (NHS) reference costs databaSL7 and com- 
munity care costs from work by Netten and Curtis. 8 Total costs 
were estimated by valuing each resource-use item by the appro- 
priate unit cost and are reported in 2002-2003 prices. 
The trial size was calculated based on data obtained during a 
pilot phase of the trial. It was estimated that to detect whether WO 
reduced the primary outcome of death or severe disability at 1 
year corrected age from 60% to 40% with an a value of . 05 (2-sided) and 80% power would require a total sample size of 
-200 preterm infants, which would also allow detection of a 
reduction in the short-term outcome of death before discharge or 
chronic lung disease from 751% to 55%. 
Analyses were based on the treatment groups as randomly 
allocatea ("intention to treat"). Comparisons of primary outcomes 
between treatment groups are presented as relative risks (RRs) 
with 951,16 confidence intervals (Cls) and y2 statistical tests for 
binary variables, and f tests and median tests for continuous data, 
as appropriate. Log-rank tests were performed to test comparisons 
between treatments for time-to-event measures of outcome. The 
primary outcome measures were stratified for the major prognos. 
tic variables: principal diagnosis leading to respiratory distress, 
postnatal age, and the severity of respiratory disease it trial entry. 
Homogeneity of RRs between strata was tested (, Mantel-Haenzel 
X2). Data were analyzed by using SAS S. 2.9 
An independent data-monitoring committee (DMQ was estab- 
lished to review confidential interim data and to make recommen. dations to the trial steering committee. There were no formal 
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stopping rules, but the DMC was guided by the Peto-Haybittle 
rule. 10 
The sponsor of the trial, the Medical Research Council, estab- 
lished a trial steering committee of which they were ex officio 
members and also had independent membership to oversee the 
conduct of the trial. 
RESULTS 
Recruitment began in February 1997 and ended as 
planned in December 2001. Neonatologists in 34 hos- 
pitals in the United Kingdom, Ireland, Belgium, 
Spain, and Switzerland agreed to contribute. During 
the pilot phase of the trial, which was intended both 
to assess feasibility and provide data for the estimate 
of trial size, 40 preterm infants were recruited. Be- 
cause there were no major changes to the protocol, 
data from infants recruited in the pilot phase were 
subsumed into the main trial (no results were made 
available to collaborators at that time). The DMC met 
3 times in total but did not recommend either early 
stopping or any additional extension to the recruit- 
ment period. 
A total of 108 infants was recruited (55 allocated to 
receive iNO and 53 controls, allocated to not receive 
WO) from 15 neonatal units in the United Kingdom 
and Republic of Ireland (Fig 1). The formal 1-year 
follow-up assessment was available for all but I of 
the surviving children (in the no-iNO group) who 
was formally assessed as alive and "normal" at 6 
months of age and known to be alive and well at 1 
year. (He was seen by a health visitor at this time but 
did not attend for formal review by the local pedia- 
trician. Sufficient data were available to be sure he 
did not meet the definition of having severe disabil- 
ity). 
Table 1 shows the characteristics of the infants at 
entry to the trial. The infants were on average 27 
completed weeks' gestation at birth and entered with 
acute preterm lung disease as the main diagnosis, 
with a median 01 of 32. All except 2 infants were 
known to have received surfactant. The group allo- 
cated to receive NO were, by chance, of higher birth 
weight and more mature, but otherwise the random- 
ized groups were broadly comparable at trial entry. 
Although most infants received the treatment al- 
located (Table 2), 3 infants in the WO arm did not 
receive WO (because they died before it could be 
administered), and 4 infants in the no-iNO arm re- 
ceived WO (2 because of a clinical decision by the 
local neonatologist, I while the infant was, at one 
stage, in a hospital that was not participating in the 
trial; and 1 for whom no reason was given). All 4 of 
these infants died. On average, infants received NO 
within 1.2 hours of randomization. In the judgment 
of the attending clinicians, most of the infants receiv- 0 
Preterm 
N= 108 
INO 
n= 55 
3 did not 
receive INO 
Fig 1. Flow diagram showing the numbers of 
children involved in the various stages of the 
study. 
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TABLE 1. Description of Infants at Trial Entry 
Inborn 
Postnatal age, d, median (IQR) 
Postnatal age : 53 d 
Gestational age, completed wk, mean (SD) 
Birth weight, g, mean (SD) 
Male/female ratio 
Principal diagnosis 
Acute preterm lung disease (: 53 d) 
Chronic preterm lung disease 
Other diagnoses 
Disease severity: 01 
<30 
>30 
Median (IQR) 
Abnormal cranial ultrasound 
(not sufficient to prevent trial entry) 
Seizures 
Antenatal corticosteroids 
Duration of ventilation, h, median (IQR) 
High-frequency/jet ventilation 
Inotrope use 
Pulmonary vasodUators 
Surfactant 
Number of doses given prior to trial entry 
1 
2 
3 
4 
IQR indicates interquartile range. 
ing WO improved within I hour, but there was little 
additional change within 12 hours of commencing 
WO. (No judgements could be made about the in- 
fants to whom WO was not administered because no 
corresponding "event" occurred to mark the start of 
the assessment period. ) Eight treated infants had 
methemoglobinemia (Table 2). Fewer of the infants 
in the WO group were given inotropic support or 
alternative pulmonary vasodilators, but more of 
them were treated with muscle relaxants. Otherwise, 
mana-ement after trial entry was similar between 
the 2 groups (Table 2). 
Fifty-nine percent (64 of 108) of the infants died, 
and 84% of the survivors (37 of 44) had signs of some 
impairment or disability, 9 (20%) of them classified 
as severely disabled. There was no evidence of an 
effect of WO on any of the prespecified primary 
outcomes: death or severe disability at I year cor- 
rected age (RR: 0.99; 95% Cl: 0.76 to 1.29; P= . 94); death or supplemental oxygen on expected date of 
delivery (RR: 0.84; 95% Cl: 0.65 to 1.02; P= . 08); or death or supplemental oxygen at 36 weeks'postmen- 
strual age (RR: 0.98; 93% CL 0.87 to 1.12; P= . 80) (Table 3). For death, the RR was 0.83 (95% Cl: 0.62 to 
1.16; P= . 30), but the trend toward benefit for WO 
with regard to mortality was outweighed by the 
trend toward increased impairment and/or disabil- 
ity in survivors. 
Fif ty-seven percent of the 28 survivors classified as 
showing "signs of impairment or disability at I year 
but not severe" (Table 3) had evidence of abnormal 
neurodevelopment (10 of 16 in the group allocated to 
receive WO and 6 of 12 in the group who were 
allocated not to receive iNO) and/or significant re- 
Allocation 
WO (n - 55) No WO (n - 53) 
50 40 
1.0(04.0) 1.0 (1.0-5.0) 
33 37 
27.4(2.6) 26.3(2.4) 
1066(395) 890(343) 
31: 24 26: 27 
33 36 
10 9 
10 8 
25 25 
30 28 
32.9 (22.2-49.8) 31.9 (17.4-51.8) 
13 is 
32 
44 42 
22.0 (9.0-92.0) 24.0 (12.0-132.0) 
33 39 
30 38 
66 
54 52 
13 10 
29 28 
8 12 
42 
spiratory problems. Details of the 1-year follow-up 
for the 44 surviving children are shown in Table 4. 
These results were obtained from multiple assessors 
C, 
using a standardized format. The children displayed 
a ranae of si-nificant abnormalities that, because of C, 0 their nature, are unlikely to represent false positives. 
A more detailed respiratory follow-up will be re- 
ported elsewhere. 
There was a trend for infants allocated to receive 
WO to spend more time on the ventilator (log rank: 
3.6; P= . 06), on supplemental oxygen (log rank: 1.4; P= . 24); and in hospital than those allocated to not 
receive WO (log rank: 3.5; P= . 06), which predom- 0 inantly reflected the infants who died (P = . 05; log- 
rank test). For survivors, on the contrary, these times 
tended to be shorter in the WO group (Table 5). 
Resource use and costs are shown in Table 6. Na- 
tional reference costs were used to value the inpa- 
tient resource use (note that E1.00 = $1.56 in 2003)11; 
the costs per hospital day were E793 (sensitivity: 
E946) for level 1 neonatal intensive care, E5S9 (sensi- 
tivity: E600) for level 2 neonatal intensive care, and 
E347 (sensitivity: E392) for special care. The unit cost 
for iNO used in this analysis was E33 per hour, which 
is the average cost per hour no%v charged to NHS 
providers for usage up to 96 hours per patient. The 
price can vary about this average according to 
the providers' level of use, which was reflected in the 
sensitivity analysis, in which the price ranged from 
; E31.50 to E33.00 per hour. The sensitivity analysis 
also tested whether the results were robust to the 
particular unit costs used for hospitalization. 
Of 44 parents, 36 completed at least 1 postal ques- 
tionnaire. The 8 parents who did not complete a 
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TABLE 2. Management Between Trial Entry and Discharge or Death 
Allocation 
WO (n - 55) No INO (n = 53) 
Administration of NO 
iNO administered 52 
Time from randomization to administration of 1.23 (0.83-2.25) 
WO, h, median (IQR) 
Duration of administration 
4 
<48 h 25 1 
>48 h/<3 d31 
>3 d 24 2 
Response Ih after establishment of dosage* 
Improved 30 2 
Deteriorated 20 
No clear change 17 2 
Other it 0 
Missing data 20 
Response 12 h after establishment of dosage* 
Improved 28 1 
Deteriorated 71 
No clear change 13 2 
Other it 0 
Not applicable- died 10 
Missing data 20 
Adverse events potentially related to NO 
Methemoalobin >2% 80 
NO, >2 ppm for >30 min 10 
Other 6§ 0 
Other management 
Inotropes 32 41 
Paralysis 32 23 
Pulmonary vasodilators 5 16 
High-frequency/jet ventilation 34 32 
Postnatal corticosteroids 22 is 
Indornethacin 11 12 
Surfactant 16 19 
Oral feeding established 28 20 
Discharged home on 
Antibiotics 00 
Steroids 21 
Anticonvulsants 00 
Supplemental oxygen 55 
IQR indicates interquartile range. 
* Based on clinical judgement. 
t Rise in PaO, of <3 kPa but 27% rise from baseline. 
t NO stopped: coagulopathy. 
§ Intraventricular hemorrhage with parenchymal involvement (n = 2); intraventricular hemorrhage 
with associated platelet aggregation problems; coagulopathy, subcutaneous bleeding; and airway 
secretions. 
questionnaire were assumed to have the mean com- 
munity costs of the survivors from the treatment or 
control groups. Because these costs form only a small 
part of total costs, no sensitivity analysis was con- 
ducted. The data presented are from the first ques- 
tionnaire. These results showed that on average 
more outpatient and community resources were 
used in the treatment arm over this 4-week sampling 
period, but the Cls around the difference are wide, 
which reflects the small sample size (Table 6). A total 
of 20 parents also completed a second questionnaire 
estimating resource use over another sampling pe- 
riod. These results were similar, so the community 
and outpatient data from the initial sampling period 
were simply extrapolated to give estimates of re- 
source use (and hence costs) at 1 year corrected age. 
Mean total costs per infant at I year corrected age 
were significantly higher in the WO group, partly 
because of the costs of the gas but mainly because of 
the difference in initial hospitalization costs (see Ta- 
ble 6). The costs of subsequent hospitalizations and 
outpatient and community services were also higher 
for the NO arm of the study. The sensitivity analysis 
showed that these findings were robust to realistic 
variations in the unit costs. 
Other than for the outcome "death or supplemen- 
tal oxygen on expected date of delivery" and the 
stratifying factor of postnatal age at entry (for which 
the P value for the test of homogeneity was . 04), the 
overall effect of NO on the 3 primary outcomes did 
not differ when the prespecified stratifying factors of 
postnatal age, principal diagnosis, and respiratory 
disease severity at trial entry were taken into account 
(Table 7). 
DISCUSSION 
The evidence from this pragmatic multicenter, ran- 
domized, controlled trial does not provide support 
for the hypothesis that the use of WO improves the 
outcome for preterm infants with severe respiratory 
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TABLE 3. Primary Outcomes 
Allocation 
VO No WO 
(n - 55) (n = 53) 
Death or severe "ability at 1y corrected age 
Yes 37 36 
No is 16 
Missing 0P 
Death by Iy corrected age 30t 34 
Age at death, d 
: 91 97 
2-6 3 10 
7-27 10 15 
Z: 28 82 
Cause of death 
Immaturity 14 20 
Immaturity and cerebral event 26 
Immaturity and other event (eg, infection) 64 
Bronchopulmonary dysplasia 63 
Congenital anomaly 21 
Postmortem examination 10 7 
Signs of impairment or disibility at 1y corrected age 
Yes, severe 72 
Yes, but not severe 16 12 
None 24 
Missing 0 1* 
Death or supplemental oxygen on expected date of delivery 39 45 
Death or supplemental oxygen at 36 wk postmenstrual age 49 48 
On supplemental oxygen on expected date of delivery 16 12 
On supplemental oxygen at 36 wk postmenstrual age 26 is 
Alive and assessed as "normal" by pediatrician at 6 months. 
t One additional infant died after I year corrected age. 
failure. This finding is not likely to be due to selec- 
tion bias, because there was well-concealed random 
allocation that generated broadly comparable groups 
in the 2 trial arms; if anything, the slight imbalance in 
gestational age and birth weightwould have favored 
the iNO arm of the study. There was very little loss 
to follow-up. Nevertheless, a number of caveats must 
be made. First, both the failure to reach the planned 
sample size and the 8% crossover to iNO increases 
the risk of a type 2 error. Second, 30% of infants in 
the no-iNO group were given other pulmonary va- 
sodilators and, if as effective as WO, Could have 
further reduced any difference between the groups. 
Third, despite the broad eligibility criteria, the in- 0 fants entered into this trial were clearly already suf- 
fering from extremely severe lung disease, and hence 
iNO may have been administered too late to help 
them; the trial cannot provide evidence about the 
effect of iNO on infants with less severe respiratory 
disease. Last, the study was not blinded, giving the '. 0 opportunity for bias to have been introduced in re- 
lation to the management of these children or in the 
assessment of outcomes. Given the team-based man- 
agement and disease severity of the infants recruited 
to this study, we feel that such an effect is extremely 
unlikely to have occurred. 
An economic assessment was incorporated into 
the initial design of this study. By the end of recruit- 
ment, concerns arose about the costs of NO to the 
NHS. 13,14 Nevertheless, although the trial data indi- 
cate significant extra costs associated with its use, 
these costs seem to be associated with changes in the 0 pattern of survival and increased morbidity (with 
associated longer hospital stays) rather than simply 
the costs of the agent itself. A broad approach to 
costing was taken with costs to a range of agencies 
included. The results suggest that subsequent hospi- 
tal and community costs also increase with the use of 
WO. The finding that the overall costs were higher 
with WO was not sensitive to the'unit costs of the gas 
or the hospitalization. In conjunction with the clinical 
evidence (no evidence of improvement in outcome), 
the cost-consequence analysis suggests that WO is 
unlikely to offer good value for the money in this 
population of preterm infants. 
It is clearly disappointing that the recruitment tar- 
gets were not met in this trial. The poorer-than- 
anticipated recruitment seems to have been the result 
of several factors. There was a perception by clini- 
cians involved in the study (ie, those in equi oise) 
that very few infants needed NO as part 
Wtheir 
treatment. Some clinicians were already convinced of 
the perceived benefits of NO (largely for infants at 
or near term) and hence unwilling to join the study. 
Indeed, based on logs returned from centers partici- 
pating in the trial, 75 preterm infants who would 
have been eli-ible for trial entry received NO out- 
side the trial. Some clinicians felt that, with such very 
ill infants, they had to try everything and did not 
want to omit the use of WO. Qualitative studies 
demonstrate the discomfort of some clinicians in 
their approach to parents of very sick infants, 15 par- 
ticularly in the present research climate in the United 
Kinadom, in which a great deal of negative publicity 
has occurred in recent years in relatioDn to the broad 
topic of perinatal research. This is particularly prob- 
lematic in terms of pathology studies, 15 as evidenced 
by the low postmortem-examination rate (26%) in 
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TABLE 4. Status at I Year Corrected Age 
WO (it - 55) No WO (n - 53) 
Pediatric assessment available 
Missing data I 
Corrected age at assessment 
<43 wk 
48-56 wk 
>56 wk 
Neuromotor 
Head control 
Normal 
Poor 
No or momentary control 
Sitting 
No problem 
Cannppor. 
ted, butt insecure Unsu 
ot be m, in ained sitting 
Hand use (worst hand) 
Uses pincer grip 
Uses other means 
Unable to pick up 
Missing data 
Difference in function between hands 
On anticonvulsants 
Fit in previous 4 wk 
Vision 
Squint 
Nystagmus 
Vision problems 
Some 
No vision or sees light only 
Hearing 
Roann,, loss 
N- 25 N- IS 
0 1* 
31 
15 9 
78 
23 16 
11 
11 
17 13 
13 
72 
19 14 
44 
0 
0 
01 
31 
30 
84 
00 
43 
10 
2 
0 
0 
...... ---- Susý--, cted 5 
Confirmed 2t 
_Helped 
by hearing aids I 
Feeding 
Oral feeding 
Can manage eating lumps 
Pureed food only 
Pureed food (and via stoma) 
Liquids only 
No (via stoma only) 
Tube feeds 
Stoma 
Respiratory 
Respiratory support day or night 
Supplemental oxygen 
Respiratory signs and symptoms on examination 
ght in last 3 mo ýýhtrezinj day or ni$ht in last 3 mo 
Respiratory medication since discharge 
Bronchodilators 
Steroids 
Overall development 
Developmental delayS 
No 
3-6 mo 
>6 mo 
Other impairments 
Growth 
Standardized heleht. SD 
17 13 
54 
2t 0 
01 
it 0 
11 
30 
32 
31 
94 
87 
13 5 
10 11 
10 7 
55 
16 11 
66 
31 
211 61 
8 
3 
Less than -2 8 
-2 to -1 8 
-1 to 05 0 to 10 
1 to 22 
rvli? siý$ 
.2 titanaaratzea weignt bu 
Less than -2 
-2 to -1 
-1 too 0 to I 
Missing 
Head circumference, mean, SID 
Admissions to hospital 
10 9 
94 
32 
22 
11 
43.5 (1.8) (n = 23) 45.2 (1.6) (n - 15) 
One short (: 52 d) 3 
One longer (>2 d) I 
Multiple 10 
6 
2 
4 
* Alive and assessed as "normal" by pediatrician at 6 months. 
t One sansorineural; I conductive. 
Three children had a stoma, but 2 were also fed orally. 
Formal developmental assessment (it -6 [iNO group] and 2 (no-NO group]). ITransient 
renal calcification; attends cardiology clinic. 
I Parents report "black outs"; patent ductus arteriosus (closing); left orcl-idopexy, h drocephalus requlr- 
ing shunt; gastroesophageal reflux/fundopUcadon/gastrostomy; unilateral ptosis o1the right eye. 
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TABLE S. Secondary Outcomes Before Discharge From Hospital 
Wo (it - 55) 
Duration of time on ventilator after randomization, d, median (IQR) 
All 
Survivors only 
Deaths only 
Duration of time on supplemental oxygen after randomization, d, 
median (IQR) 
All 
Survivors only 
Deaths only 
Duration of time in hospital after randomization, cl, median (IQR) 
All 
Survivors only 
Deaths only 
11neurnothorax or other pultrionary air leak 
Pulmonary hemorrhage 
Patent ductus arteriosus needing treatment 
Infection 
Confirmed 
Suspected 
Retinopathy of prematurity 
Not applicable: died before test was done 
Major cerebral abnormality on day-7 and/or 36-wk ultrasound scan 
(worst side) 
Missing data 
Died before I or both scans (and no major abnormality) 
One or both scans not available (and no major abnormality) 
7.0 (2.0-26.0) (n - 55) 
15.0 (6.0-28.0) (n - 25) 
3.5 (l. D-21.0) (n - 30) 
Mocation 
15.0 (2.0-71-0) (n - 50)1 
59.0 (30.0-78-0) (n - 20)* 
3.5 (1.0-28.0) (it - 30) 
43.0 (2.0-104-0) (it - 55) 
84.0 (49.0-107.0) (n = 25) 
3.5 (1.0-23.0) 30) 
20 
4 
9 
23 
12 
8 
3 
6/27t 
22 
6 
IQR indicates interquartile range. 
0 Data are missing for 9 infants (5 CNO group) and 4 [no-VO groupD discharged home on oxygen. 
t Information available from both scans or major abnormality on either scan. 
TABLE 6. Resource Use and Costs (per Want) 
NO (it - 55), No NO (n - 53), 
Mean (SD) Mean (SD) 
21 
17 
4 
6 
10/21t 
2S 
4 
Difference, 
Mean (95% CI) 
resource use (per infant) 
Inpatient resource use up to Iy corrected age 
NO, h 84.4 (115.7) 7.1(29.6) 773 (44.8 to 109.8) 
Days on ventilator 23.1(41.6) 12.4(23.5) 10.7 (-2.2 to 23.7) 
Days on supplemental oxygen 50.1(56.3) 32.0(46.6) 18.1 (-1.7 to 37.8) 
Days in hospital (initial) 58.0(57.6) 37.4(48.7) 20.6 (0.20 to 41.0) 
Days in hospital (subsequent) 3.8(12.6) 1.6(4.2) 2.2 (-1.44 to 5.76) 
Outpatient and community resource use over the 4-%Vk 
sampling period 
Outpatient visits 1,55(l. 87) 
General practice surgery visits 2.20(4.72) 
General practice home visits 0.20(0.41) 
Health visitor home visits 1.65(2.50) 
Total costs (E) (per infant) up to 1y corrected age and 
sensitivity analysis (CI. 00 = $1.56)" 
Base case 
NO 1777(1200) 
Initial hospitalizationt 30 442 (35 389) 
Subsequent hospitalization 1312(4357) 
Outpatient 946(1836) 
CP and community 771(1463) 
Personal costs SS(154) 
Total costs 35 306 (35 941) 
Sensitivity 
Low NO cost 
Higher ICU costs 
35 214 (35 918) 
40 571 (42 315) 
1.23(133) 0.30 (-0.81 to 1.41) 
0.81(0.91) 1.40 (- 1.05 to 3.82) 
0,06(0.25) 0.14 (-0.10 to 0.37) 
0.50(0.89) 1.15 (-0.19 to 2.49) 
167(654) 1610 (1239 to 1980)* 
IS 501 (20 367) 11941 (184 to 23 699)* 
563(1444) 749 (-499 to 1997)* 
623(1232) 322 (-277 to 921)* 
420(123) 331 (-114 to 815)* 
117(546) -58 (-210 to 94)* 
20 391 (26 680) 14 915 (2S03 to 27 026)* 
20 382 (26 669) 14 832 (2727 to 26 937)* 
23 473 (30 940) 17 093 (2907 to 31279)* 
0 Cl was calculated by using the nonparametric bootstrap to allow for the skewed distribution of CoStS. 12 
t Excluding NO costs. 
this trial. Each of these factors relating to recruitment 
is also important in a wider context. 
The pattern of preterm lung disease, presumably 
after the wider use of antenatal steroids and surfac- 
tant, now means that relatively few infants meet the 
criteria for severe lung disease, and infants not re- 
sponding to surfactant tend to have more compli- 
cated respiratory problems and poorer oUtCoMeS. 16,17 
Progress in these infants will require trials involving 
many more units than previously used if recruitment 
targets, to show small benefits, are to be met. The 
lack of equipoise about the role of NO by many 
No WO (n - 53) 
4.0 (1.0-9.0) (n - 53) 
12.0 (5.0-36.0) (n - 19) 
2.0 (1.0-7.0) (n - 34) 
6.0 (1.0-17.0) (n - 49)* 
81.0 (14.0-100.0) (n - 15)4 
2.0(1.0-7 . 0) (n - 34) 
7.0 (1.0-86.0) (n = 53) 
100.0 (57.0-112.0) (n - 19) 
2.0 (1.0-7.0) (n - 34) 
20 
5 
13 
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TABLE 7. Primary Outcomes Stratified by Postnatal Age, Diagnosis, and Disease Severity at Trial Entry 
Random Allocation 
WO (n - 55), n 0/6) 
Death or severe disability 
Postnatal age 
: 53 d 25/38(66) 
>3 d 12/17(71) 
Diagnosis 
Acute 23/35(66) 
Chronic 8/10(80) 
Other 6110(60) 
Severity 
01 :s 30 16/25(64) 
01 > 30 21/30(70) 
Death or supplemental oxygen at 
expected date of delivery 
Postnatal age 
53 d 23/38(61) 
>3 d 16/17(94) 
Diagnosis 
Acute 22/35(63) 
Chronic 10/10(100) 
Other 7/10(70) 
Severity 
01 : r. 30 17/25(68) 
01 > 30 22130(73) 
Death or supplemental oxygen at 
36 wk postmenstrual age 
Postnatal age 
, 93 d 32/38(34) 
>3 d 17/17(100) 
Diagnosis 
Acute 30/35(86) 
Chronic 10/10(100) 
Other 9/10(90) 
Severity 
01 :s 30 22/25(SS) 
01 > 30 27/30(90) 
No WO (n - 53), n (%) 
24/37(65) 
12/16(75) 
24/36(67) 
7/9(78) 
5/8(63) 
15/25(60) 
21/28(75) 
29/37(78) 
16/16(100) 
29/36(81) 
9/9(100) 
7/8(88) 
20/25(80) 
25/28(89) 
Adjusted RR P Interaction 
(95% Cl) Test 
0.99 (0.76 to 1.28) . 78 
0.99 (0.76 to 1.28) . 98 
0.99 (0.76 to 1.23) . 62 * 
0.83 (0.69 to 1.01) . 04 
0.83 (0.68 to 1.01) . 92 
O. S3 (0.6S to 1.02) . 87 
32/37(86) 
16/16(100) 
32/36(89) 
9/9(100) 
7/8(88) 
0.93 (0.87 to 1.11) . 92 
0.93 (O. S7 to 1.11) . 94 
22/25(88) 
26/28(93) 
0.9S (0.87 to 1.12) . 81 
cHnicians, despite quite sparse data, is clearly wor- 
rying and casts doubt on the extent to which clinical 
practice has really become evidence based. The re- 
sults of this study and others might be helpful in 
making clear that what intuitively might seem the 
best treatment might not help's and might actually 
make things worse. 19,20 
The clinical data from this study are largely in 
keeping with those from existing trials, which in 0 
general have also shown short-term improvements 
without any change in the rate of adverse events that 
might have been predicted to occur from the known 
biological actions of WO. A very recently published 
single-center trials indicated a benefit of NO on 
death and chronic lung disease, but the benefit was 
only in infants with an 01 of <6.9.21 
The data from the ININOVO trial about longer- 
term outcome is of particular importance. The deci. 
sion not to use the more formal methods of assess- 
ment at I year was made initially because there was 
an expectation that the trial would be much larger, 
and hence the use of specialized pediatric follow-up 
would not be feasible and would be prohibitively 
expensive. By the time it became clear that the trial 
would be smaller, several infants had already been 
assessed at 1 year, and it was felt inappropriate to 
change the methods at that point. The 4-year fol- 
low-up (currently underway) does, however, involve 
specialized pediatricians. Even with these caveats, 
the lack of any significant beneficial effect on any of 
the existing longer-term clinical outcomes seems 
clear. Of the 108 infants recruited in both arms of the 
study, only 6 were alive and considered normal at I 
yeir (with a seventh alive and normal at 6 months 
but lost to the 1-year follow-up). Previous experi- 
ence22 suggests that the number of infants displaying 
handicaps will grow, particularly those with abnor- 
mal neurodevelopment at I year corrected age. The 
surviving infants from this study are currently being 
reviewed at the age of 4 to 5 years. 
CONCLUSIONS 
The results of our study of preterm infants did not 
find beneficial effects of iNO; on the contrary, there 
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was some evidence of prolongation of intensive care 
and increased costs of such care, amounting to ap- 
proximately E15 000 (approximately $23 400) per in- 
fant treated. Most of the infants in our preterm group 
were very ill with severe hypoxic respiratory failure, 
and it is possible that use of WO in less-ill preterm 
infants might have some beneficial effects such as 
decreasing the risk of chronic lung disease. Trials in 
the United States and elsewhere are testing this hy- 
pothesis. Until the results of these trials become 
available, WO cannot be recommended for preterm 
infants with hypoxic respiratory failure. This view 
accords with the existing Cochrane review. ' 
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APPENDIX 1. Definitions 
Disability 
Severe disability: no/minimal head control or inability to sit unsupported or no/minimal responses to visual stimuli (equivalent to 
developmental quotient < 50, -. ýhich can be used If at correct age) 
No signs of impairment or disability- Normal head control; no apparent problem with sitting; uses pincer for right and left hand; Is 
not receiving anticonvulsant medication; no neuromotor problems; no fits In previous 4 wk, no squint; no vision problems; 
no nystagmus; no hearing loss; no hearing aids; no stoma or tube feeding or parenteral nutrition; can eat lumps; no 
developmental delay; no respiratory support; no respiratory medication other than antibiotics; and not more than I of 
respiratory signs/symptoms on examination" or coughing several times most nights for ;, -I wk during previous 3 mo or 
wheezing during previous 3 mo 
Signs of impairment and disability but not classified as severe: by subtraction 
Cerebral ultrasound scans 
Evidence of intraparenchymal lesions: an echodense area of at least equal echodensity to the choroid plexus or bone, Involving the 
parenchyma of the brain and/or existing parenchymal lesions that were echo-poor, eg, established porencephalic cysts 
Major abnormality: H3 or VI or V2 or P1 or P2; minor abnormality: H2 and VO and PO; and no abnormality: HO or HI and VO 
and PO, based on scans at either 7d or 36 wk gestational age (preterm infants)/28 postnatal d (term infants), where the H, 
V, and P are based on the following classifications: 
HO, no hemorrhage; HI, localized (subependymal/choroidal); H2, any degree confined within ventricular system; H3, 
parenchymal/ periven tricular; H4, other; VO, no dilation, Vl, dilation requiring nonsurgical intervention; V2, dilation 
requiring surgical intervention; PO, no cysts; P1, cystic leukomalacia; P2, porencephalic cyst(s); P3, other 
Other outcomes 
Pneumothorax: confirmed by transillumination, exploratory aspiration, or radiology 
Other pulmonary air leak: including pulmonary interstitial emphysema, pneumopericardium, pneumoperitoneum, and 
pneumomediastinum; 
Pulmonary hemorrhage: copious blood-stained secretions with clinical deterioration requiring change(s) in ventilatory management 
Necrotizing enterocolitis: evidence of abdominal distension, bilious aspirates, and/or bloody stools, regardless of whether 
confirmed by radiograph or laparotomy, sufficient to change management 
Patent ductus arteriosus: needing medical treatment such as diuretics and indomethacin or surgery but not simply requiring fluid 
restriction or prophylactic treatment in the absence of symptomatic patent ductus 
Treatment of retinopathy of Prematurity: grade III or more, as determined by an experienced ophthalmologist on the basis of 
indirect ophthalmoscopy 
FULLERENES 
"Fullerenes, better known as buckyballs, have been the darlings of chemists ever 
since they were discovered 2 decades ago. These novel molecules are, after all, a 
third major form of carbon, in addition to diamonds and graphite. Shaped like tiny 
geodesic domes, they also have an undeniable elegance. In recent years, they have 
emerged as one of the most valuable materials in the rapidly developing field of 
nanotechnology. But during the last year, preliminary toxicity studies on bucky- 
balls have set off warnin-s about their potential health hazards.... The worry is 0 that nanoparticles can, among other things, easily penetrate cells, producing un- 
known effects. " 
Teclinol Rev. January 2005 
Noted by JFL, MD 
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Appendix C- Publication of results of the CANDA Trial 
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Fenton, A. C. and Ward Platt, M. P. (2000). Pumactant and poractant alfa for 
treatment of respiratory distress syndrome in neonates born at 25-29 weeks' gestation: 
a randomised trial. Lancet 355: 13 87-92. 
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I Articles 
Pumactant and poractant alfa for treatment of respiratory distress 
syndrome in neonates born at 25-29 weeks' gestation: a 
randomised trial 
SB Ainsworth, MW Beresford, 0WA Milligan, NJ Shaw, JNS Matthews, AC Fenton, MP Ward Platt 
Summary 
Background Exogenous surfactant preparations vary in their 
constitution and biophysical properties. Synthetic and animal- 
dedved preparations lower the rate of death compared with 
controls. No significant differences in mortality or important 
long-term clinical outcomes have been shown between them In 
randomised trials. We did a randomised controlled trial to 
compare pumactant, a synthetic surfactant, with poractant 
alfa, an animal-derived surfactant, both of which are widely 
used In the UK. 
Methods We enrolled 212 neonates born between 25 weeks' 
and 29 weeks and 6 days' gestation who were Intubated for 
presumed surfactant deficiency and were free from life- 
threatening malformations. We randomly assigned 105 
neonates poractant alfa, and 1.07 purnactant. The primary 
outcome was duration of high-dependency care and mortality 
was a secondary outcome. Analysis was by intention to treat. 
Findings Outcome data were analysed for 199 babies. The trial 
was stopped on the recommendation of the data and safety 
monitoring committee because mortality assumed a greater 
importance than the primary outcome. Predischarge mortality 
differed significantly between groups, in favour of poractant 
alfa (14.1 vs 31.0%. p=0.006; odds ratio 0.37 195% CI 
0.1". 76). This difference was sustained after adjustment 
for centre, gestation, birthweight. sex, plurality, and use of 
antenatal steroids. 
Interpretation Mortality was unexpectedly lower among 
neonates who received poractant alfa than among those who 
received pumactant. and was independent of all the variables 
we investigated. Stopping the trial early may have widened the 
difference between the treatment groups. 
Lancet 2000; 355: 1387-92 
See CommentarY Page ???? 
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Introduction 
'Me introduction of surfactant treatment has been 
associated with significantly improved survival in preterm 
neonates who have neonatal respiratory distress 
syndrome. " The effect of combined ancenatal steroids and 
postnatal surfactant is more effective than with either of 
these treatments alone. ' 
Surfactants in current use are synthetic or manufactured 
from animal lung-surfactant extracts (animal-derived or 
"natural"). Animal-derived surfactants contain a wider 
variety of phospholipids than do synthetic surfactants, as 
well as some surfactant-associated proteins. The two types 
of surfactant significantly reduce morbidity and mortality 
compared with controls. " Meta-analyses of randomised 
controlled trials comparing synthetic and animal-derived 
surfactants sho%v significantly fewer pulmonary air leaks 
with animal-derived surfacEants. 1-1 One meta-analysis' 
showed a slightly significant difference in mortality, 
although this review included non peer-reviewed abstracts, 
the data from which changed in the final published 
versions. No other significant differences in clinical 
outcome were noted in these meta-analyses. Studies 
included involved comparisons of the synthetic surfactant 
colfosceril palmitate with the bovine-derived surfactants, 
beractant or calfactant. 
Purnactant is a synthetic surfactant and poractant alfa is 
a porcine-derivcd surfactant. These two drugs are 
commonly used in the UK. In-vitro properties of beractant, 
colfosceril palmitate, poractant alfa, and pumactant differ. '-' 
Extrapolation of findings from clinical comparisons of 
colfosceril palmitate against bovine surfactants may not, 
therefore, reflect outcome differences bmveen purnactant 
and poractant alfa. 
In one animal study, pumactant and adult rabbit 
surfactant lowered the numbers of prieumothoraces in 
preterm rabbits compared with controls, but neither 
treatment had much effect on bronchiolar epithelial 
damage and hyaline membrane formation. ' Five placebo- 
controlled trials of pumactant have been reported, "" of 
which two used a preparation similar to that commercially 
available. "-" No published study has, however, compared 
purnactant with another surfactant in neonates. The only 
published randomised clinical study comparing poractant 
alfa with another surfactant (beractant) showed short-term 
advantames for neonates treated with poractant alfa but no 
significant differences in any long-term clinical outcomes. " 
We designed a randomised controlled trial to compare 
purnactant with poractant alfa in neonates. The aim of the 
study was to investigate whether there was a difference in 
the cost of treatment with these two surfactants. 
THE LANCET -Val M -April 22,2000 1387 
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Methods 
We did the study between May, 1998, and December, 1999, in 
hospitals in the Northem and Yorkshire: Health Authority of 
England, and in Liverpool. To increase the rate of recruitment, two 
further centres; began randomising neonates in October, 1999. We 
obtained approval for the study from muldeentre (Northern and 
Yorkshire) and local research ethics committees. 
Patients 
Neonates were eligible for enrolment if they were bom between 
25 wccks' and 29 weeks and 6 days' gestation, according to best 
obstetric estimate, and were intubated for presumed surfactant 
deficiency. We excluded babies who had a congenital 
malformation likely to affect mortality or respiratory outcome. 
Neonates were deemed ta be surfactant dericienc if, in the opinion 
of the attending clinician, they had clinical signs of respiratory 
distress and required ventilation. 
Study design 
We obtained written informed parental consent before neonates 
were enrolled into the study. Parents were given information sheets 
and the study was explained to them by medical staIr as soon as the 
possibility of prcterm delivery became apparent. We randomiscd 
neonates within 2h before expected delivery or as soon as possible 
after delivery. Maternal name and unit number, best obstetric 
CSEiMUEC Of geStadunal age, and birth order were recorded on a 
standard form. RAndomisation was done centrally by telephone, 
from a computcr-gencraEcd sequence concealed in sequentially 
numbered, scaled, opaque envelopes kept at the neonatal unh in 
Newcastle upon Tyne, UIC Treatmenir assignment used random 
permuted blucks with block lengths randomly set tu four or six, 
straciried by the cenEre in which neonatal intensive care was 
provided (we stratified assignment for neonates transferred 
postnutally for continuing intensive care within the Northern and 
Yorkshire region by the centre to which they were transferred). 
DilTerences in reconstitution and dose calculation of the two 
surractants meant that clinicians were aware of treatment 
assignment. 
Timing of the first dose of surfactant after randurnisation was 
decided according to loval-unit guidelines. In Liverpool, 
jWddlesbrough, and Sunderland, neonates received the first dose 
in the delivery ruom. Elsewhere, the first dose was given after 
admission to the neonatal unit, although clinicians were 
encouraged to administer it as suun as possible aftcr birth and 
within 30 min of intubation. Poractant alfa IOU mglkg (1-25 
mIJkg) or PUMaCEanE IUO mg (1-2 mL) were administered 
403 neonates 
eligible 
191 excluded 
I 
105 assigned 
poractant alfa 
I 
6 excluded 
before 
treatment 
99 analysed 
Figure 1: Trial profile 
1388 
212 randomised 
I 
107 assigned 
purnactant 
HP 
7 excluded 
before 
treatment 
100 analysed 
Polactant &If& (n%99) Pumactant (n*100) 
Birth Ch3racterlstICS 
Median (IQR) gestation (weeks) 28-3 (26-4-29-1) 27-8 (26-3-28-9) 
Median (IQR) birthweight (g) 1026(820-1255) 949(755-1185) 
Mean (SO) birthweight Z scores -0-57(1-2) -0-65(1-2) 
Mates/females 64 (65%)/36 (35%) 53 (53%)/47 (47%) 
Multiple births 
Number of twins 30(30%) 21(21%) 
Number of triplets I(A) 2(2%) 
Antenatal steroids 
Any 
;, 2 doses 
93(94%) 93(93%) 
69(70%) 78(78%) 
Method of delivery 
Vaginal delivery (including breech) 48(48%) 50(50%) 
Caesarean section 51(52%) 50(50%) 
Table 1: Baseline characteristics of analysed neonates 
according to the manufacturers' guidelines. The second Jose was 
administered 12 h later to ventilated neonates if the oxygenation 
index (FiO, 1%] X mean arterial pressure (cm 1-1,01/PaO, Imm Hg]) 
was 5 or more. Further doses of the same surfactant were given at 
the discretion of the supervising clinician. Rescue treatment for 
severe respiratory failure with high-firequency oscillatory ventilation 
and inhaled nitric oxide was used according to local guidelines. 
We collected data prospectively for all enrolled babies and 
collated them on a specifically designed database. Surfactant 
assignment was recorded at the time of entry to the SEUdY and was 
stored independently of demographic and outcome data. We 
linked the information only in the final analysis. Disaggregated data 
necessa. y for the scoring of days in high-dependency and low- 
dependency care were collected independently, daily, by nursing 
and medical staff. We regularly checked accuracy of collected data 
agaimt existing databases. 
primary outcome was days spent in high-dcpcndency care. 
We cl-issifed high-dependcricy days as A and B days, according to 
the NurEhcrn and Yorkshire region categories of care" (A: 
respiratory support, including nasal continuous positive airway 
pressure; 13: any neonate not in category A but with an inspired 
oxygen concentration '0-4 0%, total fluid requirement administered 
intravenously in the preceding 24 h, drain in situ, or current weight 
< UUU g). 
'17he secondary outcome was neonatal mortality, delined as death 
within 23 days. '17wo neonatologists in each region, not involved in 
the orgdnisation of the trial and data analysis, established the cause 
of death from clinical and ticcropsy data. Respiratory deaths were 
those that occurred as a direct consequence of respiratory distress 
syndrome or chronic lung disease of prematurity. Nun-rcsplratory 
deaths were those attributed to other causes. Predischarge death 
was any death that occurred between birth and the time of first 
discharge home. 
Other outcomes were chronic lung disease, defined as 
depcndcn%: y on supplemental oxygen at posidnAl age 2S days and 
dependency on supplemental oxygen at 36 pustrricristruut weeks; 
pricurauthurax, dcrined as intrathoracic, cmrapulmonary air leak 
that required insertion of a chest drain; findings on cerebral 
ultrisonography, done aE postnatal age 3 days and at 6 weeks (or as 
near is possible), of hacniorrhagc (scored as 0 no hacmurrhagc, I 
lucaliwj subependymal haemurrhage, II intraventricular 
Poractant mita Pumactant 
Neonatal mortality 
Overall 11/99(11%) 25/100 (25%) 
25 we6s'pstaucn 4/12(33%) 6/13(46%) 
26 weeAs* gestat, on 3/17(18%) 6/22(27%) 
27 %eelks'lestation 0 4/17(24%) 
28 weeks* gestation 2/24(8%) 6/24 (25%) 
29 vetAs* pstancn 2/32(6%) 3/24 (13%) 
Predischarge mortality 
Ovefall 14/99(14%) 31/100(31%) 
25 weeks' jestat, cn 4/12(33%) 8,11.3 (62%) 
26, hetk$* gegat, Cn 5/17(29%) 7/22(32%) 
27 weeks'gestaticri 0 5,117(29%) 
28 weeks' gestat. en 3/24(13%) 7/24(29%) 
29 weeks* jestation 2/32(6%) 4/24(17%) 
Table 2: Neonatal and predischarge mortality 
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Day of death Suffacant M/F Birthwitight (g) Gestation 
(weeks) 
Early neonatal deaths 
I Pumactant F 910 
1 Purnactant F 690 
1 Pumactant F 728 
1 Purnactant M 880 
1 Pumactant m 910 
I Purnactant m 1126 
1 Pumactant m 1310 
1 Purnactant F 930 
2 Pumactant m 917 
2 Purnactant m 1370 
2 Pumactant F 1040 
3 Po(actant alfa m 530 
3 Poractant elfa F 620 
3 Pumactant m 734 
3 Pumactant F 825 
3 Paractant alfa m 514 
4 Po(actant alfa m 840 
5 Po(actant alla m 580 
5 Poractant alfa m 1100 
7 Poractant aft F 585 
7 Pumactant m 735 
7 Pumactant F 865 
Late neonatal death$ 
Pumactant 
Purnactant 
Purnactant 
8 Purnactant 
8 Purnactant 
10 Poractant alfa 
10 Pumactant 
10 Purnactant 
to Purnactant 
Pumacant 
Poractant alta 
Purnactant 
Pofactant alfa 
28 Po(ectant alfa 
Cause of death Primary Cause 
25 Severe ROS and air leak Respiratory 
25 Infection (suspected group 8 streptococcal infection) other 
26 Severe ROS. air leak Respiratory 
26 Severe ROS and sit leak with PPHN Respiratory 
26 Severe ROS and PPHN Respiratory 
27 Severe ROS, air lea% Respiratory 
27 RDS with air leak Respiratory 
29 Severe RDS/pulmonafy hypoplasia Respiratory 
26 Severe ROS, air leak. air embolus Respiratory 
28 Severe RDS Respiratory 
28 ROS/pneumothotax Respiratory 
26 Severe ROS. pulmonary haemorthage Respiratory 
26 lintraparturn *SphyXi3/MUft1o(&3n failure Other 
27 Severe RDS. air leak Respiratory 
28 Severe ROS Respiratory 
29 Acute renal failure, tivin-to-twin transfusion, pulmonary haemorrhagi Other 
28 Severe RD$ Respiratory 
25 Severe ROS plus infection Respiratory 
29 Severe ROS with aIr leak/pneumothorat Respiratory 
25 Perforated necrotising enteirocolitis Other 
26 Pulmonary haernorrahge secondary to patent ductus artedosus Other 
29 hydrops Other 
m 959 25 
161 ? S0 25 
m 1378 28 
m 1220 28 
m 1049 29 
m 965 25 
F 690 25 
m 692 28 
m 720 23 
F 762 25 
m 958 26 
F 760 26 
m 1220 28 
m 570 25 
Postnoonstal deaths 
30 Poractant alfa m 685 29 
59 Poractant alfa m 765 26 
110 Pumactant m 550 25 
123 Pumactant F 548 27 
133 Pumactant m 734 29 
143 Pumactant m 6m 26 
147 PumaCtant m 780 25 
217 Pumactant Pvt 700 28 
372 Po(actant aft m 553 26 
ROSwespiratory d, stress syndrome; PPHN=persisting pufmonary hypertension of the neonate. 
Table 3: Cause of death 
haemorrhage, III intraventricular haemorrhage with ventricular 
enlargement, IV parenchymal haemorrha. -ic lesions), " ventricular 
size, measured by the ventricular index, " and parenchymal cysts 
(scored as 0 no cyst, I porencephalic cyst, 11 cystic leucomalacia); 
patent ductus arteriosus, defined as murmur associated with 
clinical signs of left-to-right shunt requiring medical or surgical 
closure and confirmed by echoc3rdiography where possible; 
necrotising enterocolitis, defined according to the clinical staging 
system proposed by Bell and colleagues; " pulmonary 
haemorrhage, defined as the spontaneous appearance of blood or 
bloodstaincý fluid in the endotracheal tube; and retinoparhy of 
prematurity, Mined as threshold disease. " 
Statistical analysis 
We calculated the sample size to allow identification of important 
differences in time spent in high-deperidency care. Data for 236 
neonates born at 25-29 weeks' gestation in Newcastle upon Tyne 
and Liverpool showed a median duration of 6 days in high- 
dependency care. Ile distribution of these data were well 
approximated by an exponential distribution and we used this 
distribution to estimate the sample size. To enable detection of a 
25% difference in median time spent in high-dependency care, 
With 80% power at the 5% significance level, we needed to include 
241 neonates in each treatment group. This number was intended 
to give samples of adequate size of survivors and assumed 20% 
mortality in each group. 
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Acute renal failure. Possible SePsis Other 
Severe RDS leading to necrotising ente(ocolitis Respiratory 
Severe RDS, aw leak Respitato(y 
Antenatal myocardial Ischaernia and hydrops War 
Pulmonary haemorrhale secondary to patent ductus arteriosus Other 
Intraparturn asphyxia and multiorgan failure Other 
Staphyiococcus epide(midis septicaemia Other 
Severe ROS Respiratory 
Air leak/pneumothotax Respiratory 
Fun&31 septicaernia Other 
Enterobacter/candida sepficaemia Other 
Necrotising entefocolitis Other 
TPN hydrothorax (Iongline complication) Other 
Pulmonary haemorrhage secondary to patent ductu$ arteriosus Other 
Necrotisinill enterOCOlitiS Other 
Widespread cere0ral Ischaamia and periveritticulaf leucomalacla Other 
Chron, c lung disease Respiratory 
Chronic lung disease Respiratory 
Chron, c lung disease Respiratory 
Chronic lung disease Respiratory 
Chronic lung disease Re3Pif3t0(Y 
Hypovolaemia secoi)dary to incarcefated hemia other 
Chronic lung disease Resp4atory 
M-ie study protocol stipulated that a data and safety monitoring 
committee would meet after about half of the neonates had been 
recruited. We drew up no formal rules for stopping the trial 
because the decision would depend on outcomes relating to safety 
and deachs, as well as clinical efficacy. 
Analysis was by intention to treat. We compared the death rates 
in Ehe two treatment groups by odds ratios and 95% C1. We used 
logistic regression to adjust for Potential confounding variables. 
Treatment centre was fitted as a fixed effect, gestational age in 
weeks as a categorical variable, and birchweight as a continuous 
variable. All ocher potential confounding variables were binary. 
The models were fitted by use of STATA (version 5.0). We 
compared secondary outcomes by odds ratios and, since the 
frequency of some of the outcomes was low, we used the exact 
method of Thomas, 14 as iniplernenEed in StatsDircct (version 1.5). 
Results 
The data safety and monitoring committee met in 
December, 1999,19 months after the trial started. Data on 
recruitment (207 neonates at Dec 1), exclusions after 
randomisation (at that time 16 for suspected violations of 
study protocol), and available outcome data for 189 
neonates were presented (data on two were unavailable). 
The committee, unaware of treatment assignment, noted 
an unexpected and highly significant difference in 
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Outcoms, Poractant &Its PlImactant Odds ratio 195% Cl) 
Pneumothorax 
Total 11/99(11%) 22/100(22%) 0.44 (0-18-1-03) 
Surmors 6/85(7%) 8/69(12%) 0.58 (0-16-2-03) 
Treated patent ductus artedOSUS 
Total 20/99(20%) 10/100(10%) 2-27 (0-94-5-TT) 
Survivors 18185(21%) 6/69(9%) 2-82 
Intraventdcular haemarrhage any grade- 
Total 42/96(44%) 37/93(40%) 1-18 (0-63-2-19) 
Survivors 33/83(40%) 24/68(36%) 1-09 (0-53-2-24) 
intlaventficulgt haemarrhage grades III and IV* 
Total 7/96(7%) 7/93 (a%) 0-97 (0-28-3-38) 
Survivors 5/83(6%) 4/66(6%) 0-99 (0-20-5-23) 
Cystic petiventiricular leucomal=13' 
Total 12/96(13%) 16/93(11%) 0-69 (0-28-1-66) 
Surmors 9/83(11%) 15/66(23%) 0-4110-15-1-11) 
Necrousing enterocolitis P"Bell sta. 'O 11) 
Total 4/99(4%) 3/100(3%) 1.36 (0-22-9. S3) 
suivivors 1/85(1%) 1/69(1%) 0-81 (0-01-64-5) 
Treated retinopathy of prematurity 
Sumvors 3/85(4%) 5/69(7%) 0-47 (0-07-2-52) 
Pulmonary haemorrhage 
Total 9/99(9%) 5/100(5%) 190 (0-55-7-48) 
Survivors 6/85(7%) 2/69(3%) 2-54 (0-43-26-4) 
chronic lung disease 
Survivors at 28 days 55/88(63%) 44/75(59%) 1.17 (0-60-2-31) 
Survivors at 36 weeks 46/86(53%) 42/75(56%) 0.90 (0-46-1-76) 
morn& oxygen 31/85(36%) 23/69(41%) 0-82 CO-41-1-66) 
-Scanned neonates only. 
Table 4: Frequency of secondary outcomes 
predischarge mortality that was not explained by differences 
in gestational age or sex, and recommended that the trial be 
stopped. Ile trial coordinators stopped recruitment on 
Dec 14,1999, by which time five more babies had been 
recruited. 
From 403 eligible neonates, 212 (198 born in the level 
III neonatal units and 14 transferred) were included in the 
trial (figure 1). 191 neonates were excluded before 
randomisation because of- no ventilation (49), no consent 
from parents (37), precipitate delivery (28), congenital 
malformations (three), lack of time for medical staff (30), 
approach being thought inappropriate (seven), no reason 
(36), or other reasons (one). 13 babies were excluded after 
randomisation because of. incorrect estimation of gestation 
(three), stillbirth (four), withdrawn consent before 
treatment (one), delivery after 30 weeks (four), or 
congenital malformation (one). Of the neonates included in 
the analysis, one assigned poracEant alfa received beractant, 
and one received pumaccant. Three neonates in each group 
were not ventilated after delivery and received no 
surfactant. Baseline characteristics were similar for analysed 
neonates (table 1). 
Neonatal mortality (odds ratio 0-38 [95% CI 0- 17-0-8 1], 
p=0-0 11) and predischarge mortality (0-37 (0-18-0-74], 
p=0.004) were lower in neonates who received poractant 
alfa than in those who received purnactant (table 2). The 
differences remained significant after adjustment for centre, 
gestational age, birthweighr, sex, plurality, and use of 
antcriatal steroids (neonatal mortality 0-32 (0-13-0-771, 
P=0-011; predischarge mortality 0-27 [0-11-0-64), 
p=0-003). The difference in mortality betwecrt surfactanEs 
was consistent across cencres. 
Five of the 14 predischarge deaths among neonates 
receiving poractant alfa, compared with 21 of 
;1 
receiving 
pumactant were attributed to respiratory causes (table 3). 
Therefore, the proportions of deaths attributed to respiratory 
causes were 5% (rive of 99 neonates) for poractant alfa and 
21% (21 of 100) for pumactant (predischarge unadjusted 
Poractant alta 
50 -n 
40 -ý 
30 -ý 
20 
10 -ý 
B 
01 c 0 0 c 
Pumactant 
50 
CL 
0_ 401F 
2 
304 
20- 
10 
0" fl 
0' 
119 eto 143 blP <10 C113 -113 40, (AD _013 -NI. 
3 
-no 
Time to first dose (min) 
Figure 2: Time to first dose of surfactant 
Three neonates were given first dose of purnactant and five were given 
first dose of poractant alfa after 120 min. 
odds rado 0-20 (0-07-0-56], p=0-001). The difference 
remained significant after logistic regression (0-13 
(0,04-0-44]. p=0-001). Around 75% of deaths in the ENvo 
groups occurred before 28 days; there were more late deaths 
in the pumactant group. Five of the six late purnactant 
deaths were attributed to chronic lung disease compared 
with one of three in the poractant alfa group. 
Median duration of high-dependency care among 
survivors was 22 days (IQR 5-52) in the pumacEant: group 
and IS days (6-39) in the poractant alfa group. The groups 
did not differ significantly for secondary outcomes (table 4). 
Times to first dose of surfactant are shown in figure 2. 
Timing of the first dose of surfacEant (administration before 
30 min vs administration after this time) did not alrcr the 
treatmenE effect (test for interaction, p=0-64). 
Discussion 
The decreased neonatal and predischarge mortality 
(secondary outcomes) in the poracrant alfa group was 
unexpected and led to early stopping of the trial. This 
finding was not explained by any of the potentially 
confounding variables we assessed and the difference in 
mortality is, therefore, probably a treatment effect rather 
than a chance finding. Stopping the trial early may have 
widened the difference between groups. 
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The 13 neonates excluded after randomisation do not 
bias the analysis, which was done by intention to treat. We 
excluded neonates with malformations because the 
presence of the malformation is unequivocal and cannot be 
affected by the treatment assigned. Gestational age was 
defined as the best obstetric estimate and was, therefore, 
independent of the postnatal management. 
Lower median gestational age and birthweight in the 
purnactant group and the higher numbers of mate neonates 
and multiple births in the poractant alfa group might have 
been expected to increase mortality in the respective 
treatment groups, but inclusion of these terms in the 
logistic regression did not alter the magnitude or direction 
of the difference found. - Stratification by centre at 
randomisation compensated for differences in local 
guidelines and in policies on rescue treatment. 
We considered the possibility of controlling for disease 
severity and the protocol specified that scores for critical 
risk index for babies" should be collected prospectively. 
However, this and other published scoring sysEemsl-l' all 
use variables that were not available until after entry to the 
study and could, therefore, have affected the estimate of 
treatment effect in an unpredictable way. Masking of 
clinicians to treatment assigm-nent was not possible without 
alteration of the surfactant properties; pumaccant requires 
reconstitution in cold normal saline, whereas poractant alfa 
requires warming to body temperature and administration 
is weight dependent. Most studies included in the meta- 
analysis of synthetic and animal-derived surfactants did not 
mask treatment assignment. 
Our protocol stipulated that the second surfacrant dose 
be given to ventilated neonates 12 h after the first dose, 
which is in accordance with die poractant alfa datasheer. 
The datasheet for purnactant states a second dose may be 
given at 1h and a third at 24 h. The second dose is 
commonly omitted, and there is no published evidence to 
support or refute its value. 'Me two largest centres in this 
trial, Liverpool and Newcastle upon Tyne, exclusively used 
purnactant before this trial. In Liverpool, one dose was 
given in the delivery suite and a second dose at 12 h; in 
Newcastle, the first dose was given on admission to the 
neonatal intensive-care unit and a second dose 24 ji later. 
Predischarge mortality among ventilated babies of 25-29 
weeks' gestation in the 2 years before this trial (1996-97) 
was similar in Liverpool (26-5%) and in Newcastle 
(25-4%). 
11rcdisch3rge mortality in the pumactant group or our 
study (31-3%) was similar to the historical data, but was 
greater than mortality in the pumacEant group of the Ten 
Centre study (19-0%), " and closer to the mortality in the 
control group of that study (29.7%). Differences in disease 
severity, changes in patterns of care or demographic 
variables of babies in studies done more than 10 years apart 
may explain some of the differences. For example, 10.7% 
of neonates in the treatment group of the Ten Centre study 
were not ventilated (and received only a pharyngeal dose of 
pumactant). Gestation-specific predischarge mortality in 
the pumactant-treated neonates born at 25-26 weeks' 
gestation (42-9%) in our study was similar to that in the 
Ten Centre study (43-2%), but was higher in those born at 
27-29 weeks' gestation (24.6 vs 9-61/4). The differences in 
mortality between the studies at each gestational week did 
not reach significance (test for interaction p=O-OS). 
Most of the early clinical differences in effect between 
synthetic and animal-derived surfactants are asc6bed to 
surfactant proteins. " Surfactanx proteins B and C (SP-B 
and SP-C) are contained in animal-derived surfactant 
preparations and are especially important in alveolar 
spreading of surfactant and reduction of surface tension. " 
Addition of SP-B and SP-C to pumactant improves 
surface-tension-lowering properties in vitro, ' and lung 
compliance in preterm rabbits treated with protein-free 
surfactant was better if the surfactant was supplemented 
with SP-B, SP-C, or both. " Neonates who have a 
congenital absence of SP-B have no effective surfactant 
function and die with intractable lung disease. " The 
absence of surfactant proteins in pumactant cannot entirely 
explain the mortality difference because large trials 
comparing colfosceril (a synthetic product with no 
surfactant proteins) with beractant have shown , no 
significant differences in mortality. '"" 
'ne pathological processes leading to lung damage begin 
soon after delivery' and may be worsened by factors such 
as resuscitation manoeuvres, mechanical ventilation, and 
oxygen therapy. " Most protein leakage into the alveolus 
occurs early in the course of respiratory distress syndrome; " 
administration of exogenous surfactant lowered the rate of 
leakage in animals. '"' Early C'prophylactic") surfactant 
administration in clinical trials is more effective at reducing 
mortality and air leaks than administration after lung 
disease is established. " Comparisons of synthetic and 
animal-derived surfactants have largely used rescue 
strategies in which surfactant is given to neonates with 
established respiratory distress syndrome; the only 
exception to date is one prophylaxis trial of colfosceril 
compared with calfactant. " Early surfactant administration 
in our trial may have widened the difference between 
groups in effect on mortality. We saw no beneficial effect in 
administering surfactant before 30 min compared with 
later, but we had not designed the trial to sho%v such a 
difference. Other outcome measures did not differ 
significantly, but sample size had not been calculated on 
this basis. 
Althou. -h stopping this trial early may have increased the 
difference in mortality between the two groups, we believe 
that our findings on this secondary outcome have 
implications for clinical practice. Cost data relating to the 
primary outcome will be analysed and published separately. 
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North Thames 
Multi-centre Research Ethics Committee 
Chairman: Dr Hugh Davies 
1 May 1998 
Administrator: Mr John Richardsc 
Dr Diana Elbourne 
Medical Statistics Unit, London School of Hygiene & Tropical Medicine 
Keppel Street, London WCI E 7HT 
i Ck Dear Dr Elbourne C,. N, ; -, t 
61-74 
Appllcýtion reference numbe MREC19712141 (please quote in all correspondence) 
Protocoltitle A pilot study for a multi-centre ran domis ed controlled trial of 
entilatory support with Inhaled Nitric Oxide compared to Ventilatory support 
without inhaled nitric oxide for neonates with respiratory failure - The INNOVO 
Trial 
Ancillarv studies Pathology 
Toxicology 
Respiratory follow-up 
Views of participants in trials 
I acknowledge receipt of the letter of 30 March 1998 from Ms Claire Snowdon. 
Acting under delegated authority, the Chairman of North Thames Multi-centre 
Research Ethics Committee is satisfied that this response meets the requirements of 
the Committee following its meeting on 25 February 1998. He has agreed that there 
is no objection on ethical grounds to the studies whose titles and reference number 
are given at the head of this letter. I am therefore happy to give you the 
Committee's approval on the understanding that you will follow the protocol as 
agreed. The documents approved by the Committee are referenced in the enclosed 
Response Form, which also contains the Committee's comments. 
Conditions of approval 
Please read the notes regarding notification of change's and completion of progress 
reports at the end of the Response Form, as the MREC requires that they be 
followed. 
You will no doubt realise that whilst the MREC has given approval for your project on 
ethical grounds, it is still necessary for you to obtain management approval from the 
relevant Clinical Directors and/or Chief Executive of the Trust(s) or Health Authority 
(ies)/Board(s) in which the work will be done. 
Local submissions 
It is also your responsibility to ensure that any local researcher seeks the approval of 
the relevant Local Research Ethics Committee before starting their research. To do 
this, you should submit the appropriate number of copies of the following to the 
relevant LRECs: 
0 this letter 
0 the MREC application form and supporting documents 
0 the enclosed response form 
0 Annexe D of the MREC application form 
9 one copy of the protocol 
338 
Trust Office Central Middlesex Hospital Acton Lane London NW10 7NS 
Tel 0181 453 2336 Fax 0181 961 0012 
It is important to check with the respective LRECs on the precise numbers of copies 
required as this will vary and failure to supply sufficient could lead to a delay. 
MREC evaluation 
During the first year after its establishment, the IVIREC would like to hear your views 
and experiences while using the new system. Could you please help us by 
completing the Principal Researcher Evaluation Form enclosed with this letter and 
returning it to Jo Duggan, Centre of Medical Law and Ethics, King's College, 
London, Strand, London WC211 21-S. Your help is also appreciated in ensuring 
that local researchers are sent a Local Researcher Evaluation Form also enclosed 
with this letter. Your views and comments are vital to ensure the process evolves 
and responds to the needs of multi-centre researchers and we look forward to 
receiving your comments. 
Local sites 
While the MREC would like as much information as possible about local sites at the 
time you apply for approval, it is understood that this is not always possible. You are 
asked however to send a completed copy of Annexe C for each local site as soon as 
a researcher has been recruited. This is essential to enable the MREC to monitor 
the research it approves and for the smooth running of the evaluation. 
ICH GCP compliance 
North Thames MREC is fully compliant with the International Committee on 
Harmonisation (ICH) Guidelines for Good Clinical Practice as they relate to the 
responsibilities, composition, function, operations and records of an Independent 
Ethics Committee/independent Review Board. To this end it undertakes to adhere 
as far as is consistent with its constitution to the relevant clauses of the ICH 
Harmonised Tripartite Guideline for Good Clinical Practice adopted by the 
Commission of the European Union on 17 January 1997. The Standing Orders and 
a Statement of Compliance were included on the disk containing the guidance and 
application form and are available on request or on the Internet at 
http: //dspace-dial-pipex. com/mrec 
Yours sincerely 
C4 4- 
John Richardson 
Administrator, North Thames Multi-centre Research Ethics Committee 
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UNIVERSITY OF CAMBRIDGE 
CENTRE FOR FAMILY RESEARCH 
Social and Political Sciences Faculty Office: (01223) - 334510 
Free School Lane, Cambridge CB2 3RF Fax No: (01223) - 330574 
-I. --. I 
Director: Professor Martin Richards 
Dear Dr ................. 
E-mail: cfr-admin((_vlists. cam. ac. uK 
Personal Line: (01223) - 33 
Re: Views of participation in neonatal randomized controlled trials -a study o 
informed consent 
I am writing to draw your attention to the above study which is ongoing in the 
neonatal unit at .......... Hospital. The study is funded by the Nuffield Foundation and examines highly topical issues surrounding clinical trials. 
We are exploring participation in neonatal trials from the perspectives of each 
of three key parties; the parents, the medical staff, and the nursing staff. In the 
light of recent media interest in RCTs it is important that careful research is 
carried out to clarify the processes involved in neonatal trials and to ascertain 
the views of all of the parties concerned. The aims of the study are: to 
describe both the formal and informal processes by which parents are 
informed about RCTs; to provide information about how trials are perceived 
and understood by parents who accept or decline trial participation; to 
highlight possible sources of confusion and to provide a forum for staff to state 
the impact of trial participation upon their own practice. We hope to highlight 
areas where staff feel the need for support and information to assist the 
smooth running of trials and to improve their own and parents' experiences of 
participation. 
The process of recruitment and consent for the INNOVO Trial is of particular 
interest and we have ethical approval for conversations between doctors and 
parents to be tape-recorded. Your help in this last element of the research 
would be appreciated. If you are about to approach parents to offer 
participation in the INNOVO Trial, we would be grateful if you would consider 
asking if they would permit a tape recording of your conversation to be made. 
We do appreciate that this can be difficult and this is addressed in the 
enclosed study protocol. 
We have ethical approval for two approaches to consent, both aimed at 
interfering with clinical practice as little as possible; you can either give 
parents a very brief letter asking for their permission to make a recording, 
followed by a more detailed letter which is given after the conversation, or you 
can orally give the information to parents at first and then the detailed letter 
afterwards. The letters are held with the INNOVO Trial details. 
The tape recordings provide valuable data which are not only important in 
their own right, but also give insights to the interview data which are collected 
subsequently. Clearly there are some instances where it is inappropriate to 
approach some parents, but any recordings which are possible will make an important contribution to our understanding of consent in this area. 
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Tape recorders have been provided and are held by Dr .......... and Dr 
.......... . Details of procedures are 
in the protocol and summarised on a 
laminated sheet kept with the INNOVO Trial information. A copy of the 
protocol is enclosed for your information. I have also included a copy of our 
most recent publication from our related research with parents of babies 
recruited to the ECMO Trial. 
If you have any queries I can be contacted on 01223 334508 or emailed at 
cmsl 000@cam. ac. uk or (nurse) is acting as a contact person for the study. 
Alternatively you could contact Professor ............ who has made recordings for the study and is very familiar with this research. 
Yours sincerely 
Claire Snowdon 
Research Fellow 
enc protocol 
publication 
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UNIVERSITY OF CAMBRIDGE 
CENTRE FOR FAMILY RESEARCH 
Social and Political Sciences Faculty 
Free School Lane, Cambridge CB2 3RF 
Director: Professor MarEin Richards 
Study of communication in hospital 
Office: (01223) - 334510 
Fax No: (01223) - 330574 
E-mail: cfr-admin@lists. cam. ac. uk 
PersonalLine: (01223) - 33 
Doctors in this department are working with researchers at the Universities 
of London, Cambridge and Oxford to look at the ways that parents and 
doctors talk to each other about the care of babies in hospital. Your doctor 
has agreed to ask parents if they would take part in the study by allowing a 
tape-recording to be made of their conversations together. The point of the 
study is to see if improvements can be made for babies, children and their 
families in the future. 
Whatever you decided will not affect the care given to you and your child 
and it won't change anything that happened today. There will be no extra 
people in the room because of the research and you will not be asked to 
answer any questions. You may be invited to give your views on what has 
happened to you in a few months, but you do not need to decide about that 
now. If at any time you change your mind you can ask for the tape-recorder 
to be switched off or for the tape to be wiped clean. If you are happy to 
take part, the tape will be sent straight to the research team and will not be 
played to anyone else at any time. 
Please sign below to say whether or not you want to agree to the tape 
recording. If you do decide to take part your doctor will give you a copy of a 
letter with more details about the study. You will be able to take it away 
and read it at a more convenient time. 
Thank you for taking the time to read this. 
Consultant Claire Snowdon Diana Elbourne Jo Garcia 
Neonatal Unit Cambridge University London University Oxford University 
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Study of communication in hospital 
INVe have decided that the doctor 
IJ can make a tape-recording of our conversation 
11 cannot make a tape-recording of our conversation 
Signed .............................................. Date ....................... 
Signed .............................................. Date ....................... 
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UNIVERSITY OF CAMBRIDGE 
CENTRE FOR FAMILY RESEARCH 
Social and Political Sciences Faculty 
Free School Lane, Cambridge CB2 3RF 
Office: (01223) - 334510 
Fax No: (01223) - 330574 
E-mail: cfr-admin@lists. cam. ac. uk 
PersonalLine: (01223) - 33 Director: Professor Martin Richards 
Thank you for allowing your doctor to tape record your conversation. It will 
make a very important contribution to our study. This letter is to give you 
some more details. 
We are looking at how parents feel about clinical trials. Taping the 
conversations that doctors and parents have about a trial is the most 
important part of the study. It tells us what parents and doctors say to each 
other at this time. We will be taping about 150 conversations. We will also 
ask everyone in the study if they would fill in a short questionnaire to give 
us some basic information. That is all most of the people in the study will be 
asked to do. 
In a few months, parents of around 40 babies will be invited to talk to the 
researcher, Claire Snowdon, about their experiences. These talks will 
include some parents who decided that they would agree that their baby 
would join the trial, and some who decided that they would not. The talks 
will be arranged at a time and a place (usually at home) which is convenient 
and comfortable for the parents. We are not asking you to decide about 
whether you want to talk to Claire now but if you feel strongly that you do 
NOT want us to contact you, please say so on the attached slip. If you send 
it to us in the prepaid envelope we will take your name off the list of people 
who might be invited to talk with Claire. 
The study will also include some interviews with doctors and nurses who 
are involved in the INNOVO Trial. They will not be asked to talk about you 
or any other individuals. The interviews with staff will look at what they think 
about being involved in clinical trials. 
The tape recordings made for the study will be treated as completely 
confidential. They will not be played to anyone outside the research team 
else. If you are unhappy about the recording that has been made of your 
conversation, for any reason, tell us or your doctor and it will be destroyed 
(** if possible) and you will not be contacted again about the study. Your 
decision will not affect the care given to you and your baby. 
If you have any questions about the study you could talk to your doctor or 
you can contact Claire Snowdon. She will be happy to answer your 
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questions. Her address is at the top of this letter or you can call her directly 
on 01223 334508. 
This study will give important information about how parents, doctors and 
nurses feel about clinical trials. It will be used to guide doctors about how to 
talk to parents in the future when they ask if they would take part in a trial. 
We very much appreciate the contribution that you have already made to 
the study. Thank you for helping at this difficult time. 
Clinician's name Claire Snowdon Diana Elbourne Jo Garcia 
Title Research Fellow Senior Lecturer Social Scientist 
Neonatal Unit Cambridge Univ. London Univ. Oxford Univ. 
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Study of communication in hospital and attitudes to 
clinical trials 
INVe have decided that we would prefer you to take our name from the list of 
parents who could be invited to be interviewed. This means that we will have 
no more contact with the study team. 
Signed .............................................. Date ....................... 
Signed .............................................. Date ....................... 
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Appendix F- Parental information sheet for the CANDA 
Trial 
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Comparative trial between Curosurf and ALEC in the treatment of respiratory 
syndrome in preterm infants. 
We would like to ask for your help in a research trial that is currently in progress on 
the Special Care Baby Unit. This is part of the on-going research into problems encountered 
by babies who are born prematurely. 
Babies who are born more than 10 weeks prematurely often have problems with their 
lungs due to a lack of surfactant. Normally surfactant is produced in the lungs. It helps keep 
the air spaces open making it easier to breathe. A baby born prematurely may not have time 
to "switch on" its production of surfactant. To overcome this it has become standard practice 
to administer replacement surfactant and this has been shown in many trials to be effective. 
We are currently looking at two different surfactants. The first, ALEC (Artificial 
Lung Expanding Compound), is a man-made artificial surfactant and has been used in [this 
hospital] and other centres for several years. The second, Curosurf, is a naturally occurring 
surfactant and is derived from pig lung. This has also been used in many Special Care Units 
for some time. 
Both artificial and natural surfactants have been shown to work in premature babies. 
Natural surfactants actually work faster but whether this means they are better is unclear. 
Artificial surfactants on the other hand are cheaper and may be safer, not being derived from 
animals. The only way to be sure about this is to perform trials making a randomised decision 
about which surfactant a baby will receive, and then comparing the two groups of babies 
If you decide you would like to help us by allowing us to enrol your baby in this trial 
your baby will be randomised to receive either ALEC or Curosurf replacement surfactant. 
The only difference in treatment your baby would receive as part of the trial is the 
randomisation to one or other surfactant. The only difference in treatment your baby would 
receive as part of the trial is the randomisation to one or other surfactant. In addition we 
would like to analyse the secretions from your baby's breathing tubes. It is routine care 
for babies to have their breathing tubes cleared of secretions while they are on 
the ventilator to prevent blockage. Instead of throwing these secretions away, 
as is normally the case, we will keep them and analyse them. This does not 
entail any additional tests on your baby and collection will only be done as part 
of their normal routine care. An additional information sheet explaining this in 
greater detail is available, please ask if you would like to see this. 
We hope to recruit 500 babies into this trial here and in other hospitals. The first dose 
of either surfactant is given as soon as possible after birth, preferably within two hours in 
order to gain maximum benefit. 
PLEASE NOTE: 
0 Participation in this trial is entirely voluntary. Your baby will continue to receive 
normal neonatal care. Should you decide not to participate, and in this case the 
standard treatment would be to use ALEC. The quality of care will not be affected by 
your decision. 
You may withdraw your baby from the trial at any time without giving a reason 
and without it affecting the care your baby receives. Please tell the doctor or nurse 
looking after you or your baby. 
If you decide to allow us to enrol your baby into this study we would be happy to explain any 
queries you may have regarding his or her treatment. 
Thank you very much for your help. 
(Dr's name) 
RESEARCH REGISTRAR 
PAEDIATRICIAN 
(Dr's name) 
CONSULTANT 
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Comparative trial between Curosurf and ALEC in the treatment of respiratory 
syndrome in preterm infants. 
I ................................................... of .............................................. 
...................................................... 
........................................................................................................... 
have read the information sheet regarding this trial and discussed its contents 
with Dr ........................................ 
I agree to participate with my babylbabies . .......................................... 
I understand that they may receive either surfactant and it is not know which surfactant will be 
given in advance. I also understand secretions from routine cares of my 
babylbabies will be collected and analysed, but that this will not entail 
additional tests on my baby/babies. 
I understand that I may withdraw my consent at any time without having to give a reason. In 
the event that I withdraw my consent, my decision to do so will not affect the care afforded to 
my baby. 
Signed: ................................................. Date: ...................................... 
Witnessed by: ......................................... Date: ...................................... 
(Member of staff explaining the trial) 
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Appendix G- Parental information sheet for the INNOVO 
Trial 
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Appendix H- Literature relating to interviews with 
neonatologists 
1 Invitation to participate in the study 
2 Interview schedule 
3 Brief questionnaire 
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UNIVERSITY OF CAMBRIDGE 
CENTRE FOR FAMILY RESEARCH 
Social and Political Sciences Faculty Office: (01223) - 334510 
Free School Lane, Cambridge CB2 3RF Fax No: (01223) - 330574 
--I.. -. I 
Director: Professor Martin Richards 
Dear Dr 
E-mail: dr-adminý01ists. cam. ac. uK 
Personal Line: (01223) - 33 
Re: Study of communication in hospitals and attitudes to clinical trials 
I am writing to you with regard to some research which involves staff 
previously or currently connected to the Neonatal Intensive Care Unit at the 
.......... Hospital. 
The research is funded by the Nuffield Foundation and is 
eing carried out by researchers at the Universities of Cambridge, London and 
Oxford. We are looking at the views of those involved in a neonatal 
randomized controlled trial, the INNOVO Trial. The study involves interviews 
with parents, medical staff and nursing staff and aims to examine trial 
participation from these three perspectives. As you were involved in the 
recruitment of at least one of the babies in the INNOVO Trial we would like to 
ask you to take part in the research. 
The staff interviews examine the issues that involvement with trials raises for 
individuals. They will explore staff opinion about appropriate methods of giving 
information and will highlight any specific features of individual trials which 
may raise difficulties. You would be asked after the interview to complete a 
one page demographic questionnaire. 
There is a reply slip and prepaid envelope with this letter which you could use 
if you want to let me know whether or not you are interested in taking part in 
the study. I plan to call you some time in the next week or so unless I hear 
from you that you would prefer not to take part. In the meantime if you wish to 
know more about the research you could call me on the above number or 
email me at Cambridge (cmslOOO@cam. ac. uk). I would be happy to answer 
any queries you might have. 
Yours sincerely 
Claire Snowdon 
Research Fellow 
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Schedule and notes for interviews with staff - INNOVO Trial 
General guidelines 
If possible the tape recorder should be placed between you, away from an 
obvious source of noise. 
Try to keep your own speech to a reasonable minimum. You obviously 
need to talk to staff to engage in a comfortable conversation, but you don't 
want to inhibit their views in any way, and everything you say, including 
encouraging them in a line of thought with 'uhuh', will be transcribed. 
Unless it looks or feels artificial I usually try to nod or sometimes wait a 
little, in which case interviewees will often continue or expand on their 
thoughts quite naturally. 
Before the interview starts 
Position of the interviewer 
There are key points to make about the position of the interviewer. I usually 
make it clear that I am not a member of the trial team or linked in any way to 
any of the hospitals involved in the trial. I am employed to look at the views of 
the people involved and because I am an outsider, it does not matter to me 
what the staff have to say about the trial. Specific comments they make will 
not be reported back to their colleagues. Any information used from the 
interview in a report would not use their real names. 
The study 
The study involves any member of staff involved in the INNOVO or CANDA 
trials in actively recruiting centres, and parents of up to 50 babies who had 
breathing difficulties after birth who were asked if they would consider joining 
one of the trials. 
The interview 
The schedule outlined below is a guide to the areas I need staff to talk about. 
Some of them will cover these areas quite naturally with little prompting so the 
questions may not even be necessary. They are there not to suggest that you 
should stick rigidly to them, but to help you to know whether or not the 
interview has elicited the information needed. Sometimes you may need to 
allow staff to finish a thread of thought and then take them back to an earlier 
area which has been missed. Sometimes it will be clear that there is an 
important issue for individuals which is not part of the schedule, eg 
circumstances of a case which is particularly memorable or their own 
circumstances at the time. Although these are not part of the schedule they 
are important as they give a context to the rest of the information. It is 
therefore important to strike a balance between accessing information and 
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giving staff the opportunity to talk about things that are meaningful for them, 
and not allowing the interview to deviate excessively into unrelated areas. 
The length of time that the interview will take depends mainly on how much 
the staff have to say. If they want to set a time by which it should it should end 
that is fine. It is likely that the staff interviews will be shorter than the parental 
interviews, especially if they are seen at work. There may be interruptions 
from bleeps or colleagues needing their assistance. With their permission the 
conversation will be tape-recorded. If permission is not given (this has not yet 
occurred in any previous interview for the parents in associated studies) then 
it will be necessary to take some notes at the time and after the interview. It 
would clearly not be possible to note down all answers in full so it must be 
accepted that data will be lost in these circumstances. Staff who agree to a 
recording should be told that they may ask for the tape to be stopped at any 
time, either for a break or to end the interview. If there are any questions that 
they do not wish to answer then that is fine too. 
Questionnaire 
A short questionnaire collecting demographic details will be left at them at the 
end of the interview, with a prepaid envelope. This should be briefly 
mentioned. 
Any questions 
It should be checked whether there is anything that the staff want to know 
about the study, and whether they are happy to proceed. 
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Introduction 
We asked you if you would be interested in taking part in this research as you 
were involved in recruiting a baby to the INNOVO Trial. Although we are 
primarily looking at reactions of parents and staff to two neonatal trials, of 
which the INNOVO Trial is one, some of the questions relate to your views 
and involvement with trials more generally. We are interested in the issues 
they have raised for you and what you think about particular aspects of trial 
methods. If there are any aspects of clinical trials that you would particularly 
like to raise, feel free to do so. The questions do not require you to give any 
details of the cases you have been involved with, but if you do choose to give 
any examples of your experiences, we would safeguard patient confidentiality. 
We will use pseudonyms in any publications, as we would for you, and would 
not use obviously identifying details. If there are any questions that you would 
prefer not to answer, indicate this and we can simply move on. 
Section I 
Professional role and neonatology 
Firstly we need a little background details about you. There is a short 
demographic questionnaire for you to complete later, but for now could you 
briefly tell me: 
For current neonatal staff - what your current role is within the neonatal 
unit? 
For registrars on rotation or staff who have moved on - about your role 
when you worked on the neonatal unit and whether you have any continued 
role there? 
Do you plan to continue/go back to work in neonatology? 
Section 2 
Involvement with clinical trials 
What involvement have you had with clinical trials, both in neonatology and in 
any other specialty? NB If the interviewee has experience in trials in other 
areas, there are questions in Section 3 which cover comparisons 
between specialties. 
Do you remember when you first recruited a patient to a trial? 
How frequently do you currently recruit patients to trials? 
To what extent has your involvement been optional or were you obliged to be involved in trials? 
How have you found this aspect of your work? 
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Do you feel that trials in neonatology raise any different issues to those in 
other specialties? 
We are interested in what preparation professionals have had for working in a 
trial context, and whether you feel there are any particular training needs. For 
each of several areas we would like to know if you have had any formal 
training, when, what form the training took and how useful it was. 
Have you had any training in: - clinical trial methods and terminology? 
- ethical aspects of clinical trials? 
- recruitment to clinical trial? 
If no, have you covered any of these issues informally or on your own? 
If no to any of the above, how useful would training be? 
Section 3 
Recruitment and consent in neonatal trials 
Recruitment to clinical trials is known to be a difficuft area in terms of the 
process of informing participants to ask for consent, and because of the 
circumstances involved. 
In the past have you felt sufficiently prepared to recruit participants to trials? 
How do you feel about your role in the process of recruitment now? 
(if the above question is not answered in terms of stress that it might 
cause for staff) Do you ever find recruitment stressful? If yes, for what 
reasons? 
How do you feel about asking parents to consider taking part in research? 
Are there any factors which influence your decision whether or not to 
approach parents of babies who are eligible for a trial? 
Some people argue that a problematic aspect of trials for professional is that 
there are competing demands between the needs of the patient in your care, 
and the need for information to treat patients in the future. 
Has this been an issue for you at all? 
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We are interested in individual's approaches to giving infonnation to parents' 
when discussing a trial, and what details you think are appropriate or 
inappropriate. 
What information do you usually give to parents about a trial? 
(If not covered spontaneously ask the following questions marked # as 
prompts. Questions marked * are to be asked of all interviewees unless 
obviously repetitious) 
# Do you talk to parents about the purpose of a trial? If yes, what do you 
tell them? 
Do you talk about the different treatments in the trial? If yes, what do 
you tell them? 
Do you explain the idea of equipoise? If yes, how do you go about 
explaining it? Do you find it difficult at all? How do the parents tend to 
react? NB Use the term 'equipoise' to see if it is familiar to staff. 
If you are describing the current state of knowledge about a treatment, 
do you give your own views about the treatment. If yes, do parents 
seem to find it helpful? 
Do you find that parents often express a preference for one treatment? 
# Do you tell them about the trial methods (eg randomization, 
comparisons of groups)? If yes, what do you tell them? 
If doctors say they do explain randomization, Do you find this 
difficult at all? Do the parents seem to find it difficult? 
How do you react to the use of randomization? 
How do parents tend to react? 
Are there any terms or concepts which you think are particularly difficult 
for doctors to explain or for parents to understand? 
# Do you tell them about any follow up there might be for the trial? 
Do you ever feel that it is inappropriate to give particular pieces of information 
about a trial? 
Are there any terms that you avoid using or areas you avoid discussing? 
How realistic do you feel it is for parents to gain an understanding of clinical 
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trials in this sort of context? (This question may well have already been 
covered by earlier answers) 
Do you feel comfortable that you are getting informed consent? Do you think 
that it is a) possible and b) desirable? 
Section 4 
Parental decisions 
How commonly do you find that parents ask'What would you do in our 
situation? '? 
How do you respond to this? 
Have you thought about what you would do if faced with their situation? 
Have you ever had parents decide not to participate? If yes, how does that 
feel? 
When parents give consent to participation, how do you then find the process 
of randomization? 
What is it like to go back and tell the parents about the allocation that has 
been made? 
Once the allocation has been made, do you ever think about what it would 
have be like if a patient were allocated to the alternative arm of a trial? 
Do you feel that there are any particular benefits for patients and their families 
who decide to take part in a trial? 
Do you feel that there are any problems or difficulties for them? 
Optional question Do you think there is anything that could make the 
situation easier for patients and their families? 
Optional question Do you think there is anything that could make the 
situation easier for staff? 
Section 5 
The INNOVO Trial 
What has been your involvement in the INNOVO Trial? 
What do you think of this particular trial? (If the interviewee wants 
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expansion of the question we are interested in the aims and the 
conditions set by the trial) 
Has this trial raised any particular issues for you? These two questions are 
deliberately general to give staff the option of not referring to individual 
cases. 
Did you have any views about the use of nitric oxide before the trial started? If 
yes, where did these views come from eg personal experience, colleague's 
experiences, research literature etc 
Have your views about nitric oxide changed in any way during the trial? If yes, 
are there particular reasons for that? If yes, has this affected your view of the 
trial? 
Do you think that recruitment for the INNOVO Trial is any easier or any more 
difficult than other neonatal trials? 
For technical and practical reasons it was decided that the trial should use no 
nitric oxide rather than a placebo for the comparison group. Had it been 
feasible to use a placebo, do you think this would have changed things for a) 
the staff b) the parents? If yes, in what sorts of ways? 
Is there anything else you would like to add about the INNOVO Trial 
That is all of the questions but is there anything else that you would like to add 
about Wals in general or about the INNOVO Trial? 
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Appendix I- Literature relating to interviews with parents 
1. Invitation to participate in the study - parents of surviving babies 
2. Invitation to participate in the study - bereaved parents 
3. Consent form 
4. Interview schedule for parents of surviving babieS74 
5. Insert to indicate amendment to interview schedule for bereaved parents 
6. Post-interview questionnaire 
74 The interview schedule which was used to guide the assistant interviewers is included in order to give 
an impression of the aims and the style of the interviews. 
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UNIVERSITY OF CAMBRIDGE 
CENTRE FOR FAMILY RESEARCH 
Social and Political Sciences Faculty 
Free School Lane, Cambridge CB2 3RF 
Office: (01223) - 334510 
Fax No: (01223) - 330574 
E-mail: cfr-admin@lists. cam. ac. uk 
Personal Line: (01223) - 33 Director- Professor Martin Richards 
Dear parents 
Study of communication in hospital and attitudes to taking part in a clinical 
trial 
Some time ago when ......... was born, you were asked 
by a doctor if you would 
consider allowing him to take part in a clinical trial. The trial was called the CANDA 
Trial and compared two different types of surfactant. We are aware that the issue of 
joining the trial came at a particularly stressful time for you. In order to make things 
easier in the future for parents of sick babies and for the staff who look after them, 
we are asking parents like yourself to tell us how you felt about your experiences. 
We would like to hear what you have to say about your experiences when Joe was 
in hospital, and what it was like to make a decision about the trial. We are also 
interested in what you think about the trial now. 
The project will look at the views of everyone involved - the parents, the doctors 
and the nurses. By collecting everyone's views we should build up a picture of the 
whole situation. 
The project is being carried out by researchers from three universities with the help 
of the Neonatal Unit at ............................. If you decide to join the study, one of the researchers, Claire Snowdon, will arrange to visit you. Most people will probably 
be visited in their own homes but if you would prefer to see Claire somewhere else 
that can be arranged. We would like to hear the views of both parents where 
possible. If you would both like to take part you can choose to see Claire together 
or at a separate time. If only one of you would like to take part, that is not a 
problem. Claire would still be interested to come and meet one of you. 
Claire is based at the Centre for Family Research at Cambridge University. She is 
not part of the CANDA Trial team and will not pass on any identifying information 
that you might give him to the medical staff involved. Anything that you say will be 
treated in confidence and names, or other way of identifying you or .............. I would be changed in any reports that are written. The doctors and nurses who are 
involved in the CANDA Trial who take part in the project will not be asked to talk 
about you or any other individuals. The interviews with staff will look at what they 
think about being involved in clinical trials. 
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There is a reply slip with this letter. Please fill it in to say whether or not you would 
like to take part in this study. There is a prepaid envelope included so you will not 
need a stamp. 
If you have any questions about the study you could talk to your doctor or you can 
contact Claire. She will be happy to answer your questions. You could use one of 
the prepaid envelopes or you can call him directly on 0 1223 334508. 
Thank you for taking the time to read this letter. 
Yours sincerely 
Dr [name] Claire Snowdon Diana Elbourne Jo Garcia 
[Title] Research Fellow Professor Social Scientist 
[Hospital] Cambridge University London University Oxford University 
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Study of communication in hospital and attitudes to clinical 
trials 
Please tick a box 11 
0 I/we do wish to take part in this study 
Name (s) 
Address 
........................................................................................ 
........................................................................................ 
............ I ........................................................................... 
........................................................................................ 
........................................................................................ 
My telephone number is ............................................... 
The best times to telephone are ................................. 
...... ................................................................................. 
11 1 do NOT want to take part in this study 
Please feel free to use this space for any comments you might have. 
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UNIVERSITY OF CAMBRIDGE 
CENTRE FOR FAMILY RESEARCH 
Social and Political Sciences Faculty 
Free School Lane, Cambridge CB2 3RF 
Office: (01223) - 334310 
Fax No: (01223) - 330574 
E-mail: cfr-admin@lists. cam. ac. uk 
Personal Line: (01223) - 33 Director: Professor Martin Richards 
Dear 
Re: Study of communication in hospital and attitudes to taking part in 
clinical trials 
I gather that a few months ago you had an appointment with Dr ...... at 
........... Hospital. 
Dr ........... asked if we could write to you about a research 
project. Thank you for reading this letter at a difficult time. 
As Dr ............. explained, the project 
involves parents who were asked by a 
doctor at ............. Hospital 
if they would consider allowing their baby to take 
part in a clinical trial. The trial was called the INNOVO Trial. We are aware 
that the issue of joining the trial came at a particularly stressful time for you. 
In order to make things easier in the future for parents of sick babies and for 
the staff who look after them, we are asking parents like yourself to tell us how 
you felt about your experiences. 
We would like to hear what you have to say about your experiences, and what 
it was like to make a decision about the trial. We are also interested in what 
you think about the trial now. 
The project will look at the views of everyone involved - the parents, the 
doctors and the nurses. By collecting everyone's views we should build up a 
picture of the whole situation. 
The project is being carried out by researchers from three universities with the 
help of ............. Hospital. If you decide to join the study, one of the 
researchers, Claire Snowdon, will arrange to visit you. Most people will 
probably be visited in their own homes but if you would prefer to see Claire 
somewhere else that can be arranged. We would like to hear the views of both 
of you if possible. If you would both like to take part you can choose to see 
Claire together or at a separate time. If only one of you would like to take part, 
that is not a problem. Claire would still be interested to come and meet one of 
you. 
Claire is based at the Centre for Family Research at Cambridge University. 
She is not part of the INNOVO Trial team and will not pass on any identifying 
information that you might give her to the medical staff involved. Anything that 
you say will be treated in confidence and names, or other way of identifying 
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you or your baby would be changed in any reports that are written. The 
doctors and nurses who are involved in the INNOVO Trial who take part in the 
project will not be asked to talk about you or any other individuals. The 
interviews with staff will look at what they think about being involved in clinical 
trials. 
There is a reply slip with this letter. Please fill it in to say whether or not you 
would like to take part in this study. A prepaid envelope is included so you will 
not need a stamp. 
If you have any questions about the study you could talk to Dr ........ or you 
can contact Claire. She will be happy to answer your questions. You could use 
one of the prepaid envelopes or you can call her directly on 01223 334508. 
Thank you for taking the time to read this letter. 
Yours sincerely 
Claire Snowdon Diana Elbourne Jo, Garcia 
Research Fellow Professor Social Scientist 
Cambridge University London University Oxford University 
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Study of communication in hospital and attitudes to clinical trials 
Please tick a box 13 
0 I/we do wish to take part in this study 
Name (s) 
Address 
........................................................................................ 
........................................................................................ 
........................................................................................ 
........................................................................................ 
........................................................................................ 
My telephone number is ............................................... 
The best times to telephone are 
........................................................................................ 
[I I do NOT want to take part in this study 
Please feel free to use this space for any comments you might have. 
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Schedule and notes for interviews with parents of surviving babies 
- INNOVO Trial 
General guidelines 
Most people offer some form of hospitality, tea or coffee and sometimes food. 
I always accept something as it gives some time before the interview starts to 
break the ice and to talk about something other than the interview. I try as far 
as is realistically possible to keep off topics related to the research until we sit 
down to start. 
If possible the tape recorder should be placed between you, away from an 
obvious source of noise such as a TV. This is not always possible and if the 
TV is left on I do not ask parents to turn it off. Often it is being used as a 
means of keeping children amused, or it is just left on out of habit. It would 
seem rude to ask them to change this. If they ask if it is ok to leave it on, I 
would then feel able to ask for it to be turned down a little or for the tape 
recorder to be placed on something closer to us, such as on a coffee table, or 
even raised on books on a coffee table. 
Try to keep your own speech to a reasonable minimum. You obviously need 
to talk to parents to engage in a comfortable conversation, but you don, t want 
to inhibit their views in any way, and everything you say, including 
encouraging them in a line of thought with - uhuh, ,, will be transcribed. 
Unless it looks or feels artificial I usually try to nod or sometimes wait a little, 
in which case parents will often continue or expand on their thoughts quite 
naturally. 
Interviewing couples can be awkward as the opinions given by one can be 
taken to represent the views of the other. Whilst this is the case it is often 
worth trying to pull out the views of both parents. Even where someone looks 
like they are indicating their agreement through their body language, they may 
place a different emphasis on some aspect. Their views are worth having as 
then they can be coded in their own right. Try to pull both partners in, either by 
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asking for both of their views in turn, or observing that they seem to agree or 
disagree eg pointing out , %You were nodding-, -You were shaking your 
head- etc or more explicitly asking when their partner has made a statement 
- How do you feel about that-. This is less directive than something like - Is 
that your feeling too?, I or - Do you feel the sarne? -. 
Use the terminology that the parents use themselves, but beware of assuming 
that use of a term means that the term is clearly understood. I have fallen into 
this trap before and then had to go back over ground to work out exactly what 
the parents did mean by ,, randomisation 1 1. Try not to offer any new terms to 
parents before they use them themselves. 
Sometimes parents ask for information. The circumstances of each request 
will differ so there are no hard and fast rules about how much information to 
give and when to give it. If the parents need more information in order to 
answer your question then clearly they should be given it. An important part of 
the interview is to uncover what the parents know about the trial. If the 
information they request will change important aspects of the interview, then if 
possible a way should be found to defer answering the question until an 
appropriate time, such as after you have elicited their views on that topic, or at 
the end of the interview. Often the sorts of things that parents want to know 
can be given in a very balanced way anyway, such as questions about what 
other parents do or think, with examples of the variety of views that exist. 
Some questions will be very specific, such as -Will I be sent information 
about X?,, and in such cases it might be appropriate to suggest that they 
contact Ann Truesdale at the INNOVO Trial Office (0171927 2376). 
If parents get upset, I ask if they would like to end the interview or have a 
break. If they want to continue but are very upset, judge their degree of 
comfort with your presence. If they still want to give you the information but 
are struggling, you can always bring about a break yourself by asking if you 
can use their bathroom or offering to fetch a glass of water. Once the tape has 
actually been stopped and you have given them a few minutes, they can then 
make a decision as to whether they want to continue. 
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Before the interview starts 
Position of the interviewer 
There are key points to make about the position of the interviewer. I usually make it 
clear that I am not a member of the trial team or linked in any way to any of the 
hospitals involved in the trial. I am employed to look at the views of the people 
involved and because I am an outsider, it does not matter to me what the parents 
have to say about the trial or what happened. Specific comments they make about 
the staff or the hospital will not be reported back to the staff involved in the care of 
their child. Any information used from the interview in a report would not use their or 
their child's real names. 
The study 
The study involves parents of up to 50 babies who had breathing difficulties after birth 
who were asked if they would consider joining a trial. There are two trials involved in 
this study - the INNOVO trial which this family were offered and another trial called 
the CANDA trial which is comparing two types of a drug which is passed into babies' 
lungs to help them breathe. We will be speaking to parents and the doctors and 
nurses who ask the parents about these trials. This means that we can find out how 
the offer of a trial affects different people. 
The interview 
The length of time that the interview will take depends mainly on how much the 
parents have to say. If they want to set a time by which it should it should end that is 
fine. At least one hour should be allowed as a minimum if possible. With their 
permission the conversation will be tape-recorded. If permission is not given (this has 
not yet occurred in any previous interview for the associated studies) then it will be 
necessary to take some notes at the time and after the interview. It would clearly not 
be possible to note down all answers in full so it must be accepted that data will be 
lost in these circumstances. Parents who agree to a recording should be told that 
they may ask for the tape to be stopped at any time, either for a break or to end the 
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interview. If there are any questions that they do not wish to answer then that is fine 
too. 
Questionnaire 
A short questionnaire collecting demographic details and asking how parents felt the 
interview went will be left at them at the end of the interview, with a prepaid envelope. 
This should be briefly mentioned. 
Any questions 
It should be checked whether there is anything that the parents want to know about 
the study, and whether they are happy to proceed. If during or after the interview they 
ask for some specific information about the trial, it would be best to refer their query 
on to Ann Truesdale at the London School of Hygiene and Tropical Medicine (0171 
927 2376). If you do give Ann's number to anyone make sure that you contact her to 
tell he about the sort of query she might receive from the parents. 
The interview schedule 
The schedule outlined below is a guide to the areas I need parents to talk about. 
Some of them will cover these areas quite naturally with little prompting so the 
questions may not even be necessary. They are there not to suggest that you should 
stick rigidly to them, but to help you to know whether or not the interview has elicited 
the information needed. Sometimes you may need to allow parents to finish a thread 
of thought and then take them back to an earlier area which has been missed. it is 
important that they should tell their story with a chronology that makes sense for 
them, so unless you find it difficult to move forwards and backwards through the 
schedule, allow their descriptions to come to a natural conclusion. Sometimes it will 
be clear that there is an important issue for parents which is not part of the schedule, 
e. g. a reaction to drugs in labour, or aspects of personal circumstances such as 
previous reproductive history. Although these are not part of the schedule they are 
important as they give a context to the rest of the information. It is therefore important 
to strike a balance between accessing information and giving parents the time they 
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want to talk about things that are meaningful for them, and not allowing the interview 
to deviate excessively into unrelated areas. 
There are lots of spaces in the schedule for notes. The boxes will help you to think 
through the purpose of certain questions and contain hints for managing situations 
which might arise. 
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Interview Schedule 
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Section 1 
Pregnancy and the birth 
What was your pregnancy with [baby] like? 
Could you tell me about the birth? 
If the baby was born prematurely, there will be issues to briefly explore with 
parents. This will vary according to circumstances - some women may have had a 
history of premature birth and for others it will have been a complete shock. Try to 
gain some sense of their reactions to labour and the process, if relevant, of trying 
to stop labour. 
Some women may have been asked to participate in a trial relating to early labour 
- antibiotics to stop labour, drugs to mature the babies' lungs if delivered. If 
parents mentioned that this happened, you will need to get a description of the 
events and the information they were given, and have a brief discussion of how 
they felt about that at the time. If relevant you may want to go back to that 
experience when they later discuss the INNOVO trial, to find out how they felt 
about the various trials. 
377 
Section 2 
After the birth 
(concentrating on the period before the trial was mentioned) 
What happened after [baby] was born? 
When did you find out that [baby] had breathing problems? 
Were you given any reasons why this happened? 
Section 3 
Special/Intensive care 
Could you tell me about going to see [baby] in special/intensive care for the 
first time? 
What were you told about the treatment s/he was having at that time? 
Did you feel that you understood what was happening at that time? 
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Was s/he on a ventilator? 
How did s/he respond to the treatment? 
Did you talk to the staff much at that time? 
(If yes) Was there a particular member of staff that you preferred to talk to? (It 
would be helpful to get a name from parents of possible but not essential if it 
is uncomfortable or seems inappropriate) 
What sorts of things did you talk about? (This might elicit information that was 
given at an early stage about the prognosis they were given for the baby. You 
will have to judge how comfortable the parents are to talk about this early in 
the interview and continue or discontinue this thread as appropriate) 
Did you have any feelings at the time about what you wanted the doctors to do 
for your baby? (This is designed to tap feelings of trying to save the baby, 
whatever the consequences, or feelings that it may not be a good idea to do 
so - you may need to alter the phrasing to fit the circumstances and the 
progress/tone of the interview) 
Did you have any feelings about what the doctor thought should be done? 
What about the nurses? 
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What was happened to you at the time e. g. post-natal care, sleeping 
arrangements, employment, travel, care of other children, coping with 
relatives? 
How were each of you coping at that time? 
Section 4 
Discussion of the trial 
Could you tell me about when you were first told about the INNOVO trial? 
Who told you about the trial? 
When and where did you have this discussion? 
Who was present? 
Do you remember what you were told about [baby's] condition then? 
Do you remember what you were told about the trial? (Leave the question as 
simple as this at first to see if the following areas are covered. If any areas are 
not covered then use the following questions) 
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e. g. Were you told - why it was being done? 
- what it would involve? 
- how [baby's] treatment would be decided? 
How did you feel about the trial? 
Did you feel that you understood what you were told at that time? 
Was there anything in particular that you wanted to know? 
What did you think about inhaled nitric oxide as a treatment when you were 
first told about it? 
(Try to work out if the parents had any preferences for INO before 
randomisation, not the view they hold of it now) 
Were you told about any possible benefits? 
Were you told about any possible problems? (It is very important to try to get a 
feel for what the parents' perceptions of INO are, even if it is a simple 
statement that they don't know or can't remember. If you cannot get an 
answer to this question here, try again by a roundabout route later, possibly 
when they are asked about their views on INO when they were deciding about 
the trial ) 
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Did you have any feelings about the fact that [baby] would be taking part in 
research? (Be careful here as some parents may be unclear on this aspect of 
events) 
How did you feel about the person who explained the trial to you? 
What do you think it was like for them to talk to you about this? 
Did you feel at that time that s/he had any views on what you should do? 
Was there anyone else present when you talked to the doctor about the trial? 
(if yes) - How did you feel about that person being there? 
- Did you talk to that person at all after the doctor left? 
- Was it helpful at all? 
Was there anything that could have been done at the time to make things a 
little easier? 
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Section 5 
The decision 
If it is at all possible it would be very helpful to know what the parents views were 
at the time of decision-making, and now, on the issue of survival. Some may be of 
the view that it was important to save the life of their baby, whatever the future 
might hold; others may feel ambivalent about this. It may well be that such views 
are given spontaneously in the course of the interview, or they may be given with 
some prompting. For some parents however it would be an inappropriate line of 
questioning. It is a difficult area so tread carefully and take your signals from what 
the parents have to say. 
Were you left alone to discuss what to do? 
How much time did you have to make a decision? 
Did you talk about inhaled nitric oxide then? 
Did you think about the trial then? 
(if the previous question does not draw out views on randomisation) Did you 
talk about the way the treatment would be decided? 
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Did these things (INO, the trial, the treatment decision), affect your decision at 
all? 
Did you discuss what to do with anyone else e. g other staff, family or friends? 
(If not) Would you have liked to have done that? 
Do you feel that you were influenced by the opinions of anyone else at that 
time? 
(If yes) Who? 
Did you feel under pressure in any way? 
Did you feel that you had enough information to make up your mind? 
Did you have any differences of opinion about what to do? 
How long did it take you to decide? 
In the end, how easy or difficult was the decision? 
When you gave your consent, how well would you say you understood the 
situation? 
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How sure of your decision were you at that time? 
How happy were you afterwards with the decision? 
How did it feel to have to make this decision yourselves? 
If you were asked to give your reasons for agreeing to join the trial, what 
would you say they were? 
Did you consider not joining the trial? 
What was that time like for you? 
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Section 6 
Randomisation 
When you told the doctor that you agreed to the trial, what did s/he say? 
Did you tell the nursing staff what you had decided? 
If yes) What did the nurse say? 
What happened next? 
Did you understand how the decision was being made at that time? (Some 
parents may not be aware of randomisation. If you feel that this might be the 
case, try to pull out how they did feel the decision was made, and on what 
basis) 
At the time did you feel you understood why the decision was made that way? 
Be aware that at this point parents may continue to use the term "randomisation" 
or might say that the decision was made by a computer, but you need to get under 
the skin of both of those comment, so you have an understanding of what they felt 
was the nature and basis of the decision. Remember that you do not want to alter 
their perceptions at all, unless of course they ask you directly for information. 
386 
If no, do you feel that you understand now? (Omit these questions for parents 
who are not aware that randomisation took place) 
How long did you have to wait to find out which treatment [baby] was going to 
have? 
It is possible that some parents will feel that they decided that their baby would 
have INO and the process of randomisation will be unclear. If their baby was 
allocated to INO then their perception may remain unchanged. If allocated not to 
have INO, they may have found out why this was the case, - if so explore their 
reactions to this - or they may have found other ways of explaining why INO was 
not given e. g. doctors decided it was not necessary or it was not available after all. 
Be careful to pull out their views and not to correct them. 
What was the waiting time like? 
How did you feel about how the decision was being made at that time? (Only 
ask this question if the earlier questions have not elicited a clear reaction) 
Do you think that the staff had any views about how the decision was made? 
What did the doctor say when s/he told you which treatment [baby] would 
have? 
What was it like for you when you heard? 
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Section 7 
Treatment 
What happened next? 
Did you feel that you understood what was happening at that time? 
How did you feel going back to see [baby]? 
How did you feel about the treatment [baby] was having? 
How did you feel about the trial at that time? 
How did [baby] respond to the treatment s/he was having? 
Did you ever think about the trial after the treatment was decided? 
What happened during the rest of [baby's] stay in hospital? 
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Section 8 
Discharge from hospital 
How old was [baby] when s/he was discharged? 
How has s/he been since then? 
Section 9 
Overview 
Doctors and nurses sometimes find it difficult to ask people to take part in this 
sort of medical research. How did you feel about taking part in research? 
What do you think it was like for your doctor to ask you about this? 
What do you think it was like for the nurse? 
Did any member of staff talk to you about the trial after the event at all? 
Now that some time has passed since [baby] had all of those problems, how 
do you feel about the decision you made? 
Have your feelings about the trial changed at all? 
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Have you ever thought about what it would have been like if [baby] had had 
inhaled nitric oxide/not had inhaled nitric oxide? 
Do you feel that there have been any particular benefits from your decision to 
take part in the trial? 
Do you feel that there have been any problems or difficulties because of your 
decision? 
Some people have said that one reason for some people's decision to take 
part in a trial can be to help to find out more about a disease or a treatment. 
When you were deciding what to do, do you think that was part of your 
decision at all? 
Do you think there was anything that could have made the situation easier for 
you? 
Was there anything that made the situation more difficult for you? 
The next section involves giving a simple description of single and/or double blind 
methods in order to find out what parents think about the issue of placebo. Firstly 
give the brief description and then there are a few questions. In some instances 
you might wish to check with parents whether the explanation was clear. If 
necessary go over the description again, before asking for their views. If you come 
across any parents who are very unclear about the trial e. g. they feel they chose 
INO and are unaware of randomisation, you may judge that it is inappropriate to 
ask these questions. 
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In some trials the people involved are not told which treatment they are going to 
be given. If this method had been used for the INNOVO Trial, you would not have 
been told whether your baby was receiving nitric oxide or not. 
How do you think that would have been for you? Parents may answer this fully 
but if necessary you may need to prompt with some or all of the following. 
Do you think it would have changed things for you at all? 
Would have made things better or worse? 
How do you think the doctors and nurses might feel about this situation? 
In some trials the doctors and nurses don't know which treatment a patient is 
receiving as they are not told whether they are giving a drug, like nitric oxide, or a 
dummy drug, a placebo. 
How do you think it would have been for you if the trial had been carried out 
like this? 
What do you think it would have been like for the staff? 
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If parents want to know more about why this approach might be used, you could 
give the following information which might lead to an interesting discussion. 
There are 2 main reasons why some trials are carried out like this; 
to try to make sure that the results are more reliable. The person who 
describes the progress of the baby for the trial records might be biased 
towards one treatment or another and that might affect what they say 
to try and make it easier for the people involved, in case people are 
disappointed or worried by the treatment groups in the trial. 
Use this next question as a way of pulling together what they have said, so that we 
have a clear yes, no or don't know on this subject from each parent. 
So, do you think the trial should have been carried out the way it was, or with 
one of these different ways? 
That is all of the questions but is there anything else that you would like to say 
about what happened to you, or anything you would like to add about the trial? 
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Schedule and notes for interviews with bereaved parents - 
INNOVO Trial75 
Section 8 
What happened next? 
What happened during the rest of [baby's] time in hospital? 
At the moment we have very little idea of how bereaved parents will react in the 
interviews and what sorts of views they will express. I suggest that we simply allow 
the events surrounding the baby's death to be described and see what information 
is given. Obviously follow up on any lines that seem interesting if they are 
appropriate, especially if the parents link events to the trial in any way e. g. feeling 
that they gave their baby the best chance by joining the trial, or regretting their 
decision. We may need to modify the schedule and make the questions specific 
once we have done a few interviews. 
75 The interview schedule for the bereaved parents differed little from that of the parents of surviving 
babies in terms of the formal questions asked and so the whole schedule is not repeated here. It was 
characterised by a flexible approach with the line of the conversation dictated by the parents, as this 
extract indicates. 
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